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The dysregulation of DNA damage repair has a significant clinical impact in ovarian 
cancer. DNA double strand breaks (DSB) are repaired by the homologous 
recombination (HR) and the non homologous end joining (NHEJ) pathways. 50 % of 
ovarian cancers are HR defective (HRD), which makes these cancers sensitive to 
poly(ADP-ribose) polymerase inhibitors (PARPi). The role of PARP-1 in NHEJ, and 
the interaction between the two pathways in cancer chemo- and radio-sensitivity has 
been reported.  
In this study, a primary ovarian cancer (PCO) culture model, derived from ascites, 
was optimised and the association of HRD with PARPi and cisplatin sensitivity 
confirmed. One PCO culture spontaneously immortalised, forming a novel cell line, 
NUOC-1, which was characterised demonstrating extensive genomic instability, 
clonal evolution and genomic aberrations consistent with an endometrioid / clear cell 
ovarian cancer.  
NHEJ was found to be defective in 40 % of ovarian cancers, which was independent 
of HR and was associated with resistance to the PARPi, rucaparib. DNA-PKcs, Ku70 
and Ku80 were found to be promising biomarkers for NHEJ function, however utility 
may be limited by intra-tumour heterogeneity. The role of PARP-1 in DNA DSB 
recognition and repair was assessed. Whilst PARP-1 expression and activity were 
independent of HR and NHEJ, PARP-1 was found to interact with DNA-PK and ATR 
in DSB recognition and repair.  
HR recovery was found to lead to cisplatin and rucaparib cross resistance, and this 
appeared to be independent of BRCA and NHEJ function. Additionally, cisplatin 
resistant HRD cells were found to remain sensitive to rucaparib. Mutational and gene 
expression profiles were found to be cell and drug dependent with complex 
alterations in all resistant cell lines. 
These results demonstrate the essential role of DSBs repair pathways in platinum 
and PARPi sensitivity. Stratification of tumours by HR and NHEJ function may 
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CHAPTER 1 INTRODUCTION 
1.1 Background  
Ovarian cancer poses challenges to clinicians due to advanced presentation, poorly 
understood aetiology, limited treatment modalities at relapse and a high mortality 
rate. Worldwide, ovarian cancer accounts for around 4 % of all cancers diagnosed in 
women. The risk of developing ovarian cancer by age 75 is between 0.5 % and 1.6 % 
(National Cancer Institute, 2014). Despite recent developments, overall mortality has 
changed little over the past 20 years, with the 5-year overall survival remaining low at 
40 % (Jemal et al., 2009). The insidious onset of non-specific symptoms, coupled 
with a lack of a reliable detection method for early stage disease, results in a late 
stage at presentation at which time there are widespread metastases (Menon et al., 
2009). The current standard treatment for epithelial ovarian cancer (EOC) is surgery 
accompanied by chemotherapy based on platinum compounds, with or without 
Taxanes (Ramirez et al., 2011). Although 70-80 % of women present with advanced 
stage disease, rates of response to primary chemotherapy are good, leading to 
improved median survival times. Aggressive surgical and medical treatment for 
primary and recurrent disease is thought to be responsible for the small improvement 
seen in survival (Kitchener, 2008). However, high rates of recurrence and the 
development of chemo-resistance limits further improvements (Kaye, 1996). 
Chemotherapy in platinum resistant disease is a challenge, and is associated with 
significant toxicity with the current chemotherapeutic agents (Markman, 2009). It is 
these reasons that also make ovarian cancer an important study target, as there is 
an urgent need for new therapeutic approaches and the means to identify patients 
who will benefit from them (Schilsky, 2010). 
PARP inhibitors (PARPi) are an exciting new class of chemotherapeutic agents 
which act by exploiting defects in DNA repair pathways of cancer cells (Farmer et al., 
2005, McCabe et al., 2006, Helleday et al., 2005, Ashworth, 2008b). The response of 
cancers known to have BRCA1/2 mutations, to PARPi, has been demonstrated in 
phase III clinical trials and they are now licensed for clinical use (Kim et al., 2015, 
Scott et al., 2015). With clinical trials continuing, a better understanding of the DNA 




Attempts to stratify treatment have so far concentrated on identifying defects in the 
homologous recombination repair (HR) pathway (Mukhopadhyay et al., 2010). 
However, there is now increasing evidence for the role of PARP in the regulation of 
non homologous end joining (NHEJ) and alternative end joining (A-EJ) pathways; for 
interactive effects of PARPi and DNA-dependent protein kinase (DNA-PK) inhibitors; 
and for the role of the NHEJ pathway in PARPi resistance in HR deficient (HRD) cells 
(Boulton et al., 1999, Ruscetti et al., 1998, Veuger et al., 2003, Veuger et al., 2004, 
Mitchell et al., 2009a, Wang et al., 2006b, Audebert et al., 2006, Lu et al., 2006, 
Audebert et al., 2008, Hochegger et al., 2006, Saberi et al., 2007).  
Established primary ovarian cancer culture (PCO) models provide us with an 
opportunity to improve the understanding of ovarian cancer response to PARPi and 
allow improved patient stratification by molecular pathology on an individual patient 
basis. Therefore, the primary aim of this project was to assess NHEJ function using 
the PCO model and provide further insight into the mechanisms of interaction of DNA 
double strand break (DSB) repair pathways in sensitivity and resistance to cisplatin 
and PARPi. 
1.2 Tumour Biology in Ovarian Cancer 
The term ‘ovarian cancer’ represents a complex group of tumours in terms of 
histology, molecular characterisation, prognoses and clinicopathological features. 
EOC is the most common subtype in the adult population (90 %) and the work in this 
project concentrates on EOCs. EOCs can be divided into low and high grade serous, 
mucinous, endometrioid, clear cell, transitional (Brenner type) and mixed tumour, 
according to their histological morphology. EOCs can be further subdivided into 
malignant and borderline tumours. However, following an understanding that ovarian 
cancer subtypes develop through the disruption of distinct genetic and biological 
pathways, new classification systems have emerged (Shih and Kurman, 2004, Kobel 
et al., 2008). The commonly referenced model classifies ovarian tumours into two 
groups based on the similarities of tumour presentation, evolution, and most 
importantly genetic mutations (Shih and Kurman, 2004). Type I cancers are the low 
grade serous, mucinous, endometrioid, or clear-cell histology. These cancers are 
often diagnosed at an early stage, grow slowly, and resist conventional 
chemotherapy. The more prevalent type II cancers are high grade serous, high grade 
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clear cell / endometrioid, or carcinosarcoma. These cancers present at a late stage, 
grow aggressively, and respond to conventional chemotherapy. 
1.2.1 Molecular Characteristics of Type I and Type II Tumours 
Clear differences in molecular alterations are also noted between the two groups 
(Table 1-1). Type I cancers tend to have a normal karyotype and wild-type TP53 and 
BRCA1/2, but frequent mutations in the B-RAF and KRAS (Grisham et al., 2012). 
Clear-cell and endometrioid carcinomas share a similar gene expression pattern that 
is consistent with a common origin. These include ANXA4 and UGT1A1 genes, 
which are associated with chemo-resistance (Farley et al., 2008). Furthermore, 
inactivating mutations of ARID1A and PTEN, and activating mutations of PIK3CA that 
up-regulate phosphatidylinositol-3-kinase (PI3K) signaling, have been reported to be 
characteristic (Kuo et al., 2009, Wiegand et al., 2010, Jones et al., 2010). 
Type II cancers are characterised by copy number abnormalities and marked 
genomic instability (Romero and Bast, 2012). The Cancer Genome Atlas Project, 
which analysed more than 300 high-grade serous cancers, detected amplification of 
more than 30 growth-stimulatory genes (Vockley et al., 2012). BRCA1/2 germline 
and somatic mutations are common in type II ovarian cancers (Romero and Bast, 
2012), whilst mutations of TP53 are almost universal (Ahmed et al., 2010, Cancer 
Genome Atlas Research, 2011).  
1.2.2 Precursor Lesions for Ovarian Tumours 
Type I tumours appear to develop from well-established precursor lesions such as 
cystadenomas, atypical proliferative (borderline) tumours and endometriosis (Shih 
and Kurman, 2004). Molecular genetic alterations in PTEN and ARID1A and 
microsatellite instability, can be detected in the epithelial cells of endometriotic cysts 
and a clonal relationship between endometriosis and endometriosis related ovarian 
carcinomas has been demonstrated in several studies (Kim et al., 2014). 
Recently, precursor lesions in the fallopian tube that pass through a stage of 
intraepithelial carcinoma, so-called “serous tubal intraepithelial carcinoma (STIC)” 




Table 1-1 Molecular classification of Ovarian Cancer.  
EOC is classified into type I and type II tumours (Shih and Kurman, 2004). 
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Cacinosarcoma Not recognised TP53  
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1.2.3 Treatment Considerations for Type I and Type II Tumours 
Regardless of subtype, EOC is uniformly treated with surgical de-bulking and a 
combination of carboplatin and paclitaxel. However, the treatment of type I and type 
II tumours must be individualised.  
As type I tumours are slow growing, chemotherapeutic agents that are effective 
against the more rapidly proliferating type II tumours are not as effective. Many 
studies relate the poor prognosis of clear cell with resistance to platinum-based and 
taxane-based chemotherapy (Itamochi et al., 2008, Anglesio et al., 2011). In many 
type I carcinomas, there is constitutive activation of the MAPK signaling pathway 
because of mutations in ERBB2, KRAS or BRAF, the upstream regulators of MAPK. 
BRAF and other MAPK inhibitors could improve overall survival in patients with these 
types of tumours when combined with conventional chemotherapy (Shih and 
Kurman, 2004). Furthermore, hormone therapies such as progestogens, tamoxifen, 
luteinizing hormone releasing hormone agonists and more recently aromatase 
inhibitors, may have a role (Walker et al., 2007, Karagol et al., 2007). 
Treatment for type II tumours should also be based on the detection of sensitive and 
specific biomarkers. Type II tumours have an 80 % response rate to platinum therapy 
(Anglesio et al., 2011). More recently it has been demonstrated that hereditary or 
acquired EOC with BRCA mutations and HRD are more sensitive to PARPi, as well 
as to platinum therapy (Mukhopadhyay et al., 2012). 
1.2.4 Risk Factors 
A hereditary predisposition to ovarian cancer occurs in 10 - 15 % of cases. This is 
caused by germline mutations in the tumour suppressor genes BRCA1 and BRCA2, 
or in DNA mismatch repair (MMR) genes (Gayther and Pharoah, 2010). A genome 
wide association study identified a further EOC susceptibility locus at chromosome 
9p22.2 (Song, 2009). The lifetime risk of developing EOC in women with a germline 
BRCA1/2 mutation can be up to 66 % and 27 % respectively (Robles-Diaz, 2004). A 
greater understanding of the functional role of the various BRCA1/2 mutations is 
urgently needed to predict which women will develop gynaecological cancers.  
Although ovarian cancer aetiology remains unclear, a number of risk and protective 
factors have been identified for sporadic ovarian cancer detailed in Table 1-2 
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(Sueblinvong, 2009, Lahmann, 2010, Huncharek, 2003, Salehi, 2008). The most 
important risk factor is advancing age, with more than 85 % of patients being aged 50 
years or older at diagnosis.  
Table 1-2 Risk Factors for Ovarian Cancer Development 
A list of risk and protective factors for the development of ovarian cancer 
(Sueblinvong, 2009, Lahmann, 2010, Huncharek, 2003, Salehi, 2008). 
Risk Factors  Protective Factors 
Increasing age 
Family history 
Early menarche/Late menopause 
Hormone replacement therapy 









Combined Oral Contraceptive Pill   
Sterilisation 
Hysterectomy 
1.2.5 Hypotheses for Tumour Origin 
The initial proposed origin of ovarian cancer was from the less differentiated ovarian 
surface epithelial (OSE) cells. OSE are mesothelial-like cells that share 
embryological origin with the Mullerian tract epithelium, which eventually gives rise to 
the tubal, endometrial and endocervical epithelium (Ahmed et al., 2012). 
Subsequently it was suggested that the invaginations which develop in the OSE may 
be incorporated into the ovarian stroma, forming inclusion cysts (Folkins, 2009). The 
formation of inclusion cysts lined by OSE cells was suggested as the origin of EOC, 
but this was later refuted (Dubeau, 1999).  
A further hypothesis put forward for the development of EOCs included Mullerian 
trans-differentiation of trapped OSE cells after repeated ovulation (Roskelley and 
Bissell, 2002, Cheng et al., 2005); which goes some way to explain the risk reduction 
associated with pregnancy and oral contraception (Fathalla, 1971). Ovarian biopsies 
from women receiving ovulation stimulating fertility treatment have revealed a higher 
rate of dysplasia (Fathalla, 1971).  
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More recently, ovarian cancer development directly from mullerian derivatives has 
been suggested (Kindelberger, 2007, Lee et al., 2007b, Herrington, 2010). This is 
evident in some studies which showed dysplastic changes in fallopian tubes in 
women who underwent prophylactic removal of ovaries and fallopian tubes for BRCA 
gene mutation (Hartley et al., 2000, Carcangiu et al., 2006, McCluggage, 2011). 
Further studies systematically examined the tubes in patients with sporadic high 
grade serous ovarian carcinomas (HGSOC) and found similar lesions in up to 60 % 
of cases (Kindelberger, 2007, Przybycin, 2010).  
The heterogeneous behaviour of ovarian cancers suggests that distinct 
morphological subtypes may indeed have different pathogenic processes (Shih and 
Kurman, 2004). HGSOC may originate from the fallopian tubes implanting into 
inclusion cysts or the peritoneal cavity. Endometrioid and clear cell ovarian cancers 
have been linked to retrograde menstruation (Kurman and Shih, 2011) and 
endometriosis (Worley, 2013), and therefore may originate from the endometrial 
cavity. 
1.3 Treatment of Ovarian Cancer 
The majority of women with ovarian cancer present with stage III / IV disease. The 
current gold standard for treatment of advanced ovarian cancer is cytoreductive 
surgery in combination with platinum-based chemotherapy.  
1.3.1 Surgery 
Surgery plays a pivotal role in the management of ovarian cancer. The significance of 
optimal resection (to no tumour or less than one centimetre nodules) is well-
established and maximal cyto-reduction has been shown to be one of the most 
powerful determinants of survival among patients with EOC (Bristow et al., 2002, 
Elattar et al., 2011, Al Rawahi et al., 2013).  
Surgery can be either primary debulking surgery, performed prior to administration of 
six cycles of adjuvant chemotherapy or interval debulking surgery, performed after 
three cycles of neoadjuvant chemotherapy, followed by three further cycles of 
chemotherapy post operatively. Recent major clinical trials have not shown any 
difference in survival after primary surgery compared to survival after neoadjuvant 
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chemotherapy with interval debulking surgery in advanced ovarian cancer (Vergote 
et al., 2010). 
1.3.2 Chemotherapy 
Primary surgery, even in early disease results in a significant proportion of cases 
relapsing and two large randomised controlled trials (RCTs): ICON 1 and ACTION, 
have shown that platinum-based adjuvant chemotherapy after complete cyto-
reduction improves OS  as well as recurrence-free survival at 5 years (Colombo et 
al., 2003, Trimbos et al., 2003). Mixed results have been reported from trials 
assessing the addition of further agents. Several RCTs have shown the importance 
of the addition of paclitaxel to platinum therapy (Piccart et al., 2000, McGuire et al., 
1996) with improvements in progression free survival (PFS) and overall survival (OS) 
(Piccart et al., 2000, McGuire et al., 1996, Bookman et al., 2003). ICON3 however, 
demonstrated that there was no survival benefit between first-line treatment with 
single-agent carboplatin or with the addition of paclitaxel, and the option of single or 
double agent chemotherapy is therefore currently tailored to the individual 
(Collaborators, 2002, Redman et al., 2011). Attempts to improve the standard two 
drug chemotherapy by adding a third agent failed to affect PFS or OS, but did result 
in increased adverse effects (Bookman et al., 2009, du Bois et al., 2006, Pfisterer et 
al., 2006, Hoskins et al., 2010) . To date, standard treatment is offered to all patients 
irrespective of histological subtype, stage or surgical outcome. 
1.3.2.1 Resistance to Chemotherapy  
Both intrinsic and acquired resistance results from the numerous genetic and 
epigenetic changes occurring in cancer cells. The majority of resistance mechanisms 
described are common to several drugs.  Specific changes have also been described 
for platinum and PARPi resistance development. These are discussed in more 
details in chapter 6. One of the most important determinants of drug sensitivity and 
resistance is the cancer cell ability to repair DNA damage. This is discussed in details 
in section 1.4. 
1.3.2.1.1 Alterations in Proliferation Signalling Pathways 
Dysregulation of proliferative signaling pathways is a characteristic of cancer cells 
(Rebucci and Michiels, 2013). Two important cell proliferation pathways are the 
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MAPK and the PI3K, both of which have been reported to be mutated in ovarian 
cancer (Geyer et al., 2009, Nakayama et al., 2006, Willner et al., 2007). 
The PI3K pathway (Figure 1-1) transduces extra cellular signals, to promote cellular 
growth, proliferation and reduce apoptosis. PIK3CA proto-oncogene amplification or 
mutations increasing catalytic activity is associated with EOC (Meng, 2006, 
Yokomizo, 1998, De Luca et al., 2012). PIK3CA is increased in copy number in 40 % 
of ovarian cancer cell lines and patient tumour samples (Shayesteh, 1999). The PI3K 
inhibitor, LY294002, has been shown to inhibit ovarian cancer cell proliferation in 
vitro and to decrease ovarian cancer growth and ascites formation in mice (Hu, 
2000). LY294002 has also been proven to increase the efficacy of paclitaxel in mice 
(Hu, 2000). More recently, a dual inhibitor of PI3K and PARP has been shown to 
significantly suppress tumour growth by downregulating BRCA1/2 in xenograph 
models (Ibrahim et al., 2012). 
 
Figure 1-1 Schematic representation of the PI3K signalling pathway.  
PI3K is coupled with a variety of growth factor-dependent tyrosine kinase receptors. 
Upon stimulation of its upstream receptors, PI3K is activated and generates 
Phosphatidylinositol (3,4,5)-triphosphate (PIP3) from Phosphatidylinositol 4,5-
bisphosphate (PIP2)). PIP3 binds pleckstrin-homology domains to AKT and 
translocate to the plasma membrane where they are activated. All Akt isoforms (Akt1, 
Akt2, Akt3), once activated, promote cellular proliferation and inhibit apoptosis 
through phosphorylation of multiple substrates (Leary et al., 2013). 
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AKT1 and 2 are frequently amplified in ovarian cancer (Cheng et al., 1992, Sun, 
2001). PI3K inhibitors and mTOR (downstream effectors related to growth and 
protein synthesis) inhibitors have been shown to increase the effectiveness of 
cisplatin and tamoxifen in ovarian cancer cells with activated Akt signaling (Treeck, 
2006, Mabuchi, 2007). 
A second signaling pathway that is often overexpressed in cancer cells is the 
Ras/Raf/MAPK pathway (Rebucci and Michiels, 2013). The pathway induces cell 
proliferation and differentiation; and several components have been found to be 
mutated in different cancers.  
 
Figure 1-2 Schematic representation of MAPK pathway.  
Binding of GTP, resulting in activation of the Ras-family GTPases, enables the 
transmission of external signals to the interior of the cell. The active GTP-Ras 
complex then interacts with Raf1 (Smalley, 2003) and a cascade of MEK 
phosphorylation activation steps follows, which in turn phosphorylate ERK. On 
activation, ERK enzymes phosphorylate cytoplasmic targets or migrate to the 
nucleus, where they phosphorylate and activate transcription factors (Treisman, 
1994). They also target membrane bound proteins responsible for protecting cells 
against apoptosis (Lewis, 1998). The activation of the ERK MAPK pathway induces 




Oncogenic mutations lead to activation of the pathway in the absence of a mitogenic 
signal, causing the cell to enter the S phase and continue to divide without any 
control. If cells divide before any DNA damage is repaired, the daughter cells inherit 
the mutations, and should these mutations confer a growth advantage leading to 
bypassing the apoptotic signals, growth of these cells will be selected for in that 
population. 
In ovarian cancer mutations in KRAS, BRAF and ERBB2 oncogenes, which result in 
constitutive activation of the MAPK pathway have been reported (Mayr, 2006, 
Gemignani, 2003). KRAS mutations are reported in 2/3rds of mucinous, 1/3rd of low 
grade / borderline serous and 1/5th of endometrioid cancers (Ho et al., 2004). The 
KRAS mutation is a functional variant located in the KRAS 3’UTR in a let-7 miRNA 
complementary site, which is a significant predictor of platinum resistance (Ratner, 
2011). BRAF mutation is seen in 1/3rd of the low grade serous tumours (Nakayama et 
al., 2008). All known BRAF mutations occur within the kinase domain, with a single 
substitution of A for the T at nucleotide position 1796, accounting for at least 80 % of 
BRAF mutations (Davies et al., 2002, Rajagopalan, 2002). cMYC and ERBB2 over 
expression is seen in 36 - 76 % and 10 - 20 % of advanced stage EOCs and is 
associated with poorer prognoses (Dimova, 2006). 
1.3.2.1.2 Suppression of Tumour Suppressor Genes 
In addition to induction of positive growth signals, tumour cells also down regulate 
tumour suppressor genes (Ertel et al., 2010). Phosphatise and tensin homologue 
deleted from chromosome 10 (PTEN) inhibits the PI3K/Akt pathway. Mutations 
leading to the loss of PTEN result in the activation of the PI3K/Akt pathway and 
increased cell survival (Nagata et al., 2004). Inactivating mutations of PTEN and 
activating mutations of PIK3CA that up-regulate phosphatidylinositol-3-kinase (PI3K) 
signaling have been reported to be characteristic of type I ovarian cancers (Romero 
and Bast, 2012, Munksgaard and Blaakaer, 2012). 
The TP53 tumour suppressor gene is involved in controlling cell cycle, apoptosis and 
maintaining the genome integrity. p53 levels rapidly increase following DNA damage; 
p53 activates genes involved in cell cycle arrest to prevent the cell from entering S 
phase until the damage is repaired. If the damage to the cell genome is too extensive 
to be repaired, p53 induces apoptosis. p53 has also been implicated in the regulation 
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of BRCA1 function (Bouwman et al., 2010) and in the transcriptional regulation of 
RAD51 (Arias-Lopez et al., 2006).  
The majority of studies demonstrate that tumours harboring mutated TP53 are 
associated with resistance (Lai et al., 2012) and treatment failure (Knappskog and 
Lonning, 2012) when compared to wild type. p53 over expression has been 
associated with shorter time to progression and overall survival as well as increased 
platinum resistance (Shahin et al., 2000, Reles et al., 2001, Folkins et al., 2008). In 
HGSOC, p53 mutations are reported to be ubiquitous (Ahmed et al., 2010, Cancer 
Genome Atlas Research, 2011). The therapeutic potential of restoration of wild-type 
p53 expression in tumour cells and use of oncolytic adenoviruses, which can only 
replicate in cells that have lost p53 have failed to show promising results in ovarian 
cancer patients (Buller et al., 2002, Vasey et al., 2002). 
1.3.2.1.3 Insufficient Exposure of Cancer Cells to the Drugs 
Pharmacokinetic approaches to overcome drug resistance are based on attempts to 
improve drug delivery to the cancer cells. Initial trials concentrating on increasing 
drug dose failed to overcome drug resistance (Gore et al., 1998). Intraperitoneal 
delivery of chemotherapy has been reported to improve PFS and OS. Other 
approaches that increase tumour-cell drug exposure include the development of 
Liposomes which increase tumour-cell-specific drug delivery. An example of this 
approach is liposomal doxorubicin, which is now approved for treatment (Strauss et 
al., 2008). Antibody-directed enzyme prodrug therapy and gene-directed enzyme 
prodrug therapy approaches also aim to increase tumour cell specific drug exposure 
to overcome drug resistance with minimal toxicity to normal tissues (Tong et al., 
1998). 
1.3.2.1.4 Changes to Drug Export 
Decreased cellular drug accumulation by resistant cells is one of the major 
mechanisms of resistance. This may be due to either, an inhibition of drug uptake, an 
increase in drug efflux, or both. CTR1 regulates cellular influx of platinum (Holzer et 
al., 2006, Song et al., 2004). Two copper exporters, ATP7A and ATP7B, have also 
been proposed to be involved in cellular resistance to cisplatin (Samimi et al., 2004) 
and it has been shown that ovarian cancer patients with ATP7A expression have a 
lower survival rate than patients with undetectable levels (Samimi et al., 2003). 
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1.3.2.1.5 Tumour Microenvironment 
Tumours are not only made up of cancer cells but also of stromal cells, macrophages 
and vasculature, which all play an important role in cancer biology and drug 
sensitivity (Rebucci and Michiels, 2013). Ovarian cancer cells can regulate the 
composition of their stroma by promoting the formation of ascitic fluid and by 
stimulating the differentiation of stromal cells. Stromal cells secrete cytokines which 
activate anti-apoptotic pathways and exchange drug efflux proteins enabling 
improved drug metabolism (Castells et al., 2012). Adipocytes secrete growth factors 
which activate TLR4 signalling in macrophages and thereby stimulate the production 
of pro-inflammatory mediators involved in chemo-resistance (Roodhart et al., 2011). 
1.3.3 Treatment of Recurrent Disease 
The treatment of recurrent ovarian cancer is mainly based on chemotherapy and is 
used with palliative, rather than curative intent (Hennessy et al., 2009, Herzog, 2004). 
Secondary cytoreductive surgery has a place in a well selected population (Lorusso 
et al., 2012, Harter et al., 2006). The main prognostic factor for successful treatment 
is the disease free interval from completion of chemotherapy until recurrence. The 
cancer is regarded as platinum-resistant if this time-interval is less than six months, 
and as platinum refractory if progression occurs during treatment (Markman et al., 
1991). ICON 4 has shown increased survival in recurrent ovarian cancer with 
addition of paclitaxel to carboplatin treatment (Parmar et al., 2003). Numerous 
second line agents are now available for use in ovarian cancer (Table 1-3). Evidence 
for these therapies is limited and decisions are therefore made on individual patient 
basis. 
1.3.4 Targeted Therapies 
Besides increased toxicity with recurrent chemotherapies, development of resistance 
against the chemotherapy remains a problem. Novel biologically targeted agents 
target tumour cells and/or microenvironment by exploiting specific molecular 
abnormalities in the tumour. Multiple components of signaling cascades are aberrant 
in ovarian cancer, resulting in the activation of critical oncogenic pathways involved in 
processes such as cell proliferation, survival, migration and angiogenesis. In addition 
to PARPi, which will be discussed in detail in section 1.3.6, antiangiogenic agents are 






   
  Table 1-3 Second line systemic therapy for the treatment of ovarian cancer.  
Agents Target Resulting effect Licenced 
Indication 
Side-effect Profile Refs 
Bevacizumab 
 
A recombinant monoclonal 
antibody which binds to VEGF. 






GI perforation / fistula 
Hypertension 




Anthracycline antibiotic with 
antimitotic and cytotoxic 
activity. 
Prevents DNA ligation by 
complexes with DNA by 
intercalation between base 
pairs and inhibiting 











A nucleoside analogue 
activated intracellularly to 
dFdCTP by deoxycytidine 
kinase. 
Inhibits DNA synthesis and 
induces apoptosis.  
Pre-treated 








A synthetic camptothecan 
derivative that binds to the 
topoisomerase I-DNA complex 
Interfers with the replication 
fork at SSB, leading to 









A semisynthetic derivative of 
podophyllotoxin. Inhibits DNA 
topoisomerase II, thereby 
inhibiting DNA re-ligation 
Causes critical errors in DNA 





Diarrhoea / vomiting 
(Thavaramara 
et al., 2009) 
Tamoxifen 
 
Binds to oestrogen receptors 
altering the regulation of 
oestrogen dependent genes 
Reduces DNA polymerase 











Angiogenesis, the formation of new blood vessels, is a critical component of cancer 
growth and metastasis. Bevacizumab is a monoclonal antibody against Vascular 
Endothelial Growth Factor (VEGF). Two randomised, phase III trials, GOG 0218 
(Burger et al., 2011) and ICON7 (Perren et al., 2011) have demonstrated an 
improvement in PFS but not OS, when bevacizumab was added to the combination 
of carboplatin and paclitaxel followed by maintenance therapy, as the first line 
treatment for advanced EOC.  
Furthermore, the addition of bevacizumab to chemotherapy in platinum sensitive 
(OCEANS) (Aghajanian et al., 2012) and platinum resistant (AURELIA) (Pujade-
Lauraine et al., 2012) recurrent disease has been shown to improve PFS. A number 
of other angiogenesis inhibitors have also entered clinical trials (Karlan et al., 2012, 
Coleman et al., 2011). 
The main challenges facing targeted therapies are toxicities (Burger et al., 2007, 
Cannistra et al., 2007) and identification of the appropriate target population. 
Circulating short VEGFA isoforms, expression of neuropilin-1 and VEGF receptor 1 
and genetic variants in VEGFA are potential biomarkers for angiogenesis inhibitors 
(Lambrechts et al., 2013). 
1.4 DNA Repair Pathways 
The accumulation of DNA damage can initiate cancer and lead to genomic instability 
of the cell, which is then able to break and reform chromosomes, inactivate tumour 
suppressor genes, amplify drug resistance genes, and consequently become more 
malignant and drug resistant over time (Kennedy and D'Andrea, 2006, Lengauer et 
al., 1998). The cancer cell must first however be able to tolerate the DNA damage. 
This tolerance can be achieved firstly by the cancer cells losing DNA damage 
signaling and check point pathways such as those controlled by p53 (Macaluso et al., 
2005, Bartkova et al., 2005). Secondly, the cancer cells may knock out one of the 
major DNA repair pathways (Kennedy and D'Andrea, 2006).  Endogenous DNA 
damage occurs naturally in all cells with a high frequency of >104 spontaneous 
damage events per cell every day, as a result of replication errors, cellular 
metabolism-induced oxygen radicals, as well as environmental agents e.g. UV 
radiation (Ames and Gold, 1991, Hoeijmakers, 2001). Faulty DNA repair mechanisms 
not only predispose cells to becoming cancer cells, but also affect sensitivity to 
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treatment. Most cytotoxic chemotherapy agents induce DNA damage in order to kill 
cancer cells. Resistance to these agents can result from an ability to proliferate 
through loss of checkpoint function. This can also result in increased sensitivity as 
the cells go through the cell cycle unrepaired, which leads to cell death (Curtin, 
2012).  
There are six major mechanisms responsible for the repair of DNA lesions: direct 
repair, MMR, base excision repair (BER), nucleotide excision repair (NER), HR, 
NHEJ, and A-EJ (Hoeijmakers, 2001, Bernstein et al., 2002). 
1.4.1 Direct Repair by O6-methylguanine-DNA Methyltransferase  
Direct repair by O6-methylguanine-DNA methyltransferase (MGMT) removes the alkyl 
group of the O6 position of guanine, which causes a mismatch of the alkylated 
guanine with thymine, instead of cystosine during replication. Use of cancer agents 
such as temozolomide, dacarbazine and nitrosoureas causes alkylation of O6-
methylguanine, which, if the MGMT pathway is deficient, results in persistent 
mismatching of bases during replication. The MMR pathway attempts to correct this 
mismatch, but as the alkylated base is permanently bound with the template DNA, is 
unsuccessful; thus triggering futile cycles of excision and repair, which ultimately 
results in apoptosis.  
1.4.2 Mismatch Repair 
MMR is responsible for the recognition and repair of DNA damage caused by 
deamination, oxidation and replication errors and also targets DNA dimers and 
alkylated bases (Duval and Hamelin, 2002). MMR is subdivided into 2 pathways 




Figure 1-3 Schematic representation of MMR pathway.  
The MutSα (consisting of MSH2: MSH6) complex binds in base-base and 
insertion/deletion mismatches, and the MutSß complex (MSH2: MSH3) binds only to 
insertion/deletion mismatches. These assemble at the DNA mismatch site and recruit 
hMutLa (MLH1:PMS2), along with other proteins to initiate the repair process. 
 
The products of the genes participating in DNA MMR were originally identified for 
their involvement in the Hereditary Non Polyposis Colorectal Cancer (HNPCC) 
syndrome (Scartozzi et al., 2003). HNPCC is caused by germline mutations in one of 
the MMR genes (Bronner et al., 1994, Cyr et al., 2011). It results in an increased 
lifetime risk of colon (80 %) and ovarian (12 %) cancer (Watson and Lynch, 2001). 
Mutations in MLH1, MSH2, and MSH6 account for the majority of reported MMR 
germline variants, but there are numerous other missense mutations which can also 
result in loss of MMR function (Peltomaki and Vasen, 2004). 
Loss of MLH1 has been observed in 50 % of stage III/IV ovarian cancers (Scartozzi 
et al., 2003). Further to HNPCC syndrome, epigenetic silencing though promoter 
hypermethylation of hMLH1 has been reported in endometrial, gastric, colon and 
ovarian cancers (Geisler et al., 2003, Strathdee et al., 1999). Microsatellite instability 
(MSI) has been confirmed to be a marker of MMR deficiency and MMR deficiency 
has been reported in up to 39 % of ovarian tumours, mostly in endometrioid types 
(Helleman et al., 2006, Zhang et al., 2008). 
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Cisplatin and carboplatin function by binding to the DNA and forming DNA adducts, 
leading to intra-strand or inter-strand cross-links which disrupt the structure of the 
DNA molecule, resulting in steric changes in the helix (Sharma et al., 1995). When 
MMR is deficient, the cells bypass the intra-strand crosslinks and continue to 
proliferate in spite of the DNA damage, and are therefore resistant to platinum agents 
as well as DNA methylating agents and thiopurines (Helleman et al., 2006). Defects 
in the MMR pathway have been demonstrated to be significantly higher in tumours 
post chemotherapy, compared to untreated controls (Scartozzi et al., 2003, Cooke 
and Brenton, 2011, Watanabe et al., 2001). Therefore, research has focused on 
attempts to reactivate epigenetically silenced MLH1. After promising preclinical data 
that demonstrated chemo-sensitisation, clinical trials were stopped due to adverse 
reactions (Plumb et al., 2000). 
1.4.3 Nucleotide Excision Repair 
NER encompasses with the wide class of helix-distorting lesions that interfere with 
base pairing and generally obstruct transcription and normal replication 
(Hoeijmakers, 2001); for example, UV radiation induced thymidine dimers resulting in 
stalled replication forks. NER is the predominant pathway repairing platinum-DNA 
adducts (Figure 1-4). Different studies with ovarian cancer cell lines have 
demonstrated that high ERCC1 mRNA expression is correlated with increased 
capacity of cells to repair cisplatin-induced DNA damage, thus conferring resistance 
to the drug (Damia, 1998, Ferry, 2000, Li et al., 2000). In vitro studies have 
demonstrated sensitivity to platinum in NER defective human ovarian cell lines, in 
particular those with reduced levels of ERCC1 and XPF proteins. Knockdown of 
ERCC1 in cell lines and in mice, has shown increased sensitivity to platinum 





Figure 1-4 Schematic representation of NER pathway.  
There are two NER sub-pathways to remove these lesions: global genome NER 
(GG-NER) which surveys the entire genome for distorting injury; and transcription-
coupled repair (TCR) which focuses on damage that blocks elongating RNA 
polymerases (Christmann et al., 2003). Upon recognition of the DNA lesion, (either 
by binding of XPC-hHR23B or DNA polymerase II stalling) a cascade of proteins are 
recruited. These proteins are the same for both TC-NER and GG-NER. The XPF and 
XPA helicases and the multi-unit transcription factor TFIIH open the damaged region 
(Le Page et al., 2000). The single-stranded-binding protein replication protein A 
(RPA) binds to the corresponding undamaged strand and stabilises it. In the rate-
limiting step, the endonucleases XPG and ERCC1-XRF complex then cleave the 
open DNA strands and excise the damaged 25 – 30 bases site. DNA polymerase δ/ε, 
ligase 3 and ERCC3 re-synthetise the removed region (Hoeijmakers, 2001). 
1.4.4 Base Excision Repair  
BER is the main guardian against damage due to cellular metabolism, including that 
resulting from reactive oxygen species, methylation, deamination and hydroxylation 
(Hoeijmakers, 2001). BER is involved in the removal of either a single damaged 
nucleotide (short patch repair) or a few (2-15) nucleotides (long patch repair) (Figure 
1-5). Following DNA base damage, PARP-1 binds to the single strand breaks (SSB) 
(Benjamin and Gill, 1980). Activation of PARP-1 results in the production of PAR, 
which is attached to histones or PARP-1 itself. This leads to the relaxation of the 
chromatin fibre and facilitates the recruitment of proteins necessary for repair (Figure 
1-5) (Althaus et al., 1993, Dantzer et al., 2000). Inhibition of PARP-1 activity inhibits 
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the formation of XRCC1 foci (El-Khamisy et al., 2003), and failure of BER results in 
DSB due to collision of the SSB with the progressing replication fork (Gottipati et al., 
2010). 
 
Figure 1-5 Schematic representation of BER pathway.  
Short-patch repair takes place after the excision of a damaged base. It involves the 
PAR mediated recruitment of the scaffold protein XRCC1, followed by DNA polβ and 
DNA ligase III which conducts the ligation of the DNA. Long-patch repair occurs after 
direct DNA breaks (e.g. after IR damage); it involves recruitment of XRCC1 followed 
by polynucleotide kinase (PNK), which converts the damaged ends to 5'-phosphate 
and 3'-hydroxyl moieties. Proliferating cell nuclear antigen (PCNA) and DNA 
polymerase δ/ε extend and fill the gap by 2–15 nucleotides, and FEN1 cleaves the 
resulting flap. The nick is then ligated by DNA ligase I (Baute and Depicker, 2008). 
 
APE1 has been shown to be is overexpressed in 71.9 % of ovarian cancers and to 
correlate with tumour type, optimal debulking, and overall survival (Al-Attar et al., 
2010). Additional studies have also demonstrated that altered APE1 expression or 
cytoplasmic localisation is associated with platinum resistance and overall prognosis 
(Sheng et al., 2012, Zhang et al., 2009). Furthermore, XRCC1 399 Arg/Arg genotype 
has been shown to be linked to a lower survival rate (Cheng, 2012). 
1.4.5 DNA Double Strand Break Repair  
DNA DSBs are repaired by one of three pathways: HR, NHEJ and A-EJ. HR involves 
alignment of a homologous chromatid to provide a template for error free repair and 
is therefore limited to the S or G2 phase of the cell cycle when a sister chromatid is 
present. NHEJ is the predominant method of repair in G0/G1 but functions in all 
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stages of the cell cycle. NHEJ does not require a complementary template as it 
repairs the defect by direct ligation and is therefore error prone (Helleday, 2010, 
Lieber, 2008). A-EJ has been shown to involve BER pathway genes; predominate in 
S and G2 phase of the cell cycle; and to compete with or compensate for the loss of 
HR. A-EJ uses short sequences of microhomology, which results in large excisions of 
DNA, and is therefore extremely error prone.  
1.4.5.1 Homologous Recombination 
HR is the principal repair pathway during the S-phase of the cell cycle and so 
appears to be a critical pathway for the maintenance of genomic stability. The HR 
pathway is activated by DNA DSBs (Kanaar et al., 1998, Shrivastav et al., 2008), and 
stalled and collapsed replication forks (McGlynn and Lloyd, 2002, Petermann et al., 
2010). HR repair of DSBs uses the sister chromatid as a template, resulting in error-
free repair (Figure 1-6). DSBs activate the ataxia telangiectasia-mutated (ATM) and 
ATM and Rad3 related (ATR) kinases, which triggers a cascade of phosphorylation 
events involving CHK2 and p53 to activate cell cycle checkpoints and promote DNA 
repair (Jacquemont and Taniguchi, 2007, Hartlerode and Scully, 2009). Mediated by 
BRCA1, the RAD50-MRE11-NSB1 (MRN) complex exposes the 3’ ends on either 
side of the DSB (Paull and Lee, 2005, Zhong et al., 1999). The MRN complex binds 
to the damaged DNA and undergoes a series of conformational changes to activate 
and increase ATM affinity for its substrates, and retain active ATM at sites of DSBs 
(Paull and Lee, 2005). ATM phosphorylates H2AX, NBS1, BRCA1 and FANCD2 
(Jacquemont and Taniguchi, 2007, Hartlerode and Scully, 2009). Single strand DNA 
is rapidly bound by the RPA, which unwinds the DNA's secondary structure (Sung 
and Klein, 2006). The RPA is replaced with RAD51, which is mediated by BRCA2 
(Davies et al., 2001). The damaged 3’ advancing strand then invades the 
complementary sequence of the homologous chromosome sets up a D-loop 
intermediate and primes DNA synthesis by using the duplex DNA as a template 
(Hartlerode and Scully, 2009, Sung and Klein, 2006). If the D-loop captures the 
second end of the break, Holliday junctions (HJs) are formed (Hartlerode and Scully, 




Figure 1-6 Schematic representation of HR pathway. 
DSBs activate the ATM/ATR which in turn phosphorylates H2AX, NBS1, BRCA1 and 
FANCD2. Mediated by BRCA1 the MRN complex exposes the 3’  ends on either side 
of the DSB. RPA binds to single strand DNA and unwinds the DNA’s secondary 
structure. The RPA is replaced with RAD51, which is mediated by BRCA1, PALB2 
and BRCA2. The 3’  advancing strand from the damaged chromosome then invades 
the complementary sequence of the homologous chromosome. Following the 
synapsis, the invading strand sets up HJ and primes DNA synthesis by using the 
duplex DNA as a template. RAD54 promotes branch migration whilst BLM and GEN1 
resolve the HJ (Cerbinskaite et al., 2012). 
 
The resolution of a HJs can be executed by several enzyme complexes, such as 
BLM in complex with topoisomerase IIIα, which can dissolve double HJs to form non-
crossover products (Wu and Hickson, 2003, Bohr, 2008), or GEN1, which promotes 
junction resolution by symmetrical cleavage (Ip et al., 2008). After replication has 
extended past the region of the DSB, the strand replication continues to the end of 
the chromosome (Hoeijmakers, 2001, Khanna and Jackson, 2001). 
1.4.5.1.1 HR Defects in Cancer  
A number of inherited syndromes show a defect in HR and a predisposition to cancer 
or premature aging i.e., Ataxia telangiectasia (Milne, 2009, Taylor et al., 1975), 
Ataxia-telangiectasia like disorder (Taylor et al., 2004), Nijmegen Breakage 
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syndrome (Chistiakov et al., 2008, Digweed and Sperling, 2004) and Fanconi 
anaemia (Alter, 1996, Kennedy and D'Andrea, 2005, Kutler et al., 2003). Cells 
deficient in this pathway are susceptible to several anti-cancer agents, however, 
recombination may also result in loss of heterozygocity (LOH), leading to inactivation 
of tumour suppressor genes, or cause gross gene rearrangements that can activate 
proto-oncogenes (Moynahan and Jasin, 1997). The function of the entire repair 
pathway can be affected if one or more genes involved in the pathway are defective. 
Defects in the majority of genes involved in the HR pathway have been reported in 
human cancers, as summarised in table 1-4 and reviewed in (Cerbinskaite et al., 
2012). For the purposes of this report, only HR gene defects reported in ovarian 
cancer will be discussed in detail.   
Table 1-4 Reported links to human cancers of HR gene alterations.  
Summary of HR genes which are reported to harbor mutations, function altering 
polymorphisms or epigenetic alterations leading to reduced function in human cancer 
(Cerbinskaite et al., 2012). 
Cancer Site HR Genes 
Head and Neck ATM, FANCF  
Medullo-blastoma FANCD1/BRCA2 
Nasopharyngeal ATM 
Oral ATM  
Thyroid XRCC3  
Lung NBS1, BRCA1, FANCF, XRCC2  
Breast ATM, RAD50, NBS1, BRCA1, BRCA2, RAD51, FANCJ  
Stomach ATM, ATR, BRCA1, BRCA2  
Pancreas BRCA2, RAD51, FANCC  
Colorectal ATM, MRE11, BRCA1, BRCA2  
Ovarian MRE11, RAD50, BRCA1, BRCA2, FANCF  
Endometrial ATR  
Cervical BRCA1, FANCF  
Prostate ATM, NBS1, BRCA2  
Multiple Myeloma RAD51  
Leukaemia ATM, NBS1, RAD51, FANCA, FANCC, FANCF, FANCG  
Melanoma NBS1, XRCC3, BRCA2 
Lymphoma NBS1  
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1.4.5.1.2 Role of HR in Ovarian Cancer 
The role of the HR pathway in ovarian cancer became an important research field 
due to the function of tumour suppressor genes BRCA1 and BRCA2. These genes 
are best known as breast and ovarian cancer susceptibility genes (Gayther et al., 
1999), however, they have also been linked to a number of different human cancers 
(Table 1-4). Inactivation of the BRCA1 or BRCA2 results in genetic instability and 
chromosomal rearrangements (Bishop and Schiestl, 2002, Ban et al., 2001). 
Knockout of the BRCA1 is embryonically lethal in mice (Gowen et al., 1996) and 
down regulation of BRCA1 halts the cell cycle at the G2 to M transition, which leads 
to cell cycle arrest or apoptotic cell death (Bouwman et al., 2010). BRCA2 functions 
are largely limited to DNA repair and recombination (Chistiakov et al., 2008). The 
protein controls the availability, localisation, DNA binding and stabilisation of RAD51 
(Ayoub et al., 2009, Shivji et al., 2009, Davies et al., 2001). 
The lifetime risk of developing EOC in women with a germline BRCA1/2 mutation can 
be up to 66 % and 27 % respectively (Robles-Diaz, 2004). Cancers containing 
BRCA1 mutations are more common in younger women (<50 years at diagnosis), 
compared to cancers with BRCA2 mutations in older women (>60 years) with 
hereditary ovarian cancers (Risch et al., 2001). Mutation rates vary between patients 
of different ancestry, being higher among Jewish (26 %), Italian (24 %), and Indo-
Pakistani (14 %) and lower in British (3.5 % - 4.7 %) (Janezic et al., 1999, Stratton et 
al., 1997, Risch et al., 2001). They also vary with histological type, being higher in 
serous cancers (10.9 % BRCA1 and 5.6 % BRCA2 mutations) and lower in 
endometrioid cancers (2.1 % mutation rate for both BRCA genes) (Risch et al., 
2001). Reports of BRCA1/2 mutations in mucinous and borderline cancers are 
contradictory (Risch et al., 2001, Boyd et al., 2000, Stratton et al., 1997).  
Epigenetic silencing of BRCA genes has also been noted. BRCA1 alterations 
occurring by gene deletion, loss of gene expression (due to promoter methylation) or 
by loss of protein expression have been reported in about 5-31 % of sporadic ovarian 
cancers (Wang et al., 2004a, Jacinto and Esteller, 2007, Hilton et al., 2002). 
BRCA1/2 deficiency, defined as mutations and loss of expression, was reported in 
30 % of HGSOC (Hennessy et al., 2010). BRCA1/2 associated tumours have distinct 
clinical features tending to be HGSOC, carboplatin sensitive and to be associated 
with an improved survival (Ramus and Gayther, 2009, Cass et al., 2003). 
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1.4.5.1.3 Concept of HRD and Therapy 
Further to the loss of the BRCA genes HRD due to mutations in other genes involved 
in the HR pathway has also been described. These include mutations of EMSY, 
MRE11, RAD50, XRCC2, XRCC3 and FANC pathway genes (Brown et al., 2006, 
Heikkinen et al., 2003, Heikkinen et al., 2006, Nagaraju et al., 2009, Kennedy and 
D'Andrea, 2006, Taniguchi et al., 2003). It is believed that in fact around 50 % of 
EOCs could be potentially HR deficient (Mukhopadhyay et al., 2010, Cancer Genome 
Atlas Research, 2011).  
1.4.5.1.4 Inhibitors that Block HR Function 
Novel inhibitors that block HR function have been developed. Mirin is an inhibitor of 
MRE11 endonuclease activity and thus of HR function (Dupre et al., 2008). However, 
MRE11 function is not limited to HR as it is also upstream of NHEJ, and so mirin also 
inhibits NHEJ (Rass et al., 2009). The BCR-ABL1 inhibitor imatinib blocks HR by 
inhibiting the activation of RAD51 and sensitized cells to DNA crosslinking agents 
and IR (Choudhury et al., 2009). Other RAD51 inhibitors have also been identified 
(Huang et al., 2011a). A further way to block HR is to inhibit CDK1, which activates 
BRCA1. Preclinical studies showed that the CDK1 inhibitor AG024322 is synthetically 
lethal with PARPi (Johnson et al., 2011). ATM and ATR have crucial roles by 
signalling DNA damage to cell cycle checkpoints and DNA repair pathways. ATM 
promotes HR by recruiting BRCA1 and NHEJ by recruiting p53 binding protein 1 
(53BP1) to DSBs (Bouwman et al., 2010). ATM inhibitors have been reported to 
induce sensitisation to IR, etoposide and camptothecin in vitro (Hickson et al., 2004, 
Rainey et al., 2008). ATR is activated by the DNA single-strand–double-strand 
junction, and it activates MMR and HR pathways (Wang et al., 2004b). Preclinical 
studies have demonstrated ATR inhibitor induced in vitro chemo and radio-
sensitisation (Reaper et al., 2011, Peasland et al., 2011). ATR role and inhibitors will 
be further discussed in chapter 5. The effects of HR inhibition on patient outcomes 
still needs to be evaluated.  
1.4.5.2 Non Homologous End Joining 
In the classical or DNA-PK dependent NHEJ pathway (Figure 1-7) the end-joining 
process starts with the binding of Ku70/Ku80 heterodimers to the DNA ends, followed 
by DNA-PKcs. The nuclease functions are performed by Artemis (Ma et al., 2002), 
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however, some resection is done by the MRN complex (Dinkelmann et al., 2009, 
Quennet et al., 2011). DNA polymerase μ and λ participate in the repair and DNA 
ligase IV, supported by two components called XRCC4 and XLF, catalyses the final 
end-joining reaction (Lieber et al., 2003, Ahnesorg et al., 2006, Buck et al., 2006). 
Recent studies have also shown a role for PARP in the NHEJ pathway (Spagnolo et 
al., 2012, Mitchell et al., 2009a), however, the mechanism of this is unclear. 
NHEJ is an essential part of the DNA end-joining phase in V(D)J recombination, the 
mechanism that assembles coding regions for the variable domains of 
immunoglobulin and T cell receptors in developing lymphocytes (Grawunder et al., 
1998, Tonegawa, 1983). Lymphoid-specific RAG proteins generate DNA double 
strand breaks which are re-joined by NHEJ (Tonegawa, 1983, Grawunder et al., 
1998). Hypomorphic mutations in XLF, Artemis and LIG4 lead to a number of rare 
hereditary disorders characterised by immunodeficiency (Artemis) and/or 
developmental abnormalities (XLF, LIG4), which underscore the general importance 
of the NHEJ pathway for genome integrity and development (Jeggo et al., 2004, 
Sekiguchi and Ferguson, 2006). 
 
Figure 1-7 Schematic representation of NHEJ. 
After phosphorylation of H2AX at DNA DSB sites, NHEJ is initiated by the binding of 
the Ku heterodimer (composed of Ku70 and Ku80). DNA-PKcs is then recruited and 
binds to the DNA end, activating its serine/threonine kinase activity. The 
Ku70/Ku80/DNA-PKcs complex, referred to as DNA-PK, holds the two DNA strands 
together in a synapse. Activation of DNA-PK by phosphorylation allows the alignment 
of the DNA strands, which are subsequently joined by the ligase IV/XRCC4 complex. 
This reaction is stimulated by XLF protein, which interacts with XRCC4 to catalyse 




1.4.5.2.1 Non Homologous End Joining Defects in Cancer  
Further to the rare hereditary disorders, the NHEJ pathway activity has also been 
linked to a number of human cancers. NHEJ activity was reported to be reduced and 
increasingly error prone in bladder cancers (Bentley et al., 2009, Bentley et al., 2004, 
Windhofer et al., 2008). DNA end-joining capacities in peripheral blood mononuclear 
cells of breast cancer patients were reported to be consistently lower than those from 
healthy women (Bau et al., 2007) and dysregulated NHEJ has also been reported in 
leukaemia patients (Deriano et al., 2005, Gaymes et al., 2002).  
A number of studies have investigated individual gene mutations and polymorphisms 
in the NHEJ pathway in human cancers. Table 1-5 summarises the NHEJ genes 
which are reported to harbor mutations, SNPs or epigenetic alterations leading to 
altered function in human cancers. Overexpression of NHEJ genes and pathway 
function has also been linked to drug resistance (Kim et al., 2000, Deriano et al., 
2005). 
Table 1-5 Reported links to human cancers of NHEJ gene alterations.  
Summary of NHEJ genes which are reported to harbor mutations or epigenetic 
alterations leading to reduced function in human cancer. Adapted from manuscript in 
preparation. Full table in appendix 1. 
Cancer Site NHEJ Genes 
Head and Neck DNA-PK,  
Laryngeal PARP-1 
Glioma XRCC4, LIG IV 
Nasopharyngeal KU70 
Lung DNA-PK, XRCC4, LIG IV 
Breast DNA-PK, KU70, Ku80, XRCC4, Lig IV 
Gastric/colorectal DNA-PK, KU70, KU80 
Pancreas LIG IV 
Cervical DNA-PK, KU70, KU80 
Bladder DNA-PK, XRCC4, KU 
Multiple Myeloma Lig IV, Ku80 
Leukaemia DNA-PK, KU70, KU80,Lig IV, Artemis 
Lymphoma Lig IV 
Neuroblastoma DNA-PK 




1.4.5.2.2 BRCA1 Role in NHEJ Pathway 
Although BRCA1 is thought to be primarily involved in the HR pathway (Turner et al., 
2005), it has been implicated in the NHEJ pathway as well (Bau et al., 2004, Coupier 
et al., 2004, Bau et al., 2006). In vitro studies have demonstrated that cell extracts 
derived from BRCA1-deficient cells exhibit reduced end-joining activity (Bau et al., 
2004, Zhong et al., 2002). Moreover, recent reports have indicated that BRCA1 
functions to inhibit NHEJ (Bau et al., 2004, Wang et al., 2006a, Zhuang et al., 2006), 
this may be by protecting from excess trimming by exonucleases (Paull et al., 2001). 
This notion is also supported by the observation that, in BRCA1-deficient cells, there 
is an increased tendency towards the generation of large deletions (>2 kb) during 
NHEJ (Zhuang et al., 2006). It is therefore postulated that BRCA1 not only promotes 
HR but also reduces error-prone NHEJ processes. However, the role of BRCA1 in 
NHEJ, if any, is still poorly understood as conflicting results have been reported, 
including promotion, suppression, or no effect (Wei et al., 2008).  
1.4.5.3 Alternative End Joining Pathway 
An alternative end joining (A-EJ), also known as backup NHEJ pathway (B-NHEJ) or 
microhomology-mediated end joining (MMEJ), which lies somewhere between HR 
and NHEJ and is more error prone, has been suggested in eukaryotic cells (Wang et 
al., 2003, Iliakis et al., 2004, Yan et al., 2007, Corneo et al., 2007). Alternative end-
joining is suggested to rely on microhomologies, which are short sequences of a few 
homologous base pairs. Unlike HR, A-EJ is inherently error-prone because the use of 
microhomology leads to deletions of sequences from the strand being repaired and 
chromosomal translocations. Evidence of this pathway comes from several in vitro 
assays (Cheong et al., 1999, Wang et al., 2003, Perrault et al., 2004) and in vivo 
studies (Liang and Jasin, 1996, Audebert et al., 2008). PARP-1 / DNA ligase III / 
XRCC1 / histone 1 module and Polθ are suggested to be involved in A-EJ (Audebert 
et al., 2004, Wang et al., 2005, Wang et al., 2006b, Rosidi et al., 2008). Polθ has 
been shown to be overexpressed in HGSOC (Ceccaldi et al., 2015a). 
A-EJ is reported to be suppressed by the DNA-PK dependent NHEJ (Perrault et al., 
2004), to show cell cycle dependence with a more pronounced function during the 
G2 phase (Wu et al., 2008), and may be compromised in non-cycling cells 
(Windhofer et al., 2007). Recent publications have shown that A-EJ and HR are 
competing pathways, as evidenced by the observation of increased HR in cells 
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lacking Polθ. Furthermore, A-EJ has been demonstrated to compensate for the loss 
of HR, however, this results in chromosomal rearrangement and reduced ability of 
the cells to survive (Ceccaldi et al., 2015a, Mateos-Gomez et al., 2015). 
1.4.5.4 Selection of DNA Double Strand Repair Pathway 
The choice between which DSB pathway repairs a lesion is thought to be cell cycle 
dependent (Figure 1-8) (Symington and Gautier, 2011). In G1 phase, DSB 5’ end 
resection is halted by the 53BP1/Rif1 proteins allowing Ku to bind and NHEJ 
predominance (Chapman et al., 2012a, Chapman et al., 2013). Synthesis of BRCA1 
in S and G2 phases inhibits Rif1 and allows 5’ end resection, subsequent inhibition of 
NHEJ and repair by HR (Chapman et al., 2012a, Chapman et al., 2013). As HR 
requires homologous sequences, it may only be active in cell cycle stages where 
these are available (S and G2 phases) (Lieber, 2010). A-EJ is also thought to act on 
5’ resected lesions (Wang et al., 2006b, Bentley et al., 2004). Like NHEJ, A-EJ 
rejoins lesions with minimal end processing, however, as the DNA ends have already 
been resected, large amounts of genetic material may be lost and this pathway is 
thought to be highly toxic (Bétermier et al., 2014). The choice between HR and A-EJ 
is thought to be decided by the length of resected segments, with HR principally 
dealing with long segments and A-EJ shorter (Bétermier et al., 2014). A-EJ requires 
PARP for its activity and is susceptible to PARP inhibition (Mansour et al., 2010).  
 
Figure 1-8 Schematic representation of the pathway choice for the repair of a DSBs 
(Bétermier et al., 2014, Chapman et al., 2013). 
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1.4.6 Poly (ADP) Polymerase (PARP) 
PARP-1 has been the most studied and described enzyme in the family of 17 PARPs 
(Ame et al., 2004). The gene encoding PARP-1 protein is the ADPRT-1 located on 
1q41-q42 (Auer et al., 1989). PARP-1 is an abundant 113 kDa nuclear enzyme and 
plays a role in a number of cellular processes and therefore has a number of clinical 
applications (Sodhi et al., 2010, Pacher and Szabo, 2007, Lupachyk et al., 2011, 
Crawford et al., 2010, Giansanti et al., 2010), however, for the purposes of this 
report, only PARP-1 application in DNA repair and cancer will be discussed further.  
1.4.6.1.1 PARP Role in SSB Repair 
Following DNA base damage, PARP-1 binds to the SSB (Benjamin and Gill, 1980). 
Activation of PARP-1 results in the production of PAR, which is attached to histones 
or PARP-1 itself. This leads to the relaxation of the chromatin fibre and facilitates the 
recruitment of proteins necessary for repair (described in section 1.4.4) (Althaus et 
al., 1993, Dantzer et al., 2000). Inhibition of PARP-1 activity inhibits the formation of 
XRCC1 foci (El-Khamisy et al., 2003), and failure of BER results in DSBs due to 
collision of the SSB with the progressing replication fork (Gottipati et al., 2010). 
1.4.6.1.2 PARP Role in DSB Repair 
PARP-1 binds to and is activated by stalled replication forks (Bryant et al., 2009, 
Sugimura et al., 2008) and is necessary for the accumulation of MRE11 and NBS1 at 
the site of DSBs (Hegan et al., 2010, Benjamin and Gill, 1980, Haince et al., 2008). 
Inhibition of PARP has been shown to retard the rejoining of IR-induced DNA DSBs 
(Mitchell et al., 2009a, Boulton et al., 1999). Interaction of PARPi and DNA-PKi in 
radio-sensitisation has also been demonstrated (Ruscetti et al., 1998, Veuger et al., 
2003, Veuger et al., 2004, Mitchell et al., 2009a). In irradiated cells, the higher affinity 
of Ku for DSBs has been suggested to limit PARP-1 contribution to DSB repair, 
however, when the classical NHEJ pathway is not functional PARP-1 may be 
recruited (Wang et al., 2006b). The function of PARP-1 in the A-EJ has been shown 
by both in vitro and in vivo studies (Wang et al., 2006b, Audebert et al., 2006, Lu et 
al., 2006, Audebert et al., 2008). In other studies, PARP-1 has been shown to have a 
protective role in HR by suppressing access of NHEJ to DNA DSBs (Hochegger et 
al., 2006, Saberi et al., 2007). With on-going studies into the clinical application of 
PARPi, further clarification of the role PARP in DNA DSB repair is needed.  
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1.4.6.1.3 PARP Activity in Cancer 
V762A single nucleotide polymorphism (SNP) results in amino acid substitution in 
PARP-1 and can reduce PARP-1 catalytic activity by 30-40 % (Lockett et al., 2004). 
V762A SNP in PARP-1 has been reported to be associated with prostate cancer, 
colon cancer and multiple myeloma (Doll et al., 1996, Lyn et al., 1993, Lockett et al., 
2004, Bernstein et al., 2002). Reduced PARP activity in response to DNA damage 
has also been reported in laryngeal cancer (Rajaee-Behbahani et al., 2002). 
Conversely, reports in breast cancer are contradictory; with studies reporting PARP-1 
expression to be increased in more than 50 % of breast tumours (Bieche et al., 
1996), while others report lower (Hu et al., 1997, Lockett et al., 2004, Wang et al., 
2007, Smith et al., 2008) or no association of PARP-1 activity with risk of breast 
cancer (Zhai et al., 2006, Zhang et al., 2006). 
PARP-1 and PARP-2 expression varies widely across all nucleated human cells 
excluding neutrophils (Schreiber et al., 2002, Csete et al., 2009). Pilot studies 
measuring PARP-1 activity in peripheral blood mononuclear cells from healthy 
volunteers and metastatic melanoma patients before and during temozolomide 
therapy and in tumour biopsies, revealed large inter-individual differences in PARP 
activity in both healthy volunteers (20-615 pmol/106 cells) and cancer patients (15-
430 pmol/104 cells) (Plummer et al., 2005). This was also confirmed by a more recent 
study, comparing PARP activity in sarcoma patients with their monozygotic twins 
(Zaremba et al., 2011). This may explain the conflicting results seen in previous 
studies.  
1.4.6.1.4 Synthetic Lethality and PARP Inhibitors 
The concept of synthetic lethality describes a phenomenon where 2 non-lethal 
genetic mutations can lead to lethality in combination (Dobzhansky, 1946). This may 
involve genes in complementary pathways or acting along a single or related 
pathway, in which case, the loss of both genes, rather than just one, significantly 
affects pathway signaling and function. This concept has now been exploited in 
cancer therapy, whereby tumour cells harboring specific genetic lesions can be 
challenged by targeting the synthetically lethal partner genes or pathways leading to 
selective tumour cell death (Kaelin, 2005, Helleday et al., 2008, Brough et al., 2011). 
This allows a large therapeutic window whereby the non-cancerous cells in the body, 
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not harboring the gene defect, are not affected by the chemotherapeutic agent, 
allowing the chemotherapy to impact only on the cancerous cells.  
Studies in cell lines have showed that HR defects result in sensitivity to PARPi; there 
was an observed 100-1000 fold increase in sensitivity to PARPi in cells homozygous 
for BRCA1 or BRCA2 mutation, compared to heterozygous or BRCA wild-type cell 
lines (Bryant et al., 2005, Farmer et al., 2005). Furthermore, siRNA-mediated 
depletion of BRCA2 in BRCA wild type breast cancer cell lines also caused sensitivity 
to PARPi (Bryant et al., 2005). Cancers defective in HR pathway due to loss of 
function of other genes involved in this pathway are also hypersensitive to PARPi 
(Bryant and Helleday, 2006, McCabe et al., 2006, Drew et al., 2011). BRCA1/2 
mutation carriers are heterozygous for the defect in all other cells; therefore still have 
a functional HR pathway. PARPi are less cytotoxic to normal cells, therefore, their 
associated side-effects, including myelosuppression and nausea, are relatively mild 
(Plummer and Calvert, 2007, Mukhopadhyay et al., 2011).  
Reversion mutations have been reported in BRCA gene in ovarian cancer in vitro 
(Taniguchi et al., 2003). Furthermore, it has been shown that in cell lines and tumour 
samples, secondary reverting mutations in BRCA1/2 genes can lead to cisplatin 
resistance in BRCA1/2 mutation carriers (Swisher et al., 2008, Sakai et al., 2008, 
Sakai et al., 2009, Edwards et al., 2008). This reversion has been suggested to be 
due to the function of the NHEJ pathway, which results in secondary reverting BRCA 
mutations resulting in restoration of HR function (Ashworth, 2008a, Sakai et al., 
2009). Furthermore, pathway ‘rewiring’ may also alter responses to DNA damage in 
DNA repair deficient cells. An example of this is 53BP1 overexpression that results in 
the inhibition of NHEJ and upregulation of the HR pathway in BRCA1 deficient 
tumours (Bouwman et al., 2010, Aly and Ganesan, 2011). 
1.4.6.1.5 PARP Inhibitors in Cancer Clinical Trials 
The first PARPi to enter a clinical trial was rucaparib in 2003. It was used to 
potentiate the effect of radio- and chemo-therapies, and showed a beneficial effect in 
several cancers (Plummer et al., 2005). In ovarian cancer the initial trials 
concentrated on hereditary EOCs with known BRCA1/2 mutations (Fong et al., 2009, 
Audeh et al., 2010). The focus of research has subsequently been re-directed to 
evaluate the use of PARPi as a stand-alone therapy in patients with HRD beyond 
BRCA1/2 mutations (Plummer and Calvert, 2007, Clinical_Trials.gov, 2012). The 
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application of PARPi in platinum resistant EOCs is also being explored (Fong et al., 
2010, Audeh et al., 2010). Ongoing and completed clinical trials are summarised in 
Appendix 2. Further to on-going clinical trials into the application for PARPi, the 
identification of the HRD EOC population, through identification and validation of 
biomarkers is an active area of on-going research (Mukhopadhyay et al., 2010). 
1.4.6.1.6 The Potential Role of NHEJ in PARPi Induced Cell Killing 
It is thought the minimal end processing in NHEJ repair makes the pathway error 
prone and may lead to lethal genomic instability (Patel et al., 2011). Research 
published in 2011 suggested the erroneous repair mediated by the NHEJ pathway is 
critical in driving the lethality of PARPi in HRD cells (Patel et al., 2011). The group 
found that PARPi resulted in activation of DNA-PK and that genetic or 
pharmacological inhibition of NHEJ rescued PARP lethality in HRD cells. Although 
NHEJ may not be as toxic as A-EJ, it may still be crucial to PARPi mediated cell 
killing in HRD tumours (Bétermier et al., 2014). 
1.5 Rationale for This Project 
A number of questions still remain unanswered. Whilst there is a clear understanding 
of the importance of DNA repair in ovarian cancer, the study of DNA DSB repair has 
so far been limited to HR. The function of NHEJ and the more recently described A-
EJ pathways have had little assessment in ovarian cancer to date. It is therefore, 
difficult to be certain of the exact proportion of human cancers which are NHEJ 
defective (NHEJD), as many of the mutations are rare and have been reported from 
studies with a limited number of samples; consequently it is not always clear what the 
impact of a polymorphism is on function of the protein transcribed. Individual risk 
increases due to each SNP reported are low, therefore, the impact to individuals 
carrying these variants may be limited. However, due to the frequency of occurrence 
of these SNPs the population based risk is likely to be significant. Large genome 
association studies to identify further SNPs and mutations in NHEJ genes, and 
therefore, estimate the true proportion of NHEJD cancers are essential. These are 
however, beyond the scope of this project. 
Genome wide association studies will not provide all the answers, as the functional 
role of all mutations identified need to be assessed. The challenge is therefore to be 
able to identify the cancers which are functionally NHEJD or up-regulated, arising 
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from mutations or SNPs of any one or a combination of the genes described. Work is 
well underway to develop biomarker tests which will accurately identify those cancers 
which are HRD (Mukhopadhyay et al., 2010). Functional assays which are capable of 
assessing the NHEJ pathway are now needed to be applied in combination with 
those assessing HR. Such tests will be designed to spot defective functional 
pathways rather than just identifying one gene abnormality at a time and will 
hopefully allow treatment of patients based on tumour biology rather than by the 
organ of origin, thus potentially widening the therapeutic options available. 
With increasing evidence supporting the application of PARPi, a clearer 
understanding is required into the role of this protein in the NHEJ pathway, and the 
biological significance of inhibition of PARP in the presence and absence of a 
functional NHEJ pathway. Furthermore, whilst the interaction of DSB repair pathways 
has been suggested, this relationship in ovarian cancer still remains to be 
determined.  
The evidence to date has also demonstrated the role of DNA repair dysfunction in the 
development of chemo-resistance in ovarian cancer. Whilst a number of mechanisms 
for platinum resistance have been explored, these are still not fully understood and 
attempts to overcome this has not yet yielded clinically significant results. With the 
aim to introduce PARPi into clinical practice the mechanisms for resistance to PARPi 
also need to be understood. Furthermore, understanding the similarities and 
differences between PARPi and platinum resistance is essential for the clinical 
application of this new drug. Being able to understand, predict and prevent resistance 
development would put PARPi treatment at the forefront of ovarian cancer therapy in 









1.6 Project Hypothesis 
The interactions of multiple DSB repair pathways have an important role in ovarian 
cancer biology and sensitivity to platinum and PARPi treatment. 
1.7 Project Aims 
The primary objective of this project was to investigate the interaction of DSB repair 
mechanisms in ovarian cancer biology and to assess their role in mediating 
therapeutic response to cisplatin and rucaparib. The strategies for achieving this 
were:  
 To optimise models for the study of ovarian cancer by characterisation of the 
primary ovarian cancer (PCO) cultures and a novel ovarian cancer cell line. 
 To assess NHEJ and HR function in a panel of PCO cultures and to correlate 
these with sensitivity to rucaparib and cisplatin. 
 To assess the interactions of NHEJ and HR pathways in ovarian cancer 
biology, and the interaction of these two pathways with PARP-1, using drug 
inhibition and knockdown models.  
 To develop rucaparib and cisplatin resistant cell line models and to assess the 
role of DNA repair pathways in resistance development. Furthermore, to 
perform genome-wide molecular analysis in order to investigate mechanisms 
of resistance development.  









CHAPTER 2 MATERIALS AND METHODS 
2.1 General Laboratory Practice  
All experiments were performed in accordance with the University standards for safe 
working with chemical substances in laboratories, which comply with the Control of 
Substances Hazardous to Health Regulations (COSHH) and BioCOSHH. Routinely 
used chemicals of analytical or molecular biology grade were purchased from Sigma-
Aldrich Co. Ltd. (Dorset, UK), unless otherwise stated. Phosphate buffered saline 
(PBS) (137 nM NaCl, 83 mMKCl, 10 nM Na2HPO4) was prepared from PBS tablets 
(Invitrogen Life Technologies, Paisley, UK) and was autoclaved prior to use for 
sterility. 
2.2 Cell Culture Methods 
Tissue culture plastic ware was from Corning-Costar (supplied by VWR International 
Ltd., Leicestershire, UK). All cell culture was carried out in a class II microbiological 
safety cabinet (BIOMAT-2, Medical Air Technology Ltd., Oldham, UK) using an 
aseptic technique.  
2.2.1 Routine Cell Culture 
All cell lines were maintained as adherent cultures in media as detailed in Table 2-1 
with 10 % (v/v) heat inactivated foetal calf serum (FCS), 20 mM L-glutamine and 50 
g/ml penicillin / streptomycin in 75 cm3 sterile cell culture flasks. All media were 
stored at 4 °C and warmed to 37 °C in a water bath prior to use. Cultures were 
incubated at 37 °C (OSEC-1 and OSEC-2 at 33 °C) in a humidified 5 % CO2 
incubator (Heraeus Equipment Ltd., Essex, UK). Testing for mycoplasma was 
performed by E.C. Matheson at 2 month intervals using a MycoAlert kit (Lonza 
Biologics, Slough, UK).  
2.2.2 Primary Culture 
Ascitic fluid was collected from patients undergoing primary surgery for ovarian 
cancer or primary peritoneal cancer debulking surgery at Queen Elizabeth Hospital, 
Gateshead. All patients gave informed consent. Consent form can be seen in 
appendix 3. Ethical approval was sought, and specimens were registered in 
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accordance with the Human Tissue Act 2004. All cultures were labelled PCO 
followed by a serial number which identifies the patient from whom the sample was 
collected. All collected primary cultures were entered in the NICR central tissue 
resource database. 20 mls of ascitic fluid was added to 20 mls of culture medium, 
which comprised of RPMI 1640 medium supplemented with 20 % FCS, 20 mM L-
glutamine, and 1 % penicillin and streptomycin in 75 cm3 sterile tissue culture flasks 
and incubated at 37 °C / 5 % carbon dioxide. The medium was aspirated and 13 mls 
of warmed fresh medium replaced on day 4 to 5 of incubation. The medium was 
replaced every 4 to 5 days until cells reached >80 % confluence. 
Table 2-1 Cell lines used in the project.  
Cell line Source Medium Characteristics 
OSEC-1 Generated at 
Newcastle 
University (Davies 
et al., 2003) 
RPMI 
1640 
BRCA2 heterozygote, HRC, 
telomerase and temperature 
sensitive SV40 large T antigen 
immortalised normal OSE cell line  
OSEC-2 Generated at 
Newcastle 
University (Davies 
et al., 2003) 
RPMI 
1640 
BRCA wild type, HRC, telomerase 
and temperature sensitive SV40 
large T antigen immortalised 
normal OSE cell line  
SKOV3 ATCC ® HTB-77 RPMI 
1640 
Ovarian adenocarcinoma cell line 
derived from ascites of a patient 
with moderately well differentiated 
ovarian adenocarcinoma 
(Debernardis et al., 1997) 
OVCAR3 ATCC ® HTB-161 RPMI 
1640 
Derived from a patient with an 
ovarian epithelial adenocarcinoma 
A2780 Provided by Prof. 






Human ovarian carcinoma p53 
and MMR-proficient, (Anthoney et 
al., 1996) 
A2780-CP70 Provided by Prof. 






hMLH1 promoter hypermethylation 
(Strathdee et al., 1999) variant of 
A2780, 5-fold resistant to cisplatin 
relative to the parental A2780 cell 
line (Anthoney et al., 1996) 
IGROV-1 ATCC RPMI 
1640 
Human ovarian adenocarcinoma 
(Benard et al., 1985) 




Human ovarian adenocarcinoma 
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Malignant glioblastoma cells, 
DNA-PK mutated 
MO59FUS-1  RPMI 
1640 
Paired cell line to MO59J. DNA-PK 
competent by virtue of transfer of 
portion of Chr8 (Virsik-Kopp et al., 
2004) 




DMEM DNA-PKCS deficient Chinese 
hamster ovary cells 




DMEM Derived from V3 cells, transfected 
with a yeast artificial chromosome 
(YAC) carrying the human DNA-
PKCS gene 






BRCA1-null human ovarian cancer 
derived from papillary serous 










Ovarian carcinoma cell lines 
derived from UWB1.289, a 
BRCA1-null human ovarian cancer 
line, in which wild-type BRCA1 
was restored (DelloRusso et al., 
2007) 
PEO1 PEA - 10032308 RPMI 
1640 
Derived from malignant effusion 
from the peritoneal ascites of a 
patient with a poorly differentiated 
serous adenocarcinoma contains 
BRCA2 mutation [5193C>G 
(Y1655X)] 
PEO4 PEA - 10032309 RPMI 
1640 
Derived from the same patient as 
PEO1 after clinical resistance 
developed to chemotherapy. 
Contains a secondary BRCA2 
mutation [5193C>T (Y1655Y)] that 
cancelled the inherited mutation 
2.2.3 Pancytokeratin Staining 
To confirm epithelial cell origin, pancytokeratin staining was used in PCO cultures. A 
sterilised 22 mm2 cover slip was placed in 6-well plate prior to the seeding of cells at 
a density of 1 x 106. The plates were incubated for 24 hours (hrs) to allow cells to 
adhere. Medium was removed and cells were fixed with ice-cold methanol for 10 
minutes (min). Cells were washed with PBS and incubated in 250 µl (1:100 dilution) 
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of FITC conjugated Anti-Cytokeratin Pan mouse monoclonal antibody (Millipore) for 1 
hr. Excess antibody was washed with PBS and coverslip mounted to glass slide with 
VECTASHIELD® Mounting Medium with DAPI (Vector Laboratories). Slides were 
examined using fluorescence microscope (Leica DMR, Leica Microsystems, UK). 
Cells incubated with no primary antibody were used as negative control. Cultures 
containing greater than 95 % epithelial cells were considered to be cytokeratin 
positive and were utilised in further assays.  
2.2.4 Cell Passaging 
Cell lines and established PCO cultures were passaged when cells were 80 % 
confluent in order to maintain cells in exponential growth phase. Medium was 
aspirated and the cells were rinsed with warm sterile PBS followed by incubation in 5 
ml 0.25 % trypsin-EDTA (ethylene-diamine-tetra acetic acid, Sigma - Aldrich) for 5 
min in the incubator (until all the cells had detached). Full medium was added to 
detached cells to neutralise the trypsin. Cell suspension was centrifuged at 230 x G 
for 5 min. The supernatant was discarded; the cell pellet was re-suspended in full 
medium and plated in new flasks / culture dishes as required. Cell lines were 
passaged a maximum of 30 times, after which fresh stocks were resuscitated from 
liquid nitrogen storage.  
2.2.5 Cell Counting 
Cells were trypsinised and resuspended in 10 ml of media. 10 l of the solution was 
loaded onto a Neubauer Haemocytometer (VWR International Ltd.) and a minimum 
of 100 cells were recorded for each cell count.  
2.2.6 Cryopreservation of Cell Stocks 
Cells were trypsinised and centrifuged in sterile BD FalconTM centrifuge tubes (BD 
Biosciences, Oxford, UK) at 230 x G for 5 min. The supernatant was discarded, after 
which cell pellets were resuspended in 1 ml freezing medium [usual growth medium 
supplemented with 10 % v/v FCS and 10 % (v/v) dimethyl sulphoxide (DMSO)] and 
transferred to sterile polypropylene cryovials (Invitrogen Life Technologies). Cells 
were frozen slowly (approximately 1 °C per minute) to -80°C and transferred to liquid 
nitrogen for long term storage.  
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2.2.7 Resuscitation of Frozen Cell Stocks 
Cryopreserved cell aliquots were thawed rapidly and transferred to 5 ml pre-warmed 
RPMI medium. Suspensions were then centrifuged at 230 x G for 5 min, after which 
the supernatant was completely removed and discarded. Resulting cell pellets were 
re-suspended in 7 ml 10 % RPMI culture medium, transferred to 25 cm3 sterile cell 
culture flasks and incubated at 37 °C / 5 % CO2. Cell cultures were checked daily for 
growth and used in experiments once normal exponential cell growth had resumed. 
2.3 Clinical Data and Survival Analysis 
Patient data including age, pretreatment tumor markers, operative details and 
histologic subtype, stage, and grade were recorded from the clinical database. 
Histologic diagnosis of primary ovarian/PPC was confirmed by independent 
gynecologic-specific pathologists. Surgical stage, histologic grade, and cell type were 
classified according to the World Health Organization (WHO) and Federation 
Internationale des Gynaecologistes et Obstetristes (FIGO) standards. All patients 
received platinum-based chemotherapy with or without paclitaxel as first-line 
treatment.  
Survival data were calculated using the date of diagnosis, defined as the date of 
histologic or cytologic confirmation of EOCs. For progression free survival (PFS) 
patient who had documented progression were uncensored, whereas patients who 
had not progressed at last follow up were censored. For overall survival (OS), 
patients who died at follow-up (any cause) were considered uncensored, whereas 
patients alive at follow-up were censored. Statistical Package for Social Sciences 
Software (SPSS version 15.0; SPSS Inc.) was used for analyses. Univariate 
analyses for OS and PFS were generated by Kaplan–Meier survival curves and log-
rank (Mantel–Cox) tests for statistical significance.  
2.4 Measurement of DSB Induction and Repair 
DSB recognition and repair was assessed by estimation of the foci formation of 
γH2AX (recognition) and RAD51 and DNA-PKcs (repair) using immunofluorescent 
staining. This technique involves permibilisation of cells after DNA damage and 
subsequent detection of target proteins of interest using immunofluorence labelled 
antibodies. The antibody molecules which bind to each protein can be visualised as 
 41 
 
foci and counted, therefore protein expression levels can be compared between cell 
lines. Cells were plated on cover slips in a sterile 6 well cell culture plate at a 
concentration of 5 x 105 / well and incubated for 24 hrs to allow cells to adhere 
followed by treatment with a DNA damaging agent. 
2.4.1 Induction of DNA Damage with Ionizing Radiation  
Ionising radiation (IR) was used to induce DNA damage in the experiments to assess 
DNA-PK phosphorylation, formation of double strand breaks and radio-sensitisation 
by inhibitors. Exposure to IR was performed using a D3300 X-ray system (Gulmay 
Medical Ltd., Surrey, UK) at a dose rate of 2.4 Gy / min, 310 kV, 10 mA. 
2.4.2 Use of PARP Inhibitor, Rucaparib to Produce DSBs  
Rucaparib (Clovis), a potent inhibitor of PARP-1 and PARP-2 (Ki < 5 nM/L) was used 
at a concentration of 10 µM to prevent repair of endogeneous SSB leading to SSB 
accumulation and conversion to DSB in exponentially growing cell lines and primary 
cultures. Cells were incubated for 24 hrs following drug treatment.  
Table 2-2 DNA damage induction and detection experiments.  
Experiment  Protein detected DNA-damage 
induction 
Incubation 
prior to fixation 
NHEJ pathway 
activation 
pDNA-PKcs 2 / 4 Gy IR 1 hr 
HR assay RAD51 and ƴH2AX 10 µM rucaparib 




ƴH2AX 2 Gy IR Time line: 0, 
15min, 2, 6, 24 
and 48 hrs 
2.4.3 Cell Fixation and Staining  
Following DNA damage, cells were incubated for an optimised length of time (Table 
2-2). Cover slips in 6 well plates were then washed with cold PBS (4 °C), fixed with 
ice cold methanol for 10 min, re-hydrated with 2 changes of PBS for 20 min and 
transferred to 90 mm petri dishes covered with para film. Cells were then 
permeabilised with 150 μl / cover slip blocking buffer [KCM buffer (120 mM KCl, 20 
mM NaCl, 10 mM Tris-HCl, 1 mM EDTA, pH 8.0, 0.1 % v/v Triton X-100), 2 % (w/v) 
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bovine serum albumin, 10 % (w/v) milk powder, and 10 % (v/v) goat serum (DAKO, 
Denmark)] for 1 hr at room temperature (RT).  
Table 2-3 Antibody preparation for immunofluorescence experiments. 





1:200 1 hr at RT Anti-phospho-Histone H2AX 
(Ser139), clone JBW301 (IgG1 
mouse monoclonal antibody) 
Upstate, Millipore Corp. 
Primary Ab 
RAD51 
1:200 1 hr RT and 
ON at 4 °C 
Anti-RAD51 Rabbit pAb. (PC 130), 
Calbiochem, EMD Biosciences, Inc.  
Primary Ab 
pDNA-PKcs 
1:50 1 hr RT and 





1:1000 1 hr at RT Alexa Fluor R 546 Goat anti-mouse 




1:1000 1 hr at RT Alexa Fluor 488 Goat anti- Rabbit 
IgG (H + L). Invitrogen  
 
Primary antibody diluted in blocking buffer (Table 2-3) was added to the cover slips 
and incubated for the appropriate length of time. Cover-slips were then washed (3 x 
15 min per wash). Secondary antibodies were added to the cover slips and incubated 
in the dark at RT for 1 hr each. KCM buffer (3 x 15 min per wash) was used after 
each change of antibodies. Cover slips were mounted on slides using Vectashield 
mounting medium containing DAPI (Vector Laboratories, Inc. Burlingame). Slides 
were air dried in the dark at RT before storing them at 4 °C. All experiments were 
done alongside untreated controls and treated slides with no primary antibodies. 
2.4.4 Immunofluorescence Microscopy 
A Leica DMR (Wetzlar, Germany) fluorescent microscope was used. All images were 
captured using RT SE6 Slider Camera Spot Advanced software version 3.408 
(Diagnostic Instruments, Inc), and stored as tiff / bitmap images. The settings used to 





Table 2-4 Leica DMR fluorescent microscope settings. 
Stain  FilterColor Gamma Gain  Exposure 
time(ms) 
DAPI Blue 0.35 4/8 300 
RAD51 / 
pDNA-PKcs 
Green 0.35 16 3500 
ƴH2AX Red 0.35 16 3500 
2.4.5 Counting Foci 
ImageJ software was used to count (Abramoff et al., 2004) the total number of cells 
across 3 fields. Overlapping cells, and cells with fragmented nuclear outline on DAPI 
staining were excluded to avoid over/under estimation of foci counts. The average 
number of foci / cell (mean, SD) was calculated for each field using ImageJ software 
and make mask and foci counting macros (Znojek PhD thesis). The final count was 
taken as the mean and SEM after 3 independent experiments. 
2.5 Cytotoxicity Assays 
Cytotoxicity assays were used throughout the project to assess drug or radiation 
response in cell lines and primary cultures. Cells were assessed in pairs with their 
parental cell lines, where available. 
2.5.1.1 Reagents and Exposures 
Stock solutions of chemotherapeutic agents for use in cytotoxicity assays were 
prepared according to Table 2-5 using appropriate solvents. All stock solutions were 
aliquoted and stored at -80 °C. Working solutions were stored at -20 °C.  
2.5.1.2 Clonogenic Assay 
Clonogenic assays were performed to study the effect of drug treatments on cell 
survival by assessing the ability of cells to form colonies. Cells were seeded in a 6 
well plate for 24 hrs to allow attachment. Medium was gently aspirated and replaced 
with 2 ml of fresh full medium containing the required treatments. Cells were 
incubated for 24 hrs followed by aspiration of the medium, washed in PBS x 1, and 2 
ml of fresh full medium was added. Cells were incubated at 33 °C / 5 % CO2 for 14 
days (OSEC-2) or 37 °C / 5 % CO2 for 30 days (PEO1, PEO4, UWB1.289, 
UWB1.289+BRCA1 and NUOC-1) to check for colony formation. The medium was 
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aspirated, plates were washed in PBS once and then fixed using the Carnoy’s 
fixative (acetic acid: methanol 1:3 v/v, stored at RT) followed by staining with 1 % 
crystal violet. Colony formation efficiency was calculated as number of colonies / 
number of cells seeded x 100. Survival was determined as a fold change over the 
untreated control. 
Table 2-5 Details of cytotoxic agents and small molecule inhibitors. 




Cisplatin Bifunctional alkylating 
agent – inhibit DNA 
synthesis 
300.01 SDW 4 mM 




853.91 Methanol 10 mM 
Camptothecin Plant Alkaloids -  
Topoisomerase I inhibitor 
  
348.35 DMSO 10 mM 
Doxorubicin Anthracycline antibiotic - 
Topoisomerase II 
inhibitors 
543.52  SDW 10 mM 
Rucaparib  PARP inhibitor  421.36 DMSO 10 mM 
NU7441 Small molecule DNA-PK 
inhibitor 
413.49  DMSO 4 mM 
NU6027 A selective inhibitor ATR. 
Developed as an inhibitor 
of cyclin-dependent 
kinase-2 (CDK2) 
251.28 DMSO 10 mM 
KU55933 Small molecule ATM 
kinase inhibitor  
395.5 DMSO 10 mM 
2.5.1.3 SRB Assay 
Primary cultures do not form colonies with a high frequency, so growth inhibition 
following various treatments was assessed using a 96 well SRB assay instead. The 
sulforhodamine B (SRB) assay is used for cell density determination, based on the 
measurement of cellular protein content (Skehan et al., 1990). SRB is a bright pink 
aminoxanthene dye, with two sulphonic groups that bind to basic amino-acid 
residues under mild acidic conditions, and dissociate under basic conditions. As the 
 45 
 
binding of SRB is stoichiometric, the amount of dye extracted from the stained cells is 
directly proportional to the cell mass (Vichai and Kirtikara, 2006).  
Cells were seeded at a concentration of 1000 cells per well in 96 well plates and left 
to attach overnight. After gently aspirating out the medium, 100 μl of fresh full 
medium containing drug treatments was added to each well, using 6 replicate wells 
per condition. The plates were incubated for 3 doubling times for the cell line or 10 
days for PCO cultures, at which point the cells were fixed with 25 μl of 50 % 
trichloracetic acid (TCA) per well, and stored at 4 °C for one hr. Plates were then 
washed and dried. 100 μl of 0.4 % SRB solution (4 g SRB in 1 litre 1 % acetic acid) 
was added to each well for 30 min at RT followed by five washes in 1 % acetic acid, 
to remove unbound SRB. 100 μl of 10 mM Tris (pH 10.5) was added to each well to 
solubilise bound SRB, and absorbance read at 570 nm using a Spectra Max 250 
plate reader (Molecular Devices). The mean and SD of optical densities following 
each treatment were calculated.  
2.6 Non Homologous End Joining Assays 
In order to assess NHEJ function two previously published in vitro assays were 
selected.  
2.6.1 Cell Extract End Joining Assay  
A previously described protein extract end joining assay was selected to be used for 
this project (Diggle et al., 2003). End joining is assessed by the ability of cell extracts 
to rejoin linearised vector monomers into multimers (Figure 2-1). The vectors produce 
either compatible or incompatible ends when linearised using BstXI. Rejoining was 
visualised by agarose gel electrophoresis with gel red stain and quantified by 
densitometry. The results were expressed as: 100 x (density of multimers) / (density 




Figure 2-1 Schematic representation of cellular extract NHEJ assay. 
 
2.6.1.1 Cell-free Extract Preparation 
Cells were grown in 175 cm3 flasks until 70 % confluent. 3 flasks were used for each 
lysate sample. Cells were washed 3 times with cold PBS and once in hypotonic 
buffer (10 mM Tris–HCl pH 8.0, 1 mM EDTA, 1 mM DTT) by gently resuspending the 
cells by pipetting, followed by pelleting at 230 x G for 4 min. The cell pellets were 
resuspended in 400 µl hypotonic buffer and left on ice for 20 min, with occasional 
gentle agitation, prior to homogenisation using a 20 g needle in the presence of 
protease inhibitors (0.17 mg / ml phenylmethylsulphonyl fluoride, 0.01 U / ml 
aprotinin, 1 µg / ml pepstatin, 1 µg / ml chymostatin, 1 µg / ml leupeptin). The 
suspension was then left on ice for a further 20 min with occasional gentle agitation, 
then mixed with 0.5 volume of high salt buffer (50 mM Tris–HCl pH 7.5, 1 M KCl, 2 
mM EDTA, 1 mM DTT). The samples were ultracentrifugated at 70000 rpm for 56 
min in a Beckman TLA120 Optima table top ultracentrifuge using a TLA120 fixed 
angle rotor, then dialysed against dialysis buffer (20 mM Tris–HCl pH 8.0, 20 % v/v 
glycerol, 0.1 M KOAc, 0.5 mM EDTA, 1 mM DTT) for 2 hrs before storage at -80 °C. 
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Protein concentration was assessed using the Pierce Assay protein reagent kit 
according to the manufacturer’s instructions (Pierce Biotechnology, Milwaukee, WI). 
2.6.1.2 DNA Substrates 
Vectors were digested using BstXI enzyme (New England biolabs) as per 
manufacturer’s instructions (Figure 2-2.A). Complete digestion was confirmed using 
gel electrophoresis and gelRed stain (Figure 2-2.B). A 1 % agarose gel was prepared 
by melting UltrapureTM agarose (Invitrogen Life Technologies) in TBE buffer [89 mM 
Tris-HCl ph 8, 89 mM Boric acid, 2 nM EDTA]. Gels were stained with GelRED. 
GelRED is a DNA intercalating agent which, when exposed to UV light fluoresces 
brightly with a red colour when incorporated in nucleic acids. Its inclusion in the gel, 
therefore allows visualisation of the DNA following separation. The gel was allowed 
to set at RT. 
The gel cassette was placed in a Sub-Cell® GT Agarose Gel Electrophoresis System 
(Bio-Rad Laboratories Ltd.) filled with TBE buffer. To allow estimation of the size of 
PCR products, 5 μl of quick-Load® 100 bp DNA Ladder (New England Biolabs (UK) 
Ltd., UK) was loaded in to the first well. Electrophoresis was performed at 100 V for 
45 min. DNA was visualised using Gel DocTM XR (Bio-Rad Laboratories Ltd.). The 
Gel Doc software (Quantity OneR V4.5.0) was used to capture an image of the gel. 
Digested bands were cut out and purified using a gel purification kit (Qiagen, UK), 
following the manufacturer’s instructions. For each digestion reaction, PCR using 
NHEJ forward and reverse primers was performed to assess for any contamination 
with uncut vector. The presence of uncut vector was confirmed by a band at 551 bps 
(Figure 2-2.C). Any digested samples found to contain uncut vector were discarded. 
Digested vectors were resuspended to 5 ng / μl concentration in water and stored at -














Figure 2-2 Optimisation of BstXI digestion.  
A. Diagrammatic representation of the three vectors and products. B. Confirmation of 
BstXI digestion using agarose gel electrophoresis and gelRed staining. Digestion 
produced a 3.2kb band by excising a 1.2kbλ fragment. C. Check for uncut vector 
contamination. PCR reaction was performed using forward and reverse primers for 
each digested sample (Co, 2I and 4I). Uncut vector was used as positive control for 
PCR reaction. H2O and mastermix only reactions were used as controls for 
contamination. 
2.6.1.3 DNA End Joining Assay 
End-joining reactions (20 μl) were carried out with 50 μg protein extract and 100 ng 
DNA substrate in the presence of T4 ligase manufacturer's recommended buffer at 
37 °C for 2 hrs. Extract from DNA-PK deficient cell lines (V3) and no protein loaded 
sample, was used as a negative control, DNA-PKcs competent (V3-YAK) and T4 
ligase (New England Biolabs, Beverly, MA) were used as positive controls.  
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Monomers only are used in this assay, and therefore, repair by HR was not possible. 
Microhology sequencies in the DNA are a significant distance from the cut site. 
Repair by A-EJ therefore results in the large loss of DNA sequence and hence 
smaller product.  
Samples were incubated with RNase A (80 μg / ml) for 10 min and then protein was 
removed by incubation with proteinase K (2 mg/ml) and 0.5 % (w/v) SDS for 10 min 
followed by incubation at 65 °C for 10 min. Analysis was performed by agarose 
(0.7 %) gel electrophoresis and GelRed staining. Gels were transferred to a dark box 
with CCD camera (Fuji LAS 3000 system, Raytek, Sheffield, UK). An image was 
acquired using Fuji LAS imaging software (version 1.1), which was then analysed 
using Aida Image Analyser software (version 3.28.001, Raytek).  
2.6.1.4 Optimisation of Extract End Joining Assay 
The quantity of vector DNA required, and the maximum concentration of DMSO 
which could be used in a reaction, was optimised using OSEC-2 cells. 100 ng vector 
DNA yielded bands that were, detectable and quantifiable (Figure 2-3.A). DMSO 
inhibited end joining (Figure 2-3.B) and therefore the concentration of DMSO was 





Figure 2-3 Optimisation of cell extract end joining assay.  
A. Optimisation of amount of vector DNA loaded into the assay. B. Optimisation of 
amount of DMSO to be used in NHEJ assay. 
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2.6.2 Luciferase Cellular End Joining Assay 
The cellular luciferase assay quantifies end joining of the linearised luciferase gene 
containing pGL2 plasmid using luciferase function. pGL2 plasmid was completely 
linearised using either HindIII or EcoRI and transfected into cells using Lipofectamine 
(Figure 2-4). 
 
Figure 2-4 Schematic representation of Luciferase cellular end joining assay. 
 
The transfectants were harvested 48 hrs after transfection and assayed for luciferase 
activity. Luciferase only functions when the vector is rejoined, thus demonstrating 
NHEJ. The vector linearisation produces blunt ends and does not contain any 
microhomology sequences preventing repair by HR and A-EJ.  
The linearisation of the vector EcoRI cutting site is located within the luciferase gene, 
which therefore requires precise rejoining. The HindIII site is before the luciferase 
gene, therefore some loss of nucleotides would still result in functioning luciferase 
and thus assessed overall rejoining. Transfection of uncut vector acts as control for 
transfection efficiency for the cell line. Results were expressed as 100 * (EcoRI cut / 
uncut) / (HindIII cut / uncut). 
2.6.2.1 DNA Substrates 
Plasmid pGL2 (Promega, Madison, WI) was completely linearised using either HindIII 
or EcoRI, as confirmed by agarose gel (1 %) electrophoresis and GelRed staining. 
DNA fragments were purified using spin columns (Qiagen, UK), dissolved in sterilised 
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water at 5 ng / μl and stored at -20 °C (for up to 7 days), before use. Linearised 
plasmids were transfected into cells using Lipofectamine 2000 (Invitrogen).  
2.6.2.2 Lipofectamine Transfection 
The manufacturer’s protocol for Lipofectamine TM 2000 (Invitrogen, USA, Cat No. 
11668-027) was followed. Adherent cells were grown in 24 well plates for 24 hrs in 
10 % FCS media (2 ml / well) to attain 80 % confluency. For each well, 500 μl of DNA 
/ Lipofectamine mix (1: 2.5 ratio) was prepared as follows: each of 500 ng of plasmid 
DNA in 8 µl DSW and 0.5 μl of PLUS reagent were added to 491.5 μl of serum free 
media, shaken vigorously for 5 min then incubated at RT for 15 min. 3.0 l 
Lipofectamine LTX reagent was added, mixed well and incubated at RT for 30 - 60 
min. Media was aspirated from the cells and replaced with the 500 μl of DNA / 
lipofectamine mix.  After 5 hrs of incubation, 1.5 ml of full media with 10 % FCS was 
added per well.  
2.6.2.3 Transfection by Electroporation in Cell Lines and Primary Cultures 
A cell suspension containing 1 x 106 cells / ml of media was prepared and 250 l 
placed in 4 mm electroporation Cuvettes (Eurogentec, Product code- CE0004-50). 1-
5 μg of pGL2 plasmid was added to the cell suspension. Electroporation was carried 
out using an EPI-2500 electroporator at 100 - 500 volts. The cell suspension was the 
added to the media containing 10 % FCS in 6 well plates and incubated for 48 hrs 
before the transfectants were harvested and assayed for Luciferase activity.  
2.7 Western Immunoblotting 
To determine whether the levels of particular proteins differed in cell lines and PCO 
cultures, quantitation of protein expression was performed by western 
immunoblotting. This technique involves extraction of total cytosolic proteins, 
separation of proteins according to size, followed by immunoblotting onto a 
membrane, and subsequent detection of target proteins of interest using labelled 
antibodies. The number of antibody molecules which can bind to each protein (and 
hence the amount of label detected) is proportional to the amount of protein present, 




2.7.1 Cytosol Preparation  
Cells were plated in a 6 well plate at a concentration of 5 x 105 per well and incubated 
for 24 hrs to allow cells to adhere. The medium was then aspirated and 5 ml of fresh 
medium with required treatments was added. Cells were incubated for the 
appropriate time period.  
Culture medium was removed and cells were washed with PBS, then harvested by 
adding 3 ml of chilled PBS and scrapping the plate to ensure all cells were removed. 
The cell suspension was transferred to chilled 15 ml falcon tubes and centrifugated at 
500 x G at 4 °C for 5 min after which the supernatant was removed. The pellet was 
lysed in 50 ml Merck phosphosafe buffer (Merck Chemicals Ltd.) by incubating at RT 
for 5 min, then centrifuged at 16000 x G at 4 °C for 5 min. Protein concentration was 
estimated using Pierce® BCA Protein assay Kit (Fisher Scientific UK Ltd., 
Leicestershire, UK) as per the manufacturer’s instructions. 
2.7.2 SDS PAGE and Electrophoretic Transfer 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was used 
to separate proteins in the cytosolic extracts according to size. To a 22.5 µl of sample 
7.5 µl 4 x Bio-Rad XT Sample Buffer (Bio-Rad Laboratories Ltd.) was added and cell 
lysates were then denatured at 100 °C for 10 min prior to loading onto gels. 4 µl 
Seeblue protein ladder was resolved alongside protein samples to assess protein 
size (4 kDa to 250 kDa). For analysis of ATR, the samples were loaded into Tris-
glycine 4-15 % gel. For the analysis of all other proteins Criterion XT Tris-Acetate 3–
8 % gels were used (both purchased from Bio-Rad Laboratories Ltd.). 
Electrophoresis was performed in the reservoir buffer (77.9 % glycine, 16.6 % tris-
base, 5.48 % SDS) using a constant voltage of 200 mV until the bromophenol blue 
dye front reached the bottom of the gel.  
Following separation, proteins were transferred electrophoretically from the gels onto 
a nitrocellulose membrane (Hybond C-extra, Amersham, Biosciences). Gels were 
removed from their casing and placed in transfer cassettes with PVDF membrane 
(soaked in 100 % methanol immediately prior to use), sandwiched between 3 mm 
Whatman® chromatography papers (supplied by VWR International Ltd.) and 
transfer sponges, all of which had been pre-soaked in transfer buffer [10 mM CAPS-
NaOH pH 11, 10 % (v/v) methanol]. Cassettes were placed in an Electrophoretic 
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Transfer Cell filled with transfer buffer (78.7 % glycine, 21.2 % tris-base) and 
electrophoresis was performed at a constant voltage of 100 mV for 1 hr using a 
magnetic stirrer to maintain ion distribution in the buffer.  
2.7.3 Antibody Detection and Visualisation of Bound Proteins 
PVDF membranes with bound proteins were removed from transfer cassettes and 
immersed in 5 % blocking solution [TBS-Tween, 5 % (w/v) BSA powder] with 
constant agitation for one hr at RT to block non-specific antibody binding sites. 
Following blocking, membranes were cut into appropriate sections (depending on 
which proteins were to be detected) and transferred to 50 ml BD FalconTM centrifuge 
tubes containing 3 ml primary antibody solution (prepared according to dilution 
specified in Table 2-6). Incubation in most cases was over night at 4 °C with gentle 
agitation (using a roller mixer). 
After incubation in primary antibody, membranes were washed in 5 ml TBS/Tween 
[0.01 M TrisHCl pH 7.5, 0.1 M NaCl, 0.05 % (v/v) Tween-20] at RT for 10 min (with 
gentle agitation). This wash step was repeated twice more to ensure removal of any 
unbound primary antibody. Membranes were then transferred to fresh 50 ml Falcon 
tubes containing 3 ml 1:1000 horseradish peroxidase (HRP) conjugated secondary 
antibody (goat anti-rabbit, rabbit anti-mouse or donkey anti-goat, Dako, Ely, UK ) and 
incubated for 1 hr at RT (with gentle agitation). Following this, a total of 4 washes 
were performed, as above, to ensure any unbound antibody was completely 
removed.  
Detection of bound antibodies was performed using ECL detection fluid (Amersham) 
according to the manufacturer’s protocol. Visualisation of chemiluminescence was 
achieved via exposure of membranes to Kodak BioMax Light film (VWR International 
Ltd.) for the appropriate length of time (10 seconds to 10 min, depending on target 







Table 2-6 Antibodies used for protein detection by western blotting.  
Primary Antibody Size 
(kD) 
Dilution Supplier 
Rabbit polyclonal anti  
Oestrogen receptor α 
66 1:1000 Santa Cruz  
Rabbit polyclonal anti 
Progesterone receptor 
90 1:1000 Cell Signaling 
Rabbit polyclonal anti  
Androgen receptor 
110 1:1000 Santa Cruz  
Mouse monoclonal anti EGFR 180 1: 10,000 Cell Signaling 
Rabbit polyclonal anti Her-2 185 1:1000 Santa Cruz  
Rabbit polyclonal anti Her-3 185 1:1000 Santa Cruz  
Mouse monoclonal anti Alpha 
tubulin 
50 1:4000 Sigma Aldrich 
HRP linked anti GAPDH 37 1:30,00 Santa cruz 
Rabbit polyclonal 
Anti pDNA-PKcs 
471 1:500 Abcam 
Rabbit polyclonal 
Anti DNA-PKcs 




70 1:800 Abcam 
 
Mouse monoclonal anti Ku80 80 1:800 Abcam 
 
Mouse monoclonal 
Anti Lig IV 
104 1:800 Abcam 
 
Rabbit polyclonal anti XRCC4 38 1:1000 AbDSerotec  
Goat polyclonal anti ATR 217 1:200 Santa Cruz 
Rabbit polyclonal anti PTEN 47 1:200 Cell Signalling 
Rabbit polyclonal  
anti ATM 
350 1:1000 Calbiochem 
Mouse monoclonal anti MDM2 90 1:300 Calbiochem 
Rabbit monoclonal anti MDMX 80 
 
1:1000 Bethyl 
Mouse monoclonal anti P53 53 1:500 Vector 





2.7.4 Optimisation of Loading Control Protein 
To ensure equitable protein loading, two commonly used loading controls, α-tubulin 
and GAPDH, were compared across different cell lines (Figure 2-5). Despite protein 
quantification using the Pearce protein assay, marked discrepancies were found 
between α-tubulin levels, whereas, GAPDH had uniform expression, and was 
therefore selected for subsequent experiments. 
 
Figure 2-5 Expression of tubulin and GAPDH across a panel of cell lines.  
Blots are representative of three independent experiments. 
2.8 Immunohistochemistry  
Immunohistochemistry (IHC) involves the binding of a primary antibody specific to a 
protein of interest within histological tissue sections mounted on microscope slides. 
HRP is conjugated to the primary antibody (via a secondary antibody, where 
required) and the application of a chromogen (3,3'-Diaminobenzidine (DAB) to HRP) 
produces visible staining. Staining may be quantified by scoring based on colour 
intensity and the relative area occupied by graded intensities. Higher scores equate 
to a higher total protein expression.  
2.8.1 Formalin-Fixed Paraffin-Embedded Tissue 
Ovarian tissue from patients undergoing surgery at the Northern Gynaecological 
Oncology Centre (Gateshead, UK) was formed into formalin-fixed paraffin embedded 
(FFPE) blocks by the hospital histology department. FFPE tissue was used to 
analyse protein expression by IHC and mRNA expression by real time PCR (qPCR). 
Tissue micro arrays (TMA) were constructed by Dr Peter Donoghue. Two cores from 
each tumour, along with appropriate positive and negative control tissues, were 
included. The TMAs were sectioned at 4 µm and mounted on adhesive slides (Leica, 
IL, USA) by Dr Peter Donoghue.  
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2.8.2 Antigen Retrieval 
Slides were de-waxed in xylene for 5 min and hydrated through graded alcohols 
(99 %→95 %→70 %→50 %). Slides to be labelled with Ku70 and Ku80 primary 
antibodies underwent 10 min microwave-based antigen retrieval (2 x 5 min at 850 
watts) in tris buffer (pH 9) (Sigma-Aldrich, Poole, UK). Slides to be labelled with DNA-
PKcs primary antibody were subjected to antigen retrieval using an antigen decloaker 
for 30 seconds at 125 ºC in citrate buffer (pH 6) (VWR, Leuven, Belgium). Following 
cooling and washing, sections were drawn around with a hydrophobic marker (Dako, 
Glostrup, Denmark) to prevent reagent loss. Endogenous peroxidase activity was 
blocked through application of 3 % hydrogen peroxide solution for 10 min (30 % 
hydrogen peroxide diluted in TBS buffer). 
2.8.3 Antibody Detection  
Primary antibodies were diluted in TBS buffer and applied as shown in Table 2-7. 
Negative controls were included in all runs (TBS buffer only). Antibody detection was 
carried out using the Menapath X-Cell detection kit (Menarini Diagnostics, Berkshire, 
UK). After antibody incubation, slides were subjected to 30 min application of 
universal secondary antibody probe. All slides underwent a 30 min application of 
HRP-polymer. DAB chromogen was diluted in the supplied buffer (1 drop of 
chromogen per 1 ml of buffer) and applied to the slides. Excess DAB solution was 
neutralised in sodium hypochlorite solution. Slides were counter-stained in Gills II 
haematoxylin (Leica) and blued in Scott’s tap-water (Leica). Following rinsing, slides 
were dehydrated through graded alcohols (50 %→70 %→95 %→99 %) and cleared 
in xylene for 5 min before application of cover slips using DPX mounting agent 
(Sigma).  
Table 2-7 Antibodies, concentrations and incubation times used for IHC. 
Antibody Dilution Incubation Time Manufacturer 
Ku70 1:700 Overnight, at 4 °C Abcam (Cambridge, UK) 
Ku80 1:1250 Overnight, at 4 °C Abcam (Cambridge, UK) 




Slides were scanned using the AperioScanScope slide scanner (Leica) and images 
viewed using Aperio Spectrum Webscope (Leica). 
 
Figure 2-6 Graded scoring intensities for each antibody. 
Tissue cores were graded from 1-3 depending on intensity of staining as shown 
above. For DNA-PKcs HGSOC and Non-Serous TMAs required different example 
intensities due to a slight discrepancy between the staining of the two slides. 
2.8.5 Scoring 
TMA cores were scored independently by Richard O’Sullivan (MRes 2014) and Dr 
Peter Donoghue using a modified H-score as previously described (McCarty et al., 
1986). 
Before scoring, the scorers discussed the range of intensities produced for each 
antibody and produced examples of each intensity from 1-3 (Figure 2-6). Intra-class 
Correlation Coefficients (ICC) were calculated to assess the correlation between the 
two scorers in the scoring of TMA cores (Hecht et al., 2008). Excellent reproducibility 





Table 2-8 IHC scores for DNA-PKcs, Ku70 and Ku80.  
ICC and 95 % confidence interval between the scorers for both raw scores and after 
discussion of heterogeneous results. 
 Intraclass Correlation Coefficient 
(95 % confident intervals) 
Primary Antibody Raw Scores Post Discussion 
DNA-PKcs 0.84 (0.76-0.90) 0.95 (0.92-0.97) 
Ku70 0.91 (0.86-0.94) 0.95 (0.92-0.97) 
Ku80 0.90 (0.85-0.93) 0.94 (0.91-0.96) 
2.9 Cell Cycle Assessment using Flow Cytometry 
Propidium Iodode (PI) staining was used to study cell cycle profiles. Stoichiometric 
binding of PI to DNA results in increased dye uptake as cells synthesise DNA and 
progress through cell cycles. PI fluorescence is detected in the FL2 channel of flow 
cytometers. This quantification of DNA content of the cells allows determination of 
cells in the sub G1 (apoptotic cells) G1, S and G2 phases of the cell cycle.   
2.9.1 Sample Preparation  
Cells were plated in a 6 well plate at a concentration of 5 x 104 per well and incubated 
for 24 hrs to allow cells to adhere, the medium was then aspirated and replaced with 
fresh full medium containing 1 M rucaparib, 1 M NU7441 and 10 M NU6027 
individually and in combination. Cells incubated in full medium were used as positive 
control and stain free samples as negative controls. 48 hrs following treatment, cells 
were harvested and cell pellets were resuspended in 500 µl of 2 % FCS in PBS, with 
the addition of 125 μl of 0.25 % PI in 5 % Triton and 50 μl RNAseA solutions.  
Samples were incubated at RT for 10 min prior to analysis with flow cytometry. 
2.9.2 Sample Analysis 
Samples were run through a Becton-Dickinson FACScan Flow Cytometer (BD 
Becton Dickinson UK Limited, Oxford, UK).  Three detectors were used: one in line 
with the light beam (Forward Scatter), one perpendicular to it (Side Scatter) and 
fluorescent detector FL2 for PI florescence, measuring cell size, density, and 




The following settings were optimized for this assay: 
Parameter  Detector  Voltage  Amp Gain  Mode 
P1   FSC   E-1   3.94   Linear 
P2  SSC   304   1.00   Linear 
P3   FL1   535   N/A   Log 
P4   FL2   443   N/A   Log 
Events counted: 10000 
2.9.3 Data Analysis 
Data analysis was performed with the Window Multiple Document Interface software 
(WinMDI) version 2.8. For cell cycle analysis, forward scatter and side scatter 
dotplots were created with WinMDI software to define studied cell population and 
exclude debris and dead cells. The studied cell population were then plotted against 
cells with PI staining, with the relative DNA content which determined the proportion 
of cells in G1, G2 and S phase. Cells in G1, G2 and S phase were plotted on a 
frequency histogram and cell cycle areas designated with the use of marker settings 
with software calculated percentage of cells in each phase. 
The data was transferred and interpreted using Microsoft Excel software. The mean 
and standard deviation of the percentage of cells in each phase of cell cycle were 
calculated. Final data represented the mean of three experimental repeats, each 
experiment containing 3 replicates, with SEM. 
2.9.4 Optimising Flow Cytometry  
Population gating was necessary to establish the cell cycle phases and discriminate 
doublets by relying upon cellular DNA content (Nunez, 2001). A third population was 
noted in the NUOC-1 cell line and hypothesised to be due to NUOC-1 tetraploidy 
(Figure 2-7). This work was carried out with Eleanor Earp (MRes 2013). Cell 
incubation in serum-starved conditions has been shown to arrest cells in G1 phase. 
To assess if the third population noted was the G2/M phase of multiploid cells, 




NUOC-1 cells grown in FCS-free media displayed unaltered cellular DNA 
populations, which did not aid in identifying the third population, but gave an insight 





Figure 2-7 Gating for flow cytometry. 
A. OSEC-2 and B. NUOC-1 cell line gating using cyflogic software. A third population 
(circled in red) appears in NUOC-1 cells that is absent from OSEC-2, hypothesised to 
be derived from tetraploidy. 
2.10 Poly (ADP-ribose) Polymerase Assay 
Poly(ADP-ribose) (PAR) is quantified following maximal stimulation of a defined 
quantity of permeabilised cells. Excess NAD+, a substrate for the PARP enzyme, 
alongside oligonucleotides that induce DSBs, thereby activating PARP, are added. 
Cells are blotted on to a membrane which is treated with anti PAR primary antibody 
followed by secondary antibody conjugated with HRP. A chemilumuniscence agent is 
added, an image is captured and PARP activity is assessed as ‘luminiscent arbitrary 
units’. This assay has been previously validated in our laboratory (Plummer et al., 
2005) to GCLP standard and used as a pharmacodynamic endpoint for clinical trials 
(Plummer et al., 2008). 
NICR standard operating procedure No.212 (revision 3) was followed. PCO cell 
pellets and one 106 cell aliquot of L1210 (quality control) were defrosted, washed 
twice in ice cold PBS and permeabilised with digitonin (0.15 mg/ml) at RT for 5 min.  
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Nine volumes of ice-cold isotonic buffer (7 mM HEPES, 26 mM KCl2, 0.1 mM 
Dextran, 0.4 mM EGTA, 0.5 mM MgCl2, 45 mM sucrose dissolved in distilled water, 
pH 7.8) was added and the samples placed on ice. A 10 μl cell suspension was 
mixed 1:1 (v/v) with trypan blue and permeabilised cells counted. The cell 
suspension was diluted with isotonic buffer to a density of 6 x 105 cells / ml. Duplicate 
samples (1000 cells) were exposed to oligonucleotide at 200 μg / mL in the presence 
of excess NAD1 (7 mM) in reaction buffer (100 mM Tris–HCl, 120 mM MgCl2, pH 
7.8) for 6 min at 27°C, alongside unreacted cells. 500 μl of the PARP reaction 
mixture was loaded alongside PAR standards into a 48-well manifold containing a 
nitro cellulose Hybond-N membrane and drawn through using a vacuum pump. 400 
μl 10 % trichloro acetic acid / 2 % sodium pyrophosphate followed by 800 μl 70 % 
ethanol were drawn through the membrane as a fixative. The membrane was PBS 
washed 3 times and blocked (5 % milk powder in 0.0005 % Tween-20 PBS) for 1 hr. 
Mouse monoclonal anti-PAR 10H antibody (1:1000) was added for 1 hr, followed by 
polyclonal goat anti-mouse IgG anti-PAR HRP antibody (1:1000). Secondary anti-
body was followed by Amersham ECL detection fluid and chemiluminescence 
recorded by Fujifilm LAS 3000 imager then analysed using Aida Image Analyser 
software (version 3.28.001).  
2.10.1 Data Analysis 
A standard curve was constructed by non-linear regression of the PAR standard 
values using Graph Pad Prism 6. The resulting equation relating PAR to 
chemiluminescence (R2 ≥ 0.9) was used to calculate the amount of PAR present in 
each well. Results were expressed as picomoles of ADP-ribose monomer 
incorporated per 106 permeabilised cells. Results were normalised to PAR in internal 
controls (L1210 cell line) to account for inter-assay variability.  
2.11 Gene Expression Analysis by Quantitative Real-time PCR  
In order to determine whether the expression of particular genes involved in DNA 
DSB repair was altered in PCO cultures relative to control cell lines and in 
knockdown and resistant derivatives relative to paired parental cell lines, gene 
expression analysis was performed by real time quantitative PCR using Syber green 
chemistry. This technique involves two stages; firstly, mRNA is reverse transcribed to 
cDNA; and secondly, PCR is performed using primers specific for the gene of 
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interest, during which accumulation of the PCR products is detected in real-time. This 
is achieved through the binding of syber green to double strand DNA and emitting a 
fluorescent signal when it is bound. As the target sequence is amplified the 
fluorescent signal amplifies. With progressive PCR cycles an exponential phase is 
reached where the quantity of product and associated magnitude of fluorescence of 
an intercalated reporter molecule doubles with each successive cycle. During this 
phase an absolute quantification of the amount of product can be calculated through 
comparison with a concurrently amplified standard curve of known concentrations. 
Multiple samples can be compared by normalising quantities to that of a 
‘housekeeping gene’ assumed to be present at the same level in all samples. 
Relative quantification of expression of the target genes was performed and 
normalised to GAPDH for all cell line and PCO samples and HPRT1 for FFPE 
extracted RNA.  
2.11.1 RNA Extraction and Quantification 
For each cell line and primary culture, a frozen cell pellet obtained from a confluent 
75 cm3 flask was thawed on ice. Total RNA was extracted from thawed cells using an 
RNAeasy® Mini kit (Qiagen, Crawley, UK) according to the manufacturer’s protocol. 
Briefly, cells were lysed and homogenised, then RNA was bound to an RNAeasy® 
silica gel membrane in spin-column format, after which contaminants were removed 
by washing in the provided buffers. RNA was eluted in 30 µl nuclease-free distilled 
water (dH2O) (Invitrogen Life Technologies). Quantification of RNA was performed 
using a NanoDrop® ND-1000 spectrophotometer (Thermo Scientific, DE, USA) which 
measures the absorbance of UV light at 260 mm passed through a 1 µl aliquot of 
extracted RNA, and performs the necessary calculations according to the Beer 
Lambert Law to provide the RNA concentration (in ng / µl). 
2.11.2 RNA Extraction from FFPE Tissue 
Samples were extracted from 10 µm sections cut from the donor FFPE tissue blocks. 
Extractions were performed using the All Prep DNA / RNA FFPE Kit (QIAGEN, 
Venlo, Netherlands) as per the manufacturer’s instructions. Briefly, samples were 
deparaffinised twice in xylene and washed in 100 % ethanol. Tissues were lysed in 
the supplied Proteinase K and incubated at 80 ºC to partially reverse formaldehyde 
crosslinking. The sample was added to the supplied spin column and centrifuged with 
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720 µL of 100 % ethanol to bind the RNA to the spin column membrane. Incubation 
with DNase1 was performed to remove contaminating DNA. Following subsequent 
wash and purification steps, RNA was eluted by centrifugation with 14 µL of RNase 
free water (Life Technologies, CA, USA). 
2.11.3 Reverse Transcription of RNA into cDNA 
2 µg of the total RNA was incubated at 65 °C for 5 min followed by 37 °C for 5 min 
prior to addition of Promega MMLV-reverse transcriptase master mix (4 µl 5 x 
Moloney Murine Leukaemia Virus RT buffer, 2 µl 4 mM dNTPs, 1 µl 50 µM Oligo 
dT15 and 0.3 µl MMLV reverse transcriptase) and incubation at 37 °C for 1 hr 
followed by 95 °C for 5 min. A blank reaction was also prepared using nuclease-free 
dH2O in place of RNA, to ensure no contamination of reagents. Assuming a reverse 
transcription efficiency of 100 %, this yielded 20 µl of cDNA at the concentration of 
100 ng / µl. This was subsequently adjusted to 20 ng / µl by addition of 80 µl 
nuclease-free dH2O and stored at -20 °C until required.  
2.11.4 Real-time PCR Setup 
PTEN primer sequences were purchased from Sigma-Aldrich. All other primers were 
purchased from Sigma Genosys and all primers were diluted to 100 µM as per the 
manufacturer’s instructions. Working stocks were diluted 1:40 by addition of 390 µl 
dH2O to 10 µl of stock solution and aliquoted. Both stocks were stored at -20 °C. 
Sequences of primers are detailed in Table 2-9. 2 µl of cDNA was loaded on to a 386 
well plate in triplicate with Invitrogen SYBR green Master Mix (dNTPs, optimised 
buffer, UDG, ROX reference dye, AmpliTaq DNA polymerase UP and SYBR green 
ER dye) and 2.5 mM of the appropriate forward and reverse primers. For each gene 
two controls were also prepared, using a blank reverse transcription reaction and a 
nuclease free dH2O in place of cDNA, to ensure no contamination of reagents. 
Assays (and controls) were setup in triplicate for each gene in each cell line. 
Samples were run on an AbiPrism Applied Biosystems real time PCR machine for 10 
min at 95 °C, 40 cycles (15 s at 95 °C, 60 s at 60 °C), 15 s at 95 °C, 15 s at 60 °C, 15 
s at 95 °C. 
Following completion of thermal cycling, detected fluorescence was converted to a Ct 
value for each reaction using the SDS2.3 software, using standard parameters. The 
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means of the triplicate Ct values generated for each gene (in each cell line) were 
used for quantification of gene expression, as described below.  
Table 2-9 Primers used for PCR.  
Primer Set Sequence Annealing 
temp 
DNA-PKcs 5’ – CTAACTCGCCAGTTTATCAATC – 3’ 
5’ – TTTTTCCAATCAAAGGAGGG – 3’ 
55 
DNA-PKcs 5’ – GATCTGAAGAGATATGCTGTG – 3’ 
5’ – GTTTCAGAAAGGATTCCAGG – 3’ 
55 
Ku70 5’ – AAGAAGAGTTGGATGACCAG – 3’ 
5’ – GTCACTTCTGTATGTGAAGC – 3’ 
55 
Ku80 5’ – TTCATTCAGTGAGAGTCTGAG – 3’ 
5’ – CGATTTATAGGCTGCAATCC – 3’ 
55 
ATR 5’ – CCTTCAGATTTCCCTTGAATAC – 3’  
5’ – GCAGTTCATGTTTTGATGAG – 3’  
55 
ATR 5’ – GTAACAGAGTTCCCAAGATTC – 3’  
5’ – TCAAGTTCCTACAGAAGAGG – 3’ 
55 
LIG IV 5’- TGAGTGGAACAGATAGCCAGCCAA-3’ 





PTEN  5’ – CAGAGCCATTTCCATCCTGC - 3’  




5’ – CATGTTGCAGCAATTCAC – 3’ 
5’ – GGTATGAAGAATGTATTTACCCA – 3’ 
55 
PTEN  5’ – CCACAAACAGAACAAGATGCTAA – 3’ 
5’ – CATGGTGTTTTATCCCTCTTGAT – 3’ 
55 
HPRT1  5’ – TTGCTTTCCTTGGTCAGGCA – 3’ 
5’ – AGCTTGCGACCTTGACCATCT – 3’ 
55 
HPRT1  5’ – TGAACGTCTTGCTCGAGATGTG – 3’ 
5’ – CCAGCAGGTCAGCAAAGAATTT – 3’ 
55 
HPRT1  5’ – TTGTAGCCCTCTGTGTGCTCA – 3’ 




5’ – CGACCACTTTGTCAAGCTCA – 3’ 
5’ – GGGTCTTACTCCTTGGAGGC – 3’ 
55 
ARID1A  5’ – TATGGAGGTCCTTATGACAG – 3’ 
5’ – ATTGCCATAGGAATCATGTC – 3’ 
55 
 5’ – CCTTTCTCTCCTCATACCTC – 3’ 
5’ – CTTGATTGGTTCATGGAAGG – 3’ 
55 
 5’ – GGATTAATAGTATGGCTGGC – 3’ 
5’ – TYGGATTTGGATTCTGTCTTG – 3’ 
55 
P53 5’ – CGAGCTGTCTCAGACACTGG – 3’  
5’ – CCTTGTCCTTACCAGAACGTTG – 3’ 
58  
 5’ – CATGGGACTGACTTTCTGCTCTTG – 3’ 55  
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5’ – CGGGGACAGCATCAAATCATC – 3’ 
 5’ – GTTCTGGTAAGGACAAGGGT – 3’  
5’ – ATACGGCCAGGCATTGAAGT – 3’ 
55  
 5’ – ATCTGTTCACTTGTGCCCTG – 3’  
5’ – CAACCAGCCCTGTCGTCTCTC – 3’ 
55  
 5’ – GCCTCTGATTCCTCACTGAT – 3’  
5’ – GGAGGGCCACTGACAACCA – 3’ 
55  
 5’ – AAGGCGCACTGGCCTCATCTT – 3’  
5’ – CAGGGGTCAGCGGCAAGCAGA – 3’ 
60  
 5’ – GAGCCTGGTTTTTTAAATGG – 3’  
5’ – TTTGGCTGGGGAGAGGAGCT – 3’ 
60  
 5’ – AGCGAGGTAAGCAAGCAGG – 3’  
5’ – GCCCCAATTGCAGGTAAAACAG – 3’ 
55  
 5’ – CTTCTCCCCCTCCTCTGTTGC – 3’  
5’ – GAAGGCAGGATGAGAATGGA – 3’ 
60  
 5’ – TGGTCAGGGAAAAGGGGCAC – 3’  
5’ – GAGAGATGGGGGAGGGAGGC – 3’ 
58  
2.11.5 Data Analysis 
Relative quantification using the 2-Ct method (Livak and Schmittgen, 2001) was 
performed to determine the expression level of each gene of interest. Briefly, analysis 
by this method first involved normalisation of the expression of each gene of interest 
to the expression of house-keeping gene in all cell lines. The normalised expression 
levels of genes of interest were then compared to control cell lines, generating values 
representing fold change in expression for each gene. All calculations were 
performed using Microsoft Excel. The entire investigation was repeated a total of 
three times, using new frozen cell pellets each time.  
2.12 RNA Genome Expression Arrays 
RNA was extracted as described in section 2.7.1, quality checked, then processed by 
the Oxford Genomics Centre (Oxford, UK) using Illumina Genome Studio and 
HumanHT 12v4.0 R1 15002873 array, as per manufacturer’s instructions.  
RNA concentration and purity was checked by Agilent RNA bioanalyser and RNA 
6000 Nano Lab chip kit (Agilent Technologies, USA) as per manufacturer’s 
instructions. Briefly, 2 μl samples of concentrated RNA extract are treated for 2 min 
at 70 °C before adding 1 μl aliquots to the Agilent RNA chip. A 6-peak RNA nano 
ladder is included in the chip for control.  Data analysis was done using the 2100 
Expert software. Good quality RNA was verified by the presence of a sharp 
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distinction at the small side of both the 18 S and 28 S ribosomal RNA bands and 
peaks. Any smearing or shouldering to the rRNA bands or peaks was indicative of 
RNA degradation. An RNA integrity number (RIN) of >8.0 was considered 
satisfactory. 
The HumanHT-12 v4 Expression BeadChip consist of oligonucleotides immobilised 
to beads held in microwells on the surface of an array substrate and provides 
genome-wide transcriptional coverage of well-characterized genes, gene candidates, 
and splice variants, with high-throughput processing of 12 samples per BeadChip. 
Each array on the HumanHT-12 v4 Expression BeadChip targets more than 47,000 
probes derived from the National Centre for Biotechnology Information Reference 
Sequence (NCBI) RefSeq Release 38 (2009). Labelled cRNA are detected by 
hybridisation to 50-mer probes on the Beadchip. After washing and staining steps 
using the Direct Hybridization Assay, beadchips are scanned on the HiScan or iScan 
systems.  
2.12.1 Data Analysis 
Arrays processing, background correction, normalisation and quality control checks 
were performed using the R package ‘Lumi’. Probes intensity values were converted 
to VSD (variance stabilized data) using variance stabilising transformation. The 
robust spline normalisation (RSN) was used as an array normalization method. 
Irrelevant samples, poor quality probes (detection threshold < 0.01), and probes that 
are not detected at all in the remaining arrays were removed prior downstream 
analysis. The remaining probe normalised intensity was used in the differential 
expression analysis. Differential expression analysis was performed using the R 
package ‘Limma’, and p values were adjusted to control the false discovery rate 
(FDR) using the Benjamini–Hochberg method.  
Illumina Genome Studio Gene expression software is used to extract relative gene 
expression across samples, clustering them into differential groups. The comparative 
Ct (ΔΔCt) method was used to assess the expression level of components of each 
pathway relative to endogenous controls normalised to the reference panel. The fold 
change differences in expression of each gene between sample categories (HRC 
and HRD; NHEJC and NHEJD) was calculated. 
 67 
 
2.13 DNA Sequencing  
Sequencing of TP53 and ARID1A was performed by PCR amplification and Sanger 
sequencing. 
2.13.1 DNA Extraction and Quantitation 
Frozen cell pellets consisting of ~5 x 106 cells were thawed and resuspended in 100 
µl PBS. Genomic DNA was extracted using a QIAmp DNA Mini Kit (Qiagen) 
according to the supplied manufacturer’s protocol. Briefly, DNA extraction was 
achieved through binding of DNA to a QIAmpR silica gel membrane (in spin column 
format) after which contaminants were removed by washing using the provided 
buffers. DNA was eluted in 200 μl Buffer AE [10 mM Tris-CHL, 0.5 mM EDTA, pH 
9.0], quantification of DNA was performed using a NanoDropR ND-1000 
spectrophotometer which measures the absorbance of UV light at 260 nm passes 
through a 1 µl aliquot of extracted DNA, and performs the necessary calculations 
according to the Beer Lambert Law to provide DNA concentration (in ng / µl).  
For each sample, a 20 µl aliquot of DNA at a concentration of 100 ng / µl was 
prepared using buffer AE and stored at 4 °C for use in PCR reactions. Remaining 
DNA was stored at -20 °C. 
2.13.2  PCR Amplification 
PCR primer sequences are shows in Table 2-9. PCR reaction conditions were the 
same for each gene/exon and consisted of 1 x ReddyMix PCR buffer (Thermo 
Scientific), 10 pmol primers, 0.2 mM (each) dNTPs (Invitrogen Life Technologies), 1.5 
mM MgCl2, 0.5 units ThermoPrimeTaq DNA polymerase (Thermo Scientific) and 100 
ng cDNA in a total volume of 10 µl. For setup of reactions, the appropriate volume of 
PCR mastermix was initially prepared and 19 µl was dispensed into the appropriate 
number of wells on a 96 well PCR plate on ice. To this, 1 µl of 100 ng / µl DNA was 
added. Controls were also prepared using nuclease free dH2O in place of DNA, to 
ensure no contamination of reagents. Thermal cycles were performed as follows: 1 
min at 94 °C, 40 cycles (30 s at 94 °C, 30 s at 55 °C, 30 s at 72 °C), 5 min at 72 °C. 
In order to confirm successful PCR amplification of exons, a 5 µl aliquot of each 
reaction was assessed using GelRED stained agarose gel electrophoresis as 
described in section 2.4.4. and 15 µl of PCR reactions were diluted by addition of 85 
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µl of dH2O and sent for Sanger sequencing (Beckman Coulter Genomics). The 
samples were analysed with mutation surveyor (Softgenetics) and mutations were 
searched for in the literature using Cancer Gene Census of the Catalogue of Somatic 
Mutations in Cancer (COSMIC) database (Wellcome Trust Sanger Institute, 2013). 
Both forward and reverse sequences were analysed to ensure accurate coverage of 
entire exons.  
2.13.3 Whole exome sequencing  
DNA was extracted from parent and resistant cell lines as previously described. 
Whole exome sequencing was performed off site by Oxford gene technology (OGT) 
(Oxfordshire, UK). Briefly, Agilent SureSelect All Exon Plus v4+UTR was used for 
exome capture and Illumina HiSeq 2000 minimum (San Diego, CA) for 100 bp paired 
end sequencing. Multiple sample vcf files were created by OGT using individual raw 
bam files. Raw bam files were generated from the sequencer and contained the 
whole sequenced data aligned to the reference genome of the parental cell line. 
Genome Analysis Toolkit (GATK; Broad Institute) was used for data quality 
assurance as well as variant discovery. Variant characterization, including filtering, 
annotation, classification, prioritization and inheritance pattern analysis was 
performed using SNP & Variation Suite (SVS) v8.1.5 (Golden Helix, Inc., Bozeman, 
MT, www.goldenhelix.com). Briefly, quality-control metrics (QC) were set to only 
retain variants in the positions with Read Depth ≥20 and Genotype Quality ≥20. 
Variants were classified, annotated, and functionally profiled in SVS v8.1.5 using 
multiple publicly available databases. The impact of the mutations on protein function 
was evaluated by database of non -synonymous functional predictions (dbNSFP). 
Functional predictions were performed using track of SVS for SNPs, and Indel SIFT 
webtool for Indel mutations (http://sift.bii.atar.edu.sg/www/SIFT_indels2.html). These 
analyses were carried out by OGT. 
To identify those mutations that were of potential importance to the chemo-resistant 
phenotype from the data received, a selection criteria was applied. Firstly known 
SNPs were excluded during the analysis. Secondly the frequency of mutation 
reported in both parent and resistant lines; mutations which were present in >5 % of 
read in the parent line were excluded. Additionally, only mutations that were resent in 
more than 25 % of reads (and therefore 50 % of cells, assuming heterozygosity) in 
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the resistant lines, and were either not observed in parental cells or had more than a 
3 fold increase in frequency, were taken forward for further analysis. 
2.14 SNP Array Analysis 
SNP arrays were performed on NUOC-1 cell line subpopulations and matched 
genomic DNA. SNP arrays assess the expression of both SNPs and non-polymorphic 
sites distributed throughout the entire genome using probes hybridised to a chip. This 
data can be used to demonstrate copy number aberrations (CNAs) in individual 
samples, indicated by the deletion or amplification of particular probes. It can also 
reveal regions of copy-neutral loss of heterozygosity (cn-LOH) by comparing of SNP 
genotype to those of matched germline DNA. SNP arrays were performed offsite by 
Almac Diagnostics Ltd. (Craigavon, UK) using the Affymetrix SNP 6.0 platform. The 
SNP 6.0 array includes more than 906,600 SNPs and 946,000 non-polymorphic 
probes.  
For SNP array analysis DNA was extracted using QIAmp DNA Kit as per the 
manufacturer’s instructions. A minimum of 10 µl of DNA at a concentration of 50 ng / 
µl was analysed. 
2.14.1 Data Analysis 
Raw array-generated data in the form of .CEL files were received from Almac 
Diagnostics Ltd. Processing of raw data to identify CNAs and regions of cn-LOH in 
each samples was kindly performed by Prof J.M. Allan using Genotyping Console 
v4.0 (Affymetrix, Ca, USA).  
The work flow for data processing briefly involved initial generation of SNP genotype 
calls using the birdseed v2 algorithm. This was followed by quantile normalisation of 
data and copy number and LOH analyses (via Hidden Markov Model) using default 
software settings (with regional GC correction applied). Matched germline DNA was 
used as reference model for LOH analysis. Segment analysis of CN data was 
performed to identify regions of CAN (with detection thresholds set to exclude 
regions smaller than 100 kb and involving fewer than 5 markers).  
CNAs and regions of LOH were compared between sub-populations and parent line 
of NUOC-1 cell line, using affymetrix Genotyping Console Browser (version 1.0.12). 
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This also allowed identification of genes within affected regions (of CAN or LOH) 
based on annotations taken from the NCBI RefSeq database.  
Quality control assessment of data was performed by determining the call rate at 
control SNPs, and by measurement of concordance between sub populations and 
parent line.  
2.15 G-band Karyotyping  
Karyotyping was performed offsite by the Cancer Cytogenetics department at 
Newcastle University, according to established protocols. Briefly, tetaphase 
chromosome spreads were prepared by incubating proliferating cells with 100 ng/ml 
colcemid for 4 h followed by resuspension in 75 mm KCl for 7 min. Cells were fixed by 
resuspension in 3:1 methanol:acetic acid before karyotyping. Slide-fixed cells were 
incubated overnight at 60 °C and G-banded by soaking in the trypsin solution (1.9  
mg/ml trypsin, 74  mM NaCl, 0.469  mg/ml NaH2PO4 and 0.937  mg / ml Na2HPO4) 
for 10  s and in the staining solution [(8  ml Giemsa stain, 0.5  ml Leishman stain and 
40 ml Gurr buffer (0.469  mg / ml NaH2PO4 and 0.937  mg / ml Na2HPO4)] for 3  
min. Four metaphase chromosome spreads were analysed for each population and 
the karyotypes recorded. 
2.16 Fluorescence in Situ Hybridization for c-MYC   
Fluorescence in situ hybridization (FISH) is a cytogenetic technique that uses 
fluorescent probes that bind to only those parts of the chromosome with a high 
degree of sequence complementarity. It is used to detect and localise the presence 
or absence of specific DNA sequences on chromosomes. Fluorescence microscopy 
can be used to find out where the fluorescent probe is bound to the chromosomes. 
FISH analysis was performed offsite by the Cancer Cytogenetics department at 
Newcastle University, according to established protocols. Briefly, the Cytocell MYC 
‘breakapart’ Probe set (Figure 2-8) was hybridised to nuclei as recommended by the 
suppliers. Slides were heated to 72 °C for 5 min and then incubated for 24 hr at 37 °C 
in a humidified hybridisation chamber (HYBrite; Abbott Molecular). After hybridisation, 
slides were counterstained with 4′,6-diamidino-2-phenylindole (Vector Laboratories, 
Peterborough, UK). FISH was scored with an Olympus BX-61 fluorescence 
microscope (Olympus, Southend-on-Sea, UK) with a x 100 oil objective. Images were 
analysed using the CytoVision 7.2 SPOT counting system (Leica Microsystems, 
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Gateshead, UK). A minimum of 100 nuclei were scored per test by two independent 
analysts. 
 
Figure 2-8 Cytocell MYC ‘breakapart’ probe set. 
2.17 Mouse experiments 
To assess the ability of NUOC-1 cells to generate tumours, their ability to form 
explants in mice was assessed. The mouse injections and monitoring was kindly 
performed by Huw Thomas. All animal studies were performed in compliance with the 
UK Home Office Animals (Scientific Procedures) Act 1986 for the use of animals in 
scientific procedures, and have undergone local ethical review; project license 
number PPL 60/42222. 
2.17.1 Subcutaneous Injection 
Exponentially growing NUOC-1 cells were trypsinised and resuspended at a 
concentration of 2 x 108 / ml in 500 µl 10 % FCS RPMI 1640, mixed with 50 % (v/v) 
matrigel (Becton Dickinson) making a total volume of 300 µl. Cells were transferred 
on ice to the animal house and injected subcutaneously into the right flank of 5, 8-10 
week old mice under sterile conditions. Mice were then monitored for tumour growth 
and wellbeing for a maximum of 100 days.   
2.17.2 Intraperitoneal Injection 
Intraperitoneal (IP) injection of cells better represents ovarian cancer in humans, and 
therefore, NUOC-1 cells were injected IP into 5 further mice.  
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2.17.2.1 Cell Labelling  
To allow monitoring of IP injected NUOC-1 cells, they were first labelled with 
luciferase by transfection of a vector containing luciferase. The vector was kindly 
gifted by Dr Alex Elder. An 800 µg / ml stock solution of hexadimetrine bromide was 
prepared by dissolving 800 µg hexadimetrinebromide in 1 ml sterile dH2O. The stock 
solution was filter sterilised using a 0.2 µM filter (VWR International Ltd.), stored at 
4 °C and used neat, as required. 
Cells were seeded at 5 x 105 / 6 well plate, and after 24 hrs incubation (to allow 
adherence) 100 µl or viral vector, and 10 µl 8 µg/ml of hexadimetrine bromide was 
added to the well. A control well had hexadimetrine bromide added only. The plate 
was then wrapped in paraffin and centrifuged at 900 x G for 50 min at 34 °C; 
following which the cells were incubated at 37 °C / 5 % CO2 until confluent. Control 
cells were treated in the same way. Cells were incubated and passaged as required 
to reach the required cell numbers.  
2.17.2.2 Confirming Cell Transfection  
Once cell populations had resumed normal exponential growth, transduction 
efficiency was determined by assessment of the expression of GFP by flow cytometry 
(the principles of flow cytometry are described in section 2.8). A suspension 
containing 2 x 105 cells was dispensed into a BD FalconTM capped polystyrene tube. 
Cells were centrifuged at 450 x G for 4 min, supernatant discarded, and cells 
resuspended in 500 µl PBS. Flow cytometry was performed using a FACSCalibur 
flow cytometer with BD CellQuest Pro software (BD Biosciences) using pre-optimised 
instrument settings for detection of GFP fluorescence. A total of 10,000 cells were 
assessed from each transduced cell population. For assessment of GFP-expressing 
cells, cell debris and dead cells were first excluded from the analysis based on 
forward and side scatter signals. Percentage of GFP-expressing cells in the 
remaining cell population was then determined based on detection of GFP 
fluorescence. 
2.17.2.3 Injections into Mice 
Cells were trypsinised, washed in PBS, then 5 x 106 cells were resuspended in 300 
µl PBS. This was transferred to the animal house and injected into the peritoneum of 
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five mice by Huw Thomas. The animals were housed under sterile conditions in a 
laminar flow environment with ad-lib access to food and water. 
2.17.2.4 Imaging Mice 
Tumour formation was assessed by non-invasive whole-body imaging at 0, 10 and 
55 and 85 days after implantation using the IVIS Spectrum Imaging system (Caliper 
Life Sciences, Hopkington,MA, USA). Animal handling was kindly performed by Dr 
Helen Blair. Mice were injected IP with 3 mg / mouse D-luciferin (Promega) solution 
10 min before being anaesthetized for the imaging procedure. Photon emission was 
captured and expressed in p/s/cm2/sr using Living Image software (version 4.3.1., 
CaliperLifeSciences). Mice were labelled using ear notching to ensure florescence in 
each mouse could be followed over time. The mice were then returned to an 
incubator to recover.  
2.18 Generation of Stable PTEN, DNA-PKcs and ATR Defective Cell Lines using 
Short Hairpin RNA-Mediated Gene Knockdown 
Stable knockdown subclones of cell lines OSEC-2 and NUOC-1 were generated 
using Short Hairpin RNA (shRNA)-mediated gene knockdown. In this process, 
lentiviral particles are used to deliver shRNA constructs into cells which become 
incorporated into the host genome. Translation by RNA polymerase III (due to the H1 
promoter sequence included in the construct) results in continual production of 
shRNA molecules. These molecules are cleaved to produce small interfering RNA 
(siRNA) molecules. The siRNA molecules become bound to the RNA-induced 
silencing complex molecules, which subsequently binds to and cleaves mRNA 
molecules which match the siRNA, hence permanently blocking expression of the 
target gene.  
2.18.1 shRNA Constructs 
Pre-packaged lentiviral transduction particles containing verified MISSION®shRNA 
constructs, targeting the coding domain sequence of DNA-PKcs and ATR and PTEN 
(in pLKO.1-puro plasmid vectors) were purchased from Sigma-Aldrich, UK. The 
sequences of the shRNA constructs were not disclosed by the supplier. In addition, 
Lentiviral transduction particles containing a random shRNA construct confirmed not 
to target any known human or mouse genes (MISSION® Non-Target shRNA Control 
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Transduction Particles), were also purchased to use as controls for transduction. All 
purchased lentiviral particles were received as frozen stock and stored at -80 °C. 
Upon first use, particles were aliquoted appropriately and stored at -80 °C until 
required.  
2.18.2 Assessment of Puromycin Sensitivity 
The pLKO.1-puro plasmid used as a vector for the shRNA constructs contains a 
puromycin resistance gene, meaning the antibiotic can be used to select cells which 
have been successfully transduced. However many cell lines are inherently sensitive 
to the effect of puromycin, hence preliminary investigations were necessary to 
establish the minimum puromycin concentration required to kill all non-transduced 
cells. The following investigation was performed for OSEC-2 and NUOC-1 cells. 
A cell suspension at a densitiy of 7.5 x 103 cells / ml was established in RPMI 
medium (20 ml). 2 ml of solution was added to each well of a sterile 6 well culture 
plate and allowed to adhere overnight. An appropriate volume of working puromycin 
solution was then added to each well. Purimycin concentrations of 0 (control), 2, 4, 6, 
8 or 10 µg / ml were tested, as recommended by the manufacturer (Sigma-Aldrich). 
Plates were incubated at 37 °C / 5 % CO2 (33 °C for OSEC-2) and assessed 
microscopically each day for cell death.  
In the case of both cell lines 72 hrs in culture following puromycin administration, all 
cells in all treated cultures were found to be dead upon microscopic inspection. 
Therefore, for both cell lines, selection of transduced cells was performed using 
media supplemented with puromycin at a concentration of 2 µg / ml. 
2.18.3 Assessment of Transduction Efficiency 
Prior to performing transduction with lentiviral particles containing shRNA constructs, 
it was necessary to determine the optimum multiplicity of the infection (MOI) required 
for transduction of each cell line using MISSION®TurboGFPTM Control Transduction 
Particles. This also served as a control to determine whether the transduction 
process itself had any effect on cell growth, so that these could be separated from 
the effects of shRNA-mediated gene knockdown. Lentiviral transduction of OSEC-2 
and NUOC-1 cells was performed using MISSION®TurboGFPTM Control 
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Transduction Particles according to Section 2.17.4. MOIs of 0 (Control), 1, 2 and 5 
were prepared as recommended by manufacturer (Sigma-Aldrich). 
Once cell populations transduced with MISSION®TurboGFPTM Control Transduction 
Particles had resumed normal exponential growth following puromycin selection, 
transduction efficiency was determined by assessment of the expression of GFP by 
flow cytometry (as described in section 2.16.2). Expression of GFP was similar for all 
MOIs tested, in both cell lines. Based on the time taken to recover exponential cell 
growth MOI of 2 was selected for subsequent lentiviral transductions.  
It was also noted at this point that the growth kinetics of transduced cells was not 
significantly different from non-transduced cells, demonstrating that the transduction 
process itself has no apparent effect on the growth of OSEC-2 cells. The 
transduction process did, however, slow the growth of NUOC-1 cells. Therefore, all 
comparisons were made between non target control samples and knockdown 
samples, to take into account the slowed cell growth due to the transduction process.  
2.18.4  Lentiviral Transduction 
Cells were seeded at a density of 1 x 105 per well in a sterile 6 well plate. After 24 hrs 
an appropriate volume of thawed lentiviral particle suspension was added directly to 
the cell suspension (Table 2-10). A normal control was prepared for each cell line / 
shRNA combination according to the same procedures, but without the addition of 
lentiviral particles. After 24 hrs incubation, the media was aspirated, washed with 2 










Table 2-10 Viral titres and required volumes for each ShRNA construct. 
Construct Viral Titre (TU/ml) Volume to give MOI 2 (µl) 
DNA-PK 6255 8.0 x 106 25.0 
DNA-PK 6256 1.3 x 107 15.4 
DNA-PK 6257 1.5 x 107 13.3 
DNA-PK 6258 4.5 x 106 44.4 
DNA-PK 6259 1.5 x 107 13.3 
ATR 10300 7.8 x 106 25.6 
ATR 10301 6.7 x 106 29.9 
ATR 10302 6.4 x 106 31.3 
ATR 39613 9.2 x 106 21.7 
ATR 39614 9 x 106 22.2 
PTEN 2745 1.7 x 107 11.8 
PTEN 2746 1.3 x 107 15.4 
PTEN 2747 1.4 x 107 14.3 
PTEN 2748 1.7 x 107 11.8 
PTEN 2749 1.6 x 107 12.5 
2.18.5 Selection of Transduced Cells 
After 72 hrs incubation, the media was aspirated and replaced with 2 ml of 10 % 
RPMI media supplemented with 2 µg / ml puromycin. Cultures were incubated at 
37 °C / 5 % CO2 and selection media was replaced every 72 hrs until normal 
exponential cell growth had resumed. At this point, cell populations were deemed to 
consist entirely of transduced cells, given that only cells which had taken up a 
plasmid could survive in selection media due to acquired puromycin resistance.  
Control non-transduced parental cell populations were treated in the same way as 
above, except normal 10 % RPMI culture media was used in place of selection 
media. 
2.18.6 Assessment of Knockdown Efficiency 
The efficiency of shRNA-mediated knockdown of target genes, relative to control 
non-transduced cells, was assessed by real time q-PCR and western immunoblotting 
according to the protocols described in sections 2.6 and 2.10. The cellular amounts 
of DNA-PKcs and ATR mRNA and proteins were also assessed in cells transduced 
with the non-target shRNA control to exclude any effects of transduction and shRNA 
processing on target gene expression.  
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2.19 Generation of Drug Resistant Cell Lines by Escalating Dosage 
In order to model the development of chemo-resistance in vitro, HRD cell lines were 
cultured in the presence of escalating doses of either rucaparib or cisplatin, in an 
attempt to generate drug-resistant subclones for analysis of HR status and NHEJ 
status. PEO1 and UBW1-289 cell lines were used.  
2.19.1 Concentration Finding Assay 
In order to identify a suitable concentration for each drug in each cell line, 
concentration finding assays were performed by treating the cell lines with a range of 
concentrations of each drug, and LC50 was selected as a starting concentration. 
Concentration finding assays were performed using SRB and clonogenics assays in 
all cases as described in section 2.3. The selected treatment doses are detailed in 
Table 2-11. 
Table 2-11 Resistance development dosing. 
Cell line Treatment Initial Dose Dose Increment  Final Dose  
PEO1 Rucaparib 1 µM 1 µM 20 µM 
PEO1 Cisplatin 10 nM 0.2 µM 2 µM 
PEO1 IR 5 Gy 5 Gy Total IR of 60 Gy 
UWB1.289 Rucaparib 1 µM 1 µM 20 µM 
UWB1.289 Cisplatin 10 nM 0.2 µM 3 µM 
UWB1.289 IR 5 Gy 5 Gy Total IR of 60 Gy 
2.19.2 Drug Dosing 
For each cell line and drug combination, 1 x 106 cells were resuspended in 5 ml of 
appropriate medium supplemented with the appropriate volume of drug, and 
transferred to a sterile 25 cm3 cell culture flask. At the same time, a similar culture 
was set up using medium supplemented with DMSO but no drug. Cultures were 
incubated at 37 °C / 5 % CO2 and assessed at regular intervals for resumption of 
normal exponential growth (by microscopic appearance). Once normal growth had 
resumed in the dosed culture, the next drug dose was applied using the same 
procedure (Table 2-11). 
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2.19.3 Assessment or Resistance 
Following recovery of exponential cell growth after the final drug dose, acquired 
resistance to the drug with which cells were treated and cross resistance was 
assessed relative to respective parental cultures using SRB and clonogenics assays.   
2.20 Statistical Analysis 
Statistical analysis was performed using GraphPad Prism version 6.00 (GraphPad 
Software, La Jolla California USA). Unpaired student t tests or Mann–Whitney tests 
were used depending on a D'Agostino & Pearson omnibus normality test. Multiple 
comparisons were performed using 1-way or 2-way Anova with appropriate multiple 
comparisons correction. All statistical tests were considered statistically significant if 














CHAPTER 3 FUNCTIONAL CHARACTERISATION OF OVARIAN 
CANCER MODELS 
3.1 Introduction 
The term ‘ovarian cancer’ represents a heterogeneous group of tumours in terms of 
histology, molecular characterisation, prognoses and clinical and pathological 
features (Vaughan et al., 2011, Kurman and Shih, 2010). The differences between 
type I and type II ovarian cancer biology and treatment are discussed in chapter 1. 
To investigate novel treatments in ovarian cancer, representative models are needed 
for the different groups. A number of experimental models for the study of ovarian 
cancer are available to the research community, however all have limitations. 
Cell lines that are derived from tumours are the most frequently utilised models in 
cancer research. Existing human ovarian cancer cell lines possess the advantages of 
high proliferative capacity, clonogenicity and extended life span in culture. However, 
most have acquired significant genetic alterations from their cells of origin, loss of 
heterogeneity and are rarely derived from chemotherapy-naive patients (Daniel et al., 
2009, Domcke et al., 2013). Additionally, there is evidence to suggest that many cell 
lines contain significant misidentification, duplication, and loss of integrity (Korch et 
al., 2012, Ertel et al., 2006, Stein et al., 2004, Gillet et al., 2011, Sandberg and 
Ernberg, 2005). 
Primary cells isolated from patients are often considerably different from established 
cell lines of similar origin. The ability to culture and characterise freshly isolated 
cancer cells from patients provides an important experimental system that has the 
potential to resemble the patient situation more accurately (Dunfield et al., 2002, 
Mukhopadhyay et al., 2010). However, primary cultures have slow growth rates and 
short life spans, which limit their use.  
Mouse models have been extensively used in research. Genetically engineered mice 
(GEM) develop cancer either spontaneously (Hardisty, 1985) or following various 
'environmental' exposures such as radiation (Vankranen et al., 1995). The most 
sophisticated animal models, have either knockout of tumour suppressor genes or 
overexpression of oncogenes (Jonkers and Berns, 2002, Frese and Tuveson, 2007). 
The drawback of GEM models is that they do not encompass a human origin and 
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different mutations in the same gene may elicit different phenotypes (Frese and 
Tuveson, 2007). Additionally, human cancers are thought to develop from a single 
mutated cell, whereas in GEM the oncogenic event is initiated simultaneously 
throughout the organ (Frese and Tuveson, 2007). The development of patient 
derived xenograft (PDX) models enabled in vivo assessment of tumour tissue and 
cell lines in immunocompromised mice (Kendall et al., 2006, Rubio-Viqueira and 
Hidalgo, 2009). The drawback of PDX models is the long graft latency, the 
specialised skill set which significantly increases the cost of research and varied 
engraftment success, which has been reported to be higher in more clinically 
aggressive tumours (DeRose et al., 2011, Loukopoulos et al., 2004). Furthermore, 
genetic alterations are more prevalent in engrafted tumours compared with their 
parental cancers (Ding et al., 2010), with less differentiated tumours being more 
prone to changes (DeRose et al., 2011).  
The Helene Harris Memorial Trust meeting in 2004 (Balkwill et al., 2004), outlined a 
number of actions required to improve ovarian cancer outcomes. Development of 
more appropriate and better characterised experimental models was one of the 
actions and is the focus of this chapter.   
3.2 Aims for Chapter 3 
For this study two models for ovarian cancer were optimised. The first model was a 
primary ovarian cancer culture (PCO) model. PCO cultures are derived from ascitic 
fluid collected at the time of surgery for ovarian cancer. This model was previously 
established in the group (Mukhopadhyay et al., 2010, ODonnell et al., 2014). 
The specific aims of characterisation were:  
 To optimise antigen expression characterisation and storage of PCO cultures. 
 To assess the growth of PCO cultures. 
 To assess HR function of PCO cultures. 
 To assess PCO cultures sensitivity to rucaparib and cisplatin and correlate 
with HR function. 
During this project one of the ascitic cultures (PCO 142) immortalised spontaneously. 
This novel cell line was named NUOC-1 and is the basis for the second model to be 
used. The specific aims were to perform the following: 
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 Molecular characterisation, including expression of surface antigens and 
receptors  
 P53 function analysis 
 PTEN functional analysis 
 DNA repair assessment 
 Drug sensitivity assessment  
 Mutational analysis 
 Assessment of  tumourgenicity 
 Copy number alterations analysis 
 Clonal evolution assessment  
3.3 Results 
Between 2011 and 2013, ascites samples were collected from 78 patients. Samples 
were collected by me, Rachel O’Donnell and Angelika Kaufman. Patients enrolled in 
this study were treated at the NGOC at Queen Elizabeth Hospital, Gateshead. The 
histological diagnosis of ovarian cancer was confirmed by independent pathologists 
and surgical stage, grade and cell type were classified according to WHO and FIGO 
standards (Prat 2013). Demographic, surgical and pathological data was collected 
from the hospital and pathology databases (Table 3-1).  
Ascites samples were collected at the time of surgery (65 patients, 83 %) or at the 
time of drainage of symptomatic ascites (13 patients, 16 %). Of the samples collected 
intra-operatively, 53 (82 %) were collected during primary surgery and 12 (18 %) 
during interval surgery following chemotherapy. Erythrocytes and cellular debris from 
ascites did not adhere to the culture flask and were removed following media change. 
Successful growth was achieved in 69 cases (88 %). Three cultures were discarded 
due to infection, three due to failed epithelial characterisation, and 5 cultures were 
excluded based on the pathology reporting non-ovarian cancer. 58 (74 %) cultures 






Table 3-1 Patient characteristics for PCO culture samples. 
Age at diagnosis  Median (range) 63 (43-85) 
Histology HGSOC 41 




Low grade serous 1 
Non ovarian pathology 4 
Stage 1 2 
2 2 
3 A 1 
3 B 1 
3 C 42 
4 6 
NA 4 
Pre-op Ca125 Median 790 
Type of surgery Primary surgery 39 
IDS following NACT  17 
No surgery 2 
Outcome of surgery Complete 11 
Optimal 38 
Suboptimal 7 
No surgery  2 
 
3.3.1 PCO Culture Characterisation  
In general, the appearance of each culture was that of a cobblestone monolayer 
pattern (Figure 3-1.A), as previously described (Dunfield et al., 2002). As they 
approached senescence, cells developed a more mesenchymal phenotype, 
becoming elongated and exhibiting a markedly reduced growth rate.  
3.3.1.1 Antigen expression in PCO Cultures  
Ascitic fluid is composed of multiple cellular components, and in order to confirm 
exclusive growth of cancer cells, characterisation of cultured cells is required. 
Immunoflourescent characterisation of the cultures was carried out using a panel of 
antibodies to detect expression of pancytokeratin, CA125, EpCAM, MOC-31, D2-40 
and Vimentin (Figure 3-1.B-G). Cultures were rejected if they failed to demonstrate 
greater than 95 % cytokeratin positivity. This work was conducted by me, Rachel 
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O’Donnell, Michelle Dixon and Angelika Kaufmann. Further to expression of 
cytokeratin, the majority of PCO cultures expressed an epithelial marker (EpCAM or 
MOC31) or the ovarian marker (CA125) (Figure 3-1 and Table 3-2). 
 
 
Figure 3-1 PCO characterisation panel.  
A. Brightfield demonstrating cobblestone monolayer; immunoflourescent images with 
antibodies targeted against; B. FITC-anti-CK; C. Alexafluor 596 anti-CA125; D. 
Alexflour 488 anti-EpCAM; E. Alexafluor 596 anti-MOC 31; F. Alexaflour 488 anti-
Vimentin; G. Alexaflour 596 anti-D240 (PCO 160 – dysgerminoma).  
 
Table 3-2 Summary of PCO antigen expression. 
Tissue marker Antigen Number 
tested 
Expression N (%) 
Epithelial CK  n=50 46 (100 %) 
EpCAM  n=38 13 (44.8 %) 
MOC31  n=29 11 (45.8 %) 
Ovarian CA125  n=24 11 (45.8 %) 
Germ cell D240  n=21 0 (0 %) 
Mesenchymal Vimentin n=25 23 (95.8 %) 













3.3.1.2 PCO Cultures Growth 
The growth rate of PCO cultures was assessed using SRB assay over a period of 10 
days. The median PCO growth rate was markedly slower than many of the 
commercially available cell lines and highly variable. The median doubling time was 
135 hrs (95 % CI = 104.2 to 284.6 hrs, Figure 3.2). Senescence occurred between 
the 2nd and 8th passages, most commonly between 4th and 5th. Cultures were 
considered unsuccessful when no growth was seen after 28 days (ODonnell et al., 
2014).  
No correlation was demonstrated between growth rate, histological subtype or stage 
of disease at presentation. The relatively slow growth rate may be a consequence of 
























































































































Figure 3-2 Growth rate of PCO cultures. 
Results are doubling time with 95 % CI. Results are average of 6 experimental 
repeats grown for 10 days. Median doubling time was 135 hrs. 
 
3.3.1.3 PCO Cultures Storage  
Paired sets of 50 ml aliquots of ascitic fluid were centrifuged at 400 x G for 5 min (N = 
6). The resultant cell pellets were resuspended in cryopreservative media, stored at -
80°C or in liquid nitrogen and thawed at 6 weeks and 6 months. Cultures were 
successfully grown from both storage conditions after 6 weeks, with no difference 
observed in morphology, growth rate or functional assessment (ODonnell et al., 
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2014). However, following 6 months, a significant difference in success of 
subsequent culture from the two conditions was observed. Ascitic pellets stored in 
liquid nitrogen were successfully cultured in 83 % cases, whereas, no cultures stored 
at -80°C could be successfully grown.  
3.3.1.4 Transfection into PCO cultures 
A number of functional assays require transfection of vectors into cells (Bau et al., 
2007, Ohashi et al., 2005). Two methods of transfection were optimised in PCO 
cultures. Firstly, viral transduction using MISSION™ shRNA lentiviral transduction 
particles was attempted. Cells continued to grow in puromycin media following the 
transduction thus suggesting successful transfection (Figure 3-3). Long term 
transduction could not be assessed due to the short term life-span of the PCO 
cultures.  
Viral transduction is not applicable to all assays and therefore transfection of pGL2 
luciferase expressing vector using Lipofectamine LTX and electroporation was 
attempted. Transfection efficiency was assessed by luciferase expression and 
compared to control cell lines. Despite optimisation, both lipofectamine and 
electroporation transfection methods failed to yield a high enough transfection 
efficiency in PCO cultures for functional assays (Figure 3-4).  
 
















Figure 3-4 Transfection of pGL2 luciferase expressing vector into PCO cultures.  
A. Transfection using Lipofectamine LTX (positive control - OSEC-2 cell line); B. 
Transfection using electroporation at 350mV; C Transfection of 3mg vector using 
increasing voltage. Results are expressed as luciferase readings. 
3.3.2  HR Function in PCO Cultures 
HR function assessment was performed in 41 PCO cultures. HR assays were 
performed by me, Michelle Dixon and Rachel O’Donnell.  
Hypothesis: HR function is defective in 50 % of ovarian cancer cultures  
A two fold increase in γH2AX and RAD51 is used as a cut off to define HRC. > 2 fold 
increase in γH2AX and RAD51 cells are deemed HRC, whilst > 2 fold increase in 
γH2AX but < 2 fold increase in RAD51 cells are deemed HRD (Mukhopadhyay et al., 
2010, Drew et al., 2011). 19 out of 41 (46 %) PCO cultures were deemed HRD and 
22 out of 40 (54 %) of PCO cultures were HRC. However, as can be seen in Figure 
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Figure 3-5 HR function in PCO cultures. RAD51 foci fold rise above controls.   
 
3.3.2.1 Correlation of HR with Progression Free and Overall Survival 
Previously published data demonstrated an association of HRD with improved 
survival (Mukhopadhyay et al., 2012). In this study no significant difference in PFS or 
OS was seen between HRC and HRD groups (Figure 3-6).  
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Figure 3-6 Kaplan-Meier survival curves for PFS/OS by HR status.  
A. Median progression free survival was 14 months for HRC compared to 19 months 
for HRD group, log rank Chi square 1.0 p = 0.31. Patients who had not progressed 
were censored at last follow up. B. Median overall survival was 30 months for HRC 
group and 21 months for HRD group. Log rank Chi square 0.004 p = 0.94. Patients 
were censored at last follow up. 
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3.3.3 Sensitivity of PCO Cultures to Rucaparib and Cisplatin  
For immortalised cell lines, cytotoxicity is assessed over 3 doubling times using SRB 
assay. For PCO cultures it was not feasible to determine the doubling time of each 
culture prior to cytotoxicity assay due to their limited life span. The median doubling 
time for PCO was 134.6 hrs and therefore, a standard incubation time of 10 days was 
adopted. 
The sensitivity of PCO cultures to both rucaparib and cisplatin was assessed using 
SRB assay. The sensitivity for both drugs varied greatly; the median survival of cells 
after 10 days of treatment with 10 µM rucaparib was 63.34 %, and the median 
survival after 10 days of treatment with 10 µM cisplatin was 43.49 %. There was 
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Figure 3-7 Correlation of rucaparib and cisplatin sensitivity of PCO cultures.  
Results are the percentage cell survival after 10 µM rucaparib and the percentage 
cell survival after 10 µM cisplatin treatment. N = 42. 
 
3.3.3.1 Correlation of Rucaparib and Cisplatin Sensitivity with HR Function 
HRD cultures were more sensitive to rucaparib (p = 0.011, Figure 3-8) and more 




Figure 3-8 Rucaparib and cisplatin cytotoxicity in PCO cultures by HR function.  
Cell survival calculated as cell growth after 10 days treatment with 10 µM rucaparib 
or 10 µM cisplatin as a fraction of DMSO. Control growth for PCO cultures was 
assessed by SRB assay, and results were divided by HR status. Error bars are SEM.  
 
3.3.3.2 Correlation of Sensitivity to Rucaparib and Cisplatin with Progression Free 
and Overall Survival 
The correlation of in vitro sensitivity to rucaparib and cisplatin with patient survival 
was assessed. Cultures with < 60 % survival after 10 day treatment with 10 µM 
rucaparib and < 40 % growth after 10 day treatment with 10 µM cisplatin were 
deemed sensitive. Longer PFS and OS were found for cultures deemed to be 
sensitive to rucaparib and cisplatin (Figure 3-9), however the differences were not 
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Figure 3-9 Kaplan-Meier survival curves for PFS/OS by sensitivity to rucaparib and 
cisplatin. Patients who had not progressed were censored at last follow up. 
A. Median PFS was 18 months for rucaparib sensitive compared to 14 months for 
resistant cultures, log rank Chi square 0.15 p = 0.7. N = 20 sensitive and N = 26 
resistant cultures. Patients who had not progressed were censored at last follow up. 
B. Median OS was 67 months for rucaparib sensitive compared to 21 months for 
resistant cultures. Log rank Chi square 2.1 p = 0.14. Patients were censored at last 
follow up. C. Median PFS was 20 months for cisplatin sensitive compared to 16.5 
months for resistant cultures, log rank Chi square 0.2 p = 0.6. N = 25 sensitive and N 
= 12 resistant cultures. Patients who had not progressed were censored at last follow 
up. D. Median OS was 27 months for cisplatin sensitive compared to 21 months for 
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3.3.4 RNA Genome Expression Arrays to Assess HR Function 
DNA micro-arrays have become an established tool to study gene expression 
patterns in ovarian cancers for both diagnostic and prognostic markers (Hibbs, 2004, 
Spentzos, 2004). This approach has the advantages of high throughput analysis, as 
well as using RNA, which can be extracted easily from clinical material including 
FFPE tissues. Gene expression profiling using FFPE samples showed a BRCA-like 
profile in many of the sporadic EOC (Jazaeri, 2002, Konstantinopoulos et al., 2010). 
The ‘BRCAness profile’, now understood to be HRD has been shown to correlate 
with responsiveness to platinum and PARPi.  
Hypothesis: Gene expression profiles for HRD and HRC cultures differ and can be 
used as an assay to predict HR status 
 
Using RNA extracted from the PCO ascitic cultures characterised for HR function, 
genome wide expression was determined by the Oxford genomics centre (Oxford, 
UK) using Illumina Genome Studio and HumanHT 12v4.0 R1 15002873 array, as per 
manufacturer’s instructions, and as described in section 2.12. All RNA samples were 
extracted from the same ascitic fluid primary culture as used in the functional HR 
assay and cytotoxicity assays. 
3.3.4.1.1 Unsupervised Hierarchical Clustering 
In order to identify a potential HRD signature, RNA expression was analysed using 
unsupervised hierarchical clustering (Figure 3-10). PCOs 157 and 142 were clear 
outliers in terms of expression clustering. PCO 142 was later renamed as the NUOC-
1 cell line, as it spontaneously immortalised. The difference in mRNA expression for 
this cell line may therefore be linked to its spontaneous immortalisation. PCO 157 
however, did not immortalise and the reason for its obvious difference in mRNA 
expression is unclear.  
Despite removal of the two outlier samples no clustering by HR function was 














Figure 3-10 RNA Genome expression array.  
A. PCA plot of all PCO samples. Sample relation based on 27343 genes with sd/mean >0.1 HRD cultures are in red and HRC in black. 
B. Dendrogram after normalization. PCO142 and PCO 157 were deemed outliers. C. PCA plot after outlier cultures were removed. 




3.3.4.1.2 Hierarchical Clustering of RNA Expression 
In view of the lack of association in unsupervised clustering, the relative expression 
of 15 key components of the HR pathway were assessed and compared between 
HRD and HRC cultures (Figure 3-11).   
Illumina Genome Studio Gene expression software was used to extract relative gene 
expression across samples, clustering them into functional groups. The comparative 
Ct (ΔΔCt) method was used to assess the expression level of the components of 
each pathway, relative to endogenous controls normalised to the reference panel. 
The expression of two genes were significantly different between the two groups; 
RAD51 (p = 0.008) and XRCC2 (p < 0.0001) were both downregulated in the HRC 
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3.4 Characterisation of NUOC-1 Cell Line 
The NUOC-1 cell line was derived from the ascites of a chemotherapy naive patient 
with a mixed histology tumour. The patient was of Caucasian background and was 
62 years old at the time of diagnosis. She presented with stage IIIC high grade mixed 
ovarian carcinoma and underwent primary surgery. Ascites was collected at the time 
of surgery. The patient was considered optimally debulked, however, due to frailty did 
not receive any chemotherapy and only survived 52 days following surgery. She did 
not have any known relevant familial history. Pathology of the tumour consisted of 
80 % endometrioid, 15 % clear cell and 5 % serous carcinoma. 
The ascites was prepared and processed as described in section 2.2.2. The growth 
of NUOC-1 cells was initially slow, with a 128 hr doubling time at passage 2; but with 
continued culture this decreased to 58 hrs at passage 14.  
3.4.1 Confirmation of Epithelial Origin 
Hypothesis: NUOC-1 cells are epithelial cells 
 
Figure 3-12 NUOC-1 characterisation panel.  
A. Brightfield demonstrating cobblestone monolayer; immunoflourescent images with 
antibodies targeted against: B. Alexafluor 596 anti-CA125; C. FITC-anti-
pancytokeratin; D. Alexflour 488 anti-EpCAM; E. Alexafluor 596 anti-MOC 31; F. 




Upon bright field microscopy examination, a cobblestone morphology, characteristic 
of epithelial cells, was noted; this was maintained during repeated passage. NUOC-1 
cells stained positive for proteins characteristic of epithelial ovarian carcinoma 
(pancytokeritin, EpCAM, MOC31 and CA125), and stained negative for Vimentin 
(Figure 3-12). The epithelial cell phenotype of the NUOC-1 cells and the expression 
of antigens commonly expressed in ovarian cancer were consistently expressed at 
passage 2 and 14.  
3.4.2  Assessment of Hormone and Tyrosine Kinase Receptor Expression 
Hypothesis: NUOC-1 cells express hormone and tyrosine receptors  
The effect of steroid hormones in carcinogenesis has been studied in breast and 
endometrial cancer, with well-known and promising results for therapy. However, for 
ovarian cancer, the results have been conflicting (de Toledo et al., 2014). In NUOC-
1, hormone receptor expression was characterised using western blotting. This work 
was carried out with Eleanor Earp (MRes, 2013).  
For the expression of hormone and tyrosine receptors, appropriate controls were 
selected. The MCF7 cell line was used as a positive control for ER, PR and HER3 
expression; the LnCap cell line was used as a positive control for AR, HER2 and 
HER3 expression. The MDA-MB-231 triple negative breast cancer cell line and AR 
negative PC3 cell lines were used as negative controls. NUOC-1 cells stained 
negative for oestrogen, progesterone and androgen receptors (Figure 3-13). The 
NUOC-1 cells were found to express the HER-3 receptor and the HER-2 receptor at 














































Figure 3-13 Tyrosine kinase and endocrine receptor expression in the NUOC-1 cell 
line. 
NUOC-1 cells express the HER-3 receptor (positive control MCF7) and over-express 
the HER-2 receptor (positive control LNCAP and SKOV3). NUOC-1 cells do not 
express the oestrogen receptor (positive control MCF7), the progesterone receptor 
(positive control MCF7) or the androgen receptor (positive control LNCAP).  Blots are 
representative of three independent experiments. 
3.4.3  p53 Function Assessment 
HGSOC of the ovary is genomically characterised by ubiquitous TP53 mutations 
(Ahmed et al., 2010, Cancer Genome Atlas Research, 2011). TP53 mutational and 
p53 functional status was determined. This work was undertaken with Katharine Elliot 
(MRes, 2013).  
Hypothesis: NUOC-1 cells are wildtype for p53 consistent with endometrioid / clear 
cell origin  
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3.4.3.1 Assessment for P53 Mutations  
TP53 mutation status was assessed by PCR amplification and off-site Sanger 
dideoxy sequencing. No mutations were detected in exons 3-9, but a codon 72 C→G 
(Arg/Pro) polymorphism in exon 4 was detected (Figure 3-14).  
 
Figure 3-14 Illustration of chromatogram of TP53 gene.  
Exon 4 sense sequence codon 72 C→G polymorphism highlighted. 
 
3.4.3.2 Functional P53 assessment 
p53 transcriptionally activates MDM2, which then acts to inhibit further p53 mediated 
transactivation by binding to the transactivation domain located in the N-terminal 
(Kussie et al., 1996). MDM2 exerts further regulatory action by inducing the nuclear 
export and degradation of p53 (Gorringe et al., 2007). The MDM2 antagonist Nutlin-3 
inhibits the MDM2-p53 interaction by binding MDM2 in the hydrophobic cleft, where 
p53 would normally bind. MDM2 antagonism leads to the stabilisation of p53, with 
increases in transcriptional activity, leading to elevated p21 and MDM2 expression 
(Vassilev et al., 2004).  
Treatment with Nutlin-3 resulted in an accumulation of MDM2 in NUOC-1 cell lines, 
corresponding to a concentration-dependent increase in p53 (Figure 3-15). The p53 
downstream growth inhibitory target, p21, also increased in a concentration-
dependent manner. This was consistent with the results in the TP53 wildtype A2780 
cell line. Analysis of the same Nutlin-3 treatment in TP53 mutant CP70 cells showed 





Figure 3-15 MDM2, p53, and p21 expression in response to Nutlin3.  
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Figure 3-16 NUOC-1 cell line response to Nutlin3.  
Results are mean GI50 values between the CP70, TP53 mutant cell line and each 
TP53 wild-type cell line: A2780, NUOC-1. Results are mean of three independent 
experiments. Error bars are SEM. 
 
Nutlin-3 had a higher growth inhibitory effect in TP53 wild-type NUOC-1 cells (GI50 
0.7 µM +/- 0.03 µM) compared to mutant CP70 cells (23.5 µM +/- 0.9 µM; p < 
0.00001), but comparable to TP53 wildtype A2780 (1.3 µM +/- 0.4 µM) (Figure 3-16). 
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3.4.4  NUOC-1 DNA Repair Assessment 
Functional assessment of NUOC-1 HR was undertaken as part of PCO culture 
characterization, as discussed in section 3.3.2. NUOC-1 cells were deemed HRC 
with a 2.84 fold rise in RAD51 foci, compared to untreated controls.  
3.4.4.1 BER Function in NUOC-1 Cells  
Previous studies have reported APE1 overexpression in ovarian cancer as described 
in section 1.4.4 and XRCC1 SNPs. Defects in BER pathway in ovarian cancer have 
not been reported. 
Hypothesis: NUOC-1 cells are BER competent   
Excess production of 8-OHdG inferred the non-functioning of BER and was 
quantified by competitive ELISA in NUOC-1 cells (Figure 3-17). AA8 (BER 
competent) with its derivative EM9 cell lines (BER deficient due to XRCC1 mutation) 
were used as positive and negative controls. The HT 8-oxo-dG ELISA kit II (Trevigen, 
USA, 4380-096-K), is a competition ELISA of immobilised 8-OHdG on pre-coated 
wells with 8-OHdG in the sample for monoclonal antibody binding, which is then 
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Figure 3-17 Base excision repair of NUOC-1 assessed by competitive ELISA. 
Results are the measurement of 8-OHdG levels. AA8 (BER proficient) cell line was 





The mean 8-OHdG in EM9 cells with XRCC1 mutation conferring BER dysfunction 
was 7.42 nM +/- 2.7 Nm, compared to parental BER function in the AA8 cell line of 
0.79 nM +/- 0.54 nM, p = 0.014. NUOC-1 cell 8-OHdG level was 4.0 nM +/- 0.64 nM, 
indicating that NUOC-1 cells were BER defective. Mechanisms of BER deficiency 
were not assessed in this project but may have an important role in NUOC-1 cell 
chemo-sensitivity. 
3.4.5 Drug Sensitivity Assessment 
Ovarian clear cell carcinoma is associated with chemo-resistance and poor prognosis 
(Itamochi et al., 2008). The literature reports an initial response rate (RR) to first-line 
treatment of 22 - 56 % in clear cell carcinoma, which is significantly lower than the 
initial RR of other subtypes of EOC of 80 % (Anglesio et al., 2011).  
Hypothesis: NUOC-1 cells exhibit a chemoresistant phenotype consistent with clear 
cell carcinoma 
The sensitivity to common cytotoxics was assessed using a SRB assay, comparing 
the NUOC-1 cells to the OSEC-2 cells (Table 3-3). This work was done with Eleanor 
Earp (MRes, 2013).  
Compared to the OSEC-2 cells, NUOC-1 cells were found to be more sensitive to 
camptothecin (mean GI50 6.35 nM +/- 2.6 nM for NUOC-1 compared to 172.4 nM +/- 
71.55 nM for OSEC-2, p < 0.0001). NUOC-1 cells were more resistant to paclitaxel 
(mean GI50 251.7 nM +/- 36.5 nM for NUOC-1 compared to 100.9 nM +/- 29.4 nM for 









Table 3-3 Sensitivity of NUOC-1 and OSEC-2 cell lines to cytotoxic agents.  
Results are mean GI50 and 95 % CI assessed by SRB assay. Results are the 
average of 3 independent experiments. 
Cytotoxic agent Mean GI
50
 and 95 % confidence interval Paired t-test  
 OSEC-2                         NUOC-1 P =  
Cisplatin (µM) 2.73 
0.83 to 8.95 
1.46  
0.59 to 3.6 
0.97 
Paclitaxel (nM) 100.9 
71.63 to 142.2 
251.7 
116.2 to 545.4 
0.003 
Camptothecin (nM) 172.4 
86.41 to 343.9 
6.35 
2.98 to 13.53 
<0.0001 
Doxorubicin (nM) 35.52 
21.80 to 57.86 
31.30 
7.41 to 132.3 
0.96 
Rucaparib (µM) 5.53 
2.62 to 11.68 
5.48 
1.67 to 1.80 
0.99 
Irradiation (Gy) 5.1 
3.92 to 6.64 
3.15 
2.23 to 4.45 
0.98 
3.4.6  Assessment for ARID1A Mutations 
Located on chromosome 1, the ARID1A gene encodes for the adenine-thymine (AT)-
rich interactive domain-containing protein 1A. This protein forms an integral part of a 
complex essential in chromatin remodeling, known as the adenosine triphosphate-
dependent chromatin modeling complex switch/sucrose-nonfermentable (SWI/SNF). 
Functioning through epigenetic regulation of gene expression and chromatin, the 
SWI/SNF complex has roles in cell-cycle control, DNA repair and apoptosis (Guan et 
al., 2011, Wu and Roberts, 2013). Mutations in the ARID1A gene are reported in 
46 % of ovarian clear cell carcinomas (Wiegand et al., 2010, Jones et al., 2010).  
Hypothesis: NUOC-1 cells contain ARID1A mutation commonly found in clear cell 
carcinomas 
Assessment of the ARID1A mutation status in NUOC-1 cells and germline DNA was 
undertaken using PCR amplification and off-site Sanger dideoxy sequencing. This 
work was carried out with Eleanor Earp (MRes, 2013). A single T nucleotide insertion 
within exon 9 of the ARID1A gene was found (Figure 3-18). Using the TRANSLATE 
tool within ExPASy (Bioinformatics resource portal) it was predicted that this insertion 




Figure 3-18 Illustration of chromatogram of ARID1A gene.  




Figure 3-19 A schematic of ARID1A protein product.  
Top panel - reference ARID1A transcript and protein. The protein product shows 2 
conserved domains: ARID (located at amino acid position 1017-1104) and DUF3518 
(located amino acid position 1957-2231). Bottom panel - NUOC-1 ARID1A transcript 
and protein. The truncated protein product is 1280 amino acids shorter than the wild-
type and is missing the 2 conserved domains. 
 
As this missense mutation occurs upstream of the two known ARID1A gene 
conserved domains- ARID/BRIGHT DNA binding domain and Domain of unknown 
function (DUF3518), it would almost certainly affect protein function, and it is likely to 
result in a loss of function mutation (Figure 3-19). However, it should be noted that, 
these are virtual translations, and may never be translated due to nonsense 
mediated decay. A review of the COSMIC database did not identify previous reports 
of this exact mutation. Due to the time constraints of this project, protein expression 










3.4.7  PTEN Function  
Located on chromosome 10, PTEN is the primary negative regulator of the PI3K 
pathway. Activation of PI3K signaling is associated with poor prognosis in multiple 
tumour types, including ovarian clear cell carcinoma (Huang et al., 2011b, Kuo et al., 
2009). PTEN’s role in drug sensitivity is still unclear due to conflicting evidence. 
PTEN function in the NUOC-1 cell line and role in drug sensitivity was assessed in 
this study.  
Hypothesis: NUOC-1 cells contain PTEN mutations commonly found in endometrioid 
/ clear cell carcinomas 
PTEN mutations in exons 2-5, 6-7 and 9-10 were assessed using PCR amplification 
and off-site Sanger dideoxy sequencing in the NUOC-1 cell line and matched 
genomic DNA. A point mutation was detected (1508G>GA, 159R>R, Figure 3-20), 
however, no somatic mutations were observed in any of the PTEN coding 
sequences. 
 
Figure 3-20 Illustration of chromatogram of PTEN gene.  
Point mutation of PTEN gene in NUOC-1. 
 
PTEN expression at mRNA and protein level was assessed in NUOC-1 cells using 
RT-qPCR and western blotting (Figure 3-21). OSEC-2 cells were used as positive 
control; LnCap cells, which carry a single deletion of PTEN and a mutated remaining 
allele (McMenamin et al., 1999), and PC3 cells, which have a homozygous deletion, 
were used as negative controls. This work was done with Charlotte Leeson 








Figure 3-21 PTEN expression levels in NUOC-1 cells.  
A. mRNA expression assessed by real time RT-PCR and B. protein expression 
assessed by western blot analysis. LnCap and PC3 cells serve as negative controls 
whilst OSEC-2 is a positive control. 
 
PTEN mRNA expression in NUOC-1 was comparable to OSEC-2 cells and was 
significantly higher than negative controls: LnCap (p = 0.0001) and PC3 (p = 0.0017) 
(Figure 3-21.A). When the protein levels were assessed, NUOC-1 expression of 
PTEN was again comparable to OSEC-2 cells, and no protein bands were visualised 
in LnCap and PC3 cells (Figure 3-21.B). 
3.4.7.1 PTEN Knockdown in OSEC-2 and NUOC-1 Cells 
OSEC-2 and NUOC-1 cells were virally transduced with MISSION®shRNA lentiviral 
transduction particles containing PTEN shRNA, as described in section 2.18. Five 
constructs were used to achieve optimal silencing. Controls were transduced with a 
non-target control construct. In OSEC-2 cells, knockdown was assessed for all 5 
constructs. In NUOC-1 cells, only constructs 2746 and 2747 grew successfully. 
Knockdown levels were confirmed at mRNA level by RT-PCR (Figure 3-22). This 
work was done with Charlotte Leeson (Undergrad, 2013).  
Significant knockdown was achieved in OSEC-2 cells with constructs 2745 (53 %, p 
= 0.005) and 2746 (68 %, p = 0.0005), and in NUOC-1 cells with constructs 2746 
(87 %, p < 0.0001) and 2747 (82 %, p < 0.0001). For consistency, knockdown with 
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Figure 3-22 PTEN mRNA expression in OSEC-2 and NUOC-1 cells.  
mRNA expression was normalised to expression of GAPDH. Results are then 
normalised to non target shRNA = 1. Results are average of three independent 
experiments. Error bars are SEM. 
 
3.4.7.2 PTEN Knockdown Effect on HR  
A link between PTEN loss and HR deficiency is debated, with some groups reporting 
that PTEN attenuates RAD51 gene expression and recruitment to DSBs and 
stabilises replication forks (McEllin et al., 2010, He et al., 2015), whilst others refute 
this (Fraser et al., 2012, Hunt et al., 2012).  
Hypothesis: Loss of PTEN results in HRD 
PTEN knockdown did not significantly affect HR function in either OSEC-2 or NUOC-





Figure 3-23 The effect of PTEN knockdown on HR function. 
Assessed by ƴH2AX/RAD51 foci formation assay after 24 hr treatment with 10 µM 
rucaparib and 2 Gy IR and compared to DMSO treated un-irradiated control. BRCA1 
mutated UWB1.289 cells were used as a HRD control and BRCA1 reconstituted 
UWB1.289+BRCA1 cells were used as a HRC control. Results are mean of 3 
independent experiments. Error bars are SEM. 
3.4.7.3 PTEN Knockdown Effect on Sensitisation to Common Cytotoxics 
PTEN’s role in drug sensitivity is still unclear due to conflicting evidence. The effect of 
PTEN knockdown on drug sensitivity was therefore assessed by measuring growth 
inhibition using a SRB assay. This work was carried out with Eleanor Earp (MRes, 
2013). 
Hypothesis: PTEN in an important determinant of ovarian cancer sensitivity to 
common therapeutic agents 
In OSEC-2 cells, PTEN knock-down had no significant effect on any of the cytotoxic 
agents, sensitivity; whilst in NUOC-1 cells, PTEN knockdown enhanced sensitivity to 
all the cytotoxics assessed, with the exception of camptothecin to which NUOC-1 
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Figure 3-24 Sensitivity of OSEC-2 and NUOC-1 to common therapeutics.  
A. Cisplatin, B. Paclitaxel, C. Campthecin, D. Doxorubicin, E. Rucaparib, F. 




The results from this study suggest that PTEN inhibition increases the sensitivity of 
NUOC-1 cells, but not normal epithelium cells, to cytotoxic agents. Potentially, PTEN 
could be a tumour specific target for chemo and radiotherapy sensitisation if these 
results can be replicated in other models of tumour vs normal tissue. 
3.4.7.4 PTEN Mutations and Expression in PCO Cultures  
Hypothesis: PTEN mutations in ovarian cancer are independent of HR function, but 
are associated with chemo-sensitivity and improved survival 
To further explore the role of PTEN in ovarian cancer, PTEN expression was 
assessed in 28 unselected PCO cultures. DNA from PCO cultures and matched 
genomic DNA were screened for PTEN mutations in exons 2-5, 6-7 and 9-10 using 





Figure 3-25 Illustration of sequence chromatograms of PTEN gene.  
Two point mutations were noted in PTEN gene in PCO cultures. A. 1508G>GA, 
159R>R in 4 cultures and B.1654G>GT, 208G>G/V in 6 cultures. 
The cultures included 20 high grade serous, 7 endometroid / clear cell and 1 
mucinous carcinoma. Mutations that were observed in genomic DNA as well as PCO 
cultures, were excluded. Two somatic point mutations were detected in PCO cultures 
(1654G>GT, 208G>G/V in 6 cultures and 1508G>GA, 159R>R in 4 cultures) (Figure 
3-25). Neither mutation resulted in amino acid change in the PTEN coding 
sequences. The mutations that were found also did not correlate with histological 
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type. Mutations were noted in 2 endometrioid / clear cell carcinomas and 8 high 
grade serous carcinomas. 
Expression of PTEN mRNA was assessed in 34 PCO cultures (Figure 3-26). LnCap 
and PC3 cells were used as negative controls for PTEN expression. The median 
PTEN expression mRNA expression normalised to GAPDH for PCO cultures was 
0.79 this was significantly higher than LnCap (0.212 +/- 0.014, p < 0.0001) and PC3 
(0.006 +/- 0.0007, p < 0.0001). Point mutations which were detected in the panel 
analysed, did not correlate with the mRNA expression in this panel (Figure 3-26). 
This result suggests that the two point mutations have no functional significance.  
 
Figure 3-26 PTEN mRNA expression In PCO cultures.  
Black bars – cell line controls (negative – PC3 and LNCAP, positive – OSEC-1 and 
OSEC-2). Expression is normalised to GAPDH expression. Cultures with point 
mutations are marked with red (1508G>GA) and green (1654G>GT) arrows.  
 
Supporting the findings of knockdown experients, PTEN mRNA expression was not 
found to correlate with HR function (Figure 3-27). There was also no correlation of 
PTEN expression with the sensitivity to rucaparib or cisplatin. Pearsons correlation 



























































































































































































































Figure 3-27 PTEN mRNA expression divided by HR function status in PCO cultures.  
mRNA results are normalised to GAPDH housekeeper gene. 
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Figure 3-28 Correlation of PTEN mRNA expression with sensitivity to cisplatin and 
rucaparib in PCO cultures.  
mRNA results are normalised to GAPDH housekeeper gene. Sensitivity is expressed 
as GI50 in µM.  
 
3.4.7.5 PTEN Influence on Survival of Ovarian Cancer Patients  
The TCGA 2011 ovarian cystadenocarcinoma database was used to validate findings 
in our patient cohort. The alteration rate of PTEN in the TCGA dataset was 25/316 
(8 %) with 2 mutations (1 missense and 1 truncating), and 23 putative copy number 
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changes (2 amplification and 21 deep deletion). A trend approaching significance 
was found for PFS in PTEN mutation cases (Figure 3-29). Median disease free 
survival was 21.22 months in PTEN mutated cases, compared to 15.64 months in 
control cases (logrank test p = 0.06). A similar trend was observed for overall survival 
(median overall survival 55.88 months in PTEN mutated cases, compared to 43.5 
months in control cases (Logrank test p = 0.13), (Figure 3-29).  
Differential PTEN expression was found in 39/316 (12 %) of tumours (upregulation in 
6 and downregulation in 33 cases). There was no association between PTEN mRNA 
expression and PFS (p = 0.22) and OS (p = 0.21). 
 
Figure 3-29 PTEN association with survival benefits from TCGA database.  
Survival curves for PTEN mutated cases N=25 (red line) and control cases N = 291 
(blue line). A. Disease free survival. PTEN alterations N = 21, cases relapsed N = 13, 
median months disease free 21.22. Cases without PTEN alteration N = 239, cases 
relapsed N = 176, median months disease free 15.64. Logrank test P = 0.06 B. 
Overall survival Kaplan-meier estimate. PTEN alterations N = 25, cases deceased N 
= 11, median months survival 55.88. Cases without PTEN alteration N = 290, cases 
deceased N = 170, median months survival 43.5. Logrank test p = 0.13. 
3.4.8 Assessment of the Tumourgenic Potential of NUOC-1 Cells 
Hypothesis: NUOC-1 cells are capable of forming xenografts in SCID mice 
The tumourgenic potential of the cell line was assessed based on its ability to form 
tumours in 8-10 week old female SCID mice at subcutaneous right gluteal sites. Five 
mice were transplanted with 5 × 106 cells suspended in 50 % medium / 50 % v/v 
matrigel subcut. The animals were housed under sterile conditions in a laminar flow 
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environment with ad-lib access to food and water. Tumour formation was assessed 
by observation for 100 days, after which no tumour formation was detected. This 
work was kindly performed by Huw Thomas. 
As subcutaneous site is not the site for ovarian cancer growth, the tumorigenic 
potential of this cell line was then assessed based on its ability to form intraperitoneal 
(IP) tumours in 8-10 week old female SCID mice. 
Firstly, the NUOC-1 cells were transduced with SLIEW lentiviral vector. This vector 
was kind gift from Dr Alex Elder. Transfection was confirmed by an increase in GFP 
expression on FACS flow cytometry, as described in section 2.17.2. Five mice were 
transplanted with 5 × 106 cells suspended in PBS. The animals were housed under 
sterile conditions in a laminar flow environment with ad-lib access to food and water.  
Tumour formation was assessed by non-invasive whole-body imaging at 0, 10, 55 
and 85 days after implantation (Figure 3-30) using the IVIS Spectrum Imaging 
system (Caliper Life Sciences, Hopkington, USA). Animal handling was performed by 
Dr Helen Blair. No formation of ascites was noted in the animals. Luciferase signal 
was present at day 10 and in one mouse at day 55, however the signal reduced over 

























Figure 3-30 NUOC-1 tumourgenicity 
assessment bioluminescent images.  
Mice were transplanted with luciferase-
expressing NUOC-1 cells IP. 
Bioluminescent imaging was performed 
on day 0, 10, 55 and 85. Mice were 
marked with ear notches to allow 
recognition (left notch (LN), Right notch 
(RN), bilateral notches (BN), no 
notches (NN) and 2 left notches (2LN). 
Day 0 images are shown on a different 
radiance scale to avoid image 
saturation.
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Figure 3-31 Quantification of bioluminescent imaging.  
Mice were transplanted with luciferase-expressing NUOC-1 cells IP. Bioluminescent 
imaging was performed on day 0 and day 10. Mice were marked with ear notches to 
allow recognition (left notch (LN), Right notch (RN), bilateral notches (BN), no 
notches (NN) and 2 left notches (2LN). Graph shows the total luminescence for each 


















3.4.9 NUOC-1 Karyotype  
The NUOC-1 karyotype was assessed off-site by the Cytogenetics Laboratory at the 
Newcastle Institute of Genetic Medicine. The result was a composite of four 
metaphases (Figure 3-32). NUOC-1 cells revealed a complex, near-tetraploid 
karyotype, with loss of chromosomes 3,6,11,16 and 19, and structural abnormalities 
including rearrangements of 5q, 9q, 17p and 18q.   
  
Figure 3-32 NUOC-1 karyotype.  
Picture is a representative G-banded metaphase. The result is a composite of 4 








3.4.10  Clonal Evolution in NUOC-1 Cells 
Hypothesis: NUOC-1 cell line is a mixed population of cells which contain gene 
alterations commonly described in Type I ovarian cancers  
To assess clonal evolution, two NUOC-1 subpopulations were derived. NUOC-1 cells 
were split at passage 4 and either grown continuously to passage 14 (NUOC-1-A1) 
or frozen and stored in liquid nitrogen for 12 months before being thawed and the 
also grown to passage 14 (NUOC-1-A2).  
Intra-chromosomal copy number alterations deviating from the baseline copy number 
state (tetrapoloid) were identified in NUOC-1-A1, NUOC-1-A2 and parent NUOC-1 
cells using OmniExpress Exome BeadChip genotyping data. Both sub population cell 
lines carried numerous common copy number alterations, indicating a shared recent 
ancestry (Figure 3-33). However, each cell line also carried a small number of unique 
copy number alterations not seen in the other cell line, indicating ongoing genomic 
evolution. Specifically, NUOC-1-A1 and NUOC-1-A2 carried a total of 121 and 116 
copy number/CN LOH alterations, respectively; of which 107 were common to both 
cell lines. The vast majority (>95 %) of copy number alterations were gains, indicating 
a pro-amplification genotype in both cell lines, with an average amplicon size of 2.6 
Mb and 1.2 Mb in NUOC-1-A1 and NUOC-1-A2, respectively. Furthermore, there was 
clear evidence that both NUOC-1-A1 and NUOC-1-A2 were heterogeneous with 
respect to copy number alterations, with some alterations being present in virtually all 
of the cells whereas, other alterations were clearly carried in sub-clones. There was 
also clear evidence of multiple independent alterations affecting the same genomic 
regions. 
The vast majority of copy number alterations shared by NUOC-1-A1 and NUOC-1-A2 
were also visible in parental NUOC-1 cells. Furthermore, the vast majority of copy 
number alterations seen in NUOC-1-A2 but not NUOC-1-A1 were visible in the 
parental line, but not those copy number changes which were seen in NUOC-1-A1 
but not NUOC-1-A2. The low quality of data derived from parental NUOC-1 cells 
prohibits the visualisation of some small and/or low magnitude copy number 
alterations. The majority of copy number alterations unique to NUOC-1-A1 were not 
discernible in the data derived from parental NUOC-1 cells, thus suggesting that the 
cell population from which NUOC-1-A1 derived was present as a very minor sub-
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clone in the parental NUOC-1 cells. In contrast, the evidence suggests that the cells 
from which NUOC-1-A2 ultimately derived constituted the major population of NUOC-
1 cells.  
With regard to the unique copy number alterations, genes implicated in type II 
ovarian cancer pathogenesis are also affected by copy number alterations in NUOC-
1-A1 and/or NUOC-1-A2 (Figure 3-34). For example, the HINF1B and ERBB2 genes 
are captured by amplicons of 405Kb and 115Kb, respectively, on chromosome 17 in 
both NUOC-1-A1 and NUOC-1-A2 cells. Likewise, the AKT1 gene is captured by a 
155Kb amplicon on chromosome 14. The ARID1A gene is captured by a large region 
of copy neutral loss of heterozygosity on chromosome 1, which could unmask a 
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A- ARID1A, chr 1 
 
 
B - PIK3CA, chr 3 
 
C - PPM1D, chr 17
 
D -AKT1, chr 14
 
E - ERBB2 (HER2), chr 17 
 
F - HINF1B, chr 17 
 
Figure 3-34 Copy number profiles of NUOC-1-A1 and NUOC-1-A2 cell lines.  
Each SNP marker is represented and aligned to its position on the chromosomes as well as its designated copy number state. 
An ideogram of the chromosome is positioned below the SNP marker plots. A. ARID1A captured by a large region of copy 
neutral LOH on chr 1. B. PIK3CA located in a region of apparent copy neutral LOH. C. PPM1D located in a region of apparent 
copy neutral LOH. D. AKT1, captured by a 155Kb amplicon on chr 14. E. ERBB2 (HER2), captured by amplicon of 405Kb on chr 
17. F. HINF1B, captured by amplicon of 115Kb on chr 17.
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NUOC-1-A1 cells had a low level copy number gain affecting the long arm and some 
of the short arm of chromosome 8 that was not seen in NUOC-1-A2. However, 
NUOC-1-A2 has a complex high level amplification on chromosome 8 that captures 
the c-MYC locus (Figure 3-35), and which was present in the dominant clone. It is not 
possible to discern from the genotyping data the exact copy number in either cell line, 
although it is clear that NUOC-1-A1 and NUOC-1-A2 will differ significantly in c-MYC 
gene copy number. 
 
Figure 3-35 Copy number profile of chromosome 8 in NUOC-1 cells.  
A. NUOC-1, B. NUOC-1-A1 and C. NUOC-1-A2 cell lines. Each SNP marker is 
represented and aligned to its position on the chromosomes as well as its designated 
copy number state. An ideogram of chromosome 8 is positioned below the SNP 
marker plots. MYC gene location is marked. 
3.4.11 Assessment of MYC Amplification 
To further analyse the amplification of MYC and the differences observed between 
NUOC-1-A1 and NUOC-1-A2, FISH for MYC analysis was carried out off-site by the 
Cytogenetics Laboratory at the Newcastle Institute of Genetic Medicine. MYC was 
assessed in samples at four stages of cell line development. These included FFPE 
tissue of the tumour (collected at the time of surgery), ascites sample from which 
NUOC-1 was derived (frozen on the day of collection) and the two subpopulations of 
NUOC-1 – NUOC-1-A1 and NUOC-1-A2, using a break apart MYC probe as 
described in section 2.15. The results are shown in Table 3-4 and Figure 3-36. 
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Table 3-4 FISH for MYC results for NUOC-1. 
MYC was assessed in paraffin embedded tumour sample from the patient NUOC-1 
cell line was derived, ascites sample, NUOC-1-A1 and NUOC-1-A2 cells. The 
percentage of normal, increased chromosome and MYC amplified cells is stated. 
HSR - homogeneously staining regions. 
Sample Normal MYC (%) Modal signal 




Paraffin section  20 69 11 
NUOC-1 Ascites  14 4 82, HSR 
NUOC-1-A1 0 98 
MYC x3 (55 %) and 
MYC x6 (28 %) 
2 
NUOC-1-A2 0 0 100 
  
  
   
Figure 3-36 FISH immunofluorescent images for MYC in NUOC-1.  
Results are A. FFPE embedded tumour sample, B. NUOC-1 ascites sample, C. 
NUOC-1-A1, D. NUOC-1-A2. 
 
FFPE section of tumour was found to contain a modal MYC signal pattern x 3~6 in 
69 %, MYC amplification in 11 % and normal MYC signal in 20 % of cells analysed. 
Ascites sample contained 14 % normal MYC expressing cells. These cells are likely 
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to be normal mesenchymal cells present in ascites. The majority of cells contain MYC 
amplification (82 %) with a small number of modal signal pattern (4 %) also. This 
finding demonstrates heterogeneity between ascites and solid tumour.  
The differences of MYC between NUOC-1-A1 and NUOC-1-A2 are very clear and 
closely relate to the findings from the SNP array. Mostly modal signal pattern was 
detected in NUOC-1-A1 (98 %), which would be seen as normal copy number in the 
SNP array, in comparison to 100 % MYC amplification observed in NUOC-1-A2. Also 
consistently the results support the hypothesis that NUOC-1-A2 forms the major and 
NUOC-1-A1, the minor clones in the original cell line. Importantly NUOC-1-A1 is likely 
to represent a major clone in the solid tumour based on MYC expression. However, 
this hypothesis needs to be assessed using other targets. 
No separation of MYC probes was seen in cells with increased chromosome 
numbers, suggesting that MYC translocation was not present. In cells with HRS 
amplification, greater numbers of first compared to second probe were observed. 
This suggests the presence of varied size amplicons. 
3.5 Chapter Summary 
In this study two models of ovarian cancer were characterised. PCO cultures were 
generated with an 88 % success rate. The main findings included: 
 Slow growing and to senesce at passage 4-5.  
 Variable expression of antigens including epithelial markers and CA125. 
 Viral particle transduction into PCO cultures was optimised, but transfection 
using Lipofectamine and electroporation was not possible. 
 46 % of PCO cultures were found to be HRD. HRD correlated with increased 
sensitivity to rucaparib and cisplatin in vitro, but not clinical survival outcomes. 
During the project one PCO culture immortalised and was therefore characterised as 
a novel ovarian cancer cell line. NUOC-1 was derived from the ascites of a chemo 
naive, caucasian patient at the time of primary surgery. Evidence of intra-tumour 
heterogeneity between solid and ascites samples was found during the analysis of 
MYC expression. The main findings included:   
 Expression of Pancytokeritin, EpCAM, MOC31 and CA125, but not Vimentin.  
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 No expression of oestrogen, progesterone and androgen receptors, but 
positive expression of HER-3 and overexpression of HER-2 receptor.  
 NUOC-1 cells were wildtype for p53 and PTEN. 
 ARID1A mutation. 
 Knockdown of PTEN resulted in, growth inhibition and sensitisation to 
cytotoxic agents. 
 Near tetraploid karyotype, with chromosomal abnormalities of all 
chromosomes and mixed population of cells.  
 Failure to form tumours in SCID mice.  
 Unstable and pro-amplification tendency.  
 Two subpopulations were derived which were isogenic for MYC amplification. 
NUOC-1-A1 formed minority population in NUOC-1 parent line whilst NUOC-1-
A2 formed the majority subpopulation.  
3.6 Discussion 
In order to establish new cellular models of ovarian cancer, all the samples of ovarian 
tissue collected by our group were processed to derive PCO cultures (ODonnell et 
al., 2014). Two distinct models for the study of ovarian cancer were characterised in 
this chapter.  
3.6.1 Characterisation of PCO Cultures 
The ability to generate and utilise primary cultures of ovarian cancer has several 
advantages over other models, including established cell lines and animal models. It 
is now recognised that many cell lines in long term culture will undergo further 
genetic aberrations rendering them dissimilar from their tissue of origin. Furthermore, 
even a large panel of cell lines cannot accurately represent the heterogeneity that is 
seen in EOC. The 88 % success rate of viable cultures of epithelial cells is sufficiently 
high to justify the feasible use of these techniques in clinical practice if diagnostic 
tests were developed. Furthermore, the ability to store cultures in liquid nitrogen long 
term allows the possibility of collaboration for research or post hoc diagnostic 
analysis. One of the strengths of developing models of viable cancer cells is that it 
allows for the use of functional assays which would not be possible using FFPE 
tissue or even fresh frozen tissue. This is likely to become increasingly important in 
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the development of biomarkers for treatments which depend upon the dysregulation 
of a complete pathway, as opposed to aberration of a single gene. 
It is not clear why culture from ascites is unsuccessful in a proportion of cases, why 
senescence occurs at variable passages or why only one culture has immortalised. It 
is likely, that this is a consequence of a lack of the essential factors required for 
growth, which are provided in vivo by the complex interactions within the tumour 
microenvironment, but are absent in the artificial culture setting. A recent study 
described a novel method for establishing cell lines from primary tumour cells using a 
novel medium with a much higher success rate of immortalisation (Ince et al., 2015). 
A further explanation could be that cells in the ascites are not always the most viable 
of tumour cells and stem cells need to be considered.  
3.6.2 HR Function in PCO Cultures  
As previously demonstrated (Mukhopadhyay et al., 2010), 46 % of PCO cultures 
were found to be HRD; and HRD cultures were found to be more sensitive to 
rucaparib and cisplatin, compared to HRC cultures. Replication of these findings 
provides further support for the constancy of HRD in ovarian cancer, and the 
importance of HRD in platinum and rucaparib sensitivity. The literature suggests a 
correlation between chemo sensitivity to platinum and PARPi. In clinical studies, 
response to the oral PARPi olaparib correlated with platinum free interval (Fong et 
al., 2010). The result from PCO cultures supports this finding with a positive 
correlation between ex vivo sensitivity to rucaparib and cisplatin.  
Lack of association between HR function and survival was contradictory to previous 
evidence (Mukhopadhyay et al., 2012). Furthermore, ex vivo sensitivity to rucaparib 
and cisplatin was also not associated with a statistically significant difference in 
survival. The lack of association observed may be due to a number of factors. Firstly, 
the survival data is not complete, due to time limitations of the project. Assessment of 
this data in a few years with complete set of clinical data may provide different 
findings. Secondly, the standardised SRB protocol used, which did not take into 
account the doubling time of individual cultures, may have overestimated sensitivity 
in rapidly growing cultures and underestimated sensitivity in slow growing cultures. 
Thirdly, the assessment of ex vivo cultures only translates into clinical survival if the 
cultures are representative of the tumour. The adherent monolayer of cells cultured 
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may only represent one subpopulation of ascitic cells collected. Assessment of how 
representative PCO cultures are of the residual microscopic tumour following surgery 
are still required. Evidence from NUOC-1 MYC assessment demonstrate discordance 
between the ascites and solid tumour sample as well as a mixed population which 
over time developed into two separate cell lines. To capture the heterogeneity of 
PCO cultures the characterisation of PCO cultures should therefore ideally be 
performed at time 0, prior to passage. Finally, this analysis has not taken into 
account histological subtype, the residual volume of tumour at the end of surgery, 
and chemotherapy treatments actually given, which have all previously been 
identified as being important in the prediction of clinical outcome (Von Heideman, 
2014). 
3.6.3 Prediction of HR Function by Genome Expression Arrays 
There is a pressing need to identify biomarkers of HRD which would predict the 
benefit from PARPi in ovarian cancer and potentially multiple other cancer types, 
regardless of the underlying molecular mechanism (Turner, 2011). Several 
approaches to the identification of HRD tumours using mutational screening, gene 
expression profiling, loss of heterozygosity (LOH) assays, telomeric allelic 
imbalances and large scale transition scores have been developed (Watkins et al., 
2014). These gene signatures, however, have not yet achieved widespread use. 
Several unsupervised multi-strategy approaches and statistical methods have been 
developed from a high throughput genomic data to identify differentially expressed 
genes (Liu, 2010, Li, 2008, Kang, 2012) and may represent a superior method of 
analysis in future studies. The ongoing ARIEL 2 (NCT01891344), a phase 2 trial of 
rucaparib therapy for women with relapsed HGSOC or endometrioid ovarian cancer, 
aims to identify a molecular signature of HRD. This will be evaluated further in ARIEL 
3 (NCT01968213) which aims to assess rucaparib as a maintenance therapy.  
The unsupervised hierarchical clustering in this small dataset found no difference in 
RNA expression signatures between HRD and HRC cultures. The upregulation of 
RAD51 and XRCC2 in HRD cultures is promising, but should not be over interpreted. 
It is unlikely that one marker in isolation is capable of predicting function of the entire 
pathway. The significantly higher RAD51 expression in HRD cultures in comparison 
to HRC cultures was unexpected. Based upon the HR pathway, higher RAD51 
expression was hypothesised in HRC cultures. The HR assay is not based upon 
 126 
 
absolute levels of RAD51 to determine functional status, but a change in level in 
response to DNA damage. This higher baseline level in the HRD cultured may 
therefore represent dysfunctional Rad51 present in the nucleus of HRD cells. This 
finding needs to be explored further.  
3.6.4 Molecular Characterisation of NUOC-1 Cell Line 
In this study the establishment and characterisation of a novel ovarian cancer cell 
line, derived from a chemotherapy naïve patient has been described. PCO cultures 
provide a model that better represents the tremendous heterogeneity of ovarian 
cancer. This however, has a major limitation, in that the very short life span and slow 
growth limits the characterisation that is possible in these cultures, as well as their 
use in repeat experiments. Of the 156 primary cultures established in our laboratory 
so far, NUOC-1 is the only culture to spontaneously immortalise. NUOC-1 cells 
continue to maintain their morphology and epithelial marker expression over 
repeated passages.  
A recent meta-analysis found that progesterone receptor (PR) expression predicted 
favourable survival, while HER2 expression had a negative effect on survival. NUOC-
1 was found to be hormone receptor negative and tyrosine receptor positive. This is 
consistent with the very poor survival observed in this patient. This phenotype of 
NUOC-1 cells would make this cell line a useful model in study of receptor function.   
3.6.5 NUOC-1 Cell Line Represents Endometrioid / Clear Cell Ovarian 
Carcinoma 
NUOC-1 cells were found to contain a polymorphism in exon 4, however functional 
assessment determined that NUOC-1 cells were wildtype for p53. NUOC-1 cell line 
was derived from ascites of a mixed histology tumour. TP53 mutations are reported 
in the majority of serous ovarian cancer (Ahmed et al., 2010, Cancer Genome Atlas 
Research, 2011), therefore the p53 wildtype phenotype of NUOC-1 is inconsistent 
with HGSOC histology and suggests that the small proportion of HGSOC cells were 
not represented in the sample or failed to immortalise in culture. A recent study has 
also demonstrated that HGSOC establish cell lines less frequently (Domcke et al., 
2013).   
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Therefore, the NUOC-1 cell line probably represents endometrioid / clear cell ovarian 
carcinoma. The endometrioid and clear cell carcinomas are both linked to 
endometriosis and contain similar driver mutations. Endometrioid / clear cell histology 
for NUOC-1 is also supported by the findings of alterations in genes that are 
commonly altered in these tumours. These included an insertion mutation in the 
ARID1A gene. As well as the ARID1A gene being captured by a large region of copy 
neutral LOH on chromosome 1 found on SNP array. ARID1A is reported to be lost or 
mutated in 50 % of clear cell carcinoma (Anglesio et al., 2011, Tan et al., 2013). 
Other genes located in regions of copy neutral LOH included PIK3CA and PPM1D. 
PIK3CA has been reported to be mutated in 40 %, and PPM1D in 10 %, of clear cell 
carcinomas (Anglesio et al., 2011, Tan et al., 2013). SNP array also found AKT1, 
ERBB2 and HINF1B to be captured by amplicons. HINF1B is reported to be 
upregulated in almost 100 % of clear cell carcinoma (Anglesio et al., 2011, Tan et al., 
2013). AKT and ERBB2 amplifications are reported in 14 % of clear cell carcinoma 
(Anglesio et al., 2011, Tan et al., 2013). Resistance to paclitaxel, as exhibited by 
NUOC-1 cells, is also commonly seen in clear cell carcinoma (Itamochi et al., 2008).  
3.6.6 PTEN is a Potential Target for Ovarian Cancer Sensitisation to Cytotoxic 
Agents 
PTEN mutations are reported in 50 % of clear cell / endometrioid carcinomas. NUOC-
1 cells were found be wildtype for PTEN. As a negative regulator of growth it was 
hypothesised that PTEN inhibition would increase chemo-resistance. Chemo-
resistance, particularly to cisplatin has been reported in PTEN-mutated cancers 
(Keniry and Parsons, 2008, Stewart, 2007). However, in this study, PTEN knockdown 
caused chemo- and radio-sensitisation in NUOC-1 cells, but had no effect in OSEC-2 
cells.  
In the PCO model, no association between PTEN expression and sensitivity to 
rucaparib or cisplatin was observed. This was supported by a lack of association of 
PTEN expression with survival in the TCGA cohort. This difference may be due to 
histological differences between NUOC-1 and PCO cohorts, as the majority of PCO 
cultures were HGSOC, and only 8 endometrioid / clear cell. A further explanation for 
the difference may be that knockdown models represent in vitro alteration of PTEN 
expression, which may not be representative of baseline activity in PCO cultures 
(Hunt et al., 2012). Previous groups have similarly found that experimentally removed 
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PTEN in cell line models do not behave like cancer cells developed in a PTEN-null 
genotype context, possibly due to accumulated genetic aberrations that occur in a 
PTEN-independent manner (Hunt et al., 2012). An important further reason for the 
lack of association is that only mRNA expression was assessed. Post translational 
modification including phosphorylation, acetylation, methylation, oxidation have been 
reported (Minami et al., 2014). 
Additionally PTEN loss has been demonstrated to induce sensitivity to PARPi in cell 
line models, however recent findings from TOPARP trial (NCT01682772) indicate 
that PTEN loss does not confer sensitivity to PARPi (Mateo et al., 2015). However, 
association of PTEN mutations with a trend towards improved survival suggests that 
PTEN loss may be a useful biomarker for treatment sensitivity and survival 
outcomes. These results need to be validated in further large cohorts of ovarian 
cancer.  
A link between PTEN loss and HR deficiency is debated with some groups reporting 
that PTEN attenuates RAD51 gene expression and recruitment to double strand DNA 
breaks (McEllin et al., 2010), whilst others refute this (Fraser et al., 2012, Hunt et al., 
2012). In this study no association of PTEN with HR function was found, either in 
knockdown models or our primary culture cohort. These results provide further 
evidence to suggest that PTEN has little or no role in HR pathway function.  
3.6.7 NUOC-1 Cells are HRC, but BER Defective 
Functional assessment found NUOC-1 cells to be HRC. This finding is supported by 
the sensitivity of NUOC-1 to rucaparib, cisplatin and irradiation, being equivalent to 
the OSEC-2 cell line, which was derived from normal ovarian epithelium.  
NUOC-1 cells were found to be BER defective. NUOC-1 cells were also exquisitively 
sensitive to the Topo I poison camptothecin. Sensitivity to Topo I poisons due to BER 
defects has been previously demonstrated comparing isogenic cell lines EM9 and 
AA8 (Plo et al., 2003). Further confirmation of BER defects could be confirmed by 
assessing sensitivity to H2O2 and temozolomide and topotecan. BER defective cells 
have been shown to be sensitive to all these therapies (Illuzzi and Wilson, 2012). 
Stratification of ovarian cancer by BER status would be useful in selection for second 
line therapy with topotecan versus liposomal doxorubicin. The NUOC-1 cell line is 
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therefore a useful model for the assessment of further novel therapeutics in BER 
defective ovarian cancer. 
3.6.8 Xenograft Development was not possible from NUOC-1 Cells 
NUOC-1 cells were not able to form xenografts in SCID mice. It has been previously 
suggested that cell lines derived from patients with indolent disease exhibit low 
tumourgenicity (Laks et al., 2009). This is not the case for the NUOC-1 cell line, as 
the patient from which the cell line originated had extremely aggressive disease and 
lived only 52 days post optimal debulking surgery. Whilst the inability of NUOC-1 
cells to form xenografts limits its use by some researchers, this should not detract 
from the phenotype of this cell line. Furthermore, NUOC-1 tumourgenicity in mice 
with complete absence of immune function was not assessed due to the time and 
resource limitations of this study. 
3.6.9 NUOC-1 Cells Reflect the Genomic Instability and Heterogeneity of 
Ovarian Cancer 
The results obtained with the G-banding karyotype reflect previously published 
karyotype studies on epithelial ovarian cancer, where high genomic instability is 
observed (Deger et al., 1997). Low grade cancers generally have a normal karyotype 
and therefore the NUOC-1 karyotype would suggest it to be a high grade clear cell / 
endometrioid tumour.  
The heterogeneity of cells observed in NUOC-1 better reflects the heterogeneity of 
ovarian cancer not seen in cell lines derived from a single clonal population. SNP 
array results provide further insight into the extensive genomic alterations present in 
this cell line. Further investigation of the lesions in this cell line in the NUOC-1-A1 
and NUOC-1-A2 subpopulations may provide insights into the molecular events that 
contribute to ovarian cancer initiation and progression. 
High levels of c-MYC have been linked to poor PFS and OS in ovarian cancer and 
siRNA-mediated c-MYC silencing has been explored as a potential target in platinum 
resistant ovarian cancer with positive results (Reyes-Gonzalez et al., 2015). SNP and 
FISH analyses of MYC provide evidence for heterogeneity of solid tumour and 
ascites samples and for NUOC-1-A2 subpopulation being derived from a majority 
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and NUOC-1-A1 from a minority population of the ascites. The two subpopulations of 
NUOC-1 provide a good isogenic model for the exploration of c-MYC.  
3.7 Future Work 
Validation of targets identified by SNP array are planned to be carried out. Validation 
of ERB2 expression by IHC in FFPE tissue of the tumour is also planned. ERB2 
validation will be carried out in collaboration with the Pathology Lab at the Royal 
Victoria Infirmary. Completion of ARID1A protein and function assessment in NUOC-
1 culture would add to the characterisation of the cell line. Furthermore, assessment 
of PTEN mutational and functional status in a larger cohort of PCO cultures would 
add to the body of knowledge of the role of PTEN in ovarian cancer.   
Further to the submission of the NUOC-1 cell line manuscript for publication, the 
immediate plan for the cell line is to make it commercially available. The unique 
phenotype of the cell line which has been extensively characterised here, would 














CHAPTER 4 ASSESSMENT OF NHEJ FUNCTION IN OVARIAN 
CANCER  
4.1 Introduction 
The NHEJ pathway plays an important role in genome maintenance after DNA 
damage. NHEJ has been demonstrated to repair up to 90 % of DNA DSBs in human 
cells and to function throughout the cell cycle (Valerie and Povirk, 2003). As 
discussed in section 1.4.5.2, the classical NHEJ pathway is initiated by the binding of 
the Ku heterodimer (Ku70 and Ku80) to a DNA DSB and subsequent association, 
and autophosphorylation of the DNA-dependent protein kinase catalytic subunit 
(DNA-PKcs) (Walker et al., 2001). This trimeric DNA-PK complex facilitates ligation by 
recruitment of the XRCC4/LIG4 complex. Mutations in classical NHEJ pathway 
components have been linked to immunodeficiency and developmental abnormalities 
(O'Driscoll et al., 2004, Sekiguchi and Ferguson, 2006). Furthermore, underactivity of 
the NHEJ pathway has also been linked to bladder cancer (Bentley et al., 2004, 
Bentley et al., 2009, Windhofer et al., 2008) and leukaemia (Gaymes et al., 2002, 
Deriano et al., 2005). These findings underscore the importance of the NHEJ 
pathway for maintaining genome integrity. 
The DNA damage response (DDR) is becoming increasingly recognised as an 
important determinant of response to cancer therapeutics. This interest was initially 
provoked by the paradigm shifting discovery that inhibition of BER with PARPi was 
synthetically lethal in HRD tumours (Bryant et al 2005, Farmer et al 2005). PARPi 
were therefore selectively targeting the defect arising in the tumour, but not in normal 
tissues (Ashworth, 2008b, Bryant et al., 2005, McCabe et al., 2006). Given the 
finding that ≥ 50 % of ovarian cancer were HRD (Mukhopadhyay et al., 2010, Cancer 
Genome Atlas Research, 2011), as well as building evidence for efficacy of PARPi in 
ovarian cancer, means that PARPi are likely to play an important role in the future 
treatment of ovarian cancer. A number of studies also indicate a connection between 
NHEJ and PARP-1. In particular, PARP-1 interacts with the Ku proteins in vitro and in 
vivo (Wang et al., 2006b, Galande and Kohwi-Shigematsu, 1999, Couto et al., 2011), 
and Ku70, Ku80 and DNA-PKcs have been shown to be capable of binding to ADP 
ribose polymers (Pleschke et al., 2000, Li et al., 2004a, Gagne et al., 2008). The 
genetic ablation of KU70 and LIG4 has been shown to restore the survival of PARP1-
deficient cells exposed to agents inducing DSBs (Wang et al., 2006b, Hochegger et 
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al., 2006). Also, DNA-PK inhibition and depletion has been shown to result in HR 
function recovery and PARPi resistance in vitro (Patel et al., 2011).  
Many in vitro studies have demonstrated that complementary DNA ends are joined in 
an efficient and accurate manner by NHEJ (Baumann and West, 1998, Labhart, 
1999). However, in vivo, DSBs are often chemically modified, staggered, and/or are 
comprised partially or completely of incompatible DNA ends that require modification 
before joining can take place (Valerie and Povirk, 2003). The recruitment of proteins 
involved in the processing of DNA ends depends on the type of modification required 
(Bentley et al., 2004). Such end processing may result in the loss of a small number 
of terminal nucleotides at the resultant junctions, such that NHEJ is an error prone 
repair pathway and is potentially a mutagenic process (Lieber et al., 2003).  
In the absence of the classical NHEJ pathway, there is evidence that an alternative 
Ku-independent mechanism for the end-joining (A-EJ) of DSBs can be utilised 
(Pannunzio et al., 2014, Rai et al., 2010, Iliakis et al., 2004, Wang et al., 2003, Yan et 
al., 2007, Corneo et al., 2007). This mechanism uses small regions of microhomology 
at internal sites on the DNA substrate, but unlike HR, A-EJ is inherently error-prone. 
This is because the use of microhomology leads to deletion of sequences from the 
strand being repaired, and also to chromosomal translocations (Ceccaldi et al., 
2015a, Mateos-Gomez et al., 2015). A-EJ has recently been reported to be 
overexpressed in HGSOC (Ceccaldi et al., 2015a), however, to date NHEJ function 
in ovarian cancer is unknown. The selection of repair mechanisms has been 
discussed in section 1.4.5.4. 
A number of methods for assessing the function of a pathway are described in the 
literature. Mutations of the genes in question can be used to assess the function of a 
pathway. The benefit of this method is the applicability of a high throughput approach 
in analysing large numbers of samples. Furthermore, many publically available 
databases have already analysed mutations in genes in the NHEJ pathway. 
However, not all mutations result in functional alterations and therefore may not have 
any impact on the function of the gene or the overall pathway. In the NHEJ pathway, 
the majority of mutations reported are SNPs, with many of them having contradicting 
reports of functionality and association with cancer, as summarised in appendix 1.  
mRNA and protein expression may be a better assessment of pathway function. 
However, the minimal expression required for the pathway to function is unclear for 
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many proteins. Functional assessment of the pathway would evaluate its function 
independently of alterations of specific genes. For this study, NHEJ function was 
examined using functional assays. Furthermore, possible biomarkers for clinical 
application and heterogeneity of the NHEJ function were assessed.    
4.2 Aims for Chapter 4 
Despite the mounting evidence for NHEJ role in PARPi sensitivity, NHEJ function has 
not been investigated in ovarian cancer in vivo to date. The aim for these 
investigations was therefore to assess NHEJ function in ovarian cancer cultures, and 
to relate the function to HR competence and to rucaparib and cisplatin sensitivity. 
Specifically the experimental aims were as follows:  
 Optimise functional NHEJ assays.  
 Assess NHEJ function in a panel of ovarian cancer cell lines and a panel of 
primary ovarian cancer cultures. 
 Correlate rucaparib and cisplatin sensitivity with NHEJ function. 
 Assess the expression of NHEJ mRNA and protein, and correlate the 
expression with end joining competence. Assess the feasibility for the use of 
mRNA and protein expression as possible biomarkers. 
 Assess DNA-PK autophosphorylation, as a potential biomarker for NHEJ 
function. 
 Validate NHEJ biomarkers in FFPE tissue from tumour samples matched to 
ascites samples.  
 Examine heterogeneity of NHEJ function in ovarian cancer.   
4.3 Results 
The TCGA bioportal was used to assess the frequency of NHEJ gene aberrations in 
a primary ovarian cancer cohort (Figure 4-1). Assessment of the TCGA data found 
aberrations in NHEJ genes in 60 % of cases. The majority of alterations (41 %) were 
found in XRCC6 (Ku70). The alterations included amplifications, deletions and 
mutations. At mRNA level both up and downregulation were reported. It is unclear as 














Figure 4-1 NHEJ gene aberrations reported in the TCGA database.  
NHEJ genes were found to be altered in 190 (60 %) of 316 cases / patients.
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4.3.1 Optimising NHEJ Assay 
A number of assays are described in the literature for assessing end joining. Two 
assays were selected from a literature review, and optimised for this study. The 
selected end joining assays were initially optimised in a cell line derived from normal 
ovarian epithelium (OSEC-2) and cell lines with known NHEJ function, by using DNA-
PKcs competent and defective isogenic cell lines.  
4.3.1.1 End Joining Accuracy Depends on DSBs Compatibility 
Three vectors were used for this assay, all were a kind gift from Dr A. Kiltie, Oxford. 
Digestion with BstXI resulted in the formation of either compatible DSB (Co), 2 base 
mismatch (2I) or 4 base mismatch (4I) (Figure 4-2). The digestion optimisation is 
described in section 2.6.1.2. 
 
Figure 4-2 Diagrammatic representation of BstXI digested products. 
 
T4 ligase ligated Co substrates, but incompatible substrates could not be joined 
without the addition of the appropriate λDNA (Figure 4-3). OSEC-2 cells were able to 
rejoin 34.8 % of Co, 15.9 % of 2I and 13.7 % of 4I substrates (Figure 4-3 and Figure 
4-4). The addition of the λDNA fragment increased the rejoining rate of incompatible 
substrates (50.8 %, p < 0.001 of 2I and 43.3 %, p = 0.0004 of 4I), but had no effect 
on the rejoining of compatible substrates. As both 2I and 4I had similar rejoining 
rates, assessment of cell line and PCO panels was performed using Co and 2I 




Figure 4-3 Rejoining of BstXI substrates.  
Results are for compatible (Co), 2 base mismatch (2I) and 4 base mismatch (4I) 
substrates with or without addition of λ substrate by T4ligase and OSEC-2 cells. 
Successful rejoining is demonstrated by the presence of multimer bands. Gels are 
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Figure 4-4 Densitometry quantification of OSEC-2 rejoining of BstXI substrates.  
Results are for compatible (Co), 2 base mismatch (2I) and 4 base mismatch (4I) 
substrates, with or without addition of λ substrate. Rejoining of results are expressed 
as total rejoined products / total DNA loaded. Error bars are SEM. 
 
Comparison of the rejoining undertaken in paired DNA-PK deficient and proficient cell 
lines, demonstrated that whilst compatible ends are largely rejoined correctly by all 





Figure 4-5 PCR analysis of cell line rejoining of Co or 2I BstXI substrates. 
Cell lines used were: V3YAC (DNA-PKcs corrected) and V3 (DNA-PKcs deficient), 
M059FUS-1 (DNA-PKcs corrected), M059J (DNA-PKcs deficient). The rejoint 
products were amplified using pFOR and pREV primers. Correct rejoining produces 
products of 551bps. Inaccurate rejoining with loss of bases results in smaller or no 
product formation. Gels are representative of 3 independent experiments. 
4.3.1.2 Confirmation of NHEJ Inhibition by NU7441 
The DNA-PK inhibitor NU7441 was found to inhibit end joining in a concentration-
dependent manner in DNA-PKcs complemented V3YAC cells, but had no effect in 
DNA-PKcs deficient V3 cells (Figure 4-6).  
 
Figure 4-6 Inhibition of end joining of BstXI digested Co substrates by NU7441.  
Results are for V3YAC (DNA-PKcs proficient) and V3 (DNA-PKcs deficient) cell lines. 
End joining is analysed by agarose gel electrophoresis and GelRed staining. Gels 
are representative of three independent experiments. 
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4.3.2 DNA End Joining in Established Epithelial Ovarian Cancer Cell Lines 
To ensure the cell free extract assay represented the cellular end joining accurately, 
NHEJ function was assessed in a panel of immortalised cell lines using both the cell 
extract assay and a cellular luciferase assay.  
Whilst immortalised non-cancerous ovarian surface epithelium OSEC cells were able 
to rejoin 2I ends accurately, four of the six EOC cell lines were unable to rejoin 2I 
substrate, thus indicating NHEJ deficiency (Figure 4-7). This correlated with a mean 
accurate rejoining rate of 24.6 % (95 % confidence interval (CI) = 11.5 to 37.6 %) by 
cell lines capable of rejoining 2I substrates, compared to 11.5 % (95 % CI = 6.8 to 
16.3 %, p = 0.03) by cell lines unable to rejoin 2I substrates, when assessed using 
the luciferase cellular assay (Figure 4-8), (pearson correlation r = 0.79 p=0.007, 




Figure 4-7 End joining of compatible and 2I BstXI substrates by ovarian cell lines.  




Figure 4-8 Intracellular end joining of linearised pGL2 vector by cell lines.  
Measured as precise rejoining / overall end joining x 100. Data are average of three 
independent experiments. Error bars are SEM. 
 
Figure 4-9 Correlation of luciferase cellular assay and cell extract assay.   
4.3.3 DNA End Joining in PCO Cultures 
To understand if the frequency of NHEJ defects in immortalised cell lines represents 
the frequency in ovarian cancer in vivo, NHEJ function was assessed in a collection 































































R e jo in in g  a s s e s s e d  b y









































n  =  1 0
r  =  0 .7 9




























4.3.3.1 Cell Extract NHEJ Assay Optimisation in PCO Cultures 
Hypothesis: Functional assessment of NHEJ can be undertaken in primary ovarian 
cancer cultures  
Rejoining by PCO extracts was optimised using PCO 138, 139 and 142 (Figure 4-
10). For each PCO culture two extracts were prepared from passages 1 and 2. 
Consistent rejoining was noted between passages. For the remainder of the study, 
end joining was quantified using 3 separate lysates for each PCO culture from 












Figure 4-10 End joining of compatible BstXI substrates by PCO cultures.  
GelRed detection and quantification of end joining of BstXI A. compatible and B. 2I 
incompatible substrates. Gels are representative of 3 independent experiments. 
T4Ligase, OSEC-2 and V3YAC (DNA-PKcs corrected) were used as positive 
controls. V3 and M059J (both DNA-PKcs deficient) cell lines were used as a negative 
controls. Water was used as a contamination control. 
 
As described in section 3.3.1.4, transfection of vectors into PCO cultures was not 
possible. Therefore, the decision was made to assess end joining function using the 













4.3.3.2 NHEJ Function in PCO Cultures  
Hypothesis: NHEJ pathway is defective in a significant proportion of ovarian cancer 
cultures  
NHEJ was assessed in 40 PCO cultures. There was significant inter-sample 
variability (rejoining range 5 % to 39 % of loaded DNA). The majority of extracts end 
joined DNA substrates to form dimers whilst 5 cultures (12.5 %) also formed trimers 
and further multimers. (Figure 4-11). PCR analysis of the junctions formed 
demonstrated that the rejoining of the Co substrate was accurate (Figure 4-12).  
18 of the 40 PCO cultures were found to be NHEJD, as demonstrated by incubation 
with 2I substrates producing either no products, or forming products of significantly 
smaller size (Figure 4-12). Furthermore, some cultures formed multiple bands of 
different sizes indicating loss of differing numbers of nucleotides. Extensive resection 
has been demonstrated to be due to use of microhomologies in this vector in the 
absence of the functional NHEJ pathway (Bentley et al., 2004).  
Repair of 2I substrates was independent of the repair of competent substrates 
(median 23.59 % (95 % CI = 13.72 to 28.31 %) by NHEJC cultures, compared to 









Figure 4-11 End joining of compatible BstXI substrates by PCO cultures. GelRed detection and quantification of end joining of BstXI 
compatible substrates.  
Gels are representative of 3 independent experiments. OSEC-2 and V3YAC (DNA-PKcs corrected) were used as positive controls. V3 



































































































































































































Figure 4-12 Accuracy of rejoining of 2I BstXI substrates by PCO cultures.  
PCR analysis of rejoined DNA of Co and 2I substrates amplified using pFOR and pREV primers. Correct rejoining produces products of 
551bps. Inaccurate rejoining with loss of bases results in smaller or no product formation. Gels are representative of three independent 
experiments. N = 40.
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4.3.4 Biomarker Development for NHEJ Function 
In order to identify potential biomarkers of the NHEJ pathway which would be 
suitable for clinical use, a panel of RNA and protein species was examined and 
correlated with NHEJ function.   
Hypothesis: DNA-PK autophosphorylation is a potential biomarker for NHEJ function 
4.3.4.1 pDNA-PK Foci Formation Correlation with NHEJ Function  
The first potential biomarker which was assessed was the use of phospho-DNA-PK 
foci formation after irradiation. Consistent with the cell extract and cellular assays, a 
statistically significant increase in phospho-DNA-PKcs foci formation was 
demonstrated in NHEJC cell lines. Meanwhile, NHEJD cell lines did not show a 
significant increase in the formation of phospho-DNA-PKcs foci after DNA damage 
(Figure 4-13).  
 
Figure 4-13 NHEJ assessment by immunofluorescence.  
Phospho-DNA-PK foci count per cell in cell lines. Results are foci numbers 1 hr after 
irradiation normalised to un-irradiated controls. Results are the average of 3 
independent experiments. Error bars are SEM. Cell lines found to be functionally 
NHEJC are shown in black and NHED in white bars. 
 
However, DNA-PK autophosphorylation did not correlate with NHEJ function in PCO 
cultures (Figure 4-14). Phospho-DNA-PKcs formation in PCO cultures also did not 
 145 
 
correlate with γH2AX foci formation, therefore the amount of DNA damage induced is 






Figure 4-14 DNA-PK autophosphorylation as a marker of NHEJ function.  
A. DNA-PK foci fold rise above controls 1 hr after 2Gy IR in primary ovarian cancer 
cultures. Divided by NHEJ status. Results are average of 3 independent 
experiments. B. Correlation of pDNA-PK and γH2AX foci fold rise above controls 
after 2Gy IR in primary ovarian cancer cultures. Results are average of 3 
independent experiments. 
 
4.3.4.2 Correlation of Protein and mRNA Expression with NHEJ Status  
The proteins involved in the NHEJ pathway are required for pathway function. 
Therefore, the expression of Ku, DNA-PKcs, LIG4 and XRCC4 was assessed at both 
mRNA and protein level. 
Hypothesis: NHEJ function correlates with mRNA and protein expression levels of 
essential NHEJ protein  
The analysis of the NHEJ pathway components showed protein, but not mRNA 
expression of Ku70, Ku80 and DNA-PKcs, were all significantly lower in NHEJD 
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Figure 4-15 Prediction of NHEJ function by mRNA and protein expression of pathway 
components.  
A. mRNA expression of NHEJ components PCO cultures assessed by RT-qPCR. 
Full circles are NHEJC, open circles are NHEJD. B. Protein expression of NHEJ 
components in PCO cultures assessed by western blotting. Western bands were 
quantified using Fuji LAS-300 Image Analyser System. Full circles – NHEJC, follow 
circles – NHEJD. Protein and mRNA levels were normalised to GAPDH expression. 
Results are average of 3 independent experiments. Error bars are SEM. C. ROC 
curves for Ku70, Ku80 and DNA-PKcs protein expression as predictors of NHEJ 
function. ROC curves were generated and AUC calculated using PRISM software. 
NHEJC N = 22; NHEJD N = 18. 
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Ku70, Ku80 and DNA-PKcs protein expression levels were found to be good 
predictors (AUC 0.798, 0.762 and 0.852 respectively) for NHEJ function (Figure 4-
15.C). Discordance between protein and mRNA expression was noted. 
4.3.4.3 Prediction of NHEJ Function by Genome RNA Expression Arrays 
Using RNA extracted from the PCO ascitic cultures characterised for NHEJ function, 
the relative expression of genes was determined by the Oxford genomics centre 
(Oxford, UK) using Illumina Genome Studio and the HumanHT 12v4.0 R1 15002873 
array, as per the manufacturer’s instructions, as described in section 2.12. All RNA 
samples were extracted from the same ascitic fluid primary culture used in the 
functional NHEJ assay and cytotoxicity assays. RNA expression was analysed using 
unsupervised hierarchical clustering (Figure 4-16). No clustering by NHEJ function 
was observed in the PCO cultures.  
Differential expression analysis confirmed that after multiple test correlations, no 
genes were significantly differentially expressed between NHEJD and NHEJC 
cohorts (Table 4-1). The top 20 genes, when ranked by p value without multiple test 
correlation, did not include any DNA repair genes. This is consistent with the RNA 













Figure 4-16 PCO genome RNA expression microarray.  
A. PCA plot of all PCO samples. Sample relation based on 27343 genes with sd / mean > 0.1 NHEJD cultures are in red and NHEJC in 











Table 4-1 PCO RNA differential expression after multiple test correlation.  
No genes were found to have a significant difference in expression (adj p < 0.05). Table demonstrates the top 20 results ranked by p 
value. N = 24. 
Gene symbol Gene name Av. Expr t p =  adj. p = 
UQCC1 ubiquinol-cytochrome c reductase complex assembly factor 1 9.55 4.24 0.0003 0.93 
IRX5 iroquois homeobox 5 7.67 4.15 0.0004 0.93 
KYNU kynureninase 8.56 4.03 0.0006 0.93 
GALNT6 polypeptide N-acetylgalactosaminyltransferase 6 8.37 3.89 0.0008 0.93 
TXLNA taxilin alpha 11.00 -3.81 0.0010 0.93 
FBLN1 fibulin 1 9.21 -3.73 0.0012 0.93 
TNIP3 TNFAIP3 interacting protein 3 8.00 3.71 0.0012 0.93 
BHLHE41 basic helix-loop-helix family, member e41 8.43 3.65 0.0014 0.93 
IFNAR2 interferon (alpha, beta and omega) receptor 2 8.80 3.51 0.0020 0.93 
DMKN dermokine 8.78 -3.48 0.0021 0.93 
TNFSF14 tumor necrosis factor (ligand) superfamily, member 14 7.80 3.39 0.0026 0.93 
KYNU kynureninase 8.13 3.39 0.0026 0.93 
CBLL1 Cbl proto-oncogene-like 1, E3 ubiquitin protein ligase 9.28 -3.36 0.0029 0.93 
FNIP2 folliculin interacting protein 2 8.39 3.35 0.0029 0.93 
SCARA3 scavenger receptor class A, member 3 8.26 -3.32 0.0031 0.93 
TRIM24 tripartite motif containing 24 7.68 3.31 0.0032 0.93 
RBPMS2 RNA binding protein with multiple splicing 2 9.71 -3.31 0.0032 0.93 
HTRA4 HtrA serine peptidase 4 8.16 3.28 0.0034 0.93 
PRPF38A pre-mRNA processing factor 38A 7.84 -3.27 0.0035 0.93 
ADD3 adducin 3 (gamma) 9.66 3.27 0.0036 0.93 
 150 
 
4.3.5 Interaction of HR and NHEJ Pathways 
In vitro studies have demonstrated an interaction between HR and NHEJ pathways 
(Edwards et al., 2008, Tavecchio et al., 2012). Furthermore NHEJ pathway has been 
suggested to be critical in driving the lethality of PARPi in HRD cells (Patel et al., 
2011). 
Hypothesis: NHEJ function correlates with rucaparib sensitivity 
4.3.5.1 Effect of DNA-PKcs on Rucaparib Sensitivity and HR  
To assess the hypothesis that NHEJ function has a role in rucaparib sensitivity, DNA-
PKcs defective M059J and the paired competent M059FUS-1 cell line were used. 
DNA-PKcs competent M059FUS-1 cells were significantly more sensitive to 
rucaparib compared to DNA-PKcs defective M059J cells (mean GI50 2.75 µM 95 % 
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Figure 4-17 Rucaparib sensitivity and HR function in M059J and M059FUS-1 cells.  
A. sensitivity to rucaparib was assessed using SRB assay. DNA-PKcs was inhibited 
by addition of 1 µM NU7441 at the time of treatment. Results are mean of 3 
independent experiments and error bars are SEM. B. RAD51 and γH2AX focus 
formation was assessed 24 hrs after 2 Gy irradiation compared to untreated controls. 




The role of DNA-PK kinase activity in this sensitivity was further confirmed by a 
significant induction of resistance in M059FUS-1 cells by the addition of the DNA-PK 
inhibitor NU7441 (mean GI50 7.89 µM, 95 % CI = 5 to 11.29 µM, p = 0.035). NU7441 
had no significant effect in DNA-PKcs defective M059J cells. To assess if HR 
function was different between the two cell lines, the γH2AX/RAD51 formation assay 
was used. Both cell lines were deemed HRC with a >2 fold rise in RAD51 foci 
formation after induction of DNA damage compared to controls. However, the mean 
fold rise in RAD51 foci in M059J cells was significantly higher compared to 
M059FUS-1 cells (mean 12.54 +/- 6.2 fold compared to 2.96 +/- 2.5 fold, p < 0.0001, 
Figure 4-17.B). This finding suggests that in the absence of NHEJ function, HR is 
increased.  
4.3.5.2 Interaction of NHEJ and HR in PCO Cultures 
In the cohort of PCO cultures, NHEJ function was independent of HR competence. 
12 cultures were functional for both pathways, 6 cultures were defective for both 
pathways, while 10 and 12 cultures showed defects in either NHEJ or HR but not 
both, respectively.  
HR and NHEJ function were found to be independent of PCO culture growth rate 


































































Figure 4-18 Growth of PCO cultures divided by HR and NHEJ status.  
Growth was assessed by SRB assay over 10 days. 
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4.3.6 Effect of NHEJ Function on Sensitivity to Rucaparib and Cisplatin  
Increased sensitivity of HRD PCO cultures to rucaparib and cisplatin has been 
previously demonstrated (Mukhopadhyay et al., 2010), and has been confirmed in 
chapter 3. Sensitivity of immortalised cell lines and each PCO culture to rucaparib 
and cisplatin was determined using SRB proliferation assays. Sensitivity was 
assessed over 3 doubling times for immortalised cell lines and 10 days for PCO 
cultures.  
When cell lines were grouped by NHEJ status, NHEJC cell lines were found to be 
more sensitive to rucaparib (mean GI50 2.6 µM 95 % CI = 0 to 11.6 µM vs 14.15 µM, 
95 % CI = 1 to 27.3 µM, p = 0.036, Table 4-2). The difference in cisplatin sensitivity 
was not statistically significant.  
Table 4-2 Rucaparib and cisplatin cytotoxicity and NHEJ status of cell lines.  
GI50 was determined by SRB assay. 
Cell line NHEJ status GI50 for 
Rucaparib (µM) 
GI50 for Cisplatin 
(µM) 
OVCAR3 NHEJC 0.93 0.26 
A2780 NHEJC 0.14 2.49 
CP70 NHEJD 8.10 2.22 
SKOV3 NHEJD 17.87 4.13 
IGROV-1 NHEJD 16.46 1.79 
MDAH NHEJD Not determined Not determined 
 
4.3.6.1 Correlation of Rucaparib and Cisplatin Sensitivity with DNA DSBs Repair 
There was no association between end joining rates of Co BstXI substrates and drug 
sensitivity. Co substrates assessed overall end joining which includes end joining by 
A-EJ pathway. Therefore, the lack of association is not surprising. Defects in the 
NHEJ pathway, as defined by the inability to rejoin 2I BstXI substrates, were 
associated with resistance to rucaparib in PCO cultures (p = 0.002, Figure 4-19). 
NHEJ function had no significant effect on cisplatin sensitivity (Figure 4-20). Inhibition 
of DNA-PK resulted in rucaparib resistance in sensitive cultures (p = 0.002, Figure 
4-19). DNA-PK inhibition had no effect on rucaparib resistant cultures and no effect 




Figure 4-19 Rucaparib cytotoxicity in PCO cultures divided by NHEJ status.  
Cell survival calculated as mean cell growth after 10 days treatment with 10 µM 
rucaparib, as a fraction of DMSO control growth for PCO cultures, as assessed by 
SRB assay. Results were divided by NHEJ status (NHEJC/ NHEJD) or comparison of 















Figure 4-20 Cisplatin cytotoxicity in PCO cultures divided by NHEJ status.  
Cell survival calculated as mean cell growth after 10 days treatment with 10 µM 
cisplatin as a fraction of SDW control growth for PCO cultures, as assessed by SRB 
assay. Results were divided by NHEJ status (NHEJC / NHEJD) or cell growth after 



































































































When HR and NHEJ functions were taken into account, only NHEJC/HRD cultures 
were sensitive to rucaparib (Figure 4-21). As predicted from HR function association 
with rucaparib sensitivity, both groups with HRC cultures were resistant to rucaparib 
(NHEJC/HRC and NHEJD/HRC). The surprising and interesting group, however, was 
the NHEJD/HRD group. From HR function alone, this group would be expected to be 
sensitive to rucaparib, however the percentage of cells surviving at 10 µM rucaparib 
was similar to that of the two HRC groups. Importantly this also correlated positively 










Figure 4-21 Rucaparib and cisplatin cytotoxicity plotted by NHEJ and HR status.  
Results are percent mean cell survival after 10 days treatment with A. 10 µM 
rucaparib compared to DMSO control and B. 10 µM cisplatin compared to SDW 
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4.3.6.2 The Effect of Cisplatin on NHEJ Function  
Cisplatin has previously been reported to inhibit NHEJ (Diggle et al., 2005). In view of 
the lack of association of NHEJ function with cisplatin sensitivity in both cell lines and 
PCO cultures, the effect of cisplatin on NHEJ function was assessed in OSEC-2 
cells. Cisplatin was found to inhibit rejoining of Co and 2I ends significantly at a 
concentration of 4 nM, when compared to the control (Figure 4-22). Therefore the 
lack of association observed at 10 µM of cisplatin treatment is likely to be due to 
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Figure 4-22 Cisplatin inhibition of end joining of Co and 2I BstXI substrates.  
End joining was assessed in OSEC-2 cell line. Results are average of three 
independent experiments. Error bars are SEM.
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4.3.7 Correlation of NHEJ Status with Clinical Outcomes  
No significant differences were observed between the clinical outcomes and 
histological characteristics of the NHEJC and NHEJD PCO culture groups (Table 
4-3). 
Table 4-3 Patient characteristics for PCO samples divided by NHEJ status.  
  Total 
(N=40)  







Median  66 68  64 0.42 
 Range 45-85 46-85 45-78 - 
Histology HGSOC 28 16 12 0.88 
 Endometrioid / 
clear cell  
5 3 2 >0.99 
 Mixed 3 1 2 0.85 
 Mucinous 2 1 1 > 0.99 
 Carcinosarcoma 1 0 1 0.92 
 Low grade 
serous 
1 1 0 0.97 
Stage 1 1 0 1 0.99 
 2 1 0 1 0.99 
 3 A 1 0 1 0.99 
 3 B 1 1 0 0.99 
 3 C 32 19 13 0.58 
 4 4 2 2 > 0.99 
Pre-op 
Ca125 





29 16 13 0.85 
 Following NACT  11 6 5 0.85 
Outcome 
of surgery 
Complete 5 2 3 0.83 
 Optimal 28 15 13 0.98 
 Suboptimal 6 4 2 0.86 




4.3.7.1 Correlation of NHEJ with Progression Free and Overall Survival 
As the patients from whom the PCO cultures were collected were treated with 
standard therapy, and NHEJ function did not correlate with cisplatin sensitivity, it was 
hypothesised that no correlation with clinical outcomes would be seen.  
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Figure 4-23 Kaplan-Meier survival curves for PFS/OS by NHEJ status.  
A. Median PFS was 14.5 months for NHEJD compared to 12 months for NHEJC 
group, log rank Chi square 0.16, p = 0.68. B. Median overall survival was 27 months 
for NHEJC group, and 26 months for NHEJD group. Log rank Chi square 1.0, p = 
0.32. 
 
There was no significant difference between the PFS or the OS between NHEJC and 
NHEJD groups (Figure 4-23). When PFS was sub divided into NHEJ and HR 
competence there was no significant difference between PFS (NHEJC/HRC - 11.5 
months, NHEJC/HRD - 9.3 months, NHEJD/HRC - 18 months, NHEJD/HRD group 
failed to reach median follow up). 
4.3.8 Assessment of NHEJ Targets in FFPE Tissue 
Tumours collected during surgery in clinical practice were formalin fixed and paraffin 
embedded. The DNA-PK complex protein (DNA-PKcs, Ku70 and Ku80) were 
individually assessed as biomarkers of the NHEJ pathway. This work was performed 
with Richard O’Sullivan (MRes, 2014) and Dr Peter Donoghue. 
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Hypothesis: NHEJ function can be assessed in FFPE tissue by using differentially 
expressed protein targets 
Table 4-4 DNA-PKcs, Ku70 and Ku80 mRNA and protein expression by NHEJ 
status. 
  IHC Protein Expression 
 
qPCR mRNA expression 
Normalised to HPRT 







139 Competent    0.27  0.60 
142 Competent 6.71 12.40 8.45 0.78 18.57 1.14 
143 Competent 14.38 2.04 7.79 0.15 2.25 0.18 
144 Competent 4.57 1.55 4.22 0.03 0.29 0.08 
156 Competent    0.34 2.97 0.34 
160 Competent 5.16 2.73 4.97 1.18 0.44 1.10 
168 Competent 12.05 3.07 4.27 1.05 1.68 1.46 
187 Competent 16.15 13.25 14.97 0.29 0.05 0.36 
197 Competent    0.14 2.55 0.16 
202 Competent 11.81  11.36 0.51 0.10 0.47 
211 Competent 9.48 9.18 11.65 0.36 3.18 0.28 
149 Defective 11.30 11.86 12.44 0.12 0.20 0.25 
153 Defective 12.07 9.96 12.19 0.29 0.90 0.28 
154 Defective 6.25   0.77 6.07 0.49 
157 Defective 13.32 1.90 5.70 0.19 0.05 0.19 
158 Defective 12.85 6.10 13.47 0.55 3.70 0.46 
162 Defective 10.77 8.16 6.47 0.70 10.75 0.70 
163 Defective 15.65 12.73 16.56 0.37 0.05 0.32 
174 Defective 9.64 1.53 6.46 0.38 2.95 0.38 
175 Defective 5.27 11.37 8.94 0.19 0.51 0.22 
184 Defective 14.86 9.94 12.94 0.75 2.60 0.46 
209 Defective    0.56 1.34 0.49 
210 Defective 12.03 9.44 13.44 0.22 0.81 0.31 
221 Defective 7.71  11.93 0.82 0.15 0.61 
 
4.3.8.1 Protein Expression of DNA-PKcs, Ku80, Ku70 
Ovarian cancer TMA sections were stained for DNA-PKcs, Ku70 and Ku80 as 
described in section 2.8. No significant differences in biomarker expression were 




Figure 4-24 DNA-PKcs, Ku70 and Ku80 protein expression grouped by NHEJ status.  
Protein expression was assessed by modified H Score. Scoring was performed by 2 
scorers. 
4.3.8.2 mRNA Expression of DNA-PKcs, Ku80, Ku70 
24 study samples were amplified by QPCR. No significant differences in biomarker 
expression were noted between NHEJC and NHEJD tumours (Figure 4-25).  
 
Figure 4-25 DNA-PKcs, Ku70 and Ku80 mRNA expression grouped by NHEJ status.  
mRNA expression is normalised to HPRT1 expression. 
 
Discordance was found between the protein and mRNA expression of all targets 
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Figure 4-26 Correlation of DNA-PKcs, Ku70 and Ku80 mRNA and protein 
expression. 
4.3.9 Assessment of NHEJ Heterogeneity 
Hypothesis: Subpopulations of ovarian cancer cells exist exhibiting heterogeneity in 
NHEJ function 
Inter and intra tumour heterogeneity of HR function has been demonstrated in 
ovarian cancer (O'Donnell et al., 2015). For NHEJ function biomarkers to be used to 
select patients for treatment, an assessment of heterogeneity is required. From the 
data so far, inter tumour heterogeneity of NHEJ is clear, with important effects on 
rucaparib sensitivity. Gene expression studies have indicated different biological 
profiles in the cancer cells derived from ascites and solid ovarian cancer tumours 
from the same patient, in terms of metastasis, invasion and angiogenesis (Le Page et 
al., 2006).  
4.3.9.1 Protein and mRNA Expression in FFPE Tissue and Matched Ascites 
In view of lack of correlation between DNA-PK complex protein expression in FFPE 
tissue and NHEJ function of matched ascites samples, the expression of the mRNA 
and protein from FFPE and ascites samples were correlated. Spearman’s rank 
correlation was performed to assess correlation between FFPE and ascites mRNA 
and protein expression (Figure 4-27). No positive correlation was noted between 
protein or mRNA expression in FFPE and in ascitic samples from matched patients.  
Expression discordance could be due to the different techniques used to assess 
protein expression, and different house keeper genes used for mRNA quantification. 
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Different housekeeper genes were used for FFPE tissue mRNA due to excessive 
degradation of GAPDH in FFPE extracted mRNA (Richard O’Sullivan MRes thesis, 
2014). However, more importantly, discordance may also be due to intra tumour 
heterogeneity between the solid cancer cells captured in FFPE and that of cancer 
cells in ascites samples.  
 
Figure 4-27 Correlations of FFPE and ascites mRNA and protein expression.  
 
4.3.9.2 Intra-tumour Heterogeneity of NHEJ Protein Expression  
To explore tumour heterogeneity further, multiple solid samples were collected from 
six patients undergoing primary surgery for ovarian carcinoma. There was no 
correlation noted between DNA-PK, Ku70 or Ku80 protein expression in multiple 
biopsies (Figure 4-28). The expression for both samples was analysed using the 
same method of extraction and western blotting technique. The discordance noted is 
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Figure 4-28 Correlations of NHEJ protein expression in multiple biopsies.  
A. DNA-PKcs, B. Ku80, C. Ku70 protein expression normalised to expression of 
GAPDH. Two solid samples were collected at the time of surgery. The site of solid 
sample varied between cases.  
 
In order to assess if the tissue of origin affected the expression of DNA-PK complex 
protein, multiple solid samples collected from patients were assessed. Ovarian, 
fallopian tube and omental cancer deposits were sampled. There was no significant 
difference noted between the expression of DNA-PKcs, or Ku protein between the 
three sampling sites (Figure 4-29). 
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Figure 4-29 DNA-PKcs, Ku70 and Ku80 protein expression grouped by tumour site.  
Protein expression was normalised to the expression of GAPDH. 
 163 
 
4.3.9.3 Expression of NHEJ Proteins in Tumour and Ascites Samples Compared to 
Normal Ovarian / Fallopian Epithelium from Healthy Volunteers  
Solid samples from ovarian and fallopian tube tissue were collected from patients 
undergoing hysterectomy for menorrhagia. Samples from these patients were used 
as normal controls to cancer samples. The expression of DNA-PKcs, Ku80 and Ku70 
protein was assessed using western blotting and correlated with solid samples 
collected from patients undergoing surgery for ovarian carcinoma and PCO ascites 
cultures (Figure 4-30).  
Expression of all three proteins was significantly lower in PCO ascites samples 
compared to normal controls. When comparing normal control samples to solid 
cancer samples, there was significantly higher expression of DNA-PKcs in normal 
samples compared to cancer samples (normalised to GAPDH mean expression 3.62 
+/- 1.4 fold vs 0.67 +/- 0.17 fold, p = 0.005). The differences for Ku protein were not 
statistically significant. The expression of Ku70 was significantly higher in cancer 
samples compared to ascites cultures (normalised to GAPDH mean expression 4.4 
+/- 1.2 fold in solid cancer samples vs 0.93 +/- 0.05 fold in ascites, p < 0.0001).  
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Figure 4-30 DNA-PKcs, Ku70 and Ku80 protein expression in ovarian carcinoma and 
healthy control samples.  
Protein expression was assessed by western blotting and normalised to GAPDH 
expression. Results are mean of 3 independent experiments. N = 19 cancer solid 
samples, 11 normal control samples and 38 ascites culture samples. 
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4.4 Chapter Summary 
 NHEJ function can be measured in extracts from ovarian cancer cell lines and 
primary cultures and 40 % of PCO cultures are NHEJD. 
 NHEJD is associated with resistance to rucaparib.  
 Cisplatin was found to inhibit NHEJ function and cisplatin sensitivity was 
independent of NHEJ. 
 NHEJ function was found to be independent of HR competence. 
 There was no significant correlation of NHEJ function with clinical outcomes in 
this cohort. 
 NHEJ function can be predicted by the protein expression of DNA-PKcs, Ku70 
and Ku80, in primary cultures. However, further biomarker development is 
required, as these correlations could not be demonstrated in FFPE or fresh 
solid tissue.  
 Heterogeneity of NHEJ function was noted in primary ovarian cancer.    
4.5 Discussion 
In this chapter NHEJ function was measured in extracts from ovarian cancer cell lines 
and PCO cultures. NHEJ function assessment was optimised by two different 
functional assays. 60 % of ovarian cancer cell lines and 40 % of PCO cultures were 
found to be NHEJD. This is the first study to assess NHEJ function in a primary 
ovarian cancer cohort and to quantify the frequency of defects. The differences in the 
frequency of NHEJ defects between cell lines and PCOs may be due to a small 
number of cell lines assessed. The cell lines assessed are also known to harbor 
other defects. Such as p53 status and MMR status, namely the CP70 cell line was 
derived from the A2780 and is MMR deficient and mutant for p53, which are also 
known to affect sensitivity to cisplatin. 
4.5.1 NHEJ Function is Independent of HR and NHEJD is Associated with 
Rucaparib Resistance 
Contrary to HRD association with rucaparib sensitivity, NHEJD was found to be 
associated with resistance to rucaparib. Previous studies in cell lines have shown 
that deletion of DNA-PK can restore HR function and PARPi resistance in BRCA 
mutated cells (Patel et al., 2011). This is the first study to demonstrate this correlation 
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in primary cultures. The sensitivity of HRD cancers to PARPi has been attributed to 
the concept of synthetic lethality, however, the exquisite sensitivity of HRD cells seen 
in vitro has not been reproduced in clinical trials. The concept of synthetic lethality 
has been based on the theory that HRD cells are unable to repair DNA DSBs. 
However, as HR repairs unpaired DSBs (such as collapsed replication forks) and is 
not functional in the G0/G1 phases of the cell cycle, the majority of DSBs are 
repaired by the NHEJ pathway (Bentley et al., 2004). The role of NHEJ function in 
error free repair has been shown in this study by the mainly error free rejoining by 
DNA-PKcs proficient V3YAC and M059-FUS1 cell lines compared to the mainly error 
prone repair in DNA-PK deficient V3 and M059J counterparts. The role of NHEJ 
function in PARPi sensitivity is supported by the observation that NU7441 caused 
rucaparib resistance in all sensitive cultures, independent of HR function. Therefore, 
NHEJ is an important determinant of DSB repair and as shown in this study, 
sensitivity to PARPi.  
HR and NHEJ function were found to be independent of one another; with some 
PCO cultures were found to be competent in both, some defective in just one, whilst 
a small cohort were defective in both pathways. Independence of the two pathways is 
documented in the literature (Bee et al., 2013). The two pathways function in different 
stages of the cell cycle and repair different forms of DSBs (Bee et al., 2013). As 
PARPi causes collapsed replication forks in cycling cells, which can only be repaired 
by HR, it is also unsurprising that HRC cultures were resistant to rucaparib (Bryant et 
al., 2009, Sugimura et al., 2008). However, the role of PARP1 in DSBs, beyond 
causation of collapsed replication forks due to unrepaired SSBs, is also documented 
in the literature (Hegan et al., 2010, Benjamin and Gill, 1980, Haince et al., 2008); as 
well as the interaction between PARP1 and the NHEJ pathway (Ruscetti et al., 1998, 
Veuger et al., 2003, Veuger et al., 2004, Mitchell et al., 2009a). The independent role 
of NHEJ function in PARPi sensitivity is demonstrated in this study. The hypothesis 
put forward for the role of NHEJ in PARPi resistance is based on the error proneness 
of NHEJ. The errors in repair are suggested to cause lethal defects in DNA, which, in 
the absence of HR, results in apoptosis. Therefore, NHEJC/HRD cells are sensitive 
to PARPi. Cells with competent NHEJ and HR pathways are able to repair DNA 
damage and are, therefore, resistant to PARPi. In the abscence of NHEJ, the slower 
error free HR takes over repair. This notion is supported by findings of greater HR 
function, demonstrated by greater RAD51 foci formation in the DNA-PK deficient cell 
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line in this study as well as literature (Middleton et al., 2015). Therefore, in the 
absence of NHEJ function, the lack of error prone repair results in resistance to 
PARPi (Patel et al., 2011). In cells which are NHEJD/HRD repair is undertaken A-EJ, 
which is a mutagenic process due to excessive resection. The interaction of A-EJ is 
still not fully understood and its assessment was beyond the scope of this project. 
The precise interaction between HR, NHEJ and PARP-1 is further explored in 
chapter 5.  
4.5.2 Cisplatin Inhibits NHEJ Function 
An important observation is the finding of a lack of association of NHEJ function with 
cisplatin sensitivity in the primary cultures. Whilst HRD has been shown to sensitise 
cancers to cisplatin and PARPi (Mukhopadhyay et al., 2012), NHEJ appears to be 
important for PARPi sensitivity only. Inhibition of NHEJ function by cisplatin has been 
previously reported (Diggle et al., 2005), and has been reproduced in this study, 
which is likely to be the reason for the lack of association observed. Whether cisplatin 
inhibition of NHEJ has important consequences to ovarian cancer genomic instability 
remains to be explored.  
There was also no association noted between NHEJ status and the clinical outcomes 
of patients the PCO cultures were collected from. As all patients in this cohort were 
treated with standard platinum based therapy, the lack of correlation is therefore not 
surprising. To assess the role of NHEJ in patient outcomes, NHEJ function needs to 
be determined in a cohort of patients treated with PARPi. 
4.5.3 Protein Expression of Ku and DNA-PK are Potential Biomarkers for NHEJ 
Function 
For an assay to be clinically applicable, simple and reliable biomarker tests are 
required. This study suggests that expression of the NHEJ related proteins Ku70, 
Ku80 and DNA-PKcs may be useful as biomarkers to determine NHEJ status in 
cancer samples. Failure to see a positive correlation between mRNA expression and 
pathway function in PCR and genome expression arrays may be due to a number of 
reasons. Firstly, this may be due to assay limitations as only single mRNA samples 
were collected, and therefore, repeat expression assessment was not possible. As 
mRNA extraction was performed in batches and stored at -80 ºC prior to use, 
different handling of the samples may affect the results. Furthermore, samples for 
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this cohort were collected over a period of two years, and so different biological or 
experimental mRNA and protein degradation rates might affect the mRNA and 
protein correlations. Secondly, differences between mRNA and protein expression 
may also be due to biological processes, i.e. transcriptional splicing, post-
transcriptional splicing, translational modifications and regulation, and protein 
complex formation; these might all affect the relative quantities of mRNA and protein, 
to various degrees (Guo et al., 2008, Chen et al., 2002). Discordance between mRNA 
and protein has been reported previously in the literature in other cancer tissues 
(Guo et al., 2008, Chen et al., 2002). 
4.5.4 Tumour Heterogeneity of NHEJ Function  
The assessment of Ku70, Ku80 and DNA-PKcs in FFPE and fresh solid samples did 
not correlate with the same proteins assessed by WB, or with NHEJ function in the 
PCOs. A number of explanations may account for these findings. Firstly, both FFPE 
and fresh solid samples studies were limited by the small sample size available. 
Secondly, it was clear from the scatter plots presented that within both competent 
and defective tumours there was a wide range of protein and mRNA expression. This 
could point to both tumour and sample heterogeneity. IHC scoring only assessed an 
extremely small area of tumour and it was noted that varying intensities of expression 
were observed between cores from the same tumour, and also within individual 
cores. Some areas of a tumour may be NHEJC, whilst others are NHEJD, and so a 
more widespread assessment of a tumour, with possibly more cores, is required. 
Differences between populations of cells in ascites and within solid tumour may also 
account for the differences seen. Gene expression studies have indicated different 
biological profiles in the cancer cells derived from these two sources from the same 
patient in terms of metastasis, invasion and angiogenesis (Le Page et al., 2006). A 
further explanation for the differences however, could also be the difference in the 
sample nature and handling; namely ascites samples were cultured in the laboratory 
whilst solid samples were lysed directly. Significant genetic alterations in cell line 
during culture have been reported (Korch et al., 2012). This notion is supported by 
the finding of significantly lower expression of DNA-PKcs and Ku protein in ascites 
compared to both normal and cancer solid samples. Assessment of ascites directly 
after collection may provide lower heterogeneity in the samples.   
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Tumour heterogeneity of NHEJ function is an important finding of this study to 
consider. Whilst the areas of tumour which are NHEJC, and so are sensitive to 
PARPi treatment, are likely to respond to treatment and regress, areas of NHEJD 
tumour would remain refractory to treatment and continue to grow. Therefore, only 
partial response to treatment would be seen, with refractory disease developing over 
time. Treatment with PARPi in clinical practice has been found to prolong life, rather 
than cure, and NHEJD areas of tumour may be one of the explanations for the 
refractory disease development. For this theory to be assessed, repeat biopsies for 
NHEJ function assessment over the length of treatment are required.  
The expression of DNA-PKcs protein in cancer samples was overall, lower than in 
solid samples collected from healthy patients. Ku70 and Ku80 were also reduced in 
the ascites cultures, suggesting an overall reduction in NHEJ capacity. Lower NHEJ 
function has been reported in other cancers; namely, in the peripheral blood 
mononuclear cells of breast cancer patients (Bau et al., 2007). Furthermore, a dose-
response relationship is reported between end joining capacity and the risk of breast 
cancer (Bau et al., 2007). NHEJ activity has been reported to be reduced and 
increasingly error prone in invasive, as compared to non-invasive, bladder cancers 
(Bentley et al., 2009, Bentley et al., 2004, Windhofer et al., 2008). The evidence for 
the role of the NHEJ pathway in tumourgenesis is further provided by reports of 
increased DNA binding by Ku in low grade, low stage bladder tumours (grade 1–2, 
pTa–T1), but a 1.5 to 3 fold decrease in Ku binding in high grade invasive tumours 
(Stronati et al., 2001). Therefore, defects in the NHEJ pathway may cause sufficient 
genomic instability for cancer to develop due to failure to repair DSBs. The frequency 
of NHEJ defects noted in ovarian cancer may have important implications beyond 
PARPi sensitivity. HGSOC have been reported to almost universally carry 
inactivating mutations in p53 and a large number of genomic deletions/amplifications, 
as well as a copy number alterations (Ahmed et al., 2010, Cancer Genome Atlas 
Research, 2011). NHEJD combined with p53 mutation, resulting in the highly 
mutagenic joining of DSBs via sequence microhomologies, may contribute to the 
increased genomic instability observed.  
The ability to select the correct patient for the correct treatment at the right time is 
required for personalised medicine. Whilst attempts are currently being made to 
develop predictive biomarkers of HR function, this study suggests that in ovarian 
cancer, NHEJ function is also an independent predictor of sensitivity to PARPi.  
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4.6 Future Work 
Assessment of NHEJ function in a larger cohort of homogenised fresh / frozen 
tumour tissue, along with biomarker expression, is required to gather further 
evidence for the role of NHEJ function in ovarian cancer. It is also not clear if NHEJ 
has a role in ovarian cancer development. This needs to be assessed by analysing 
NHEJ in multiple biopsies from different stages of EOCs.     
NHEJ function will only have an important role in cancer biology, if it is associated 
with clinical outcomes. As the patients in this cohort were treated with platinum 
chemotherapy and platinum has been found to inhibit NHEJ, the lack of association 
was not surprising. However, the effect of NHEJ function on survival outcomes in 















CHAPTER 5 ASSESSMENT OF THE EFFECT OF ATR AND DNA-PK 
INHIBITION ON CELLULAR BIOLOGY AND PARPI SENSITIVITY  
5.1 Introduction 
As cells face an ongoing assault from environmental and endogenous sources of 
DNA damage, the DNA damage response (DDR) is essential to maintain genomic 
stability (Hoeijmakers, 2009). The DDR signals cell cycle checkpoints that arrest the 
cell cycle to allow sufficient time for repair or apoptosis to be completed. The 
response to DSBs and collapsed replication forks is crucial, as these are difficult to 
repair. The independent functions of the NHEJ and HR pathways that were found in 
chapter 3 in PCO cultures require further investigation. The aim of this chapter is, 
therefore, to assess the biological interaction of the two pathways in ovarian cancer 
and normal ovarian epithelium, and to assess the interaction of HR and NHEJ with 
PARP-1.  
Three PI3-Kinase-related kinases (PIKKs), ATM, ATR and DNA-PKcs are intimately 
connected with DDR (Thompson, 2012). This study concentrates on two – ATR and 
DNA-PKcs.  
5.1.1 ATR 
The ATR gene is located at chromosome position 3q23 and comprises 2644 amino 
acids (approximately 301kDa) (Bentley et al., 1996). ATR−/− mice die on embryonic 
day 7 due to increased apoptosis and chromosomal fragmentation (Brown and 
Baltimore, 2000). No human germ-line homozygous ATR deletions have been 
identified, however, autosomal-recessive disease Seckel syndrome sufferers have a 
hypomorphic mutation in ATR resulting from an A2101G substitution, causing 
changes in splicing and resulting in low levels of the protein. Sufferers exhibit growth 
restriction, short stature, microcephaly and are hypersensitive to UV (O'Driscoll et al., 
2003). 
5.1.1.1 Role of ATR in DNA Damage Repair 
ATR is possibly the most versatile of the three PIKKs in that it is activated by single-
stranded DNA adjoining double-stranded DNA that occurs during NER, following 
resection of DSBs and collapsed replication forks (Cortez, 2003, Dunkern et al., 
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2001, Minca and Kowalski, 2011, Cortez, 2005). ATR is activated by these lesions to 
phosphorylate a number of targets involved in HR and the re-start of replication forks, 
but its major target is CHK1 (Chen et al., 2012). By phosphorylation of CHK1, ATR 
initiates the S and G2 checkpoint cascade (Zhao and Piwnica-Worms, 2001). ATR 
has also been shown to be activated by the MMR protein (Yoshioka et al., 2006), to 
phosphorylate DNA-PKcs (Yajima et al., 2006), and to indirectly influence the BER 
pathway (Stauffer et al., 2007).  
5.1.1.2 ATR Activity in Cancer 
Many studies have investigated ATR mutations in relation to breast and ovarian 
cancer risk; however, no germline mutations have been reported to be involved 
(Durocher et al., 2006, Heikkinen et al., 2005, Kontorovich et al., 2008). A high 
frequency frameshift mutation of the A(10) repeat from the codon 774 of the ATR 
gene, resulting in a truncated form of ATR, was noted in 21 % of stomach cancers 
(Menoyo et al., 2001). The A(10) repeat has also been found to be altered in a third 
of MSI positive endometrial cell lines (Mironov et al., 1999, Lewis et al., 2005, 
Vassileva et al., 2002). Microsatelites are unstable in MMR defective cancers. MMR 
deficiency has been reported in up to 39 % of ovarian tumours, and therefore the 
A(10) repeat in ATR may have an important role in some ovarian cancers (Buller et 
al., 2001, Helleman et al., 2006). 
Many of the anticancer agents that are in routine clinical use act by causing DNA 
damage. Platinum agents cause bulky adducts or ICLs, IR and topoisomerase II 
poisons induce DSBs, and gemcitabine is incorporated into DNA causing chain 
termination and therefore, stalled replication forks (Hoeijmakers, 2001). All these 
lesions trigger ATR, thus inhibition of ATR should promote cell killing. Cancer cells 
undergo continuous proliferation and often have dysregulated G1 control, making 
them reliant on their remaining S and G2 checkpoints (Massague, 2004). This means 
that cancerous cells are much more likely than normal cells to enter S-phase with 
damaged DNA. Therefore, they have a high level of replicative stress, stalled 
replication forks and DSBs. In addition, there are higher levels of ROS in tumours 
due to increased metabolic activity, mitochondrial dysfunction and various oxidases 
(Storz, 2005). These give rise to approximately 100-fold higher levels of oxidative 
DNA lesions in tumours than in normal tissues (Wiseman and Halliwell, 1996). 
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Therefore, inhibition of ATR is thought to have a significant effect on the tumour, but 
not normal cells, thus limiting toxicity to the patient. 
5.1.1.3 ATR as a Therapeutic Target 
Recent studies identified that numerous cellular defects confer sensitivity to single 
agent ATR inhibitors (ATRi). These include defects in ATM, XRCC1 and BRCA1 and 
overexpression of DNA-PKcs (Peasland et al., 2011, Sultana et al., 2013, Middleton 
et al., 2015, Mohni et al., 2014). Inactivation of ATR is also synthetically lethal in 
oncogene-activated cancer cells (Gilad et al., 2010), and cells with induced over-
expression of cyclin E (Toledo et al., 2011). Two ATRi, VX-970 and AZD-6738, are 
currently undergoing clinical evaluation. VX-970 is being evaluated both as a single 
agent and in combination with both platinum-based chemotherapy (clinicaltrials.gov 
identifier: NCT02157792) and AZD-6738 in haematological malignancies with 11q 
deletions (ATM defective) (clinicaltrials.gov identifier: NCT01955668). In this study, 
the Newcastle-developed ATR inhibitor, NU6027, which has Ki of 100nM and IC50 of 
6.7µM, was used. NU6027 was developed as a CDK2 inhibitor, and although its 
potency for CDK2 is limited, it has to be noted that, some of the effects seen, may be 
through CDK2 inhibition rather than ATR.  
5.1.2 DNA-PK 
DNA-PKcs is a key player in the NHEJ pathway of DSB repair and has additional 
functions in the mammalian cell including telomere maintenance and induction of 
apoptosis (Burma and Chen, 2004, Kim et al., 1999). The DNA-PKcs is located at 
chromosome position 8q11 and comprises 4128 amino acids (approximately 
469kDa). Mouse knockout models remain viable but demonstrate growth restriction, 
whilst mouse DNA-PKcs mutant models demonstrate immunodeficiency (Thacker 
and Zdzienicka, 2003, Burma et al., 2006). 
5.1.2.1 Role of DNA-PKcs in DNA Damage Repair 
The recruitment of DNA-PKcs to DSBs by Ku results in activation of its kinase 
function such that it can now phosphorylate other proteins as well as itself. DNA-
PKcs tethers the broken ends to facilitate rejoining (Cary et al., 1997), and also 
recruits and activates proteins involved in DNA end-processing and ligation. The 
dissociation of DNA-PKcs from DNA breaks is dependent on phosphorylation of 
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several S/TQ residues, most notably on T2609 and S2056 (Burma and Chen, 2004, 
Chen et al., 2005). DNA-PKcs interacts with artemis and the artemis:DNA-PKcs cuts 
various forms of damaged DNA ends (Ma et al., 2005). Pol µ and pol λ can bind to 
the Ku:DNA complex, and are capable of template-dependent, and in the case of pol 
µ, template independent synthesis. DNA-PKcs also stimulates the ligase activity of 
the XLF:XRCC4:LIGIV complex which can ligate across gaps and ligate incompatible 
DNA ends with high efficiency (Gu et al., 2007b, Gu et al., 2007a). DNA-PKcs is also 
phosphorylated by ATM and ATR (Yajima et al., 2006, Chen et al., 2007). 
5.1.2.2 DNA-PKcs Activity in Cancer 
DNA-PKcs down regulation, in many instances through SNPs of the DNA-PKcs 
gene, has been reported in several human cancers (McKean-Cowdin et al., 2009, 
Moll et al., 1999, Sakata et al., 2001, Danoy et al., 2008, Lee et al., 2007a, Kurimasa 
et al., 1999, Someya et al., 2006, Robinson-Bennett et al., 2008). A further 
mechanism for loss of DNA-PKcs function is by mutation in one of the two 
microsatellite mononucleotide repeats [poly(A8) and poly(A10) tracts]; this has been 
reported in gastric, colorectal and urothelial carcinomas (Lee et al., 2007a, Li et al., 
2004b, Mongiat-Artus et al., 2006). Loss of DNA-PKcs function has also been 
reported to be associated with a higher risk of metastasis to lymph nodes, tumour 
progression and poor survival in malignant spindle cell tumours of the extremities, 
lung and gastric cancers (Cho et al., 2002, Xing et al., 2008, Lee et al., 2007a, Lee et 
al., 2005).  
On the other hand, DNA-PKcs over expression was reported in oral cancer (Shintani 
et al., 2003, Um et al., 2004) and neuroblastoma (Deutsch et al., 2001). In breast and 
lung cancers, DNA-PKcs has been suggested to be a potential susceptibility gene 
(Someya et al., 2006), with significantly lower DNA-PK activity in peripheral blood 
lymphocytes in cancer patients compared to healthy controls (Moll et al., 1999, Fu et 
al., 2003, Auckley et al., 2001). Contrary to the prognostic effects of loss of DNA-
PKcs function, increased DNA-PKcs expression has been reported to be associated 
with drug resistance in B-CLL (Shen et al., 1998, Kim et al., 2000, Deriano et al., 
2005). The increased DNA-PKcs expression in cancer tissues is likely to be due to 
increased genomic stress, and its association with poor survival may not only provide 
a useful prognostic marker but also a treatment target. It would appear, therefore, 
that in addition to SNPs which predispose to various cancers, pertubations in the 
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DNA-PKcs gene are common. In general, loss of expression is associated with poor 
survival, but interestingly, increased expression may be associated with 
chemotherapy resistance. 
5.1.2.3 DNA-PK as a Therapeutic Agent 
Cells defective in NHEJ are not only sensitive to IR, but also topoisomerase II 
poisons that cause DSBs (Jeggo et al., 1989). Inhibition of DNA-PK is, therefore, an 
attractive target for modulating resistance to therapeutically induced DSBs. DNA-PKi 
have been suggested as radio- and chemo- potentiators by in vitro and in vivo 
studies (Rosenzweig et al., 1997, Boulton et al., 2000, Kashishian et al., 2003, 
Shinohara et al., 2005, Tavecchio et al., 2012, Zhao et al., 2006). A proof-of-principle 
study of dual DNA-PK and PI3K inhibitor (KU-0060648) has demonstrated chemo-
sensitisation in vitro and in vivo with limited toxicity, thus suggesting that further 
evaluation of DNA-PKi is required (Munck et al., 2012). PARP-1 and DNA-PK 
interaction in radio-sensitisation has also been demonstrated, which suggests that 
the combined use of these inhibitors may also be effective; although, whether this 
would be by mutual stimulation or competition is still unclear (Ruscetti et al., 1998, 
Veuger et al., 2003, Veuger et al., 2004, Mitchell et al., 2009a, Boulton et al., 1999). 
In this study the Newcastle-developed potent DNA-PKi, NU7441 was used. NU7441 
has an IC50 of only 13 nM and at least 100-fold selectivity for this enzyme compared 
with other PI3KK family kinases (Leahy et al., 2004).  
5.2 Aims for Chapter 5 
The aim of this study was to assess the role and the interaction of ATR and DNA-PK 
in DNA damage recognition in ovarian cancer. Furthermore, this study aimed to 
assess the interaction of DNA-PK and ATR with PARP inhibitors. Specific aims were: 
 to assess the effect of ATR and DNA-PK inhibition on cell growth, cell survival, 
cell cycle, and DSBs recognition and repair, in normal ovarian epithelium and 
in ovarian cancer.  
 to assess the interaction between ATR and DNA-PK with PARP-1 inhibition in 
terms of cell growth, cell survival and DSBs recognition and repair.  




Two cell line models were selected – a normal ovarian epithelial cell line (OSEC-2) 
and an ovarian carcinoma cell line (NUOC-1) (Table 5-1). OSEC-2 cell line was 
developed at Newcastle University (Davies et al., 2003). NUOC-1 cell line is a 
spontaneously immortalised PCO culture that was characterised in chapter 3. 
 Table 5-1 Cell line models.  
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culture derived from 
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5.3.1.1 Selection of ATR vs ATM for Inhibition of HR Function 
Both ATR and ATM are signaling proteins that are reported to initiate HR. The HR 
assay was carried out using ATR and ATM inhibitors to assess which of the two 
proteins has a more important role in HR. A two fold increase in γH2AX and RAD51 
is used as a cut off to define HRC. > 2 fold increase in γH2AX and RAD51 cells are 
deemed HRC, whilst > 2 fold increase in γH2AX but < 2 fold increase in RAD51 cells 
are deemed HRD.  
Relative to un-irradiated controls, neither ATR nor ATM inhibitors had a significant 
effect on γH2AX foci number 24 hrs after treatment with 10 µM rucaparib and 2Gy IR 
(Figure 5-1). ATR inhibition caused HRD, as there was only a 1.4-fold increase in 
RAD51 foci after IR+rucaparib. ATM inhibition did not impair HR, as there was a 2.2-
fold increase in RAD51 foci after IR+rucaparib in ATM inhibited cells. Therefore, ATR 
was selected for this study. Inhibition of NHEJ by the DNA-PK inhibitor NU7441 was 












































































Figure 5-1 Assessment of HR in response to ATR and ATM inhibition.  
DNA damage by ƴH2AX foci and HR function assessed by the formation of RAD51 
foci 24 hrs after 2Gy IR in OSEC-2 cells. ATR (NU6027) and ATM (KU59403) 
inhibitors were added 1 hrs prior to IR treatment. 
5.3.1.2 Optimisation of Inhibition of ATR and DNA-PK 
To avoid the complication of off-target cytotoxicity of the inhibitors the minimum 
concentration needed to inhibit enzymatic activity in cells by 80 % was determined by 
assessing phosphoDNA-PK expression after 2 Gy IR by western blotting. Although 
significant inhibition of DNA-PK phosphorylation was found at all concentrations, 1 
µM NU7441 was selected, as it produced a mean 78 % reduction in activity, and this 





Figure 5-2 Optimisation of inhibition of DNA-PK in OSEC-2 cell line.  
A. Representative western blot and B. band density results for pDNA-PK inhibition by 
NU7441 1 hr after 2 Gy IR. 
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ATR function was assessed by the assessment of phosphorylation of CHK1 after 
treatment with HU. All those concentrations tested except 1 µM NU6027, significantly 
reduced pCHK1 (Figure 5-3). 10 µM NU6027 was selected, as it produced a mean 
80 % reduction in activity and this concentration had been used in previous studies 






Figure 5-3 Optimisation of inhibition of ATR in OSEC-2 cell line. 
Western blot and band density results of pCHK1 inhibition after 24 hr incubation with 
NU6027. 10 µM Hydroxyurea (HU) was used to induce DNA damage. 
5.3.1.3 Development of Knockdown Models for ATR and DNA-PK 
Knockdown models of ATR and DNA-PKcs were generated to assess the effect of an 
absent protein, as compared to an inhibited protein. OSEC-2 and NUOC-1 cells were 
virally transduced with MISSION®shRNA lentiviral transduction particles. Five 
constructs for each protein were assessed. A non target control construct was used 
for control of transduction. In OSEC-2 cells knockdown was assessed for all 5 
constructs for ATR and DNA-PKcs. In NUOC-1 cells 4 DNA-PKcs and 3 ATR 
knockdowns grew successfully for analysis.  
5.3.1.3.1 Assessment of Knockdown by mRNA and Protein Expression 
Knockdown levels were confirmed at mRNA level by RT-qPCR and at protein level by 
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Figure 5-4 Silencing of ATR and DNA-PKcs in OSEC-2 and NUOC-1 cells.  
A. DNA-PKcs mRNA expression analysed by real time RT-qPCR. Expression was normalised to GAPDH housekeeper gene. Results 
were then normalised to non target control. B. ATR mRNA expression C. DNA-PKcs protein expression analysed by western blotting. 
Densitometry was normalised to α-tubulin loading control. Results were then normalised to non target control. D. ATR protein expression. 
All results are average of three independent experiments. Error bars are SEM. 
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For DNA-PKcs knockdowns the 6255 construct achieved the best knockdown, as 
measured by both mRNA (61 % knockdown in OSEC-2, p = 0.0002, and 52 % 
knockdown in NUOC-1 cells, p = 0.001) and protein (46 % knockdown in OSEC-2, p 
= 0.006 and 73 % knockdown in NUOC-1 cells, p < 0.0001) levels in both OSEC-2 
and NUOC-1 cells, and therefore, this construct was selected for use in further 
experiments (Figure 5-4). 
For ATR knockdown no single construct was comparable in both cell lines, and 
therefore, construct 10613 was selected for OSEC-2 (68 % knockdown at mRNA, p = 
0.003, and 94 % knockdown at protein level, p < 0.0001) cells and 10300 for NUOC-
1 cells (61 % knockdown at mRNA, p = 0.0006, and 78 % knockdown at protein level, 
p = 0.0004) for use in further experiments. 
5.3.1.3.2 Development of Double Knockdown Models 
To analyse the interactions of ATR and DNA-PK, double knockdown models were 





Figure 5-5 ATR and DNA-PK double knockdown in OSEC-2 cells.  
A. DNA-PKcs and ATR mRNA expression was analysed by real time RT-qPCR. B. 
DNA-PKcs and ATR protein expression was analysed by western blotting. 
Expression was normalised to GAPDH housekeeper gene. Results were then 
normalised to controls. All results are average of three independent experiments. 
Error bars are SEM. 
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Greater than 50 % DNA-PK knockdown was successful in all combinations of 
knockdown (Figure 5-5). However, the only combination where ATR knockdown was 
successful was when ATR knockdown was performed first, followed by DNA-PK 
knockdown, thus producing a 30 % ATR and 50 % DNA-PK knockdown. The level of 
knockdown was below that achieved with individual knockdowns. Furthermore, when 
protein levels were assessed double knockdown was found not to be possible. 
Therefore, the decision was made to combine knockdown with drug treatments.   
5.3.1.3.3 Assessment of HR and NHEJ Function in Knockdown Models 
Functional assessment of knockdown models for HR and NHEJ was undertaken 
using validated assays. Knockdown of ATR blocked the increase in RAD51 foci after 
DNA damage (mean 1.0 +/- 0.1 fold rise in OSEC-2 10613 knockdown, compared to 
2.6 +/- 0.1 fold in OSEC-2 controls, p = 0.003, and mean 1.3 +/- 0.3 fold in NUOC-1 
10300 knockdown, compared to 2.5 +/- 0.2 fold in NUOC-1 controls, p = 0.007) 
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Figure 5-6 HR and NHEJ function in knockdown models.  
A. HR function assessed by fold rise in RAD51 foci after 2Gy IR and 24 hr treatment 
with 10µM rucaparib in OSEC-2 and NUOC-1 non target shRNA controls and ATR 
knockdowns (10613 and 10300). RAD51 foci were assessed by immunofluorescence 
and quantified using ImageJ. B. NHEJ function assessed by rejoining of 2I BstXI cut 
vector DNA by OSEC-2 and NUOC-1 non target shRNA and DNA-PKcs knockdown 
(6255). Rejoining was assessed by GelRed stained agarose gel and quantified by 




To determine NHEJ function, the rate of rejoining of 2I BstXI substrates was 
assessed. Knockdown of DNA-PKcs approximately halved the rejoining of 2I BstXI 
cut vectors (mean 11.5 +/- 1.3  % in OSEC-2 6255 knockdown compared to 24.1 +/- 
2.8 fold in OSEC-2 controls, p = 0.001, and mean 12.0 +/- 0.5  % in NUOC-1 6255 
knockdown compared to 21.1 +/- 2.1 fold in NUOC-1 controls, p = 0.02), and so were 
deemed NHEJD (Figure 5-6.B). 
5.3.2 Assessment of the Effect of ATR and DNA-PK Inhibition on Cellular 
Biology 
Both ATR and DNA-PKcs have cellular effects outside the DDR. Therefore, the effect 
on cellular biology was assessed for the inhibitors and knockdown models 
individually and combined. 
Hypothesis: Inhibition of ATR and DNA-PK results in reduction in cell growth and cell 
survival with synergistic effect due to inhibition of DNA repair 
5.3.2.1 The Effect of ATR and DNA-PK on Cell Growth 
Inhibition of ATR resulted in significant growth inhibition in OSEC-2 and NUOC-1 
cells (Figure 5-7). The results were consistent between inhibitor (47 % reduction, p = 
0.007 for OSEC-2, and 78 %, p < 0.0001 for NUOC-1) and shRNA knockdown (29 % 
reduction, p = 0.03 for OSEC-2, and 41 % reduction, p = 0.02 for NUOC-1). This 
finding is likely to be due to the impairment of DNA damage repair.  
DNA-PK inhibition was found to have inconsistent results between knockdown and 
inhibition in NUOC-1 cells (30 % reduction when treated with inhibitor and 40 % 






Figure 5-7 The effect of ATR and DNA-PK inhibition on cell growth.  
All results are normalised to DMSO controls for drug treatments and non target 
shRNA for knockdown models. All treatments were grown for three doubling times. 
Results are average of three independent experiments with 6 experimental repeats. 
Error bars are SEM. Statistical significance was assessed by two way Anova with 
Bonferroni correction for multiple analysis. 
 
Combined pharmacological inhibition of ATR and DNA-PKcs resulted in significant 
inhibition of cell growth in both cell lines (56 % reduction, p = 0.001 for OSEC-2, and 
82 % reduction, p < 0.0001 for NUOC-1), which was similar to the result of ATR 
knockdown combined with NU7441 (56 % reduction, p = 0.001 for OSEC-2, and 
65 % reduction, p = 0.0001 for NUOC-1). However, the addition of NU6027 to DNA-
PK knockdown was found to have no effect on cell growth in either cell line compared 
to controls. In the NUOC-1 cell line, addition of NU6027 to DNA-PK shRNA did 
significantly reduce cell growth compared to DNA-PK shRNA alone (39 % reduction, 
p < 0.0001).   
5.3.2.2 The Effect of ATR and DNA-PK on Cell Survival 
To assess if, further to inhibition of cell growth, overall cell survival is inhibited by loss 
of ATR and DNA-PKcs, clonogenics assays were used (Figure 5-8). Despite 
significant growth inhibition by ATRi in OSEC-2 cells, the only treatment found to 
have a significant reduction in cell survival was the combination of ATR shRNA with 
NU7441 (65 % reduction in cell survival, p = 0.045).  
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Figure 5-8 The effect of ATR and DNA-PK inhibition on cell survival.  
All results are normalised to DMSO controls for drug treatments and non target 
shRNA for knockdown models.  OSEC-2 treatments were grown for 14 days and 
NUOC-1 for 30 days. All treatments were grown for three doubling times. Results are 
average of three independent experiments with 3 experimental repeats. Error bars 
are SEM. Statistical significance was assessed by two way Anova with Bonferroni 
correction for multiple analysis. 
 
In NUOC-1 cells, neither inhibition, nor knockdown of ATR or DNA-PK individually 
reduced cell survival significantly. Combination of ATR and DNA-PK inhibitors 
together (83 % reduction in cell survival, p = 0.028) and shRNA knockdown with ATRi 
(79 % reduction in cell survival, p = 0.042) and DNA-PKi (90 % reduction in cell 
survival, p = 0.014) resulted in reduced cell survival. 
5.3.2.3 The Effect of ATR and DNA-PK on Cell Cycle  
Hypothesis: Inhibition of ATR and DNA-PK results in cell cycle arrest 
Due to the observed discrepancy between growth inhibition and cell survival assays, 
cell cycle analysis was performed. The effects of ATR and DNA-PKcs inhibition and 
knockdown on phases of the cell cycle were analysed using PI staining and FACS 
analysis (Figure 5-9).  
In OSEC-2 cells, ATR inhibition resulted in significant G1 arrest (15 %, p < 0.0001), 
whilst knockdown of DNA-PKcs resulted in a significant G2/M arrest (9 %, p = 
0.0007). The results between knockdown and drug inhibition were not consistent. 
Also non target shRNA produced a significant G1 arrest (14 %, p < 0.0001), which 
suggests off target cell cycle effects. This effect of non target shRNA may also be 
masking any effects from the ATR and DNA-PK knockdown. Due to NUOC-1 
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tetraploid and mixed population phenotype, cell cycle analysis could not be 
performed in NUOC-1 cells (determined in section 2.9.4).  
 
Figure 5-9 The effect of ATR and DNA-PKcs on cell cycle.  
DNA-PKcs was inhibited with NU7441 or knockdown with shRNA, and ATR was 
inhibited with NU6027 or shRNA knockdown in exponentially growing cells. 10,000 
cells were counted. Pharmacologically inhibited cells are compared to DMSO control, 
and shRNA-knockdown cells are compared to non target shRNA control. Results are 
mean of 3 independent experiments. 
5.3.2.4 The Effect of ATR and DNA-PK on DNA Repair 
ATR and DNA-PK are essential for DSB repair. DSBs repair was assessed by 
inducing DSBs using 2 Gy IR, and measuring the mean numbers of γH2AX foci, a 
marker for DSBs, and the mean numbers of RAD51, a marker for HR. OSEC-2 cells 
were used for these experiments. 
Hypothesis: Inhibition of ATR and DNA-PK results in reduction of DNA damage 
recognition. DNA-PK is involved in fast phase of repair via NHEJ, whilst ATR 
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Figure 5-10 DSBs formation and recovery after inhibition of ATR and DNA-PKcs.  
Inhibitors were added to OSEC-2 cells 1 hr prior to irradiation. Foci formation was 
assessed using immunofluorescence after 2Gy IR. Foci numbers were quantified 
using ImageJ. Average number of foci per nucleus are expressed. A. γH2AX foci, B. 
RAD51 foci. The results are average of three independent experiments. Error bars 
are SEM.   
 
An initial rapid peak in γH2AX foci was seen after 2 Gy IR, peaking at 2 hrs in this 
cell line model (Figure 5-10). After the initial peak, the γH2AX foci disappeared in a 
biphasic manner with an initial rapid disappearance, followed by a more gradual 
decline. RAD51 foci increased steadily peaking at 12 hrs after irradiation; the counts 
were then maintained until 24 hrs, after which, the number of foci had returned to the 
baseline count by 48 hrs.   
Inhibition of ATR with NU6027 resulted in the inhibition of γH2AX foci formation, 
consistent with γH2AX phosphorylation by ATR, with 25 % lower foci counts at 2 hrs 
(p = 0.033, Figure 5-10.A); and also in the reduction of RAD51 foci formation, with 
55 % lower RAD51 foci counts at 12 hrs (p = 0.004), and 43 % lower at 24 hrs (p = 
0.03) (Figure 5-10.B).  
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Inhibition of DNA-PK with NU7441 resulted in a lower peak γH2AX foci count at 2 hrs 
(28 % lower, p = 0.03), consistent with γH2AX phosphorylation by DNA-PK; and a 
delay in γH2AX foci recovery, consistent with the impairment of DSB repair by NHEJ, 
with 69 % higher γH2AX foci counts at 6 hrs (p = 0.008), 200 % higher at 12 hrs (p = 
0.004), 250 % higher at 24 hrs (p = 0.005) and 230 % higher at 48 hrs (p = 0.007) 
(Figure 5-10.A.). Furthermore, significantly higher RAD51 foci counts were found at 
24 hrs (21 % higher, p = 0.047) and 48 hrs (297 % higher, p < 0.0001) (Figure 
5-10.B).  
Combination of ATR and DNA-PKcs inhibitors resulted in a lower γH2AX peak, with 
60 % lower mean counts at 15 min (p = 0.005), and 50 % lower at 2 hrs (p = 0.003). 
The γH2AX foci peak was also delayed to 6 hrs after IR, compared to 2 hrs in the 
controls. This result demonstrates the synergistic actions of ATR and DNA-PKcs in 
DSBs recognition. RAD51 foci numbers were found to be lower than in IR control 
cells, but higher than in cells treated with ATR inhibitor alone; these differences were 
not statistically significant. ATR and DNA-PK, therefore, have opposing effects on the 
numbers of RAD51 foci forming in these cells after irradiation. 
5.3.2.5 The Effect of ATR and DNA-PK Inhibition on Chemo-sensitivity Ovarian Cells 
Further to the baseline assessment of the sensitivities of NUOC-1 and OSEC-2 cell 
lines to common therapeutics, as discussed in chapter 3, the role of ATR and DNA-
PKcs inhibition in chemo-sensitivity was assessed.  
Hypothesis: Inhibition of ATR results in sensitisation to common therapeutics due to 
inhibition of HR, whilst inhibition of DNA-PK results in radio-sensitisation, but 
resistance to PARPi due to inhibition of NHEJ 
Growth inhibition assays were performed to evaluate the effect of ATR and DNA-
PKcs inhibition in OSEC-2 and NUOC-1 cell line sensitivity to irradiation, rucaparib, 
cisplatin and paclitaxel. Inhibition and shRNA knockdown models for ATR and DNA-
PKcs were used. Inhibition was compared to DMSO treated controls, and shRNA 









Table 5-2 Sensitisation of NUOC-1 and OSEC-2 cells to common therapeutics by ATR and DNA-PK inhibition and knockdown.  
Treatments assessed were radiation, rucaparib, cisplatin and paclitaxel with ATR or DNA-PKcs inhibition using drug and shRNA 
knockdowns. Multiple T tests compared to controls were carried out, with bonferroni adjustment for multiple comparisons. Significant 
results are marked in bold. 













Control 4.14 - 8.3 - 1.18 - 0.41 - 
ATR inhibited 4.46 0.82 4.67 0.003 0.51 0.014 0.35 0.06 
DNA-PK inhibited 2.01 0.009 6.55 0.41 0.97 0.18 0.32 0.53 
Non target 2.95 - 7.01 - 1.07 - 0.32 - 
ATR shRNA 2.53 0.50 2.53 0.014 0.38 0.044 0.18 0.53 
DNA-PK shRNA 0.75 <0.0001 5.19 0.09 0.80 0.61 0.25 0.90 





Control 5.84 - 17.47 - 2.83 - 0.44 - 
ATR inhibited 3.77 0.17 12.82 0.39 1.43 0.11 0.39 0.89 
DNA-PK inhibited 1.36 0.025 34.76 0.12 2.33 0.51 0.45 0.19 
Non target 2.99 - 7.21 - 4.33 - 0.24 - 
ATR shRNA 3.63 0.95 4.82 0.009 2.96 0.49 0.24 0.74 
DNA-PK shRNA 3.35 0.88 8.38 0.26 4.35 0.99 0.15 0.14 
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DNA-PK inactivation was found to have significant radio-sensitisation in the NUOC-1 
cell line as seen in the inhibition (51 % reduction in GI50, p = 0.009) and shRNA 
knockdown (75 % reduction in GI50, p < 0.0001) cells (Table 5-2). In OSEC-2 cells, 
the radio-sensitisation was statistically significant for NU7441 treatment (76 % 
reduction in GI50, p = 0.025), but not shRNA knockdown.  
ATR inhibition resulted in significant sensitisation of NUOC-1 cells to rucaparib (44 % 
reduction in GI50, p = 0.003 for ATR inhibition, and 64 % reduction in GI50, p = 0.014 
for shRNA knockdown), and cisplatin (57 % reduction in GI50, p = 0.014 for ATR 
inhibition, and 65 % reduction in GI50, p = 0.044 for shRNA knockdown). The only 
statistically significant sensitisation of OSEC-2 cells was to rucaparib in ATR shRNA 
knockdown (p = 0.009).  
Neither ATR nor DNA-PKcs inhibition had any significant effect on sensitivity of either 
cell line to Paclitaxel. This result was anticipated as paclitaxel is a mitotic spindle 
inhibitor; and thus DNA is not its primary target. 
5.3.3 Interaction of ATRi and DNA-PKi with PARPi 
Interaction of PARPi and DNA-PKi in radio-sensitisation has also been demonstrated 
(Ruscetti et al., 1998, Veuger et al., 2003, Veuger et al., 2004, Mitchell et al., 2009a). 
In other studies, PARP-1 has been shown to have a protective role in HR by 
suppressing the access of NHEJ to DSBs (Hochegger et al., 2006, Saberi et al., 
2007). The interaction of PARPi with DNA-PKi and ATRi in cell biology was assessed 
in this study. 
5.3.3.1 Optimisation of PARP Inhibition  
To reduce the complication of off-target cytotoxicity, the minimum concentration of 
rucaparib necessary to inhibit PARP activity by > 80 % was determined. 1 µM 
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Figure 5-11 Optimisation of inhibition of PARP.  
PAR assay A. representative blot and B. band density results for PARP activity 
inhibition by rucaparib. 
 
5.3.3.2 The Interaction of PARP Inhibition with ATR and DNA-PK Inhibition on Cell 
Growth 
Hypothesis: Addition of rucaparib results in synergistic inhibition of cell growth and 
survival with ATRi, but opposing effects with DNA-PKi 
The growth of OSEC-2 and NUOC-1 cells was not inhibited by 1 µM of rucaparib 
alone. The interaction of PARPi with ATRi and DNA-PKi on cell growth was assessed 
by treatment with 1 µM of rucaparib with 1 µM NU7441 or 10 µM NU6027 or shRNA 
knockdown of either protein.  
In OSEC-2 cells, there was no additional growth inhibitory effect of rucaparib above 
ATRi or ATR shRNA (Figure 5-12 and Appendix 4). Furthermore, no significant 
alteration of cell growth, compared to controls, was seen when rucaparib was 




Figure 5-12 The effect of PARPi combined with ATRi and DNA-PKi on cell growth.  
All results are normalised to appropriate control. All treatments were grown for three 
doubling times. Results are average of three independent experiments with 6 
experimental repeats. Error bars are SEM. Statistical comparisons are in appendix 4. 
 
In NUOC-1 cells, inhibition with rucaparib resulted in a significant reduction in cell 
growth when added in combination with ATR shRNA (61 % growth reduction, p < 
0.0001), and DNA-PKcs shRNA (52 % growth reduction, p < 0.0001) knockdowns 
(Figure 5-12 and Appendix 4). This growth inhibition was not reproduced when 
inhibitor combinations were used. However, the combination of all three inhibitors 
resulted in a significant reduction of cell growth compared to rucaparib alone (52 % 
reduction, p = 0.02, in OSEC-2, and 66 % growth reduction, p = 0.03, in NUOC-1 cell 
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5.3.3.3 The Interaction of PARP Inhibition with ATR and DNA-PK Inhibition on Cell 
Survival 
To assess if the combination of rucaparib with ATRi and DNA-PKi were cytotoxic, as 
well cytostatic, clonogenic assays were performed (Figure 5-13 and Appendix 4).  
In the OSEC-2 cell line, rucaparib resulted in a 27 % reduction in cell survival, 
compared to DMSO control. The combination of rucaparib with NU6027 resulted in a 
51 % reduction in cell survival, compared to NU6027 alone, but this change was not 
significant compared to rucaparib alone. After correction for multiple comparisons, 
these results were also not found to be statistically significant. The addition of 
rucaparib to ATR shRNA resulted in a 63 % reduction in cell survival, compared to 
rucaparib alone, and a 61 % reduction in cell survival, compared to ATR shRNA. 
Consistent reduction in cell survival was also seen when rucaparib was added to 
NU7441 (52 %) and DNA-PK shRNA (52 %).  
The combination of the three inhibitors only produced a 27 % reduction in cell 
survival, however, triple inhibition when either DNA-PK shRNA or ATR shRNA were 
used produced a 50 % and a 77.5 % (p = 0.04) reduction in cell survival, respectively, 
compared to untreated controls.  
In NUOC-1 cells rucaparib alone, and also in combination with ATRi and DNA-PKi 
did not produce a significant reduction in cell survival. However, the addition of 
rucaparib to ATR shRNA resulted in a 67 % reduction in cell survival, compared to 
ATR shRNA, and 99 % reduction, when compared to rucaparib alone (p = 0.01). The 
addition of rucaparib to DNA-PK shRNA also resulted in a reduction of cell survival 
(38.5 % compared to DNA-PK shRNA and 86 % compared to rucaparib).  
In NUOC-1 cells, using triple inhibitors produced a 47 % reduction in cell survival, 
however, triple inhibition when shRNA was used resulted in only 1.5 % cell survival 
for DNA-PK shRNA + NU6027 + rucaparib (p = 0.013), and no cell survival at all 




Figure 5-13 The effect of PARPi combined with ATRi and DNA-PKi on cell survival.  
All results are normalised to appropriate control. OSEC-2 treatments were grown for 
14 days and NUOC-1 for 30 days. All treatments were grown for three doubling 
times. Results are average of three independent experiments with 3 experimental 
repeats. Error bars are SEM. Statistical comparisons are in appendix 4. 
 
5.3.3.4 The Interaction of PARP Inhibition with ATR and DNA-PK Inhibition on DNA 
Repair 
PARP-1 binds to and is activated by stalled replication forks (Bryant et al., 2009, 
Sugimura et al., 2008) and is necessary for the accumulation of MRE11 and NBS1 at 
the site of DSBs (Hegan et al., 2010, Benjamin and Gill, 1980, Haince et al., 2008). 
The role of PARP-1 in DSBs recognition and repair was assessed by time-course of 
γH2AX / RAD51 foci formation and recovery.  
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PARP-1 inhibition resulted in a 35 % reduction in γH2AX foci numbers at 2 hrs (mean 
32.6 +/- 7.6 foci / cell in rucaparib treated, compared to 50.5 +/- 4.4 foci / cell in 
untreated controls, p = 0.025) (Figure 5-14). The number of RAD51 foci was lower in 
PARPi treated cells, but this was not statistically significant.   
 
Figure 5-14 DNA DSBs formation and recovery after inhibition of PARP-1.  
Assessed by γH2AX and RAD51 foci formation in OSEC-2 cells. Inhibitors were 
added 1 hr prior to irradiation. Foci formation was assessed using 
immunofluorescence after 2Gy IR. Foci numbers were quantified using ImageJ 
macro. Average number of foci per nucleus are expressed. Black lines – γH2AX foci, 
red lines – RAD51 foci. The results are average of three independent experiments. 
Error bars are SEM. 
 
To test the interaction of PARP-1 with DNA-PK and ATR in DSBs repair, cells were 
treated with a combination of PARPi, ATRi, and DNA-PKi and γH2AX and RAD51 
foci formation was then assessed (Figure 5-15).  
The combination of ATRi and PARPi resulted in a rise in γH2AX foci, compared to 
control level at 2 hrs, and whilst a delay in foci recovery was seen, this was not 
statistically significant. RAD51 foci formation again returned baseline IR levels when 










Figure 5-15 DNA DSBs formation and recovery after inhibition of PARP-1 and ATR.  
Assessed by γH2AX and RAD51 foci formation in OSEC-2 cells. Inhibitors were 
added 1 hr prior to irradiation. Foci formation was assessed using 
immunofluorescence after 2Gy IR. Foci numbers were quantified using ImageJ 
macro. Average number of foci per nucleus are expressed. A. γH2AX foci, B. RAD51 
foci. The results are average of three independent experiments. Error bars are SEM. 
 
A statistically significant delay in γH2AX foci recovery was seen after the combination 
of PARPi and DNA-PKi (Figure 5-16). 59 % more foci, compared to IR controls were 
found at 8 hrs, 157 % more foci at 12 hrs (Tukeys multiple comparison p = 0.015), 
222 % at 24 hrs (p = 0.014) and 188 % at 48 hrs (p = 0.044). The difference between 
DNA-PKi and the combination of inhibitors was not significant. This finding 
demonstrates the predominant role of NHEJ in DSBs repair.  
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Figure 5-16 DNA DSBs formation and recovery after inhibition of PARP-1 and DNA-
PK.  
Assessed by γH2AX and RAD51 foci formation in OSEC-2 cells. Inhibitors were 
added 1 hr prior to irradiation. Foci formation was assessed using 
immunofluorescence after 2Gy IR. Foci numbers were quantified using ImageJ 
macro. Average number of foci per nucleus are expressed. A. γH2AX foci, B. RAD51 
foci. The results are average of three independent experiments. Error bars are SEM. 
 
Whilst PARPi resulted in a non-statistically significant reduction in RAD51 foci 
formation, RAD51 foci formation was significantly increased when the inhibitors were 
combined above the level for DNA-PKi alone at 6 hrs (133 % higher, p = 0.0006, 
compared to IR; 290 % higher, p < 0.0001, compared to rucaparib; and 179 % 
higher, p = 0.0001 compared to DNA-PKi), at 24 hrs (92 % higher, p < 0.0001, 
compared to IR; 180 % higher, p < 0.0001, compared to rucaparib; and 41 % higher, 
p = 0.026, compared to DNA-PKi.) and at 48 hrs (643 % higher, p < 0.0001, 
compared to IR; 977 % higher, p < 0.0001, compared to rucaparib; and 64 % higher, 
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p = 0.013, compared to DNA-PKi) (Figure 5-16.B). This finding suggests that PARP-1 
inhibits HR. This is in contradiction to reports of the PARP-1 protective role of HR 
(Hochegger et al., 2006). However, it is in agreement with reports that in the absence 
of PARP-1, HR is increased (Helleday et al., 2005). PARP-1 has been reported to 
function in the A-EJ pathway, and A-EJ has been reported to compete with HR 
(Ceccaldi et al., 2015a, Mateos-Gomez et al., 2015). In the absence of NHEJ and A-
EJ, HR appears to be increased.  
5.3.4 DNA Damage Recognition and Repair in Primary Cultures 
To see if the findings from cell line experiments could be extended to primary human 
tissue the PCO culture collection was used. 
Hypothesis: Expression of ATR and DNA-PK and PARP function are variable and 
independent of each other in PCO cultures  
5.3.4.1 Expression of ATR and DNA-PKcs at mRNA Level 
The expression of ATR and DNA-PKcs mRNA was assessed by RT-qPCR. A range 
of expression of both ATR and DNA-PKcs mRNA was found in all the PCO cultures 
assessed. All PCO cultures expressed a lower level of ATR and DNA-PK mRNA, 
compared to the OSEC-2 cell line. The mRNA level in OSEC-1 closer resembled the 
expression in PCO cultures. Therefore, differences are unlikely to be due to higher 
expression in normal cells as both OSEC-1 and OSEC-2 were derived from normal 
epithelium. There was a positive correlation between expression of ATR and DNA-











Figure 5-17 ATR and DNA-PKcs mRNA expression and correlation in PCO cultures.  
Expression was assessed by RT-qPCR and normalised to expression of 
housekeeper gene GAPDH. A. ATR mRNA expression. B. DNA-PKcs mRNA 
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PARP activity was analysed in a selection of PCO cultures. The experiments were 
kindly performed by James Murray. A range of PARP activity was found in PCO 
cultures. There was no correlation with the expression of ATR or DNA-PKcs mRNA 







Figure 5-18 PARP activity in PCO cultures correlated with ATR and DNA-PKcs 
mRNA expression.  
A. PAR assay band density results for activated PAR. Activity in each PCO was 
normalised to activity in control cell line L1210. B. correlation between PAR activity 
and ATR mRNA. C. Correlation between PAR activity and DNA-PKcs mRNA. 
 
As previously discussed, the interaction of PARP-1 with HR and NHEJ is still not 
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cultures was assessed. No positive correlation between PARP function and either 
HR or NHEJ was noted (Figure 5-19).  
The expression of PARP-1 mRNA was assessed in a RNA Genome expression array 
(Figure 5-20). Consistent with PARP activity, the expression of PARP-1 mRNA was 
independent of HR and NHEJ function in PCO cultures. Furthermore, no correlation 



























































Figure 5-19 PARP-1 activity in PCO cultures shown by NHEJ and HR status.  
Stimulated PAR activity expressed as mean PAR pmol/106 cells was assessed in 
duplicate and normalised to L1210 control. Error bars are SD. 
 
Figure 5-20 PARP-1 expression in PCO cultures shown by HR and NHEJ status.  
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Figure 5-21 Correlation between PAR activity and PARP-1 mRNA.  
PAR assay band density results for activated PAR. Activity in each PCO was 
normalised to activity in control cell line L1210. Expression was assessed using RNA 
genome microarray. 
5.3.4.2 ATR Induced Sensitisation to Rucaparib and Cisplatin 
The results from section 5.3.2.5 demonstrating ATRi sensitisation to rucaparib and 
cisplatin were encouraging. Therefore, in a cohort of PCO cultures the effect of ATRi 
on sensitivity to rucaparib and cisplatin was assessed (Figure 5-22). The addition of 
ATRi reduced the mean survival after 10 days treatment with 10 µM rucaparib from 
56 % to 42 % (p = 0.0065), and the mean survival after 10 days treatment with 10 µM 
cisplatin from 34 % to 22 % (p = 0.0028).  
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Figure 5-22 ATRi sensitisation of PCO cultures to rucaparib and cisplatin. 
Results are percent cell survival after 10 days treatment with 10 µM rucaparib and 10 
µM cisplatin, +/- 10 µM NU6027, compared to DMSO control. Error bars are SEM. 
 
5.3.4.3 DSB Activation and Repair in Primary Ovarian Cultures 
In the cell line experiments in section 5.3.2.4, inhibition of ATR resulted in a reduced 
peak of γH2AX foci formation. Meanwhile, inhibition of DNA-PK reduced the peak of 
γH2AX foci formation and delayed recovery. To confirm the results from cell line 
inhibition experiments, the rate of γH2AX formation and recovery was assessed in 
PCO cultures.  
Hypothesis: γH2AX foci formation in HRD cells is lower than in HRC cells. γH2AX 
foci formation is lower and recovery delayed in NHEJD, compared to NHEJC cultures  
Each culture was irradiated at 2Gy and cover slips were fixed at the following time 
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Figure 5-23 DNA DSBs formation and recovery in PCO cultures.  
Assessed by γH2AX foci formation after 2Gy IR using IF in A. HRC compared to 
HRD cultures, and B. NHEJC compared to NHEJD cultures. Foci numbers were 
quantified using ImageJ macro. Average number of foci per nucleus are expressed. 
The results are average of three independent experiments. Error bars are SEM. 
 
Confirming the results of the cell line experiments, the HRD cultures had a lower 
peak of γH2AX foci. However, the difference was not statistically significant (Figure 
5-23.A). NHEJD cultures had a delayed peak of γH2AX foci (Figure 5-23.B). 
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Significantly lower number of foci formed immediately after irradiation (mean 20.3 +/- 
2.9 foci in NHEJC, compared to mean 12.4 +/- 2.2 foci in NHEJD, p = 0.029) and at 1 
hr (mean 25.8 +/- 1.9 foci in NHEJC, compared to mean 17.5 +/- 2.3 foci in NHEJD, p 
= 0.01). A slower recovery of γH2AX foci was also observed in NHEJD PCO cultures 
(Figure 5-23.B).  
In PCO cultures RAD51 foci formation was assessed at 24 hrs only. The mean 
increase in RAD51 foci above controls was significantly higher at 5.45 fold in HRC 
compared to 1.28 fold HRD cultures (p < 0.0001) (Figure 5-24.A). The increase in 
RAD51 foci was also higher in NHEJD cultures compared to NHEJC cultures (p = 
0.03). The increase in HR in the absence of DNA-PK is consistent with the inhibition 
results in section 5.3.2.4, and previous studies (Cornell et al., 2015) suggesting that 
when NHEJ is impaired there is a shift to HR.  
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Figure 5-24 RAD51 foci fold rise and DNA-PK expression shown by HR or NHEJ 
status.  
A. RAD51 foci fold rise above controls in primary ovarian cancer cultures divided by 
HR or NHEJ status. RAD51 foci were assessed as mean foci count per cell in 
samples after 24 hrs of 10 µM rucaparib and 2 Gy IR treatment, compared to 
untreated controls. Foci were counted across 3 fields of view for each sample 
counting >50 cells in each sample. N = 40. Error bars are SEM. B. DNA-PKcs protein 
expression in primary ovarian cancer cultures shown by HR or NHEJ status. DNA-PK 
protein expression was assessed by western blotting and normalised to GAPDH 
house keeper gene. N = 36. Error bars are SEM. 
 
DNA-PKcs expression was 64 % higher in NHEJC (0.72 of GAPDH expression, 95 % 
CI = 0.5 - 0.9), compared to NHEJD cultures (0.26, 95 % CI = 0.2 - 0.4, p < 0.0001) 
(Figure 5-24.B). Interestingly, DNA-PKcs expression was also 59 % higher in HRC 
 204 
 
cells (0.78 of GAPDH expression, 95 % CI = 0.6-0.9), compared to HRD cells (0.32, 
95 % CI = 0.2-0.4, p < 0.0001) (Figure 5-24.B).  
5.3.4.4 Correlation between γH2AX foci recovery and sensitivity to rucaparib and 
cisplatin 
To validate the observation that γH2AX foci formation and recovery differs depending 
on HR and NHEJ function, the association of γH2AX foci formation and recovery with 
rucaparib and cisplatin sensitivity was assessed (Figure 5-25). 
A                                                                  B 
 
 
Figure 5-25 The association of γH2AX foci formation and recovery with rucaparib and 
cisplatin sensitivity. 
A. PCO cultures were divided into two groups based on median foci numbers at 2 
hrs. Sensitivity was assessed by SRB assay after 10 days growth in 10 µM rucaparib 
and 10 µM cisplatin treatment, compared to DMSO treated controls. B. PCO cultures 
were divided into two groups based on median foci numbers at 4 hrs. Sensitivity was 
assessed by SRB assay after 10 days growth in 10 µM rucaparib and 10 µM cisplatin 
treatment, compared to DMSO treated controls. One way Anova with Sidak multiple 
analysis correction was performed. Error bars are SEM. 
 
Cultures with a reduced peak in γH2AX foci at 2 hrs were found to be more sensitive 
to rucaparib (p = 0.001) and cisplatin (p = 0.04). Cultures which had a delay in 
γH2AX foci recovery, with above median γH2AX foci numbers at 4 hrs were found to 
be less sensitive to rucaparib (p = 0.021) but not cisplatin. These cultures were 
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association found in chapter 4. The results suggest that sensitivity to rucaparib and 
cisplatin could be predicted by a single test assessing overall DSBs repair in PCO 
cultures.  
5.4 Summary of Chapter 
In this study HR and NHEJ pathway interaction was assessed using pharmacological 
inhibition and shRNA knockdown models of ATR and DNA-PK in OSEC-2 (cell line 
derived from normal epithelium) and NUOC-1 (cell line derived from endometrioid / 
clear cell carcinoma).  
Both ATR and DNA-PK inhibition was found to be cytostatic and causing G1 and G2 
arrest, respectively. Inhibition of DNA-PK resulted in reduced recognition of DNA 
DSBs and delay in repair. It was also found to increase HR. Inhibition of ATR 
resulted in reduced DSBs recognition and reduction in HR, but not in the overall rate 
of DSBs repair. Combination of the two inhibitors resulted in continued HR, 
suggesting an alternative activation. Previously reported radio-sensitisation induced 
by DNA-PKi, and sensitisation to rucaparib and cisplatin by ATRi were confirmed. 
The sensitisation was specific to the NUOC-1 cell line, and was not reproducible in 
OSEC-2 cells, thus suggesting a cancer cell specificity. ATRi sensitisation to 
rucaparib and cisplatin was confirmed in PCO cultures. 
ATR and DNA-PK interaction with PARP-1 was assessed by the addition of a 
nontoxic dose of rucaparib to ATR inhibited and DNA-PKcs inhibited models. The 
previously reported role for PARP-1 in DSB recognition was confirmed. Combination 
of PARPi and DNA-PKi resulted in a delay in DSBs repair and a synergistic increase 
in HR. The combined inhibition of ATR and PARP also caused a reduction in DSB 
recognition, but an increase in HR, overcoming the inhibition of HR by ATRi.  
The observations were validated by assessing the interaction of ATR and DNA-PKc 
in PCO cultures. In PCO cultures a positive correlation was found between ATR and 
DNA-PK mRNA expression. PARP function was independent of HR and NHEJ. 
Reduced DSBs recognition in HRD, and reduced recognition and delayed repair in 
NHEJD cells was observed. Rucaparib and cisplatin sensitivity correlated positively 
with a high γH2AX foci peak at 2 hrs, and rucaparib sensitivity correlated with a rapid 
recovery of γH2AX foci. These results suggest that rucaparib and cisplatin sensitivity 




In this study interaction of NHEJ, HR and PARP-1 was assessed by using cell line 
and PCO culture models.  
5.5.1 Protein Inhibition and Knockdown may not be Directly Comparable  
The level of inhibition achieved using inhibitors was higher than that achieved using 
knockdown. Whilst both HR and NHEJ function were reduced in both knockdown and 
inhibited cells, some function of both pathways remained. It was not ascertained if a 
critical level of either protein exists in the cells. Thus, some of the differences 
observed may be due to different levels of inhibition of each protein. Furthermore, the 
presence of inactive protein rather than absence of the protein achieved in 
knockdown models may have a dominant negative effect. A further important point to 
consider is that NU6027 is also a CDK2 inhibitor. Therefore some of the observed 
effects may be CDK2 driven. Confirmation of these findings in a larger cohort of cell 
lines, and by using different inhibitors for ATR and DNA-PK is required.  
5.5.2 ATR and DNA-PK Inhibition Effects are Cell Line Specific 
The most important observation noted was that throughout the study the loss of ATR 
or DNA-PKcs had a significantly more pronounced effect in NUOC-1 than in OSEC-2 
cells, suggesting that NUOC-1 cells are more reliant on the DDR mechanism than 
OSEC-2 cells. Cancer cells often contain dysregulation of their cell cycle control 
(Massague, 2004), have high levels of replicative stress, stalled replication forks and 
DSBs, therefore, inhibition of DDR is thought to have a significant effect in tumour, 
but not normal cells (Wiseman and Halliwell, 1996), thereby limiting toxicity to the 
patient.  
However, these observations may also be due to differences seen in the level of 
inhibition of both ATR and DNA-PK between the two cell lines and baseline levels of 
these proteins. Knockdown achieved by shRNA was different between the two cell 
lines, DNA-PK was only 44 % knockdown in OSEC-2, compared to 73 % in the 
NUOC-1 cell line. This is likely to explain the lack of radio-sensitivity observed in the 
OSEC-2 cell line after DNA-PK shRNA knockdown, despite the documented role of 
DNA-PK in radio-sensitivity in the literature, and the observation with NU7441 
inhibitor. The converse was seen in ATR knockdown were >90 % knockdown was 
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achieved in OSEC-2, but only 78 % knockdown in NUOC-1 cells. In this case, 
despite a higher level of knockdown OSEC-2 cells were not sensitised to rucaparib or 
cisplatin by the absence of ATR. This was consistent with the NU6027 inhibitor, and 
is therefore, likely to represent a true difference between reliance of NUOC-1 and 
OSEC-2 cells on ATR.  
5.5.3 ATR and DNA-PK Inhibition are Cytostatic 
Both ATR and DNA-PK inhibition was found to be cytostatic, but not cytotoxic, as 
assessed by SRB and Clonogenics assays. Cytostatic effects are likely to be due to 
cell cycle arrest induced by the lack of both proteins. This is in agreement with 
multiple studies, that inactivation of ATR causes a G2/M checkpoint failure and 
subsequent G1 arrest (Brown and Baltimore, 2003, Peasland et al., 2011). 
Conversely, G2 arrest follows DNA-PK inhibition, as DNA-PK is thought to 
phosphorylate p53, which mediates G1 arrest (Kachnic et al., 1999). The cytotoxic 
effects of ATRi have, however, been described in the presence of BER defects 
(Peasland et al., 2011, Sultana et al., 2013, Mohni et al., 2014) in cells with 
oncogene-activation (Gilad et al., 2010) and cyclin E over-expression (Toledo et al., 
2011). NUOC-1 cells were found to be BER defective, as described in chapter 3, 
therefore, would be expected to be sensitive to ATR inhibition. These results are 
contradictory and demand further investigation.  
The inhibition of both ATR and DNA-PK was found to be cytotoxic in NUOC-1 but not 
OSEC-2 cells, and underlies the importance of DDR mechanisms in cancer cell 
survival. This finding has also been observed with the combination of NU7441 and 
VE-821 ATRi (Middleton et al., 2015).  
5.5.4 DNA-PK is required for the Rapid Phase Whilst ATR in Slow Phase of 
DNA DSBs Repair 
The role of ATR and DNA-PKcs in DSB repair is well described. In this study the 
interaction between the two proteins in DSB repair was assessed. Inhibition of either 
ATR or DNA-PK resulted in lower mean γH2AX foci numbers. The combination 
further impaired focus formation, reflecting the phosphorylation of H2AX by both 
DNA-PK and ATR. The recovery of γH2AX foci was significantly delayed in DNA-PK 
inhibited cells, but the speed of recovery was not significantly affected by ATRi.  
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When repairing DSBs, HR is more accurate than NHEJ, because it uses an 
undamaged sister chromatid as a template for repair, but it is therefore, restricted to 
the S-G2 phases of the cell cycle (San Filippo et al., 2008). HR is a more complex 
form of repair and takes more than 7 hrs to complete, whereas, NHEJ can be 
completed in 30 min (Mao et al., 2008). Therefore, the effect of inhibition of DNA-PK, 
and thus NHEJ, has a pronounced effect on the rapid phase of γH2AX foci decline; 
whilst ATR, and thus HR inhibition, does not affect this phase of γH2AX foci decline.  
The combination of ATRi and DNA-PKi resulted in a further reduction in mean γH2AX 
foci and delay in the timing of the peak foci numbers. Curiously, inhibition of both 
ATR and DNA-PK did not appear to affect the rate of disappearance of γH2AX foci, 
suggesting other mechanisms of repair may be activated under these circumstances. 
To confirm this, physiological measures of DNA breakage and repair, e.g. Comet 
assay, would be needed. 
As the rapid phase of repair was completed, the emergence of RAD51 foci was 
observed, which accumulated during the slow phase of γH2AX foci resolution. This 
demonstrates the shift from the faster NHEJ to the slower HR repair. The later 
accumulation of RAD51 foci could also reflect IR induced single-stranded lesions 
encountering the replication fork. Experiments in synchronised cells would need to be 
performed to assess this finding.  
Assessment of RAD51 foci noted opposing effects of ATR and DNA-PK. As 
expected, the absence of DNA-PK resulted in an increase in RAD51 foci, and thus, 
HR, despite DNA-PK having no direct role in HR. This data suggests that when NHEJ 
is inhibited there is a shunting of DSB repair to HR, which has been observed 
previously (Allen et al., 2003). This is consistent with NHEJ and HR competing for 
DSB repair (Allen et al., 2003, Chapman et al., 2012b). Potential crosstalk between 
HR and NHEJ, mediated by DNA-PK, has been investigated, and certain specific 
phosphorylation sites on DNA-PKcs which promote HR whilst inhibiting NHEJ have 
been identified (Convery et al., 2005, Neal et al., 2011).  
As previously demonstrated, inhibition of ATR, essential in HR, resulted in a 
reduction of RAD51 foci (Peasland et al., 2011). Inhibition of RAD51 by the ATRi was 
lower when combined with the DNA-PKi. This observation has been previously 
described in isogenic cell lines (Middleton et al., 2015). This finding suggests that 
that DNA-PKcs suppresses HR and in the absence of both ATR and DNA-PK, HR 
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continues and must be reliant on another mechanism of activation. The primary 
activation of HR in this setting is likely to be ATM. ATM signals in response to 
chromosomal DNA damage by phosphorylating BRCA1, NBS1 and RAD51 (Cortez 
et al., 1999, Gatei et al., 2000). To validate these findings the effect of ATM inhibition 
alone, and in combination with ATR and DNA-PK inhibition needs to be determined. 
Further investigations could be to use comet assays to assess overall DSBs repair, 
and to repeat these experiments in other cell lines.  
5.5.5 ATR Inhibition Sensitises to Rucaparib and Cisplatin whilst DNA-PK 
Inhibition to Irradiation 
Inhibition of DNA-PK has been consistently shown to cause radio-sensitisation in a 
number of different studies (Price and Youmell, 1996, Rosenzweig et al., 1997, 
Boulton et al., 2000, Kashishian et al., 2003, Shinohara et al., 2005, Tavecchio et al., 
2012, Zhao et al., 2006). This has been confirmed in this study.  
The HRD phenotype has been demonstrated to result in cisplatin and rucaparib 
sensitivity (Mukhopadhyay et al., 2012, Mukhopadhyay et al., 2010, Li et al., 2016). 
This has been confirmed by the inhibition of ATR in the NUOC-1 cell line, and in PCO 
cultures. In clinical terms, the effect of ATRi and DNA-PKi combination suggests that 
the inhibition of ATR on the background of functional NHEJ, would result in a HRD 
phenotype. Therefore, ATRi may be an important chemo sensitiser in ovarian cancer. 
An ongoing trial investigating ATRi as a single agent, and in combination with 
platinum-based chemotherapy (clinicaltrials.gov identifier: NCT02157792), is likely to 
provide important knowledge in this field. However, the mechanisms of HR activation, 
independent of ATR, need to be assessed.    
Importantly, sensitisation was achieved in NUOC-1 cells, but not OSEC-2 cells. 
These findings are important on 2 counts. Firstly, this provides evidence for the use 
of ATRi to sensitise HRC cancers to platinum based chemotherapy and PARPi. 
Secondly, this data suggests that the intrinsic molecular defects in cancer cells 
combined with DDR inhibition causes chemo- and radio-sensitisation, supporting the 
concept of cancer-cell specific synthetic lethality. It has to be noted that the OSEC-2 
cell line has been altered, and is functionally p53 mutant, therefore, its function 
cannot be directly extrapolated to represent normal ovarian epithelium. However, it is 
the closest model of normal ovarian epithelium available in laboratory settings and 
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sets a useful basis for hypothesis generating. This observation does need to be 
validated by in vivo studies.  
The failure of paclitaxel sensitisation with the DSB repair pathway inhibition is 
unsurprising, given its chemotherapeutic effects do not come through elicitation of 
DNA damage. However, this finding is contradictory to reported paclitaxel 
sensitisation by DNA-PK inhibition in multidrug resistant ovarian cancer cell lines 
(Mould et al., 2014), and needs to be evaluated in other cell line models. 
5.5.6 Interaction of ATR and DNA-PK with PARP-1 
The overall aim of this project was to improve the understanding of the interaction 
between NHEJ, HR and PARP-1. In the second part of this study the interaction 
between ATR and PARP-1, and DNA-PK and PARP-1 was analysed. In terms of 
growth, the combination of 1 µM rucaparib with either 1 µM NU7441 or 10 µM 
NU6027, did not produce additional growth inhibition in either cell line. The addition 
of 1 µM of rucaparib to ATR and DNA-PK knockdown in NUOC-1 cells, however, 
resulted in significant growth inhibition compared to each knockdown alone. The 
result is cell line specific as this effect was not observed in OSEC-2 cells. The result 
is also in contradiction to resistance induced by NU7441 inhibition in PCO cultures, 
as described in chapter 4. PARP-1 inhibition has been reported to lead to the 
activation of DNA-PK in BRCA2-deficient cells, but not in cells with wild-type BRCA2 
(Patel et al., 2011). The interaction between DNA-PK and PARP-1 may therefore be 
cell specific, and dependent on other cell defects. An alternative explanation may be 
that the effect of experimental knockdown of DNA-PK is different to that of the 
defective NHEJ pathway. These findings need to be further evaluated in other cell 
line models. 
5.5.7 PARP-1 Affects DNA DSBs Recognition and Selection of Repair Pathway 
The role for PARP-1 in DNA DSBs repair has been previously described. PARP-1 
binds to and is activated by stalled replication forks (Bryant et al., 2009, Sugimura et 
al., 2008) and is necessary for the accumulation of MRE11 and NBS1 at the site of 
DSBs (Hegan et al., 2010, Benjamin and Gill, 1980, Haince et al., 2008). Inhibition of 
PARP-1 has been shown to retard the rejoining of IR-induced DNA DSBs (Mitchell et 
al., 2009b, Boulton et al., 1999). In this study 1 µM rucaparib significantly reduced the 
peak number of γH2AX foci and delayed the recovery of γH2AX. This supports the 
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essential role for PARP-1 in DDR. The effect on RAD51 foci was not significant, 
suggesting that PARP inhibition does not affect HR directly. This is in contrast to 
studies reporting PARP-1 to have a protective role in HR by suppressing access of 
NHEJ to DSBs (Hochegger et al., 2006, Saberi et al., 2007).  
When combined with ATR inhibition, both the mean number of γH2AX and RAD51 
foci at each time point resembled that of the IR control, and not each inhibitor alone. 
This supports previous reports that the role of PARP-1 in DSB repair is in the A-EJ 
pathway. The function of PARP-1 in the A-EJ has been shown by both in vitro and in 
vivo studies (Audebert et al., 2006, Lu et al., 2006, Audebert et al., 2008). A-EJ has 
been described to compete with HR, as well as act in the absence of HR (Nik-Zainal 
et al., 2012, Ceccaldi et al., 2015a, Mateos-Gomez et al., 2015). Therefore, PARP 
inhibition may re-establish HR by inhibiting the A-EJ pathway. This may be the 
possible explanation for the observed resistance of NHEJD/HRD PCO cultures to 
rucaparib in chapter 4.  
The combination of rucaparib with DNA-PK inhibition resulted in a lower peak of 
γH2AX foci and slow recovery, which is similar to DNA-PKi alone. This finding agrees 
with previous reports, which suggest that PARP-1 and DNA-PK are epistatic (Mitchell 
et al., 2009a). The combination of DNA-PKi and PARPi resulted in a further increase 
in RAD51 foci formation, again suggesting that PARPi increases HR. This finding is 
consistent with that of ATR and PARPi combination, however, it is in contradiction to 
the finding of sensitisation of ATR inhibitor to rucaparib treatment. These findings 
therefore, need to be further explored. 
5.5.8 In PCO Cultures ATR and DNA-PK Expression Correlate but are 
Independent of PARP-1  
To determine the clinical relevance of the cell line findings, the interaction of ATR and 
DNA-PK in PCO cultures was assessed. Whilst the expression of each protein varied 
in the unselected cohort of PCO cultures, a positive correlation between ATR and 
DNA-PK mRNA levels was found. This finding suggests that the expression of ATR 
and DNA-PKcs may be concomitantly regulated in certain tumours. This has been 
previously noted in glioblastoma (Middleton et al., 2015). The correlation was 
suggested to be due to DNA-PKcs and ATR being held in a complex with cMYC and 
CHK1. Discordance between mRNA and protein levels were seen in chapter 4. A 
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comparison of the expression of ATR and DNA-PK protein is required for this finding 
to be validated.  
There was no correlation observed between PARP activity and either ATR or DNA-
PK mRNA levels. Furthermore, the assessment PARP activity by HR and NHEJ 
function confirms the independence of PARP activity from the HR and NHEJ 
functions. This result is supported by the finding of no correlation of PARP-1 mRNA 
expression with either the HR or NHEJ status of PCO cultures. These findings are in 
contrast to previous studies describing the interaction of PARP-1 with HR, and need 
to be explored further. 
5.5.9 DNA DSBS Recognition and Repair is Inhibited in NHEJ and HRD PCO 
Cultures 
Confirming the findings of inhibition experiments, a lower peak of γH2AX in both the 
NHEJD and HRD PCO cultures. Lower peak of γH2AX foci was associated with 
increased sensitivity to both rucaparib and cisplatin. Also, as seen in the inhibition 
experiments, NHEJD cultures were found to have a delay in γH2AX foci recovery, 
whilst the recovery rate was not significantly different between HRD and HRC cells. 
Confirming association of NHEJD with rucaparib resistance, PCO cultures with 
delayed recovery of γH2AX foci were less sensitive to rucaparib. These findings 
suggest that HR and NHEJ function can be predicted by the assessment of γH2AX 
foci formation and recovery. Whilst further development is required, a single assay for 
DNA DSBs formation and repair may be a potential tool for patient selection for 
treatment. 
RAD51 foci time line experiments were not performed in PCO cultures, however, the 
RAD51 foci fold increase at 24 hrs was assessed as part of the HR assay. Similarly 
to the inhibition experiments NHEJD PCO cultures also had a mean RAD51 foci 
which was higher than NHEJC cultures. Therefore, NHEJD may result in an increase 
in HR, however, this may be dependent on the type of defect resulting in HRD. The 
effect of DNA-PK inhibition in HRD cells due to different mutations is assessed in the 
next chapter.  
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5.6 Future Work 
In this study, inhibitors and shRNA knockdown were used to assess the roles of ATR 
and DNA-PK. Inhibitors are known to have off target effects, and therefore, validation 
with knockdown supports the findings. To further strengthen these findings, validation 
using isogenic cell lines is important undertake in the future.  
The assessment of DNA repair by different methods is also required. To further 
develop on the possibility to assess HR and NHEJ by a single method, assays such 
as, single point comet assays, need to be explored. The benefit of this assay over a 
functional NHEJ / HR assay is that it does not require growing cells. Therefore, 
frozen cells could be used. Use of frozen cells is a more likely to translated into 
clinical practice compared to cell culture.  
Although growth inhibition data demonstrated that ATRi significantly sensitised cells 
to cisplatin, and that rucaparib and DNA-PK inhibition potentiated radiation 
sensitivity, this needs to be confirmed in an in vivo setting. An in vivo study design 
could involve xenograft studies to confirm the enhanced efficacy of the combinations, 
and to confirm that they are specific to cancer cells by assessing the toxicity of the 
combinations. Furthermore, the toxicity of the combinations of inhibitors with 
chemotherapy agents could be evaluated. If this study yielded positive findings, a 
human explant xenograft study would then be undertaken to further evaluate the role 







CHAPTER 6 ASSESSMENT OF THE ROLE OF DNA REPAIR IN 
RESISTANCE TO RUCAPARIB AND CISPLATIN  
6.1 Introduction 
The current standard treatment of ovarian cancer, in both early and advanced 
stages, consists of cytoreductive surgery followed by chemotherapy, based on 
carboplatin with or without paclitaxel (Bristow et al., 2002, Elattar et al., 2011, Al 
Rawahi et al., 2013). The initial response rate is high (70 - 80 %), but the majority of 
patients with advanced disease relapse within two years. Recurrent ovarian cancer is 
not curable, due to the development of chemo-resistance (du Bois et al., 2005). 
Platinum-resistant disease is also characterised by resistance to other cytotoxic 
agents (Ledermann and Kristeleit, 2010). Studies have confirmed a correlation 
between platinum sensitivity and PARPi response, with higher response rates in 
platinum sensitive compared with platinum-resistant and refractory patients (Fong et 
al., 2010). However, responses in the platinum resistant and refractory cases provide 
evidence for different mechanisms of resistance and suggest incomplete crossover of 
sensitivity. The mechanisms for cisplatin and rucaparib resistance were investigated 
in this study.   
6.1.1 Mechanism of Platinum Chemotherapy 
Platinum agents are transported into the cell by passive diffusion or mediated by a 
copper transporter (CTR1). Once inside the cell, cisplatin / carboplatin are activated 
and bind DNA (Jamieson and Lippard, 1999), forming monoadducts. Intra- and inter-
strand DNA crosslinks are subsequently formed causing conformational DNA 
changes, impairing replication and DNA synthesis (Siddik, 2003). Platinum-induced 
DNA lesions attract DNA binding proteins which either signal for apoptosis or initiate 
DNA repair (Tapia, 2012).  
6.1.2 Mechanisms of Platinum Resistance 
Whilst platinum resistance is still not completely understood, three main mechanisms 
have been documented. These include reduced intracellular accumulation of 
platinum, intracellular inactivation of platinum, and increased DNA repair. Each 
mechanism will be discussed in turn and summarised in Figure 6-1. 
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6.1.2.1 Reduced Intracellular Drug Accumulation 
Decreased cellular uptake of cisplatin by resistant cells is one of the major 
mechanisms of resistance described in vitro. This is either by reduced influx 
mediated by internalisation of the CTR1 copper transporter (Holzer et al., 2004), or 
by increased efflux, with exporters ATP7A, ATP7B, MRP-related transport proteins 
and P-glycoprotein (P-Glyc) (Samimi et al., 2004, Korita et al., 2010, Hoffmann et al., 
2010). 
6.1.2.2 Intracellular Cisplatin Inactivation  
Glutathione (GSH) contributes to the detoxification and inactivation of many cellular 
toxins, including cisplatin and its analogues. GSH has been associated with cisplatin 
resistance in ovarian, cervical and lung cancer cell lines (Li et al., 2009b). 
Platinum sensitive cell  
 
Platinum resistant cell  
 




6.1.2.3 Increased DNA Repair 
The NER pathway is predominantly responsible for repairing intra-strand platinum-
DNA adducts in cellular DNA, and increased NER has been correlated with cisplatin 
resistance (Dabholkar et al., 1994). Loss of DNA MMR has also been linked to 
platinum resistance (Helleman et al., 2006). 
During DNA replication inter-strand DNA cross-linking causes DNA DSBs. These 
DSBs are repaired by HR. HRD has been linked to increased platinum sensitivity and 
concomitant survival benefits (Mukhopadhyay et al., 2012). However, BRCA1/2 
mutated cancers also develop platinum resistance, which has been suggested to be 
mediated by secondary intragenic mutations in BRCA1/2. Secondary mutations can 
reverse stop codons, usually resulting in an open reading frame, thereby restoring 
HR function (Sakai et al., 2008, Swisher et al., 2008, Edwards et al., 2008). BRCA1/2 
restoration does not, however, explain all cases of cisplatin resistance, therefore 
further investigations are still required. 
6.2 PARP Inhibitor Function  
PARP-1 reaches DNA damage sites rapidly and activates different cellular responses 
to DNA damage (Javle and Curtin, 2011). The activated PARP-1 splits the substrate 
nicotinamide adenine dinucleotide (NAD+) to release ADP-ribose, nicotinamide, and 
protons (Shah et al., 2011). PARP-1 then forms polymers of ADP-ribose (PAR) that 
post-translationally modify nuclear proteins, largely PARP-1 itself and histones. 
PARP-1 controls a wide array of cellular processes, such as cell death, transcription, 
cell division, and DNA repair (Krishnakumar and Kraus, 2010). Among the DNA 
repair pathways, PARP-1 is widely recognised for its impact on BER, but it also 
influences HR, NHEJ, MMR and NER (Pines et al., 2012, De Vos et al., 2012, Liu et 
al., 2011). Competitive PARPi are analogs of nicotinamide that compete with the 
substrate NAD+ to bind to the enzyme (Montoni et al., 2013). PARPi have been 
shown to be lethal as a monotherapy to HRD cells (Aly and Ganesan, 2011, 
Mukhopadhyay et al., 2010, Patel et al., 2011). Furthermore, it has been suggested 
that since PARP-1 plays a role in reactivating stalled replication forks, this may be a 
further mechanism of PARPi function (Helleday, 2011). PARPi sensitivity has also 
been reported via inhibition of NF-kB, which mediates transcription of prosurvival 
genes in breast cancer cells (Nowsheen et al., 2012). Further to use as 
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monotherapy, PARPi also potentiates lethality of chemotherapeutic agents or IR 
(Javle and Curtin, 2011).  
6.2.1 Mechanisms of PARP Inhibitor Resistance 
PARP inhibitor resistance has been described via four main mechanisms. These are, 
decreased levels or activity of PARP-1, decreased intracellular availability of PARPi, 
increased HR capacity and altered NHEJ capacity (Montoni et al., 2013). The 
mechanisms of PARPi resistance are summarised in Figure 6-2. 
 PARPi sensitive cell  
 
PARPi resistant cell  
 
 
Figure 6-2 Schematic of the mechanisms contributing to PARPi resistance. 
 
6.2.1.1 Decreased Levels or Activity of PARP-1 
PARPi prevent activation of the PARP-1 that is bound to DNA strand breaks to form 
PAR, or facilitate DNA repair events. Therefore, reduced levels of PARP-1 could 
result in resistance to PARPi, as has been demonstrated in colorectal carcinoma (Liu 
et al., 2009). The effectiveness of PARPi is also linked to the catalytic activity of 
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PARP-1. Thus, decreased activity of PARP-1 independent of normal expression 
could influence the efficacy of PARPi (Oplustilova et al., 2012, Gottipati et al., 2010). 
Furthermore, variant forms of PARP-1 with decreased catalytic activity, such as those 
created by the single nucleotide polymorphism (SNP)V762/A (Lockett et al., 2004), 
could make cancer cells resistant to PARPi. 
6.2.1.2  Decreased Intracellular Availability of PARPi 
Further to the role of P-glycoprotein in cisplatin resistance described earlier, P-Glyc is 
also involved in the efflux of the PARPi Olaparib (Oplustilova et al., 2012). Inhibition 
of P-Glyc has been reported to re-sensitise PARPi-resistant BRCA1 deficient cells to 
PARPi (Rottenberg et al., 2008, Jaspers et al., 2013). 
6.2.1.3  Increased HR Capacity 
Resistance to PARPi in BRCA deficient tumours can occur via reverse mutations in 
BRCA1/2 and restoration of HR function (Sakai et al., 2008, Swisher et al., 2008, 
Edwards et al., 2008, Barber et al., 2013, Norquist et al., 2011). The genomic 
instability associated with BRCA loss could be a cause for reverse mutations of 
BRCA genes (Aly and Ganesan, 2011). Selection of cells with restored BRCA 
function could confer resistance to PARPi. A further alteration to BRCA function is by 
regulation of BRCA expression. BRCA1 expression is negatively regulated by the 
microRNA miR-182, and overexpression sensitises BRCA1-proficient breast cancer 
cells to PARPi, whereas, downregulation results in resistance (Moskwa et al., 2011).  
53BP1 is a nuclear protein that plays a key role in DNA repair responses and 
checkpoint control (Bunting et al., 2010). Together, BRCA1 and 53BP1 determine the 
balance between NHEJ and HR. Loss of 53BP1 suppresses NHEJ and promotes 
HR. While cells with a defect in BRCA1 alone are susceptible to PARPi, an additional 
loss of 53BP1 was shown to increase HR repair and induce PARPi resistance 
(Bunting et al., 2010, Brandsma and Gent, 2012, Oplustilova et al., 2012). 
6.2.1.4  Altered NHEJ Capacity 
It has been suggested that one of the causes of synthetic lethality of PARPi in HRD 
cells is an upregulation of the error-prone NHEJ pathway that is normally suppressed 
by PARP-1 (Patel et al., 2011). However, data from chapters 4 and 5 do not support 
this model. Decreased NHEJ capacity in HRD cells has been suggested to lead to 
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resistance to PARPi. This has been demonstrated in vitro in BRCA2-deficient cell 
lines, where inhibition or downregulation of Ku80, Artemis, or DNA-PK resulted in 
resistance to PARPi (Patel et al., 2011), and which has been confirmed in chapters 4 
and 5.  
A further mechanism implicating NHEJ in PARPi resistance, is the suggestion that 
normal NHEJ function leads to genomic instability. This could be responsible for the 
reversion of mutated BRCA1/2, restoration of partial HR capacities and development 
of resistance to PARPi in HRD tumours (Chiarugi, 2012). Depletion of NHEJ 
components DNA-PK and Ku80 also results in PARPi sensitivity in HRC cells (Bryant 
and Helleday, 2006). Thus, both increased and decreased NHEJ capacity has been 
hypothesised to result in PARPi resistance. The results in chapter 4 suggest that in 
ovarian primary culture NHEJ is defective in 40 % of cultures, which is associated 
with PARPi resistance. 
Research into resistance mechanisms (“insights into treatment failure”) was outlined 
as one of the key lines of research in the “Focus on Cancer” March 2011 issue of 
Nature Medicine. Resistance to cisplatin has been intensively researched and a 
number of mechanisms have been described, however, it still remains poorly 
understood. Furthermore, PARPi are a new treatment still in clinical trial settings, 
therefore, further insight into the mechanisms of function will emerge as the trials 
mature. Understanding of the overlapping and separate mechanisms of resistance 
not only provides the ability to better select the correct treatment for patients based 
on the cancer genetics, but also possibly provide targets for overcoming the 
resistance of both platinum and PARPi.  
6.3 Aims of Chapter 6 
The purpose of these investigations was to determine the roles of DNA repair 
pathways in chemo-resistance in ovarian cancer. Furthermore, to investigate whether 
common or different mechanisms are involved in the resistance to cisplatin and 
rucaparib. Specifically the experimental aims were as follows: 
 Treat cell lines with escalating doses of cisplatin or rucaparib over an 
extended period of time to determine if stable drug resistant cultures could be 
established.  
 Determine the HR, NHEJ and BER status of the resistant cultures. 
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 Assess the mechanisms of resistance by performing exome mutational 
analysis and whole genome expression array.  
 Identify any potential targets of resistance to cisplatin and rucaparib. 
6.4 Results  
Two HRD cell lines were selected for use in these experiments, UWB1.289 and 
PEO1 cells. These cell lines were selected as they harbor BRCA1 and BRCA2 gene 
mutations respectively. They also have paired HRC isogenic cell lines for controls. 
The PEO1 cell line was also selected as it has been previously used in the 
development of cisplatin resistance. 
6.4.1 Basal Cell Line Characteristics 
Cell line pairs were characterised prior to resistance induction. The cell line 
morphology was assessed using light microscopy. Both cell line pairs had 
cobblestone appearance and were morphologically similar to their BRCA 
complemented pairs. Cell doubling time was determined using the SRB assay as 
described in chapter 2, and consistently the BRCA-mutant cells showed a slower 







Table 6-1 Cell line model characteristics. 
Cell line BRCA status Histology of tumour 




Source Morphology  Doubling 
time 
(hrs) 
UWB1.289 Germline BRCA1 
mutation within exon 
11 and a deletion of 
the wild-type allele 
p53 mutant 





cancer at age 42, 
ovarian cancer at age 










UWB1.289 cell line by 
transfection of human 
BRCA1 
Derived from 




PEO1 BRCA2 mutation 
[5193C>G (Y1655X)] 
Derived from peritoneal 
ascites of a patient with 
a poorly differentiated 
serous 
adenocarcinoma 








PEO4 Secondary BRCA2 
mutation [5193C>T 
(Y1655Y)] which 
restored full length 
BRCA2  
Derived from the same 














6.4.1.1 HR Status of Cell Line Models 
The HR status of the four cell lines was determined using the previously described 
γH2AX/RAD51 foci assay. > 2 fold rise in γH2AX was used as an indication of 
induction of DNA DSBs. >2 fold rise in RAD51 was used as a definition of HRC. As 
expected, in BRCA1 and BRCA2 deficient cell lines there was no significant increase 
in RAD51 foci after IR+rucaparib (Figure 6-3). HR function was not significantly 
affected by DNA-PK inhibition in UWB1.289+BRCA1 and PEO4 cells, as expected. 
However, treatment with NU7441 of BRCA1-mutant UWB1.289 cells recovered HR 
function, and there was a nearly 3-fold increase in RAD51 foci following exposure to 
IR+rucaparib. NU7441 treatment did not, however, recover HRC in the BRCA2 
mutant PEO1. Thus, HR function recovery in BRCA1 but not BRCA2 mutant cells, 
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Figure 6-3 HR status of model cell lines.  
HR status was assessed using ƴH2AX/RAD51 assay. A. Cells were treated with 2 Gy 
IR and 10 µM rucaparib for 24 hrs before number of ƴH2AX and RAD51 foci in each 
cell was determined. Two fold RAD51 foci increase above controls in deemed HR 
competent. B. RAD51 foci counts of HR assay performed +/- 1 µM NU7441. Results 






6.4.1.2 NHEJ Status of Cell Line Models  
The NHEJ status of the four cell lines was assessed using the previously described 
cellular luciferase vector rejoining assay. The DNA-PKcs deficient V3 cell line was 
used as a negative control, and its DNA-PK corrected cell line, V3YAC, provided a 
positive control for rejoining. All four human ovarian cancer cell lines were deemed 





























































Figure 6-4 NHEJ status of model cell lines.  
NHEJ status was assessed by using luciferase vector rejoining assay. Intracellular 
end joining of linearised pGL2 vector by cell lines was measured by luciferase 
activity. Measured as precise rejoining / overall end joining x 100. Data are average 
of three independent experiments. Error bars are SEM.  
 
6.4.1.3 Sensitivity to Rucaparib and Cisplatin 
As expected BRCA mutant cells were found to be significantly more sensitive to both 















Figure 6-5 Chemo-sensitivity of cell lines assessed by Clonogenic assay.  
A. UWB1.289 cell sensitivity to Cisplatin. B. PEO cells sensitivity to cisplatin. C. UWB1.289 cells sensitivity to rucaparib. D. PEO cells 
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Table 6-2 Sensitivity of UWB1-289 and PEO cell lines to rucaparib and cisplatin. 
Rucaparib and cisplatin GI50 (assessed by SRB assay) and LC50 (assessed by 
clonogenics) in paired UWB1-289 and PEO cell lines. 
Cells GI50 rucaparib LC50 rucaparib GI50 cisplatin LC50 cisplatin 
UWB1-289 1.6µM 1.3µM 280nM 75nM 
UWB1-289-
BRCA1 
14.3µM 13.92µM 1420nM 183nM 
Fold increase  









PEO1 7.8µM 0.78µM 552nM 9.3nM 
PEO4 16.59µM 9.6µM 1238nM 1440nM 
Fold increase  









6.4.2  Development of Resistant Cell Lines 
Hypothesis: Stable drug resistant cell lines can be derived from HRD cell lines by 
treatment with escalating doses of drug and incremental irradiation. 
UWB1.289 and PEO1 cells were grown in T75 flasks in recommended media at 
37 °C, and supplemented with increasing concentration of cisplatin or rucaparib over 
a period of 18 months. The starting drug concentrations were the LC50 for each drug 
for each cell line. The media was changed twice a week, and cells were passaged as 
required. The concentration of drug was increased when exponential growth was 
achieved at each concentration. Parallel flasks at the lower concentration were 
maintained alongside higher concentration, in case the higher concentration proved 
lethal. In those cases a smaller incremental increase in drug concentration was used. 
The final drug concentrations achieved were 20 µM rucaparib for PEO1 (2.5 x GI50 
and 25 x LC50) and UW1.289 (12.5 x GI50 and 15 x LC50) 2 µM cisplatin for PEO1 
(3.6 x GI50 and > 200 x LC50) and 3 µM cisplatin for UWB1.289 (10.7 x GI50 and 40 x 
LC50). The final concentrations exceeded the LC50 and GI50 of BRCA corrected 
paired cell lines PEO4 and UWB1.289+BRCA1.  
A further method for the assessment of resistance development is the induction of 
nonspecific DNA mutations prior to selection for resistance. Irradiation was used to 
induce DNA mutations in PEO1 and UWB1.289 cells. The flasks were exposed to 
fractional irradiation of 5 Gy, followed by cell recovery, and the next irradiation was 
performed after a single passage and exponential growth was regained. Total 
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irradiation for each derived cell line was 60 Gy. The 5 Gy fractioning was used as it 
has been previously described in other studies (Wade et al., 2015). 
6.4.3 Validation of Resistant Models 
Resistant lines were passaged without additional drug 3 times before being used for 
further experiments. Initially the cells were characterised by assessing morphology, 
growth and sensitivity to cisplatin and rucaparib. No changes in the morphology of 
the UWB1.289 resistant lines were noted (Table 6-3). Rucaparib resistant PEO1 lines 
were morphologically similar to PEO1. However, PEO1-CDDPR cells were 
morphologically more similar to the PEO4 cell line (Table 6-4). 










































































BRCA competent UWB1.289+BRCA1 and PEO4 were found to have faster growth 
rates compared to their BRCA deficient pairs. The growth of resistant cell lines was 
also found to be consistently higher that the parent lines. 
6.4.4 Assessment of Sensitivity to Rucaparib and Cisplatin 
Cytotoxicity assays following passage in drug free media demonstrated that all 
UWB1.289 derivatives were resistant to cisplatin, compared to UWB1.289 cells. This 
indicates that the mechanisms of resistance were stable and that cells did not require 
continuous exposure to the drugs they were derived in. The sensitivity was not 
significantly different from that of the UWB1.289+BRCA1 cell line. The only exception 
was UWB1.289-CDDPR cells, which were significantly more resistant to cisplatin 
than all the other derivatives, including the UWB1.289+BRCA1 cell line (Figure 6-6.A 
and Table 6-5). This suggests that there are multiple methods of resistance beyond 
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Figure 6-6 Chemo-sensitivity of derived cell lines assessed by Clonogenic assay. 
A. UWB1.289 derivative cells sensitivity to Cisplatin. B. PEO derivative cells sensitivity to cisplatin. C. UWB1.289 derivative cells 
sensitivity to rucaparib. D. PEO derivative cells sensitivity to rucaparib. Results are average of 3 independent experiments with 3 







Table 6-5 Cisplatin and Rucaparib sensitivity in derivative cell lines. LC50 assessed by clonogenics assay.   
Cell line Cisplatin  
LC50(µM) 
95 % CI 
(µM) 
Comparison 
to parent line  
Fold increase 




increase   






to parent line  
Fold 
increase 




increase   
(F test p = ) 
UWB1.289 0.04 0.02 to 
0.07 
-  0.3 
(0.015) 










































































































UWB1.289-699R and UWB1.289-CDDPR derivatives were resistant to rucaparib 
(Figure 6-6.C and Table 6-5). Again, resistance was not significantly different from 
the UWB1.289+BRCA1 cell line. UWB1.289-IR cells were sensitive to rucaparib at a 
similar level to the UWB1.289 parent line, which was significantly lower than 
UWB1.289+BRCA1 cells (Figure 6-6.C and Table 6-5). 
All PEO1 derivatives showed similar levels of resistance, compared to the BRCA2 
competent PEO4 cells (Figure 6-6.B and Table 6-5). Again, all derivatives with the 
exception of PEO1-IR were resistant to rucaparib (Figure 6-6.D and Table 6-5). 
6.4.4.1 Assessment of HR Status in Resistant Cell Lines 
Hypothesis: Resistant cell lines regain HR competence 
HR function was assessed using the γH2AX/RAD51 assay for all derivatives. All 
derivatives grown in rucaparib and cisplatin were found to be HRC (Figure 6-7). Both 
PEO1 and UWB1.289 IR derivatives remained HRD, consistent with the HR status of 


















































































































Figure 6-7 HR status of derivative cell lines.  
HR status was assessed using the ƴH2AX/RAD51 assay. Cells were treated with 2 
Gy IR and 10 µM rucaparib for 24 hrs before the number of ƴH2AX and RAD51 foci 
in each cell was determined. Two fold RAD51 foci increase above controls is deemed 
HR competent. Results are average of 3 independent experiments expressed as fold 
increase above controls. Error bars are SEM.  
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6.4.4.2 Assessment of NHEJ status in Resistant Cell Lines 
Hypothesis: Resistant cell lines will develop NHEJ deficiency during the process of 
resistance development. 
All derivatives were able to rejoin compatible (Co) and incompatible (2 base 
mismatch - 2I) BstXI vectors (Figure 6-8 and Figure 6-9).  
 
Figure 6-8 End joining of Co BstXI substrates by resistant cell lines. 
V3YAC and T4Lig were used as positive controls, V3 was used as a negative control. 
Gels are representative of three independent experiments. 
 
 
Figure 6-9 End joining of 2I BstXI substrates by resistant cell lines.  
V3YAC was used as a positive control and V3 as negative control. H2O was used as 





The ability to rejoin both indicated NHEJ competence. A second band was seen in all 
derived cell lines, suggesting some error prone rejoining, however, competent 
rejoining was also evident (Figure 6-9). No change of end joining from the parent 
lines was seen. When protein expression was assessed, again no change in 
expression of DNA-PKcs, Ku70 or Ku80 was seen in the derived cell lines, compared 
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Figure 6-10 DNA-PKcs, Ku80 and Ku70 protein expression in resistant cell lines.  
M059J was used as a negative control, M059FUS-1 and OSEC-2 as positive 
controls. A. UWB1.289 derivative cell lines, B. PEO1 derivative cell lines. The results 
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6.4.4.3 Assessment of BER Function in Resistant Cell Lines 
Hypothesis: Resistant cell lines will develop BER deficiency during the process of 
resistance development. 
The BER status of all cell lines was assessed using the previously described 
competitive ELISA assay. AA8 (BER competent) with its derivative EM9 cell lines 
(BER deficient mutant with XRCC1 mutation) were used as positive and negative 
controls. Mean 8-OHdG for cell line models ranged from 3.11 to 5.26 (Figure 6-11). 
No significant change of 8-OHdG levels from the parent lines were observed for any 










































































































Figure 6-11 BER function in resistant cell lines assessed by competitive ELISA.  
Results are the measurement of 8-OHdG levels. AA8 (BER proficient) cell line was 
used as positive control, EM9 (BER deficient) cell line was used as a negative 
control. 
6.4.5  Mutation Analysis 
Exome sequencing analysis was performed off site by Oxford Gene Technology 
(OGT). A number of novel somatic mutations were noted in the resistant, compared 
to parent cell lines. The majority of the mutations were heterozygous. Numerous 
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mutations were present in the parent line at low allelic frequency, but were noted at a 
higher frequency in the derived lines. These mutations are likely to have been 
selected for in the resistance development process.  
To identify those mutations that were of potential importance to the chemo-resistant 
phenotype, selection criteria was applied to the raw data. Firstly known SNPs were 
excluded during the analysis. Secondly, the frequency of mutation reported in both 
parent and resistant lines was determined; mutations which were present in > 5 % of 
read in the parent line were excluded. Mutations that were present in less than 25 % 
of reads (and therefore < 50 % of cells, assuming heterozygosity) in the resistant 
lines were excluded. And lastly, mutations which were found to be less than three 
times higher in resistant compared to parent cell line were excluded. The mutations 
which met the selection criteria were plotted on circos plots using http://circos.ca/ 
(Krzywinski et al., 2009) by Dr Sirintra Nakjang (Figures 6-12 to 6-14). Mutations are 
located throughout all the chromosomes. OGT software applied predictions for the 
likely mutations which had deleterious protein consequences.  
Hypothesis: Mutational analysis will show different targets for rucaparib compared to 
cisplatin resistant cell lines. 
Novel gene mutations in UWB1.289-699R and PEO1-699R are shown in Figure 
6-12. Significantly more new mutations were noted in the UWB1.289-699 model, 
compared to the parental PEO1-699R model, although this did not include mutations 
in BRCA1/2. This suggests that HR function recovery in both cell lines was by 
mechanisms other than BRCA gene reversion. Numerous post translational 
modifications of the HR protein have been described (Heyer et al., 2010) and would 
need to be assessed in these cell lines. Common to both rucaparib resistant cell lines 
was a novel mutation in the GMPR2 gene, which is involved in metabolism, and has 
















Figure 6-12 Circos plots for rucaparib resistant cell line derivatives.  
A. New mutations in UWB1.289-699R compared to UWB1.289. B. New mutations in PEO1-699R compared to PEO1. Genes with 
mutations present in parent line but selected for in resistant lines are noted in black, novel mutations are shown in blue, mutations which 











Figure 6-13 Circos plots for cisplatin resistant cell line derivatives.  
A. New mutations in UWB1.289-CDDPR compared to UWB1.289. B. New mutations in PEO1-CDDPR compared to PEO1. Genes with 
mutations present in parent line, but selected for in resistant lines are noted in black, novel mutations are shown in blue, mutations which 













Figure 6-14 Circos plots for irradiation cell line derivatives.  
A. New mutations in UWB1.289-IR compared to UWB1.289. B. New mutations in PEO1-IR compared to PEO1. Genes with mutations 
present in parent lines but selected for in resistant lines are noted in black, novel mutations are shown in blue, mutations which are 
predicted to be deleterious are shown in red, and those which are novel and predicted to be deleterious are shown in green.
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Figure 6-13 demonstrates the novel mutations in UWB1.289-CDDPR and PEO1-
CDDPR cells, which carry mutations across all chromosomes. Again, whilst HR 
function was regained in both cell lines, no novel BRCA mutations were noted. Two 
common genes were found to contain mutations - PRSS1 and LRP1. LRP1 codes for 
an endocytic receptor involved in several cellular processes, including intracellular 
signaling, lipid homeostasis, and clearance of apoptotic cells. PRSS1 encodes for a 
trypsinogen, which is a member of the trypsin family of serine proteases, and 
mutations in this gene are associated with hereditary pancreatitis (Pfuetzer et al., 
2001). 
As noted in rucaparib resistant cell line derivatives, UWB1.289-IR was found to 
contain significantly more novel mutations, compared to PEO1-IR (Figure 6-14). Two 
commonly mutated genes were found. RGSL1 (Regulator Of G-Protein Signaling 
Like 1) has been reported to be mutated in breast cancer (Wiechec et al., 2011). 
COL19A1 codes for the alpha chain of type XIX collagen, although there are no 
reports of this gene being involved in ovarian cancer or radio-sensitivity. 
6.4.5.1  Mutations in DNA Repair Genes in Resistant Cell Lines 
The first aim was to identify mutated genes involved in DNA repair pathways. No 
novel BRCA1 or BRCA2 mutations were noted in any of the derived cell lines when 
compared to the parent cell lines. A number of other DNA repair genes were 
somatically mutated (Table 6-6). In all three UWB1.289 resistant derivative lines, an 
identical A to T base change substitution was noted on Chromosome 14, at position 
68331668, mapping to the RAD51B. This mutation was not observed in the parental 
cells. Mutation in other HR gene EME1 was noted in UWB1.289-IR cell line.  
No novel mutations in the BER genes were noted. This is consistent with the 











Table 6-6 Somatic mutations in DNA repair genes in derived cell lines not found in parent cell lines.  
Derived cell lines Gene 
Name 

























UWB1.289-699R RAD51B 68331668 A T 22 0 21 13 38 W HR 
ERCC1 45918893 C +AA 24 2 18 8 31 */+AA NER 
UWB1.289-CDDPR XRCC2 152346278 G C 152 0 95 51 35 S HR 
GTF2H1 18380070 A T 33 0 34 13 28 W NER 
RAD51B 68331668 A T 22 0 18 8 31 W HR 
UWB1.289-IR RAD51B 68331668 A T 22 0 25 9 26 W HR 
EME1 48456440 T A 28 0 19 15 44 W HR 
PEO1-699R TP53BP1 43739686 G -A 22 0 14 7 33 */-A NHEJ 
PEO1-CDDPR                     
PEO1-IR  RAD23B 110086162 G A 26 0 6 20 77 A NER 





No novel mutations were noted in the NHEJ pathway genes. This finding is 
consistent with no change in the NHEJ function in the derived cell lines. A novel 
mutation in TP53BP1 was noted in PEO1-699R. Overexpression of 53BP1 results in 
inhibition of NHEJ and upregulation of HR. The effect of this mutation on protein 
expression is not known, but no significant effect on NHEJ function was noted in the 
PEO1-699R cell line.  
A number of NER pathway genes were found to be mutated in the UWB1.289-699R, 
UWB1.289-CDDP and PEO1 derived cell lines. As functional assessment of NER 
was not undertaken, the significance of these mutations is unknown.  
6.4.5.1.1 Pathway Analysis of Novel Mutations in Resistant Cell Lines  
To understand the mechanism of resistance development, pathway analysis was 
performed on the mutated genes list. Analysis was performed with Dr. Sirintra 
Nakjang. Ingenuity (http://www.ingenuity.com) and KEGG pathway analysis 
programs were used, and the results are detailed in Table 6-7. The two different 
analysis programs yielded different pathways for the mutated genes. Differences 
between the two software programs are likely to be due to the differences in the 
annotation used by each software package, and have been reported previously (Li et 
al., 2009b). This, therefore, warrants further investigation. 
Cell proliferation MAPK and the PI3K pathways have both been reported to be 
mutated in ovarian cancer (Geyer et al., 2009, Nakayama et al., 2006, Willner et al., 
2007). Pathway analysis found that at least one gene in the MAPK pathway was 
mutated in all the resistant cells (table 6-8). 
Furthermore, although not yet functionally validated, mutations in the PI3CA/AKT 
pathway were noted in all except the PEO1-IR derivative (Table 6-9). The frequent 
mutation of this pathway suggests an important role in cisplatin resistance. 
Importantly, in vivo studies have demonstrated that inhibition of PI3K downregulates 
BRCA1/2 and sensitises to PARPi. Phase one trial combining PI3Ki and olaparib in 





Table 6-7 Pathway enrichment of mutated genes in resistant cell lines.  
Resistant 
cell line 
Ingenuity (top canonical pathways) KEGG (top pathways) 
UWB1.289-
699R 
CDK5 Signaling (p=1.12E-03) 
IL-15 Signaling (p=8.23E-03) 
STAT3 Pathway (p=9.99E-03) 
BMP signaling pathway (p=1.08E-02) 
Endocytosis 
PI3K-AKT signaling pathway 
MAPK signaling pathway 
cAMP signaling pathway 
UWB1.289-
CDDPR 
Glutamate Receptor Signaling 
(p=1.04E-02)  
Histidine Degradation (p=2.15E-02)  











Glutathione Redox Reactions II 
(p=8.25E-03) 
CNTF Signaling (p=9.06E-03) 
Growth Hormone Signaling (p=1.56E-
02) 
Selenocysteine Biosynthesis II 
(p=p=1.64E-02) 
TNF signaling pathway 
cAMP signaling pathway 
PI3K-Akt signaling pathway 
Focal adhesion 
PEO1-699R Phototransduction Pathway (p=2.83E-
02)  
Regulation of Cellular Mechanics by 
Calpain Protease (p=3.04E-02) 
Gs Signaling (p=5.75E-02) 





Methylmalonyl Pathway (p=3.84E-05) 
2-oxobutanoate Degradation I 
(p=6.39E-05) 






Cell adhesion molecules  
 
PEO1-IR Cell Cycle: G2/M DNA Damage 
Checkpoint Regulation (p=2.86E-02) 
Cytokine Signaling (p=3.66E-02) 
 
Purine metabolism 
Nucleotide excision repair 
MAPK signaling pathway 










Table 6-8 MAPK pathway genes mutated in resistant lines. 
Resistant cell line Genes 
affected 

























UWB1.289-699R NTRK1 156843742 C A 80 0 56 21 27 C → M 
MAPK13 36098412 C T 64 0 32 19 37 C → Y 
FLNA 153581219 C A 37 0 19 17 47 C → M 
UWB1.289-CDDPR PLA2G4C  48591828 T G 37 0 17 13 43 T → K 
UWB1.289-IR RPS6KA4   64128672 C T 39 2 45 15 25 C → Y 
AKT1 105242929 A C 50 0 9 11 55 A → M 
PEO1-699R MECOM 168862931 A -
ACACAC 
32 1 20 7 26 A → */-
ACACAC 
PEO1-CDDPR PDGFRB 149500563 C G 35 0 16 20 56 C → S 
PEO1-IR MAPK8IP2  51042447 G A 62 0 43 28 39 G → R 
MECOM 168862931 A -
ACACAC 











































C T 60 0 29 12 31 C → Y 
LAMA1 6949179 T G 70 0 27 24 47 T → K 
IL2RB  
 
37539613 C A 51 2 21 25 54 C → M 
PRKCZ 2121101 A G 33 1 19 7 27 A → R 
UWB1.289-
CDDPR 
TNN 175036953 G A 50 0 19 12 39 G → R 
UWB1.289-
IR 
AKT1  105242929 A C 50 0 9 11 55 A → M 
CCND1 69458653 C T 90 1 64 22 26 C → Y 
LAMA1 7012218 C T 31 0 16 7 30 C → Y 
PEO1-
699R 
LAMA4 112537566 T G 129 0 111 41 27 T → K 
PEO1-
CDDPR 
PDGFRB  149500563 C G 35 0 16 20 56 C → S 
COL4A6           







































CAMK2A 149631531 T A 40 0 35 12 25.53 T → W 
UWB1.289-
CDDPR 
TRHR 110100496 G C 25 0 15 8 34.78 G → S 
UWB1.289-
IR 
RYR2 237617933 G T 45 0 17 8 32 G → K 
BDKRB2 96707166 G A 43 0 22 12 35.29 G → R 
PEO1-
699R 
HRH2 175112511 C T 126 0 89 31 25.83 C → Y 
PEO1-
CDDPR 
PDGFRB 149500563 C G 35 0 16 20 55.56 C → S 
PEO1-IR ATP2A2 110788113 G T 77 0  29 15 34.09 G    → K 
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Calcium is a prominent regulator of cell migration, exerting multiple effects on the 
contractility of the actin cytoskeleton (Leung et al., 2014, Furukawa et al., 2003). 
Furthermore, dysregulation of calcium signaling has been linked to platinum 
resistance and ovarian cancer metastasis in vitro (Al-Bahlani et al., 2011, Leung et 
al., 2014). Mutations in the genes involved in the calcium signaling pathway were 
noted in all derived cell lines (Table 6-10). This data supports previous reports 
suggesting a role for calcium signaling in cisplatin resistance.  
6.4.6 Gene Expression Profiling and Analysis 
Further to the assessment of gene mutations, gene expression profiling was 
undertaken. Gene expression profiling studies have reported putative signatures for 
resistance to a number of chemotherapies (Devapatla et al., 2014, Sherman-Baust et 
al., 2011). Gene expression profiling offers functional assessment of the cell 
alteration in resistance development, which is not possible to see from gene mutation 
analysis alone.  
Hypothesis: mRNA expression analysis will show different gene alterations for 
rucaparib compared to cisplatin resistant cell lines. 
The top 10 upregulated and top 10 downregulated genes for each derived cell line 
compared to parent control expression are listed in Table 6-11. LogFC is also listed 
for each gene. A number of genes were noted in more than one cell line list, and 
these are highlighted.  
S100A4 was upregulated in both UWB1.289-IR and PEO1-IR. Considerable 
evidence suggests that activation of the WNT signaling pathway plays an important 
role in human tumorigenesis and radio-sensitivity (Chang et al., 2008b). A further 
inhibitor of WNT signaling is DKK1, which inhibits cell motility and blocks invasion 
(Anastas and Moon, 2013), was downregulated in both UWB1.289-BRCA1 and 
PEO4. Furthermore, DKK1 negatively regulates cellular resistance to cisplatin in 








Table 6-11 Top 10 genes differentially expressed in resistant cell lines.  
Top 10 upregulated and top 10 downregulated genes in each cell lines compared to parent line controls were selected. Genes which are 
































































































































































































































































































































































TPK1 and CLDN1 were commonly altered in UWB1.289-699R and UWB1.289-
BRCA1. TPK1 is reported to potentiate the growth inhibitory effects of cisplatin in 
ovarian cancer cell lines (Arora et al., 2010). CLDN11 encodes the extracellular 
matrix protein that functions as cell-cell adhesion molecules, and when disrupted, 
may contribute to the invasion and metastasis of cancer (DelloRusso et al., 2007). 
Contrary to previous studies reporting that MGST1 is elevated in cisplatin resistant 
ovarian cell lines (Li et al., 2007), in this study MGST1 was downregulated in both 
UWB1.289-699R and UWB1.289-CDDPR derivatives. FOXC1 was upregulated in 
both PEO1-CDDP and PEO1-IR cell lines. This gene has been previously associated 
with cisplatin resistance in lung cancer (Guo et al., 2010), and may also have an 
important role in cisplatin resistance in these cell lines.  
In the top 10 altered genes, MARCKSL1 was upregulated in PEO1-699R, but 
downregulated in UWB1.289-699R. This finding suggests no consistent role in 
resistance development.  
6.4.6.1 Common Gene Expression Alterations in Resistant Cell Lines 
Gene expression profiling from the two parent cell lines identified very different 
expression signatures, which were initially analysed separately. The majority of the 
over- and under-expressed genes were specific for each derived cell line, but some 
were common to both cell lines. All UWB1.289 cell line derivatives were found to 
overexpress four, and under-express five common genes (Figure 6-15.A). Common 
genes found to be upregulated in platinum resistant UWB1.289 cells, including 
CXXC5, PJA2, NDUFA2 and TUBB2B, have not been previously reported in the 
cancer literature. However, some of the downregulated genes have been reported to 
be linked to a number of human cancers, including LCN2, TMED3, and SEMA4B, as 
summarised in Table 6-12. All three are reported to be have roles in the inhibition of 
progression, growth and metastasis. Therefore, the downregulation seen in the 







Figure 6-15 Differential expression analysis of resistant cell lines.  
Venn diagrams of differentially expressed gene counts in each cell lines compared to 
parent line controls (http://bioinfogp.cnb.csic.es/tools/venny). Genes included in 







Table 6-12 Reported links to human cancer of genes with altered expression in 
resistant cell lines. 
Gene Potential role Cancer Reference 




(Cheng et al., 2014, 
Slater et al., 2013) 




(Duquet et al., 2014, 
Vainio et al., 2012) 





GI cancers  
Prostate and 
breast cancers  
Ovarian cell lines 
(Zhou et al., 2015, 
Hoefer et al., 2014, 
Haffner et al., 2007) 
(Varma et al., 2005) 
IFI16 Growth suppressor Prostate cancer (Bui et al., 2009) 
SLCO2A1 Mediate invasion  
Modulate susceptibility 
Lung cancer  
Colorectal cancer 
(Zhu et al., 2015) 
(Pereira et al., 2014) 





(de Ronde et al., 
2013) 
TMEM158 Biomarker for cisplatin 
sensitivity 
Lung cancer (Mohammed et al., 
2012) 
SERPINE2 Promotor for lymph 
node metastasis 
Testicular cancer (Nagahara et al., 
2010) 
AKR1C3 Regulator of 
proliferation and 
doxorubicin resistance  
 
Pathogenesis 





(Murugan et al., 
2012) (Zhong et al., 
2015) (Liu et al., 
2015, Yepuru et al., 
2013) 
BAIAP2L1 Promotion of cell 
proliferation and 
inhibiting apoptosis 
Ovarian cancer (Chao et al., 2015) 
MCM7 Progression Prostate cancer (Ren et al., 2006) 
RHBDD2 Over expressed Breast cancer and 
advanced 
colorectal cancer 
(Lacunza et al., 2012, 
Abba et al., 2009) 
SF3A1 Polymorphisms increase 
the risk   
Pancreatic and 
colorectal cancer 
(Tian et al., 2015, 
Chen et al., 2015) 
SLIT2 Hypermethylation  
 







(Dong et al., 2012) 
(Gonin et al., 2010, 
Qin et al., 2015) 
(Gohrig et al., 2014, 
Tseng et al., 2015) 




When PEO1 derivatives were analysed, no common overexpressed genes were 
noted, however two under expressed genes were common to all the cell line 
derivatives these were SOCS2 and CBLN1 (Figure 6-15.B). The SOCS2 reported 
role in promoting growth and oxaloparib resistance (Table 6-12) suggests that it may 
be an important target for resistance to both platinum and rucaparib. 
When only rucaparib resistant cell lines were analysed, five common genes were 
found to be upregulated and twenty five downregulated (Figure 6-15.A). Of those that 
were downregulated, a number may be potential targets for drug resistance; with 
previously reported roles in growth, metastasis and chemo resistance, these include 
IFI16, SLCO2A1, BEX1, TMEM158, SERPINE2 and AKR1C3 (Table 6-12) (Bui et al., 
2009, Zhu et al., 2015, de Ronde et al., 2013, Mohammed et al., 2012, Nagahara et 
al., 2010, Murugan et al., 2012, Zhong et al., 2015).  
In PEO1 derivatives resistant to rucaparib, twelve upregulated and ten 
downregulated genes were found to be common (Figure 6-15.B). Of these genes, 
two may be important targets; these are BAIAP2L1, which promotes cell proliferation 
and inhibits apoptosis (Chao et al., 2015), and MCM7 which promotes progression 
(Ren et al., 2006). Of the genes which were found to be under expressed, a number 
have also been reported in the literature to be linked to human cancers, and 
therefore, could be potential therapeutic targets; these include SLIT2, which is 
associated with metastases (Gonin et al., 2010, Qin et al., 2015, Gohrig et al., 2014, 
Tseng et al., 2015), and IER3, a mediator of apoptosis (Jin et al., 2015). The altered 
function of all of these genes may represent potential mechanisms for rucaparib 
resistance, which are independent of platinum sensitivity. However, no common 
targets were found between the two cell lines.  
Next, gene expression profiles in cell lines derived by exposure to the same 
treatment were compared (Figure 6-16). Rucaparib derived cell lines share only 2 
commonly upregulated genes (ARHGEF35 and BAIAP2L1) and no down regulated 
genes (Figure 6-16.A). Irradiated cell lines were found to have three upregulated and 
four downregulated genes in common (Figure 6-16.B). Cisplatin derived cell lines had 
24 upregulated and 26 downregulated genes in common (Figure 6-16.C). Of the 
genes discussed already, SLIT2 and SOD2 were found to be upregulated in both 
PEO1-CDDPR and UWB1.289-CDDPR cells, and are therefore, likely to be important 








Figure 6-16 Differential expression analysis by drug treatment in resistant cell lines.  
Venn diagrams of differentially expressed gene counts in each cell line compared to 
parent line controls. A. Rucaparib derived cell lines, B. Irradiated derivative cell lines, 
C. Cisplatin treatment derived cell lines, D. BRCA competent paired cell lines.  Genes 
included in analysis were found to have >1.5 fold alteration in expression and 
adjusted p < 0.05. 
 
Interestingly, the largest similarities were found between the two BRCA competent 
cell line controls, UWB1.289+BRCA1 and PEO4 (Figure 6-16.D), with 41 upregulated 
and 55 downregulated commonly shared genes. These two cell lines were generated 
in very different ways; UWB1.289+BRCA1 was derived from UWB1.289 by 
transfection of BRCA1, whilst PEO4 was derived from the same patient as PEO1 
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after clinical resistance development. This finding is therefore surprising and needs 
further exploration. 
6.4.6.2 Pathway Enrichment of Genes with Altered Expression in Resistant Cell 
Lines 
In order to gain some insight into the possible mechanisms that are important in the 
development of resistance to these drugs, pathway analysis was performed using 
genes that were found to show significant differences in expression, in each 
resistance phenotype. KEGG, GO, and IPA databases were used for enrichment of 
any potential pathways/terms in the drug resistant cell lines (Table 6-13). While many 
pathways were found to be enriched in each resistant phenotype, some pathways 
emerged as consistently identified in at least two databases.  
In UWB1.289-699, the predominant pathway noted was involved in cell cycle control 
(Table 6-13), which has been linked to anoikis and taxol resistance in ovarian cancer 
in vitro (Carduner et al., 2014, Wang et al., 2013a).  In contrast, in PEO1-699R, actin 
regulation was the predominant pathway with altered expression (Table 6-13). A 
recent study reported actin remodelling as a potential mechanism in cisplatin 
resistance (Sharma et al., 2012). The ribosome biogenesis was the pathway 
consistently altered in UWB1.289-CDDPR cells. Altered ribosomal biogenesis has 







Table 6-13 Pathway enrichment analysis in resistant cell lines.  
Pathways/Terms found enriched in the indicated databases for each of the resistance derivatives. 
Cell line Ingenuity (top canonical pathways) KEGG (adjP<0.05) GO (p<0.02) 
UWB1.289-
699R 
Cyclins and Cell Cycle Regulation 
(p=3.25E-05) 
Isoleucine Degradation I (p=7.78E-05) 
Cell cycle (adjP=0.0005) 
Metabolic pathway (adjP=0.042) 
Apoptosis (adjP=0.001) 
Amino acid metabolism (adjP=0.001) 
Protein binding (adjP=4.99e-08) 
UWB1.289-
CDDPR 
Mitochondrial Dysfunction (p=1.32E-03) 
Protein Ubiquitination (p=1.63E-03)  
Putrescine Degradation III (p=3.30E-03) 
Metabolic pathways (adjP=0.004) 
Glycosphingolipid biosynthesis 
(adjP=0.04) 
Ribosome biogenesis (adjP=0.04) 
Apoptosis (adjP=0.009) 
Ribosome biogenesis (adjP=0.009) 
Cellular component biogenesis (adjP=0.0004) 
Response to chemical stimulus (adjP=0.001) 
rRNA metabolic process (adjP=0.009) 
Response to oxidative stress (adjP=0.009) 
UWB1.289-
IR 
Histamine Degradation (p=8.96E-04) 
Fatty Acid oxidation (p=1.79E-03) 
- Protein binding (adjP=0.002) 
PEO1-699R Cleavage and Polyadenylation of Pre-
mRNA (p=1.09E-03) 
Actin Nucleation (p=1.62E-03) 
Regulation of Actin-based Motility 
(p=5.64E-03) 
Endocytosis Signalling (p=7.16E-03) 
Fc gamma R-mediated 
phagocytosis (adjP=0.0009) 
Regulation of actin cytoskeleton 
(adjP=0.005) 
Actin polymerization (adjP=0.01) 
Negative regulation of chemotaxis (adjP=0.01) 
PEO1-
CDDPR 
Endocytosis Signaling (p=2.13E-03) 
Phagosome maturation (p=6.03E-03) 
Phosphatidylcholine Biosynthesis  
(p=6.60E-03) 
Superoxide Radicals Degradation 
(p=6.60E-03) 
- Cellular component organization (adjP=0.005) 
Cell morphogenesis and migration (adjP=0.01) 
Cell-substrate junction assembly (adjP=0.01) 
Cell growth (adjP=0.014) 
Signal transduction (adjP=0.014) 
Protein binding  (adjP=1.60e-05) 
PEO1-IR Mismatch Repair (p=6.17E-03) 
Cell junction signalling (p=6.26E-03) 
ERK5 Signalling (p=1.11E-02) 















Reported in  Ref 
UWB1.289-
699R 
EFEMP2 -1.33 8.48 -8.62 0.00 Biomarker for early detection of colorectal cancer (Yao et al., 2012) 
PCNXL4 -0.65 9.09 -4.74 0.01   
TIAM2 0.59 8.01 4.23 0.01   
UWB1.289-
CDDPR 
SOD2 -1.11 9.92 -10.70 0.00 Increased risk of ovarian cancer and pro-survival 
in ovarian cancer cells in vitro. Implicated in lung, 
colon and prostate. 
(Dier et al., 2013, Miar et 
al., 2015) 
LRSAM1 0.75 8.89 10.07 0.00   
PDE2A 0.82 7.14 7.06 0.00   
LTBP4 0.84 7.40 4.91 0.01   
GNL3 -0.62 10.67 -4.73 0.01 Biomarker predicting treatment response in breast 
cancer  
Metastasis susceptibility gene in prostate cancer  
(Tamura et al., 2010, 
Lee et al., 2015) 
UWB1.289-IR ETFA -0.61 10.51 -6.08 0.00   
PHLDB1 0.81 8.24 4.80 0.01   
LAMA1 0.63 7.05 3.95 0.04   
PEO1-699R LZTR1 -0.66 8.56 -5.95 0.02   
        
PEO1-CDDPR DLX1 -0.98 8.42 -5.50 0.00   
SF3A3 0.61 10.22 4.99 0.01   
ABCA1 0.92 7.03 4.06 0.02 Poor prognosis in serous ovarian carcinoma  (Hedditch et al., 2015, 
Chou et al., 2015) 
PCCB 0.70 10.39 4.03 0.02   
LAMB3 -0.89 9.32 -3.72 0.04 Susceptibility gene in cervical cancer 
Pro-metastasis gene in lung cancer  
(Wang et al., 2013b, 




6.4.6.3  Genes with Mutations and Altered mRNA Expression  
A subset of genes was noted in which gene mutations were accompanied with an 
altered expression (Table 6-14), with either up or down regulation at the mRNA level. 
Assessment of the protein level alteration is needed before the functional effects can 
be ascertained, however these genes may potentially be important resistance 
targets. Of the genes in Table 6-14, two, ABCA1 and SODS2 have previously been 
reported in association with ovarian cancer. LAMB3, EFEMP2 and GNL3 have been 
reported in association with other human cancers, and may be potential targets for 
chemo-resistance.  
6.4.6.4  The Expression of Potential Target Genes in PCO Cultures 
The effect of gene alteration on survival would provide the greatest information of the 
role of these targets in resistance development. However, publically available 
databases that contain gene alteration and survival outcomes are for patients treated 
with standard therapy and not PARPi. Therefore, targets for PARPi resistance may 
not have a measurable effect on survival outcomes. In order to address this question, 
a selected sample of PCO cultures were assessed for gene expression, and for 
rucaparib and cisplatin resistance in vitro. Differences for the expression of 
potentially important genes were assessed. 
Of those genes assessed, SERPINE2 and IER3 were significantly differentially 
expressed between the rucaparib resistant and sensitive PCO cultures (Figure 6-17). 
In PCO cultures, expression was higher in resistant cohorts, but expression from this 
gene was downregulated in the resistant cell line derivatives. IER3 gene expression 
was found to be significantly lower in resistant cell lines and PCO cultures, and may 
therefore be an important target to explore in further studies. Of the potential targets 
selected for platinum resistance, no significant differential gene expression was 






Figure 6-17 Expression of potential rucaparib resistance target genes in PCO 
cultures. 
Expression was assessed by full genome array. Expression of individual genes was 
plotted by level of PCO sensitivity to rucaparib, assessed by SRB assay.  
 
 
Figure 6-18 Expression of potential cisplatin resistance target genes in PCO cultures.  
Expression was assessed by full genome array. Expression of individual genes was 










































































5 0 0 0
1 0 0 0 0
















S e n s itiv e  c u ltu re s
R e s is ta n t c u ltu re sp = 0 .0 4 9 p = 0 .0 3
U n d e re x p re s s e d
in  re s is ta n t  c e ll l in e s
O v e re x p re s s e d
in  re s is ta n t  c e ll l in e s







































1 0 0 0
2 0 0 0
4 0 0 0
6 0 0 0
















S e n s itiv e  c u ltu re s
R e s is ta n t c u ltu re s




6.5 Summary of Chapter 
In this study resistant cell lines were derived from BRCA mutant ovarian cancer cell 
lines by continued exposure to cisplatin, rucaparib or fractionated irradiation. 
Characterisation of these cell lines found that:  
 Cell lines derived by exposure to cisplatin and rucaparib were cross resistant 
to both drugs, whereas, cell lines derived by fractionated irradiation were only 
resistant to cisplatin. 
 Cell lines derived by increasing the concentration of cisplatin and rucaparib 
were HRC. 
 No significant alteration in NHEJ or BER pathways was seen in resistant 
derivatives.  
 Multiple mutations were noted in all derived cell lines, compared to parent 
lines. The majority were somatic single nucleotide alterations. 
 Genome expression arrays found a number of gene expression levels to be 
altered. Gene expression levels of each parent cell line derived lines were 
very different from each other.  
 A few potential targets for resistance mechanisms were identified, which had 
altered expression in common across all rucaparib or all cisplatin resistant 
lines. 
6.6 Discussion 
In this study six resistant cell lines were derived from two parent HRD cell lines. In 
both models cells grown in either rucaparib or cisplatin were resistant to both agents. 
Therefore, significant overlap between the two resistance mechanisms is evident. In 
both models, cells which were irradiated were resistant to cisplatin, but not rucaparib, 
thus suggesting that some mechanisms which result in cisplatin resistance do not 
produce resistance to rucaparib. This is evident from studies demonstrating the 
response of cisplatin resistant tumours to PARPi in clinical trials (Fong et al., 2010).   
6.6.1 Regaining of HRC is Associated with Rucaparib Resistance 
In these models rucaparib and cisplatin derived resistant cells regained HR function. 
Irradiation derived cell lines did not regain HR function. Results from this study 




literature (Sakai et al., 2008, Swisher et al., 2008, Edwards et al., 2008, Barber et al., 
2013, Norquist et al., 2011). However, in contrast to published reports, reverse 
mutations in BRCA were not found in any of the resistant cell lines. Also, no 
significant change in expression level of BRCA were found in any of the resistant cell 
lines. Epigenetic alterations and protein expression of BRCA genes was not 
assessed in this study. Furthermore, the genome expression arrays carried out did 
not include microRNA, and so the expression of microRNA miR-182 which negatively 
influences BRCA1 expression (Moskwa et al., 2011) could not be assessed. 
Therefore alteration in BRCA function may still be a potential mechanism for HRC 
recovery however, not by mutation or BRCA genes.  
A somatic point mutation in 53BP1 in PEO1-699R was noted in 33 % of reads. This 
translates to 66 % of cells harboring a 53BP1 mutation. The evidence from the 
literature supports an interaction of 53BP1 with BRCA1 (Bunting et al., 2010, 
Brandsma and Gent, 2012, Oplustilova et al., 2012). The PEO1 cell line harbors a 
BRCA2 and not a BRCA1 mutation. Therefore, mutations in 53BP1 may also have a 
role in regaining HR competence beyond interaction with BRCA1. An increase of HR 
function by 53BP1 mutation could be the explanation for gaining HR function in this 
cell line, and may be linked to rucaparib resistance. However, further assessment of 
this interaction is required before conclusions could be drawn. Also 53BP1 mutations 
were not found in any of the other derived cell lines, therefore, it alone is unlikely to 
explain HR function recovery. 
RAD51B mutations were noted in all three UWB1.289 derivatives. The most likely 
explanation for finding the same point mutation in all three cell lines is that this 
mutation is found in a subclone of the parent line. UWB1.289-IR also harbors the 
RAD51B mutation, however this cell line derivative did not regain HR function. It is 
therefore unlikely that this mutation has an important role in HR function or rucaparib 
resistance. RAD51B mutations have been reported as a predisposition risk for breast 
cancer (Golmard et al., 2013, Orr et al., 2012). The patient from whom the UWB1.289 
cell line was derived developed breast cancer at age 42, followed by ovarian cancer 
at age 54. Therefore, as well as the BRCA1 mutation, the RAD51B mutation may be 
a germline mutation that this patient carried. As germline DNA for this patient is not 




Mutations in a number of NER pathway genes were also noted in derived cell lines. 
These include ERCC1, GTF2H1, RAD23B and ERCC2. Platinum-based 
chemotherapy forms DNA adducts, which subsequently inhibit DNA replication. 
Removing platinum intra-strand DNA adducts requires the NER pathway. Links 
between NER defects and platinum sensitivity are well described. However, a recent 
study, using the TCGA ovarian dataset, has described a subgroup of HGSOC with 
NER alterations associated with a phenotype of platinum sensitivity similar to that of 
BRCA1/2 mutated tumors, with improved OS and PFS (Gayarre et al., 2016, 
Ceccaldi et al., 2015b). Importantly however, NER alterations were also linked to 
PARPi resistance. The reported alterations were polymorphisms of genes ERCC4 
and ERCC6, which were not noted to be mutated in resistance lines from this cohort 
(Ceccaldi et al., 2015b). However, an ERCC1 mutation was noted in the UWB1.289-
699R cell line in this project. Therefore, NER defects may have a potential role in 
rucaparib resistance in this cell line. Validation of NER pathway function in all the cell 
lines is required before any conclusions could be drawn.  
6.6.2 NHEJ Pathway was not Altered During Resistance Development 
Contrary to the evidence of NHEJ function in the resistance to rucaparib in the 
literature and in chapter 4, no change in NHEJ function was found in any resistant 
cell lines. The explanation for this may be that NHEJ function is an inherent 
determinant of sensitivity, and is not an acquired resistance mechanism. Further 
evidence for this is the fact that the BRCA competent counterparts of these cell lines 
had the same NHEJ function as the BRCA defective cell lines at the start of the 
study. Cisplatin has been shown to inhibit NHEJ function in this study and by other 
groups (Diggle et al., 2005). The fact that NHEJ function remained unchanged after 
cisplatin treatment was removed would suggest that NHEJ inhibition by cisplatin is 
only a temporary effect whilst the drug is applied to the cells. This finding needs to be 
further assessed as it may have important implications for clinical practice. 
Combination therapy is commonly used in the treatment of ovarian cancer, a number 
of trials are underway combining platinum and PARP inhibitors. These include phase 
one trials to assess the maximum tolerated dose of olaparib in combination with 
carboplatin (NCT02418624), as well as in combination with carboplatin and/or 
paclitaxel (NCT00516724) and a phase 1b trial of olaparib plus weekly carboplatin 
and paclitaxel in relapsed ovarian cancer (NCT01650376). Therefore, as NHEJ 




therapy could be predicted to have no significant benefits. Results of ongoing 
combination trials will be important for observation of this effect.  
6.6.3 Mutations Signatures are Dependent on Pre-existing Defects and Drug 
Treatment 
The mutation signatures obtained were very different for each derived cell line. This 
echoes a number of studies in the literature which all report different signatures for 
resistance. Furthermore, the signatures for resistance to different drugs, whilst very 
different, resulted in cross resistance in -699R and -CDDPR derivatives. This finding 
suggests that mutations in the cells are dependent on existing defects, as well as the 
drug treatment used. The important differences observed were between the number 
of mutations noted in UWB1.289 derivatives, compared to PEO1 derivatives treated 
with rucaparib and irradiation. The relatively few mutations in PEO1 cell lines suggest 
that the resistance in this line is more likely to be clone selection, rather than 
mutation based. This cannot be concluded without validating each mutation that was 
found.  
No point mutations in PARP-1 were noted in these resistance cell lines, and PARP-1 
expression at mRNA level was not significantly altered. Due to the time limit of this 
study, PARP activity was not assessed, which may provide important answers into 
the resistance mechanisms of these cell lines.  
Mutations in PI3CA/AKT and MAPK pathways were found in all resistant cell lines, 
and therefore are likely to have an important role in platinum resistance. Again, as 
mutations in these pathways are found in all derivative cell lines, these are likely to 
be a generic resistance mechanism, as described in the literature.  
6.6.4 Gene Expression Signatures are Dependent on Pre-existing Defects and 
Drug Treatment 
Expression array analysis demonstrated that the derivatives of the two cell lines were 
very different from each other. This adds further evidence to the complexity of 
resistance development, as both cell lines were exposed to the same drug and 
irradiation treatments at the same time. The evidence for the significant difference 
between RNA profiles of cells resistant to different drugs has previously been 




this study provide support to the notion that resistance development is both drug and 
tissue specific. A possible explanation for this clear difference may be that the 
majority of the resistance mechanisms are found in subclones in the parent lines and 
the drug treatments select for these subclones. This is supported by the finding of a 
number of mutations which were selected for from parent to resistant line. Therefore, 
assessing the common expression profiles of all the derived cell lines resistant to 
rucaparib, from PEO1 and UWB1.289 derivatives, produced a short list of potential 
targets for rucaparib resistance. An assessment of literature has noted that a number 
of these targets have been reported to be associated with either cancer susceptibility, 
metastasis, drug resistance or poor outcome. However, most of the evidence is from 
small studies in different cancers. Assessment of publically available databases, 
such as the TCGA database, provides some insight into the role of targets in ovarian 
cancer chemo-sensitivity; however, as the patients in the database were treated with 
standard platinum therapy and not PARPi, it does not provide all the answers. An 
assessment of these targets in a rucaparib treated population is required for full 
validation.  
6.7 Further Work 
To validate the findings of this study, identified targets will need to be validated. This 
is planned to be done firstly by RT-qPCR of the selected top candidates of the genes. 
Furthermore, as protein expression can be altered post transcription, western blotting 
validation is required for the top candidates. Validation of these targets by 
experimental inhibition / upregulation is then required to assess their function. The 
assessment of BRCA1 and BRCA2 protein expression is especially important, as the 
literature reports BRCA mutations as the mechanism for HR recovery. Protein 
expression and function of other proteins involved in HR would give a greater insight, 
demonstrating any post translational modification which resulted in HR recovery.  
An assessment of the other DNA repair pathways documented to result in platinum 
resistance needs to be undertaken in the resistant cell lines. This includes NER and 
MMR function of all derived cell lines. These assays were not performed in the 
laboratory at the time of this project, but the NER assay has now been optimised 
(Woodhouse et al., 2014) and assessment of these cell lines is planned. Assessment 





Important further work planned, is to develop xenografts from the parent and derived 
cell lines, and assess their biology in vivo. This would give insight into tumour 























CHAPTER 7 CONCLUDING DISCUSSION AND FUTURE DIRECTIONS  
Increased understanding of the underlying genetics and aetiology of ovarian cancer 
provides further insights into its complexity, and subsequently, the hope that a single 
cure will be developed begins to dissipate. A major limitation for the treatment of 
ovarian cancer is the late stage of presentation. The search for effective screening 
tools has so far failed to translate into improved outcomes (Menon et al., 2009). 
Earlier diagnosis would rely on a better understanding of the development and 
progression of ovarian cancer. It is therefore more realistic, whilst further 
understanding is being gathered, to concentrate on life prolonging treatment and 
patient selection for treatment, rather than a cure. The immediate aim should 
therefore be to turn ovarian cancer into a chronic disease, rather than the ‘silent killer’ 
which it is currently regarded as.  
Surgery plays an essential role in the management of ovarian cancer, and this should 
be undertaken at a time when complete cytoreduction is thought to be achievable. A 
good response at presentation is observed from the combination of platinum and 
taxane agents, and more recently by addition of bevacizumab. At relapse the 
development of resistance limits the available choice of agents. The polypharmacy of 
secondary chemotherapy agents has not been shown to be effective. Furthermore, 
the toxic profile of most of the available agents, coupled with the typically advanced 
age and multiple comorbidities of patients, limit the use of polypharmacy (Markman, 
2009). A better treatment strategy would be to select patients for the appropriate 
treatment at the appropriate stage of the disease, based on the biomarkers for 
response. This strategy is restricted by our limited ability to accurately predict the 
response to treatment. Further understanding of the response and resistance 
mechanisms, for not only standard chemotherapy, but also novel agents and 
biomarkers to predict response is essential. This understanding would not only allow 
prediction and monitoring for resistance development and clinical relapse, but also 
selection of the most appropriate novel agents for each phase of treatment, which 
may add overall survival benefit, whilst limiting toxicity.  
DNA damaging chemotherapy has been at the forefront for cancer therapy since the 
discovery of nitrogen mustard (Gilman, 1963). Genomic instability is an enabling 
characteristic of cancer (Hanahan and Weinberg, 2011), with dysregulation of DNA 




Chemotherapy drugs have become increasingly more targeted, however, they still 
rely on the underlying derangement of DNA repair mechanisms in the cancerous 
cells. DSBs are the most toxic form of DNA damage, and if unrepaired result in cell 
death. The application of PARPi in clinical practice is currently limited to BRCA 
mutant tumours. This is based on the association of HRD with sensitivity to PARPi. 
However, DSBs are repaired by the three pathways described so far, and in ovarian 
cancer only HR has been evaluated. Also, understanding of the interaction of the 
three pathways is still incomplete. This project addressed the function and interaction 
of the two main DNA DSBs repair pathways NHEJ and HR, and their role in 
determining chemo-sensitivity.  
7.1 Summary of Results 
A summary of the main objectives, and the additional objectives added during the 
evolution of the project are shown in Table 7-1. 
Table 7-1 Project aims and outcomes  




PCO cultures were successfully derived with an 
88 % success rate. Varied growth and 
expression of epithelial antigens and CA125 
was noted. 46 % of PCO cultures were found to 
be HRD and associated with increased 
sensitivity to rucaparib and cisplatin in vitro, but 




a novel ovarian 
cancer cell line  
NUOC-1 cells were found to be of epithelial 
origin, and to be hormone receptor negative, but 
tyrosine kinase receptor positive. NUOC-1 cells 
were found to be wildtype for P53 and PTEN, 
but to carry mutations in ARID1. NUOC-1 cells 
were HRC and NHEJC, but BER deficient. 
Two subpopulations of NUOC-1 were derived 
which contain a number of differences including 
copy number changes and MYC amplification. 
New genomic alterations occurred during the 




To assess the 
role of PTEN in 
ovarian cancer 
PTEN mutations in ovarian cancer are rare, but 
may be associated with a survival benefit. 
Inhibition of PTEN is a potential chemo-
sensitiser. 
(McCormick 






in PCO cultures 
and correlate 
with sensitivity 
to rucaparib and 
cisplatin 
Assays to assess NHEJ function were 
optimised, and 40 % of PCO cultures were 
found to be NHEJD. HR and NHEJ function in 
PCO cultures were independent of each other. 
Intra-tumour heterogeneity of NHEJ function 
was noted. NHEJD was associated with 
resistance to rucaparib. When combined 
together, only HRD/NHEJC cultures were 












To assess the 
interactions of 




ATR and DNA-PK inhibition was found to be 
cytostatic. DNA-PKi resulted in reduced 
recognition and delay in DSBs repair and 
increase in HR. Inhibition of ATR resulted in 
reduced DSBs recognition and reduction in HR.  
Combination of the two inhibitors resulted in 
continued HR, suggesting an alternative 
activation. DNA-PKi induced radio-sensitisation, 
whilst ATRi induced sensitisation to cisplatin 
and rucaparib in NUOC-1 but not OSEC2 cells.  
Poster 
presentation 
To assess the 
interactions of 
NHEJ and HR 
with PARP-1 
PARPi inhibited DSBs recognition and repair. 
Combination of PARPi and DNA-PKi resulted in 
a delay in DSBs repair, and synergistic increase 
in HR. The combined inhibition of ATR and 
PARP caused a reduction in DSBs recognition, 
but an increase in HR, overcoming the inhibition 






lines, and to 
assess the role 
of DNA repair in 
resistance  
Resistant cell lines were derived from two HRD 
cell lines. Cross resistance between rucaparib 
and cisplatin was linked to HR recovery. 
Cisplatin resistance in the HRD cell line model 
was also noted. NHEJ and BER pathways were 










A number of mutations and gene expression 
alterations were discovered in resistant cell 
lines. BRCA1 deficient cell line derivatives were 
found to contain more mutations, compared to 
BRCA2 deficient cell line derivatives. No BRCA 
revertant mutations were noted in any of the 
resistant lines. No single target for resistance 
was identified.   








7.2 Models for the Research of Ovarian Cancer 
Two models for the study of ovarian cancer biology were characterised: primary 
cultures and a novel ovarian cancer cell line. The use of primary ascitic cultures, 
described in this project, has provided a valuable resource for the study of ovarian 
cancer biology. Use of this model has many advantages over commercially available 
cell lines, but also has several limitations. The heterogeneity of PCO cultures in terms 
of antigen expression, growth rate, morphology, and DNA DSB repair is now clear. 
Whilst the multiple biopsy cohort in this study was small, intra-tumour heterogeneity 
of NHEJ function was also evident. Without assessing the intra-tumoural 
heterogeneity, it is unrealistic to expect a single assay to accurately predict the 
response to a particular cytotoxic agent, and there is a danger that clinical trials that 
do not take this into account may underestimate the actual clinical benefit.  
Cell lines are the most commonly used models to study ovarian cancer with a 
number of advantages; including high proliferative capacity, clonogenicity and 
extended life span in culture. However, a number of disadvantages have also been 
reported with acquired genetic alterations from their cells of origin and loss of 
heterogeneity (Daniel et al., 2009, Domcke et al., 2013). Furthermore, the majority of 
the most commonly used cell lines have been shown not to represent HGSOC 
(Domcke et al., 2013). These disadvantages question the application of many cell 
lines as models for the heterogenous nature of ovarian cancer. However with 
increasing understanding of the genomics of ovarian cancer, appropriate cell lines 
models can be selected. The novel ovarian cancer cell line (NUOC-1), has provided 
further insight into the complexity of ovarian cancer, as well as clonal evolution during 
the growth of the cell line. The mixed population of NUOC-1 cells represents a better 
model for the study of the heterogenous nature of ovarian cancer compared to cell 
lines derived from single clone cells. Further models of this nature are required for 
the academic community. 
An important aspect to consider for the academic community is the difference 
between protein absence and protein inhibition. In this study opposing results were 
found between absence and inhibition of PTEN and of DNA-PKcs. Previous groups 
have also reported that experimentally knockdown protein in cell line models do not 
behave like cancer cells developed in absence of that protein (Hunt et al., 2012, 




aberrations in absence of PTEN or DNA-PKcs. However, inhibited protein may also 
produce effects which are not seen in its absence; namely DNA-PKcs auto-
phosphorylation is thought to be necessary for its dissociation from DNA for the 
NHEJ pathway to complete DSB repair. DNA-PKcs binding to DNA DSB may also 
obstruct the recruitment of HR protein. Therefore, inhibition of the kinase activity may 
hinder DNA-PKcs dissociation and hence further impair DNA repair, leading to cell 
death. These differences between inhibition and knockdown have also been 
observed for PARPi (Horton and Wilson, 2013), ATMi (Yamamoto et al., 2012) and 
for the combination of NU7441 and VE-821 ATRi (Middleton et al., 2015). The 
differences between the role of the protein and the pathway also need to be 
considered. Many protein involved in DNA repair have other described functions, 
therefore, inhibition may exert effects through the alternative roles. An example of 
this is increased sensitivity of Ku80 but not in DNA-PKcs defective cell lines to ATRi 
VE-821 (Middleton et al., 2015).  
7.3 DNA DSBs Repair in Ovarian Cancer 
This study provides growing evidence of the degree of dysfunction within the DNA 
repair pathways in ovarian cancer. This is the first study to assess NHEJ function in 
primary ovarian cancer and to quantify the frequency of the deficiencies. Importantly, 
this study has shown that whilst inhibition of NHEJ results in an increase in HR, the 
competencies of the two pathways in PCO cultures are independent. Therefore, 
assessment of both pathways is needed for best selection of patients for treatment 
with PARPi. The lack of assessment of NHEJ function may be one of the factors 
responsible for the variable response to PARPi seen in clinical trials (summarised in 
appendix 2).  
The evolution of HR and NHEJ loss within the pathogenesis of ovarian cancer 
remains however unknown. Whilst evidence exists for the loss of HR being a driving 
mechanism for ovarian cancer, understanding of NHEJ is lacking. The evidence from 
this project suggests that NHEJ is an inherent mechanism of resistance, and not 
acquired during treatment. Evidence in the literature shows a reduced NHEJ function 
in the healthy cells of cancer patients (Bau et al., 2007) – does this mean that NHEJ 
is a driver for carcinogenesis? The assessment of NHEJ function in healthy cells of 




The third mechanism of DSBs repair, A-EJ, was not formally assessed during this 
project, however, evidence is building for the role of A-EJ in ovarian cancer, 
(Ceccaldi et al., 2015a, Mateos-Gomez et al., 2015). In this project evidence of A-EJ 
was also seen in primary cultures which were NHEJD. Formal assessment of A-EJ 
and its interaction with HR and NHEJ still remains to be investigated.  
Further to the three DNA DSBs pathways, three DNA SSBs repair pathways have 
been described. All of these have also been shown to have variable functions, with 
clinical implications in ovarian cancer. However, DNA repair is only a small fraction of 
the biological function in the cell, with a number of other pathways altered in ovarian 
cancer. As the ability to profile tumours continues to grow, and the effects of 
molecular aberrations on overall function of the cells and subsequent response to 
therapy increases, then more questions arise. If multiple pathways are dysfunctional, 
then how will the pathways interact? Are there dominant pathways or mutations that 
are most important, and if present, do they dictate management? Understanding the 
interplay of all the important pathways in ovarian cancer, alongside the highly 
variable and influential clinical factors, is a sizable challenge for the academic 
community. This challenge is perhaps unachievable using current technologies and 
with groups working in isolation on single aspects. The introduction of novel 
technologies, such as biological programming with artificial intelligence systems 
(Enshaei, 2015), will allow greater profiling and selection of patients for the best 
available therapy. 
7.4 Prediction of Response to PARPi 
Olaparib has been licensed for clinical use for BRCA mutated patients. It has been 
recently demonstrated that 15-20 % of ovarian cancers are BRCA mutated, and 
therefore mainstream clinical testing for germline BRCA mutations is being rolled out 
at present. However, this approach will limit the number of patients who are likely to 
benefit from PARPi, due to much higher rates of HRD in the ovarian cancer 
population. Conversely, not all patients who harbor a BRCA1/2 mutation are HRD, 
and are therefore there will be non responders to PARPi in this group. NHEJ function 
will not be assessed in these patients. Results from this and previous studies have 
demonstrated NHEJD results in resistance to PARPi. Furthermore, the loss of the 
53BP1 protein has been show to restore PARPi resistance in previously sensitive 




develop HRC during the process of resistance development through cell and drug 
specific complex mechanisms, which are yet to be fully understood. Therefore, these 
patients will be wrongly selected for a treatment from which they will not benefit.  
Identification of HRD cells by a functional RAD51 assay, and NHEJD cells by a 
functional end joining assay, have been described in this study. The function of both 
of these pathways has been shown to affect in vitro sensitivity to PARPi. Application 
of these assays in clinical practice would allow the selection of patients for the correct 
treatment, however, this approach is still a long way off. A number of weaknesses in 
using such assays have previously been put forward, although many of which have 
been addressed. Firstly, obtaining viable replicating cancer cells from patient 
sources, such as ascites or pleural fluid. The growth and storage of ascitic fluid 
cultures was optimised in chapter 3, with an 88 % success rate. Expanding the use of 
the assay to solid culture biopsies (ODonnell et al., 2014) and effusion from other 
cancers (Patterson et al., 2014) widens the applicability of the assay.  
There is a risk that in developing primary cultures one might exhibit a selection 
pressure on the cell tumour burden. Significant differences have been described 
between cultured cells and primary tumour samples. Heterogeneity between the 
ascites that the NUOC-1 cell line was derived from, and the solid tumour from the 
same patient, as well as observed clonal evolution, further demonstrates these 
differences. Therefore, functional assays need to be optimised to use fresh tissue, 
without the development of primary cultures. An example of this, NHEJ function using 
the monomer end joining assay can be assessed directly using fresh solid samples, 
as described in chapter 4 and also previously described in bladder cancer (Diggle et 
al., 2003). Efforts were also made to adapt the HR assay to be used on fresh tissue 
(ODonnell et al., 2014), however, this has so far been unsuccessful and needs 
further study.  
Another challenge for the development of biomarkers is that the DNA repair function 
may be dependent on the tumour environment. For example, Chan and colleagues 
demonstrated that chronic hypoxia results in the reduced synthesis of essential HR 
proteins, with a three-fold reduction in HR capacity and increased sensitivity to DNA 
damaging agents and PARPi (Chan and Bristow, 2010, Chan et al., 2008). This is 




cancers to PARPi (Benafif and Hall, 2015). Hypoxia is a common feature of solid 
tumours, however may not be replicated in laboratory environment.  
A number of genome wide sequencing approaches are being explored to predict HR 
function. These include sequencing of all HR genes (Turner et al., 2004, Pennington 
et al., 2014), gene expression profiling (http://www.almacgroup.com/news/almac-
validates-novel-test-for-ovarian-cancer-patients), assessing methylation (Ibragimova 
and Cairns, 2011), and patterns of genomic profiling (Abkevich et al., 2012, 
Stefansson et al., 2009). However, as shown in chapter 6, it is not always possible to 
predict HR function from gene mutations or expression studies. More recently 
combination scores encompassing a number of tests, such as genome wide SNP 
profiles, BRCA1/2 mutation screening, and BRCA1 promoter methylation data 
combined HRD score have been explored (Timms et al., 2014). These assays utilise 
high through put technology, do not rely on live cells and have demonstrated an 
association with HRD and cisplatin sensitivity (Telli et al., 2016). Patterns of genomic 
profiling may be acquired during cancer development in HRD tumours, however, 
tumours whose genome has undergone one or more events that restore HR function 
are likely to be misclassified as HRD as a result of prior repair deficiency and its 
genomic scarring (Watkins et al., 2014). Proposals have been made to integrate a 
genomic scar-based biomarker with a marker of resistance in an attempt to improve 
the performance of any companion diagnostic for PARPi, but as yet this has not been 
tested in clinical samples (Watkins et al., 2014). Furthermore, as demonstrated in 
chapter 6, clear biomarkers for resistance to PARPi are still required. In the current 
climate, the cost of genomic studies also need to be taken into account, as it is 
currently not practical for every cancer patient to undergo genomic profiling of the 
tumour.  
7.5 New Treatment Strategies for Ovarian Cancer 
Unlike other cancers, development and approval of new chemotherapy agents in 
ovarian cancers has been limited in the last decade. Bevacizumab and Olaparib are 
the first two drugs to have been approved since 2006. This is likely to be due to the 
improved understanding of ovarian cancer biology and the move away from 
managing ovarian cancer as one disease. These new therapies move us a step 
closer to targeted therapy, and make ovarian cancer an exciting field of development, 




proven most effective cytotoxic agent, platinum, should remain central to the primary 
management. However, the addition of targeted agents should be based on 
biomarker selection. Importantly, in view of tumour heterogeneity, it is the residual 
tumour that cannot be excised at the time of surgery that should be sampled for 
biomarker selection, as it is this residual tumour that will expand and cause 
relapse/recurrence, and therefore, it is the biology of this tumour that is important for 
targeted therapy.  
In view of the altered function of HR in a resistance setting, as shown in chapter 6, at 
the time of relapse, the tumour should be re-biopsied and re-characterised with 
regards to a biomarker panel. This will enable the selection of the subsequent 
targeted cytotoxic agent, and thus enable the provision of an effective therapy, whilst 
minimising side effects and, hopefully, improve the survival for the patient. 
However, this treatment strategy is not currently possible. Despite the excitement 
from the introduction of the new drugs, the current choice of cytotoxic agents 
available for the treatment of ovarian cancer is relatively limited. Furthermore, no 
current treatments have been paired with a reliable biomarker. This project adds to 
the understanding of sensitivity of ovarian cancer to PARPi and platinum agents. 
Further mechanisms of sensitivity and resistance still need to be explored to ensure 
the correct selection of therapy with minimal toxicity. Further novel agents also still 
need to be developed, which will work predictably in cancers identified by a clinically 
useful assay to be sensitive to that agent.   
A major finding of this study is the complex mechanism of resistance development to 
cisplatin and rucaparib. This study adds to the knowledge of tissue and drug specific 
mechanisms of resistance. Furthermore, the results demonstrate that in addition to 
the published mechanisms of HRC recovery, there are likely to be further 
mechanisms that will need to be explored.  
As well as novel therapies and patient selection, patient monitoring also needs to be 
updated. RECIST (Response Evaluation Criteria In Solid Tumours) is a set of 
published rules that define responsive, stable or progressive disease during 
treatment (Eisenhauer, 2009). RECIST helps to categorise tumours based upon their 
radiological appearance, giving an overall summary of the changes seen. With the 




distinct areas of tumour are likely to behave differently, modification of RECIST may 
be needed to enable the description of individual tumour areas.  
7.6 Strengths and Weaknesses of This Project  
There are numerous models for the study of cancer that can be applied by the 
research community, and a broad selection of these were used throughout this study. 
The demonstration of the differences between experimental alteration of a target, 
compared to the biological absence in clinical samples is an important strength of this 
project. Whilst this does mean that conflicting results were found in some cases, it 
demonstrates the importance of good models, and use of primary tissue to elucidate 
true roles of targets in ovarian cancer.    
A significant limitation of this project is the lack of complete assessments of the 
mechanisms of resistance in chapter 6. This was mostly due to time limitations, as 
the resistance development took significantly longer than initially expected, thus 
limiting the remaining time for characterisation. Importantly, however the results 
obtained provide evidence of extreme complexity of resistance development. This 
provides an explanation for why, despite extensive research and a number of 
suggested targets, chemo-resistance remains a huge burden to the treatment of 
ovarian cancer. This work will also form the basis of a planned grant application.  
The heterogeneous group of primary cultures, in terms of histological subtypes, 
timing and outcome of surgery, initially appears to be a limitation of this project; 
especially in regard to the current move of clinical trials to separate different 
histological subtypes. However, this is also a great strength of this project, as it 
demonstrates that functional characterisation of tumours is a superior method of 
categorisation, compared to histology, in predicting outcome or response to 
treatment.  
The fact that the patients were treated with standard therapy and not PARPi was 
another important limitation of this study, as the effect on clinical survival could not be 
assessed. However, one strength of our study, in terms of clinical, pathological and 
survival data, is that it was a prospective study collecting sequential samples. The 
clinicians involved in managing the patients were not aware of the in vitro results 




The limited number of solid samples is an important limitation of this study. However, 
even this number was able to provide evidence of tumour heterogeneity, in terms of 
NHEJ function, and provides sufficient pilot data to justify a larger trial. Clearly, 
standardisation of the number and location of biopsies and a larger number of 
participants will be required for a meaningful analysis of the effect of heterogeneity 
upon patient outcome.  
7.7 Future Work 
The work in this study adds to the growing evidence regarding the importance of the 
DNA DSBs recognition and repair pathways within ovarian cancer. However, it has 
also generated a number of further questions. In order to answer these questions, a 
number of potential future projects are being considered. The immediate plan for the 
NUOC-1 cell line is to make the cell line commercially available, and to undertake a 
MYC project in collaboration with Prof JM. Allan, utilising the isogenic nature of the 
two NUOC-1 subcultures in terms of MYC amplification. Validation of the targets that 
have been identified by SNP array in NUOC-1 cell line, is also planned.  
The assessment of NHEJ function in a larger cohort of fresh / frozen tumour tissue, 
along with biomarker expression in PARPi treated patients is required to gather 
further evidence for the role of NHEJ function in ovarian cancer. As recognition and 
repair of DSBs in NHEJD cells is lower than NHEJC cells, it may be possible to 
predict NHEJD cultures by experiments, such as single point comet assay. This 
needs to be explored alongside assessment of NHEJ function. 
In vivo xenograft studies to confirm ATRi and DNA-PKi interactions are required. In 
vivo experiments would also allow toxicity of the combinations of inhibitors with 
chemotherapy agents to be evaluated.  
To validate the findings of the resistance mechanism study, a number of further 
experiments are planned, and the identified targets will need to be validated. In the 
first instance, this is planned to be done by RT-qPCR of the selected top candidates 
of genes. As the protein expression can be altered post transcription, western blotting 
validation is required for these candidates as well. The next step of validation 
planned is to perform resistance target identification, by experimental knockdown or 




resistant cell lines. Assessment of PARP activity in resistant cell lines would also 
provide further insight into PARP resistance.  
To gain further understanding into the mechanism for HR recovery, it is important to 
assess the protein expression and function of individual HR genes. This would 
provide a greater insight into any post translational modification which resulted in HR 
recovery. An assessment of the other DNA repair pathway documented to result in 
platinum resistance, would need to be undertaken in the resistant cell lines too. This 
includes NER and MMR function of all the derived cell lines. These assays were not 
performed in the laboratory at the time of this project, but the NER assay has now 
been optimised (Woodhouse et al., 2014), and assessment of these cell lines is 
planned.  
And lastly, the development of xenografts from the parent and derived cell lines, and 
assessment of their biology in vivo, would give insight into tumour development and 
spread of the HR defective and HR recovered resistant cell lines, as well as, the 


































Appendix 1: NHEJ Gene Defects in Human Cancers  


















KU70 rs2267437 5'UTR C-61G 42016699 C>G  0.278 Breast (Willems et 
al., 2008, Fu 
et al., 2003) 
  
rs5751129 5'UTR T-991C 42015765 C>T  0.288 Renal cell, 
Gastric  
(Chang et al., 
2012, Wang 
et al., 2012, 
Yang et al., 
2011) 
  
rs132770 5'UTR A-31G 42017264 A>G  0.157 Renal cell (Chang et al., 
2012, Wang 
et al., 2012) 
  
rs132793 3’UTR A46922G 42063681 A>G  0.157 Breast (Sobczuk et 
al., 2010) 
  
KU80 rs2440 3’UTR G841A 217070766 C>T  0.466 Breast (Willems et 
al., 2008) 
  
rs1051677 3’UTR G-238A 217070248 T>C  0.125 Thyroid (Gomes et al., 
2010) 
  







6721G 48770702 C>A  0.291 Glioblastoma (McKean-









(Fu et al., 
2003, Chiu et 
al., 2008b, 


















Zhou et al., 
2012, Chang 
et al., 2008a), 
(Bau et al., 
2010),(Mittal 
et al., 2012) 
rs28360071 Intron 3 intron3 
DIP 




rs28360317 Intron 7 intron7 
DIP 
82619560 ->CCT  N/A Bladder, 
prostate 
(Mandal et al., 
2011, Mittal et 
al., 2012) 
  
rs3734091 Exon 6 G739T 82500734 G>T Ala247Se
r 
0.037 Oral (Tseng et al., 
2008) 
  
rs2075685 5'UTR G-652T 82372665 G>T  0.386   Breast (Zhou et al., 
2012) 
rs10057194 3'UTR A9509G 82658571 A>G  0.184   Breast (Zhou et al., 
2012) 
rs10080123 Intron 7 A-30323C 82461266 A>C  0.284   Breast (Monsees et 
al., 2011) 
rs2075686 5’UTR C-571T 82372746 C>T  0.092 Breast (Zhou et al., 
2012) 
  
rs1193693 Intron 6 G-17030A 82537319 G>A  0.304   Breast (Monsees et 
al., 2011) 
rs1017794 Intron 1  82382055 C>A  0.404   Breast (Monsees et 
al., 2011) 
rs10040363 Intron 3  82473645 A>G  0.404   Breast (Monsees et 
al., 2011) 
rs1011981 Intron 1  82393688 A>G  0.314   Breast (Monsees et 
al., 2011) 









rs4591730 Intron 3  82447802 G>A  0.4   Breast (Monsees et 
al., 2011) 
rs11949301 Intron 6  82505153 C>A  0.224   Breast (Monsees et 
al., 2011) 
LIG IV rs1805388 Exon 4 C54T 108863591 C>T Thr9Ile 0.153 Pancreatic, 
NSCLC,  
(Li et al., 
2009a, Lieber 
et al., 2003, 
Tseng et al., 













Sallmyr et al., 
2008),(Hill et 
al., 2006) 
rs3093739 Intron 1 T5482C 107665402 T>C  0.131 Glioma (Liu et al., 
2008) 
  








rs1805386 Exon 4 T1977C 108861913 T>C Asp568As
p 
0.093 Breast (Goode et al., 
2002),(Han et 
al., 2004) 




Exon 4 G833A 108862784 G>A Agr278Hi
s 
ND Leukaemia (Riballo et al., 
1999) 
  
rs1805389 Exon 4 C26T 107661610 C>T Ala3Val 0.057   MM, ALL (Roddam et 
al., 
2002),(Andre











Appendix 2: Summary of Clinical Trials of PARPi use in Ovarian Cancer 
Cancer Study 
Population 
Regimen Phase Outcome Refs 
BRCA1/2 breast/ovarian,  
Triple negative breast,  
Sporadic ovarian  
Olaparib 100 mg bd to 
600 mg bd 
I RECIST criteria partial / complete response reported 
in 23 %. GCIG criteria of the CA-125 level, six patients 
with a BRCA mutation had a decline of more than 50 
%.  
Most toxicities were grade 1-2, consisting of nausea 
(32 %), fatigue (30 %), vomiting (20 %), taste 
alteration (13 %), anorexia (12 %), anaemia (5 %), 
and 3 % developed grade 4 thrombocytopenia.  
(Fong et al., 
2009) 
Advanced stage pre-
treated ovarian with 
BRCA1/2 mutations 
Olaparib 40mg od to 
600mg bd.  
I Overall clinical benefit in 46 % (95 % CI, 32 % to 61 
%) of BRCA patients. Median response duration was 
28 weeks. RECIST criteria stable disease / partial / 
complete response or CA125 response was reported 
in 69 %, 45 % and 23 % respectively in platinum 
sensitive, platinum resistant and platinum refractory 
subgroups. 
(Fong et al., 
2010) 
BRCA1/2 ovarian   
Recurrent sporadic 
ovarian  
Olaparib 400mg bd or 
100mg bd  
II Objective tumour response in 33 % for 400mg dose. 
The median progression free survival was 5.8 months 
and clinical benefit rate (complete response / partial 
response / stable disease for >/= 8 weeks) was 52 % 
in the 400 mg bd cohort. Grade 1-2 toxicity: nausea 
(42 %), fatigue (30 %) and anaemia (15 %). Grade 3-4 
toxicity: nausea (6 %), fatigue (3 %) and anaemia (3 
%). 









Sporadic triple negative 
breast  
Sporadic ovarian 
Olaparib 400mg bd II 25/63 ovarian cancer patients had clinical response 




treated with 2+ platinum 
agents 
Olaparib 400mg bd vs. 
placebo 
RCT  PFS: median, 8.4 months for Olaparib vs. 4.8 months 
for placebo. Hazard ratio for progression or death - 
0.35. No significant difference was seen for OS.  
Grade 1-2 toxicity - nausea (68 % vs. 35 %), fatigue 
(49 % vs. 38 %), vomiting (32 % vs. 14 %), and 




ovarian after platinum 
therapy 
Olaparib 400mg bd vs. 
doxorubicin 50mg/m2 
iv every 4 weeks 
II   (NCT00628251) 
BRCA1/2 breast and  
ovarian  







Olaparib 400 mg BID 
PO d1–7 q21d with 
escalating dosages of 
carboplatin 
II Grade 3/4 neutropenia (23 %) and thrombocytopenia 
(20 %).  





prostate with BRCA1/2 
mutations 
Olaparib 400 mg 
BID PO daily 
 
II Tumor response rate 31.1 % (ovarian); 12.9 % 
(breast); 21.7 % (pancreatic); 50.0 % (prostate). 






Olaparib 200 mg 
BID PO daily vs. 
olaparib 400 mg 
BID PO daily vs. 
II PFS and RECIST assessed odds ratio not significant 
for combined olaparib doses vs. PLD. 
 











PLD 50 mg/m2  i.v. 
q28 days 
Platinum sensitive, 
HGS ovarian, platinum 
pretreated, 
progression free 
at least 6 months 
Paclitaxel 175 mg/m2  
i.v. day 1 + / - olaparib 
200 mg BID PO d1–10 
followed by 
monotherapy 400 mg 
BID daily Carboplatin  
II PFS for olaparib 12.2 months vs. 9.6 months  
ChemoRx arm. Hazard ration 0.51 (0.21 for BRCA 
mutation carriers).  
Grade 3 toxicity: neutropenia and anemia.  




recurrent, HGS / 
endometrioid 
ovarian, tubal / 
peritoneal with BRCA1/2 
mutations 
Olaparib 400 mg BID 
PO or olaparib 200 mg 
BID PO plus cediranib 
30 mg PO daily 
II median PFS 17.7 vs.9.0 months (hazard ration 0.42).  
Grade 3-4 toxicity: fatigue, diarrhea, hypertension. 
(Liu et al., 
2014) 
HGS / endometrioid with 
BRCA1/2 mutations 
platinum sensitive 
Olaparib III  (NCT01844986) 
HGS / endometrioid Valiparib III  GOG3005 




Olaparib III  NCT01874363 
Relapsed HGS / 
endometrioid, platinum 
sensitive 
Rucaparib III  NCT01968213 
Relapsed HGS with 
BRCA1/2 mutations 













Appendix 4: Multiple Comparisons for Inhibition and Knockdown of ATR and DNA-PK with PARPi 
Table 8-1 Tukey’s adjusted for multiple comparisons two way Anova comparisons of treatments in OSEC-2 and NUOC-1 cells.  
Significant results are marked in bold. 





adjusted P = 
Percent  
reduction in cell  
growth   
     Tukey’s 
adjusted P = 
Control vs. Rucaparib 9.4 0.9999 36 0.1854 
Control vs. NU6027 47 0.0189 68 < 0.0001 
Control vs. NU6027 + rucaparib 56 0.0024 72 < 0.0001 
Control vs. NU7441 -8.7 > 0.9999 41 0.0698 
Control vs. NU7441 + rucaparib 18 0.9619 53 0.0042 
Control vs. NU6027 + NU7441 + rucaparib 58 0.0013 83 < 0.0001 
Control vs. ATR shRNA 29 0.4982 30 0.4381 
Control vs. ATR shRNA + rucaparib 35 0.2302 73 < 0.0001 
Control vs. DNA-PK shRNA 5.4 > 0.9999 -39 0.0992 
Control vs. DNA-PK shRNA + rucaparib 34 0.2722 33 0.2985 
Control vs. DNA-PKcs shRNA + NU6027 + rucaparib 35 0.2238 49 0.0116 
Control vs. ATR shRNA + NU7441 + rucaparib 57 0.0018 77 < 0.0001 
Rucaparib vs. NU6027 + rucaparib 50.6 0.0244 36.3 0.2008 
Rucaparib vs. NU7441 + rucaparib 9.23 > 0.9999 26.56 0.9679 
Rucaparib vs. NU6027 + NU7441 + rucaparib 52.8 0.0142 73.4 0.0203 
Rucaparib vs. ATR shRNA + rucaparib 27.5 0.6987 37.8 0.1596 
Rucaparib vs. DNA-PK shRNA + rucaparib 26.4 0.7538 -4.7 > 0.9999 
Rucaparib vs. DNA-PKcs shRNA + NU6027 + rucaparib 27.5 0.6893 20.3 0.9965 
Rucaparib vs. ATR shRNA + NU7441 + rucaparib 51.7 0.0183 64 0.0670 








NU6027 vs. NU6027 + NU7441 + rucaparib 20.75 0.9996 43.8 0.9928 
NU6027 vs. DNA-PKcs shRNA + NU6027 + rucaparib -22.6 0.9982 -19.4 0.9372 
NU6027 + rucaparib vs. NU6027 + NU7441 + rucaparib 5.23 > 0.9999 39.3 0.9992 
NU6027 + rucaparib vs. DNA-PKcs shRNA + NU6027 + rucaparib -21.7 0.8952 -22 0.8430 
NU7441 vs. NU7441 + rucaparib 24.6 0.6314 20.3 0.9985 
NU7441 vs. NU6027 + NU7441 + rucaparib 60.9 0.0001 71.2 0.0638 
NU7441 vs. ATR shRNA + NU7441 + rucaparib 60 0.0002 13.7 0.1791 
NU7441 + rucaparib vs. NU6027 + NU7441 + rucaparib 40.8 0.0886 30.8 0.4661 
NU7441 + rucaparib vs. ATR shRNA + NU7441 + rucaparib 43.0 0.1091 24 0.7609 
ATR shRNA vs. ATR shRNA + rucaparib 8 > 0.9999 61.4 0.0506 
ATR shRNA vs. ATR shRNA + NU7441 + rucaparib 39.4 0.5579 67.1 0.0183 
ATR shRNA + rucaparib vs. ATR shRNA + NU7441 + rucaparib 33.9 0.8452 17 > 0.9999 
DNA-PK shRNA vs. DNA-PK shRNA + rucaparib 29.5 0.5407 51.4 < 0.0001 
DNA-PK shRNA vs. DNA-PKcs shRNA + NU6027 + rucaparib 30.5 0.4716 63.6 < 0.0001 








Table 8-2 Tukey’s multiple comparisons adjusted two way Anova comparisons of treatments with PARPi in OSEC-2 and NUOC-1 cells.  
Significant results are marked in bold. 
Comparisons OSEC-2   NUOC-1 
 Percent reduction 
in cell growth 
Tukey’s 
adjusted P = 
Percent  
reduction in cell  
growth   
     Tukey’s 
adjusted P = 
Control vs. Rucaparib 26.6 0.9968 -3 > 0.9999 
Control vs. NU6027 -26.8 0.9966 40.4 0.9137 
Control vs. NU6027 + rucaparib 38.5 0.9372 5.4 > 0.9999 
Control vs. NU7441 5.3 > 0.9999 11.8 > 0.9999 
Control vs. NU7441 + rucaparib 49.2 0.7388 48 0.7700 
Control vs. NU6027 + NU7441 + rucaparib 26.6 0.9969 46.6 0.8007 
Control vs. ATR shRNA 30.1 0.9905 29.6 0.9917 
Control vs. ATR shRNA + rucaparib 72.9 0.1774 97 0.0151 
Control vs. DNA-PK shRNA -39.4 0.9258 44.4 0.8460 
Control vs. DNA-PK shRNA + rucaparib 33 0.9797 83 0.0250 
Control vs. DNA-PKcs shRNA + NU6027 + rucaparib 49.4 0.7354 98.5 0.0127 
Control vs. ATR shRNA + NU7441 + rucaparib 77.5 0.0352 100 0.0105 
Rucaparib vs. NU6027 + rucaparib 11.8 > 0.9999 8.4 > 0.9999 
Rucaparib vs. NU7441 + rucaparib 22.6 0.9993 51 0.6947 
Rucaparib vs. NU6027 + NU7441 + rucaparib 0.9 > 0.9999 49.6 0.7291 
Rucaparib vs. ATR shRNA + rucaparib 46.3 0.8083 100 0.0106 
Rucaparib vs. DNA-PK shRNA + rucaparib 6.4 > 0.9999 86 0.0512 
Rucaparib vs. DNA-PKcs shRNA + NU6027 + rucaparib 22.7 0.9993 100 0.0088 
Rucaparib vs. ATR shRNA + NU7441 + rucaparib 50.9 0.6977 100 0.0073 
NU6027 vs. NU6027 + rucaparib 65.2 0.3216 -35 0.9684 
NU6027 vs. NU6027 + NU7441 + rucaparib 53.3 0.6320 6.2 > 0.9999 








NU6027 + rucaparib vs. NU6027 + NU7441 + rucaparib -11.9 > 0.9999 41.2 0.9016 
NU6027 + rucaparib vs. DNA-PKcs shRNA + NU6027 + rucaparib 10.9 0.9307 93.0 0.0237 
NU7441 vs. NU7441 + rucaparib 54.6 0.5974 59.8 0.4564 
NU7441 vs. NU6027 + NU7441 + rucaparib 31.9 0.9846 58.4 0.4923 
NU7441 vs. ATR shRNA + NU7441 + rucaparib 82.8 0.0707 112 0.0024 
NU7441 + rucaparib vs. NU6027 + NU7441 + rucaparib -22.7 0.9993 1.3 > 0.9999 
NU7441 + rucaparib vs. ATR shRNA + NU7441 + rucaparib 28.3 0.9945 52.1 0.6655 
ATR shRNA vs. ATR shRNA + rucaparib 42.8 0.8758 67.4 0.2761 
ATR shRNA vs. ATR shRNA + NU7441 + rucaparib 47.4 0.7830 70.4 0.2179 
ATR shRNA + rucaparib vs. ATR shRNA + NU7441 + rucaparib 4.5 > 0.9999 3.1 > 0.9999 
DNA-PK shRNA vs. DNA-PK shRNA + rucaparib 72.4 0.1848 38.5 0.9366 
DNA-PK shRNA vs. DNA-PKcs shRNA + NU6027 + rucaparib 88.8 0.0379 54 0.6130 
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